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ABSTRACT 
Antimalarial drug resistance is a major cause of the increasing burden due to P. falciparum 
malaria. Artemisinin-based combination therapies (ACTs) are now recognised to be the ideal 
choice for the first-line treatment of uncomplicated malaria, in order to achieve two beneficial 
outcomes: improvement of treatment efficacy and delay in the development of drug resistance. 
However uncertainties remain about the current and future benefits, risks and costs of ACTs and 
in particular how these outcomes are affected by differences in malaria epidemiology, health 
care settings, human behaviour and implementation strategies. 
This thesis seeks to address these uncertainties by creating a comprehensive, dynamic, bio- 
economic model of malaria transmission and the spread of drug resistance, which incorporates 
vector factors, human immunity, human behaviour, drug characteristics and costs. Central to 
the model is a biological model, developed in collaboration with a mathematician, which 
outputs the proportion of drug resistant infections and the incidence of new and recrudescent 
infections. Parasite biomass is also tracked in order for human "infectiousness" to be measured 
and fed-back into the model. Sub-models are used to calculate severe malaria, deaths, costs and 
cost-effectiveness. 
Data were obtained to develop and populate the model. This included a community drug usage 
survey in Cambodia, which was undertaken in order to document the adherence and coverage 
rates to ACT following the implementation of locally blister-packaged ACT. Coverage was 
found to be extremely low, and the use of artemisinin derivatives on their own was widespread. 
However, both of these outcomes were improved by interventions to increase coverage, 
particularly village malaria volunteers. 
Application of the model in a low transmission setting suggests that with a 10-year time-frame, 
switching from monotherapy to an ACT is very cost-effective and results in overall cost savings 
in a range of scenarios. High coverage rates with an ACT are required to delay the spread of 
drug resistance if resistance has already arisen to one of the partner drugs. Running the model 
with data from Cambodia suggests that even in settings with low coverage, the change will be 
cost-effective and significant benefits are gained from the implementation of the specific 
delivery interventions. Strategies for optimising the implementation of ACTs are discussed in 
light of the findings. 
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CHAPTER 1 
BACKGROUND 
This chapter introduces the thesis and gives a brief overview of malaria, antimalarial drug 
resistance and current antimalarial drug policy. This is followed by background information on 
Cambodia, where the field work for this thesis was undertaken. The chapter ends with a 
summary and outline of the remainder of the thesis. 
1.1. Introduction 
Over three billion people living in 107 countries are at risk of malaria transmission, with an 
estimated 350-660 million clinical malaria episodes annually. Plasmodium falciparum is 
responsible for many of these cases and for more than one million deaths each year. More than 
80% of these deaths occur in sub-Saharan Africa, where it is the cause of about 18% of deaths 
in children under five years of age (Snow, Guerra et al. 2005; WHO 2005b). In economic 
terms, the disease is estimated to be responsible for an estimated average annual reduction of 
1.3% in economic growth for those countries with the highest burden (Gallup and Sachs 2001). 
Antimalarial drug resistance is now generally acknowledged to be the main cause of our 
inability to "Roll Back Malaria". Chloroquine, which has been quietly responsible saving 
millions of lives since the 1950's, is now useless for the treatment of P. falciparum malaria in 
Asia, Latin America and much of Africa. Resistance to sulfadoxine-pyrimethamine (SP) spread 
even faster when it was introduced to replace chloroquine and is now widespread across much 
of Africa (WHO 2005b). Chloroquine and SP are both affordable drugs at around $0.10-0.20 
per adult course, and their safety and previous efficacy as oral regimens mean they have been 
easily accessible and widely used. Mefloquine, the next drug to be deployed in Southeast Asia, 
the historic epicentre for multi-drug resistant P. falciparuns malaria, fell to drug resistance 
within six years of its introduction in Thailand in the 1980's (Nosten, ter Kuile et al. 1991). It is 
much more costly and has never been deployed on wide scale in Africa. Fortunately, just as the 
supply of new antimalarials was running dry, artemisinins, a "new" class of drugs used 
originally in traditional Chinese medicine, were rediscovered and were increasingly being used 
in China and Vietnam in combination with other drugs. In 2000, Cambodia became the first 
country in the world to make an artemisinin-based combination therapy (ACT), of artesunate 
and mefloquine, their nationally recommended first-line drug (CNM 2000b). 
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Artemisinin-based combination therapies (ACTs) are now recognised to be the ideal choice for 
the first-line treatment of P. falciparum malaria. They are efficacious, rapid acting, well- 
tolerated, safe, available in all formulations, require only three days of treatment and reduce 
transmissibility. As for any combination therapy, which involves two effective drugs from 
different classes, both component drugs are less prone to the development of drug resistance, 
thus prolonging the useful lifespan of the available antimalarial drugs. However, at more than 
US$1 per adult dose, although not expensive by developed world standards, they are too costly 
to be afforded by communities and governments in poorer countries (Table 1-1). 
Although ACTs were officially recommended by the World Health Organisation in 2001 (WHO 
2001a), the initial response by policy makers was slow. Chloroquine and SP continued to be 
recommended and used across sub-Saharan Africa, exacting an enormous and increasing toll in 
terms of morbidity, mortality and associated economic costs. After several years of controversy 
apparent inertia (Nantulya and Liden 2004; Watkins, Kokwaro et al. 2004), there is now 
widespread political and financial support for the switch to ACT and countries are switching to 
an ACT with increasing momentum (Arrow, K. J., Panosian, C. et al. 2004; WHO 2006b) 
Thus in the few years since the inception of this study, the key questions regarding antimalarial 
drug policy have shifted from whether or not to change from monotherapy to combination 
therapies, to questions about their implementation and financing. In particular there are concerns 
about how to maximise coverage of the populations at risk of malaria in order to reduce current 
morbidity and mortality and to reduce the likelihood of drug resistance developing. Although 
providing easy access to free ACTs may achieve this aim, it has to be balanced against the costs, 
the wastage of drugs and the implications of their widespread inappropriate use. When the 
partner drugs are not co-formulated, the main risk is that artemisinins will be used on their own 
leaving them exposed to the development of drug resistance (Bioland, Ettling et al. 2000; 
Whitty, Allan et al. 2004). For the benefit of future generations the life of the currently 
available drugs must be prolonged for as long as possible. This is one of the main rationales for 
using ACTs but is also the reason that they must be deployed carefully. 
Questions remain about the choice of combination therapy and timing of change, and there is 
still considerable uncertainty about the implications in terms of future costs, risks and benefits. 
In order for national governments and donor institutions to make rational decisions regarding 
drug policy and strategies for implementation, there is a need for a framework in which the 
current and future risks and costs of antimalarial drug resistance, can be balanced against the 
cost and benefits of different policies and strategies. 
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Policy issues such as this, where outcomes are uncertain and decisions complex, are 
increasingly being explored with the help of models (Rauner and Brandeau 2001; Evans, Edejer 
et al. 2005). They are ideally suited to exploring both biological and economic influences on 
outcomes and moreover, they can be used to produce the estimates of the cost-effectiveness of 
policy options (Weinstein, Toy et al. 2001). However static economic models of malaria do not 
capture the change in disease transmission or antimalarial drug resistance and ignore the 
externality benefits and fundamental goals of malaria control: reduction in the number of cases 
and prolonging the useful life of antimalarial drugs. The development of a sound economic 
analysis is dependent on the robustness of the underlying epidemiological model of malaria that 
predicts these changes. Existing mathematical models of malaria have focused on infra-host 
dynamics, epidemiology, or specific aspects of drug resistance. However the factors affecting 
the effectiveness of drugs, the development of resistance and disease transmission are complex. 
Previous models have not incorporated all these important drug, epidemiological, 
parasitological and human behavioural factors. 
The aim of this thesis was to develop a bio-economic model of antimalarial drug resistance, 
which incorporates all relevant factors and can be used to elucidate different antimalarial drug 
policy options. In order to maximise the realism of the model, the collection of an extensive 
amount of data formed an important part of the study. Secondary data including a systematic 
literature review were used to populate the model and primary data were collected in Cambodia. 
Cambodia was chosen as the site for the empirical data collection because it was the first 
country to switch the national antimalarial drug policy to an ACT. In addition the change was 
accompanied by a number of innovative implementation strategies including the local blister- 
packaging of an ACT, the social marketing of the ACT through the private sector and the use of 
village malaria volunteers (VMVs) and outreach to increase coverage with biological diagnosis 
and ACT. In this thesis the focus of work was on low transmission areas. However, the model 
can be applied to explore the spread of drug resistance and the impact of combination therapy in 
high transmission settings. 
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Table 1-1: Antimalarial drug prices 
Drug Estimated cost estimated for adult course (Source) 
Monotherapies 
Chloro nine US$ 0.05 - 0.10 (depending on supplier) (2) 
Sulfadoxine/Pyrimethamine (SP) US$ 0.06 - 2.80 (depending on supplier) (2) 
Amodia uine US$ 0.15 (5) 
Meflo uine US$ 1.05 - 2.95 (depending on supplier) (2) (3) 
Artesunate US$ 0.50 - 2.68 (depending on supplier) (1) 
Quinine US$ 0.88 - 3.02 (depending on supplier) (2) 
Artemisinin-based 
combination therapies (ACTs) 
Artesunate + Amodia uine US$ 1.30 (4) (5) 
Artesunate + SP 
(Blister-packaged) 
US$ 1.24 - 2.42 (depending on number of treatments) (1) 
Artesunate + Mefloquine 
(Blister-packaged in Cambodia) 
US$ 2.59 - 3.80 (depending of manufacturing efficiency) 
(3) 
Artemether +Lumefantrine 
Co-formulated as Co-artem® 
US$ 2.40 (for public services in developing countries) (1) 
Dihydroartemisinin + 
Piperaquine 
(Co-formulated as Artekin® 
US$ 1.00 (1) 
(1) J. M Kindermans in Saving Lives, Buying Time (Arrow, K. J., Panosian, C. et al. 2004) 
(2) Based on International Drug Price Index, Management Sciences for Health, 2003 (drug cost 
only) (Mangement Sciences for Health 2003) 
(3) Cost to National Malaria Centre in Cambodia (Tsuyuoka R, personal communication) 
(4) From Snow 2003 (Snow, Eckert et al. 2003) 
(5) J. M Kindermans in Changing malaria treatment protocols in Africa: What is the cost and who 
will pay? (Kindermans, Pecoul et al. 2002). 
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1.2. Malaria 
1.2.1. The malaria life-cycle 
Plasmodium falciparuin malaria, the focus of this thesis, is the most lethal and most prevalent 
type of malaria out of the four types that cause malaria in humans (P. vivax, P. ovale, P. 
malariae and P. falciparum). It is transmitted by the bite of an infected female anopheles 
mosquito and has a complex life cycle involving an asexual stage in humans and a sexual stage 
in the mosquito (Figure 1-1). 
Following inoculation in humans, there is an initial liver stage of reproduction, which is 
asymptomatic and unaffected by drug treatment. After about 10 days the parasites burst out of 
the liver cells and into the blood stream. 
During this stage in the blood stream, asexual parasites invade red blood cells in which they 
grow and multiply. Each blood-stage cycle takes 48 hours during which time the parasites 
transform from small ring-like forms into "schizonts" which contain eight to 24 parasites 
("merozoites"). Schizonts adhere to the walls of some small blood vessels in a process called 
"sequestration", which results in obstruction of blood flow to certain organs including the brain 
and placenta, thereby contributing to the pathophysiology of severe malaria. The schizonts 
eventually rupture releasing the merozoites into the blood stream where they invade new blood 
cells, causing a logarithmic expansion in parasite biomass at a rate of about 10-fold every 48 
hours. On average, parasites are detectable in the blood by microscopy on the 11`h day after 
initial inoculation, when the density of parasites is around ; 0-50 parasites/µl of blood. At this 
stage the human host may still feel well or only experience vague symptoms, and usually 
becomes only febrile two days later. 
After a series of asexual cycles, a sub-population of parasites differentiates into male and female 
sexual forms known as "gametocytes". These do not multiply or cause symptoms but are 
responsible for transmission of malaria via mosquitoes. Once they are ingested in the blood- 
feed of a female mosquito, the male and female gametocytes fuse and undergo meiosis (sexual 
reproduction) and then multiply asexually in the mid-gut of the mosquito in "oocysts". After 
about 7-10 days these rupture, releasing parasites that penetrate multiple body sites, including 
the salivary gland, ready to be inoculated into a human host with the next blood-feed, thereby 
completing the Plasmodium life-cycle. 
This process also means that schizonts are rarely visible in the blood on microscopy leading to a 
systematic underestimation of total body parasite burden. 
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Figure 1-1: The malaria life-cycle 
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1.2.2. Clinical malaria 
The outcomes of infection with P.. falciparum malaria range from self-limiting asymptomatic 
infections to rapid death. This depends on a number of factors, the most important being host 
immunity, age and drug treatment. Symptoms are manifest when a threshold parasite density - 
"the pyrogenic density" - is reached and is related to the rupturing of red blood cells. Non- 
immune patients may become febrile before the parasites become visible by microscopy, 
whereas immune patients can tolerate parasite densities of up to 10,000/µl of blood without 
symptoms. 
Acute uncomplicated malaria is classically associated with episodes of high fever, chills. 
sweating, headache, malaise, back and abdominal discomfort, anorexia, pallor and in children, 
often seizures. Other symptoms such as diarrhoea, cough, and fast breathing are also not 
uncommon. 
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Severe malaria can affect any organ, with the onset and manifestation of symptoms again 
largely dependent on age and immunity. In areas of very high transmission, severe malaria is 
confined to the first few years of life, and is mainly manifest as severe anaemia. As 
transmission intensity falls, the age distribution of severe malaria moves upwards so that severe 
malaria is seen in older children as well, in whom it more often manifests as cerebral malaria, 
lactic acidosis and hypoglycaemia (Snow, Omumbo et al. 1997; WHO 2000b). In areas of low 
transmission and in non-immune travellers, severe malaria is seen in all age groups. In addition 
to the manifestations described in children, it can manifest as renal failure, pulmonary oedema, 
shock, jaundice and macroscopic haematuria ("blackwater fever"). Approximately 3% of adults 
and 10% of children develop a persistent neurological deficit following cerebral malaria2 (Van 
Hensbroek, Palmer et al. 1997). Although in the majority of cases there is complete recovery 
within the first month, a proportion of children have more subtle persisting deficits in 
intellectual and behavioural development (Holding and Snow 2001; Murphy and Breman 2001; 
Idro, Carteret a1-2006). 
cA R, 
Mortality rates for treated cases of severe malaria are around 15% in children and 20% in non- 
pregnant adults (Zucker, Lackritz et al. 1996; Bojang, Van Hensbroek et al. 1997; Dondorp, 
Nosten et al. 2005). However, rates vary widely reflecting differences in case definition, host 
immunity, access to treatment, type of treatment and settings. Most of the available data are 
from hospital settings and as untreated severe malaria is rapidly fatal, the actual mortality rate in 
the community is probably higher (Breman 2001). 
1.2.2.1. Co-morbidity 
A significant proportion (4 to 9%) of patients presenting with symptoms of P. falciparum 
infection will be bacteraemic (Berkley, Maitland et al. 2005). In addition, there is a complex 
synergistic interaction between infection with HIV and malaria with recent studies showing that 
HIV-infected adults are more likely to develop symptomatic and severe malaria, and that acute 
malaria infections are associated with increased 1-11V viral load (Francesconi, Fabiani et al. 
2001; Grimwade, French et al. 2004; Cohen, Karstaedt et al. 2005; Kublin, Patnaik et al. 2005). 
1.2.2.2. Malaria in pregnancy 
Pregnant women are at particular risk of malaria as they are relatively immunocompromised and 
often anaemic. The clinical course is largely dependent on their pre-pregnancy immune status 
and therefore on transmission intensity. Non-immune pregnant women are three times more 
likely to develop severe malaria and to die from it if they do (Luxemburger, Ricci et al. 1997). 
2 This is associated with protracted coma, and specific neurological deficits such as hemiparesis, speech 
and visual problems. 
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Their pregnancies are more likely to terminate early and to result in pre-term birth and low 
birth-weight (Luxemburger, McGready et al. 2001). In high transmission settings, although 
severe malaria is less likely, malaria during pregnancy (especially first pregnancies), is a 
significant cause of anaemia, pre-term birth and low-birth weight (Shulman, Marshall et al. 
2001; Steketee, Nahlen et al. 2001) and is therefore a significant cause of infant mortality 
(Guyatt and Snow 2001). 
1.2.2.3. Diagnosis 
Diagnosis of malaria relies on the presence of symptoms and the presence of parasites in the 
blood. However, in immune patients the presence of both does not mean that the symptoms are 
due to malaria, as they may well be due to a concomitant infection. In reality, malaria diagnosis 
is usually made presumptively based on clinical symptoms, leading to both over- and under- 
diagnosis. 
Microscopy has long been the mainstay of biological diagnosis 3. More recently, rapid 
diagnostic tests (RDTs) based on the detection of parasite antigens, have become popular in 
some low transmission settings (Mayxay, Newton et al. 2004; Singh, Saxena et al. 2005). They 
are quick (<20 minutes), sensitive and easy to use and cost less than $1 per test for a P. 
falciparum specific test. However, these particular tests remain positive for several weeks, due 
to the persistence of the antigen, histidine rich protein 2 (HRP2)4 (Mayxay, Pukrittayakamee et 
al. 2001). They are therefore less useful in high transmission settings because patients 
presenting with a fever unrelated to malaria may have a positive test. The use of polymerase 
chain reaction (PCR) technology is currently limited to clinical and epidemiological studies of 
drug resistance, where its application has expanded rapidly. Using PCR, parasites can be 
detected at densities much lower than possible by microscopy and individual parasite clones can 
be identified, enabling recrudescent infections to be differentiated from initial infections (WHO 
2005a). 
1.2.3. Epidemiology 
An estimated 350-660 million clinical disease episodes occur annually of which about 60% 
occur in sub-Saharan Africa (Snow, Guerra et at. 2005). Although sub-Saharan Africa carries 
the greatest burden, malaria remains a significant problem in Southeast Asia and Latin America 
(Figure 1-2). The former in particular, is estimated to carry 25% of the burden of P. falciparun? 
3 This involves the examination of a drop of blood, usually from a finger prick, on a glass slide. The 
sample is smeared, stained and fixed and examined in order to identify and quantify parasites. The latter 
requires counting the number of parasitized red cells in relation to the number of red cells or white cells in 
a certain number of microscopic fields and then multiplying up the number according to the total red cell 
or white cell count in order to obtain a quantity in terms of parasites per µl of blood. 
4 RDTs based on the detection of plasmodial lactate dehydrogenase are also available for testing for other 
species. 
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clinical episodes and 10% of the deaths (WHO 2005b). In addition to acute disease episodes 
and deaths, malaria also contributes significantly to anaemia in children and pregnant women, 
adverse birth outcomes such as spontaneous abortion, stillbirth, premature delivery and low 
birth-weight, and overall child mortality through synergy with other illnesses. The disease is 
estimated to be responsible for an estimated average annual reduction of 1.3% in economic 
growth for those countries with the highest burden (Gallup and Sachs 2001; Sachs and Malaney 
2002). 
Until well into the 20`h century, malaria was common in many parts of the world including 
Europe and North America. Eradication in these areas was due to socio-economic development 
and malaria control programmes, particularly the Global Malaria Eradication campaign in the 
1950s and 1960s (Bradley 1998; WHO 2005b). The latter involved widespread spraying with 
DDT and treatment with chloroquine. In contrast malaria continued to blight much of sub- 
Saharan Africa and areas in Latin America and Southeast Asia. Relative success in control in 
South Asia in the 1970s and 1980s was followed by a re-emergence in areas where it had almost 
been eradicated and an increase in the severity of infection and mortality elsewhere (WHO 
2005b). In sub-Saharan Africa, as childhood mortality fell from other causes, mortality due to 
malaria doubled (Korenromp, Williams et al. 2003). Although other factors have contributed' 
to the failure to control malaria, the main reason for this resurgence is the emergence and spread 
of antimalarial drug resistance. Although difficult to quantify, it has been estimated that 
chloroquine has been responsible for a two to 11-fold increase in childhood mortality in Africa 
(Trape, Pison et al. 1998; Trape 2001). 
1.2.4. Antimalarial drug resistance 
Resistance to chloroquine was first reported in South America (Moore and Lanier 1961) and 
Southeast Asia (Harinasuta, Suntharasamai et al. 1965). There was then a 17- year time lag 
before its appearance in East Africa after which dispersal occurred in a `step by step country to 
country' fashion (Payne 1987). Chloroquine resistance has been linked to mutations in the pfcrt 
gene that encodes the P. falciparum resistance transporter (PJCR7) protein and to a lesser extent 
the P. falciparum multi-drug resistance gene (pfmdrl). Recent evidence suggests that most of 
the currently existent pfcrt mutants arose from four original mutants, one in Southeast Asia that 
spread to Africa, two in South America and one in Papua New Guinea (Fidock, Nomura et al. 
2000; Wootton, Feng et al. 2002). In addition there may be one or two other origins in 
Philippines (Chen, Wilson et al. 2005) and Cambodia (Lim, Chy et al. 2003). 
S Other factors that have caused local epidemics include population movement, the breakdown in control 
programs and local primary health services, vector resistance to insecticides and the HIV/AIDS epidemic. 
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As chloroquine efficacy has fallen, sulfadoxime/pyrimethamine (SP) has taken its place6. 
However resistance developed much more rapidly following its deployment than to chloroquine 
and is now widespread in Asia, Latin America and increasingly Africa (EANMAT 2006), as 
shown in Figure 1-3. The rapidity of its spread may in part be due to its long half-life (Watkins 
and Mosobo 1993) and the fact that it appears to stimulate the production of gametocytes (von 
Seidlein, Drakeley et al. 2001). Pyrimethamine resistance is acquired in a step-wise fashion and 
arises from the sequential acquisition of four point-mutations in the gene encoding for 
L dihydofolate reductase (dhfr) (Plowe, Cortese et al. 1997). It is easy to generate in the laboratory (Paget-McNicol and Saul 2001) and it was therefore widely believed that existing 
drug resistant mutants arose from multiple new mutations. However recent evidence suggests 
that, like chloroquine resistance, the existing highly- resistant "triple mutant" was transported 
into Africa from Southeast Asia (Roper, Pearce et al. 2004). Less is known about sulfadoxine 
resistance, but this too is associated with the sequential acquisition of mutations in a gene, in 
this case, encoding for dihydropteroate synthase (dhps). 
Mefloquine, like SP has a long half-life and therefore only needs to be taken in a single dose 
and is useful for chemoprophylaxis. It is significantly more expensive than chloroquine or SP 
and is not commonly available in Africa. Resistance developed to mefloquine within six years 
of its introduction in Thailand (Nosten, ter Kuile et al. 1991) and is associated with gene 
amplification of the pfmdrl gene (Price, Uhlemann et al. 2004). 
Quinine is the mainstay of treatment of severe malaria. It has also been used for the treatment 
of drug-resistant uncomplicated malaria. It is relatively cheap and widely available and safe to 
use in pregnancy. However its use as a first-line treatment is limited mainly by the frequency 
and duration of treatment (three times daily for seven days) and its association with frequent 
minor side effects. Although it remains widely efficacious, its efficacy has waned in areas of 
multi-drug resistant malaria (WHO 2005a). Amodiaquine is related to chloroquine and is 
effective against chloroquine-resistant P. falciparum. However there is cross-resistance and 
amodiaquine is not sensitive against highly chloroquine resistant parasites (Olliaro, Nevill et al. 
1996) and high levels of resistance have been recorded in East Africa (Mutabingwa, Anthony et 
al. 2005b). Atovaquone is a new class of antimalarial. It is available only in co-formulation 
L 
with pr uanil as Malarone®. It is highly effective and well tolerated but its use is currently 
mainly limited to chemoprophylaxis for non-immune travellers, largely because of its cost. 
Resistance to atovaquone is linked to a single mutation in cytochrome b gene codon and is easy 
to induce in the laboratory and develops rapidly if the drug is used on its own (Looareesuwan, 
Chulay et al. 1999). 
6 Sulfadoxime and pyrimethamine are two different drugs that belong to the same group of drugs and are 
only available as a co-formulation. "SP" is therefore commonly referred to as a single monotherapy drug. 
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Figure 1-2: Estimated incidence of clinical P. falciparum episodes resulting from local 
transmission, country level averages, 2004 
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Figure 1-3: Drug resistance to P. falciparum from studies in sentinel sites, 2004 
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1.2.5. Artemisinin-based combination therapy (ACT) 
Artemisinin derivatives are the most powerful class of antimalarial drugs we have to date. 
Artemisinin or Qinghaosu as it is known in Chinese, is derived from the plant Artemisia annua 
(sweet wormwood) and has been used in China as a traditional remedy for thousands of years 
(see Annex 1 for more history and detailed information about ACTs). They produce the fastest 
decline in parasite mass and have the broadest range of action and are therefore effective in 
severe malaria, as well as having the potential to reduce transmissibility. They are rapidly 
absorbed, are available orally as well as parenterally and have excellent tolerability (Taylor and 
White 2004). Although they have an extremely short half-life that protects them from drug 
resistance, this also means that they need to be taken for seven days. With an effective partner 
drug, only three days of treatment are required and protects both drugs from drug resistance. 
Artemisinin derivatives are therefore only recommended for treatment in combination with 
another effective drug as an artemisinin-based combination therapy (ACT). 
There are more published randomised control trials (RCTs) on artemisinins than any other class 
of drug (Adjuik, Babiker et al. 2004; Myint, Tipmanee et al. 2004). The efficacy of ACTs in the 
treatment of uncomplicated malaria has been shown in numerous studies in Asia (Price, Nosten 
et al. 1997; Nosten, van Vugt et al. 2000; Mayxay, Khanthavong et al. 2004; Tran, Dolecek et 
al. 2004) and Africa (von Seidlein, Milligan et al. 2000; Adjuik, Agnamey et al. 2002). 
Intravenous artesunate has also recently been shown to be more efficacious than intravenous 
quinine for the treatment of severe malaria in adults resulting in a 35% reduction in mortality 
(15% versus 22%) (Dondorp, Nosten et al. 2005). Artesunate and artemether can both be given 
rectally and therefore have the potential for being life-saving if used for the early treatment of 
severe malaria in the community (Barnes, Mwenechanya et al. 2004; Aceng, Byarugaba et al. 
2005). 
So far, clinical resistance to artemisinin derivatives has not been demonstrated and resistance 
has been difficult to produce in the laboratory. However in-vitro susceptibility has been found 
to correlate with gene amplification of the pfindrl gene (Price, Uhlemann et al. 2004). 
1.2.6. Combating antimalarial drug resistance 
Recent molecular studies have clearly indicated that it is extremely rare for a new resistant 
mutant to emerge, and that the spread of existing mutants is responsible for most cases of 
antimalarial drug resistance today (Wootton, Feng et al. 2002; Roper, Pearce et al. 2004). 
However, for years this was uncertain and there has been, and continues to be, much interest in 
elucidating the factors affecting the emergence and spread of drug resistance. Such an 
understanding of drug resistance is central to the design of rational antimalarial drug policies 
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that will not only treat malaria effectively now, but will result in the prolongation of the useful 
life of drugs. 
The factors affecting the initial emergence of a de novo mutation include variation between 
different drugs and parasites (Rathod, McErlean et al. 1997; Paget-McNicol and Saul 2001), 
host immunity, and whether drugs are used alone or in combination. The latter is one of the key 
rationales for using combination therapy. Simply put, if each parasite has a one in a million 
chance of spontaneously mutating to become resistant to drug A and a similar but independent 
chance of spontaneously mutating to become resistant to an unrelated drug B, then the chance 
that both mutations occur in a single parasite is one in 1012 (1x106 multiplied by 1x106) (White 
1999a). In addition, because two independent mutations are required, it is much more likely that 
these will be broken down during sexual recombination resulting in a loss of the double 
mutation (Hastings and D'Alessandro 2000). 
Once a drug resistant infection has emerged, the subsequent spread is dependent on the presence 
of drug pressure, which results in the cure of sensitive infections but the survival of resistant 
mutants. Therefore the proportion of parasites that are exposed to drugs, especially at sub- 
therapeutic levels, is particularly important to the rate of spread. This proportion is higher when 
most infections are symptomatic and therefore treated (i. e. non immune patients), when parasite 
densities are high (i. e. non-immune patients who remain untreated), when the half-life of the 
drugs is long, when inadequate amounts of antimalarial drugs are taken (poor adherence) and 
when antimalarial drugs are taken in the absence of malaria infection. The latter may be 
because antimalarial drugs are taken presumptively for malaria-like symptoms, for 
chemoprophylaxis or as part of a mass drug administration programme? (D'Alessandro and 
Buttiens 2001). Human population movement is also important in transporting drug resistance 
between areas. Other factors include clone multiplicity, cross-resistance between drugs, the 
"fitness cost" of drug resistances (Kublin, Cortese et al. 2003) and the PJEMP1 var gene switch 
rate (Gatton, Hogarth et al. 2001)9. 
Strategies to delay the development of antimalarial drug resistance can therefore be targeted at 
any of these factors. Some strategies also succeed in addressing goals other than the control of 
drug resistance. For example the use of an ACT will result in an increased cure rate in an area 
where the current monotherapy is failing, as well as hopefully decreasing the likelihood of a 
This occurred with chloroquine in the early 1960s when the WHO added pyrimethamine or chloroquine 
to cooking salt. 8 In the absence of drug treatment resistant parasites may experience a survival disadvantage ("fitness 
cost") which may lead to a decline in the prevalence of the resistant mutants once drug pressure is 
removed. 
9 One of the important difference between malarial parasites and bacteria is the ability of parasites to 
introduce antigenic variation to the immunogenic protein P, JEMP1, which enables it to evade host 
immunity. 
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new drug resistant mutant emerging and, in a low transmission area, may also decrease the 
incidence of malaria. This was dramatically demonstrated in the KwaZulu-Natal in South 
Africa when SP monotherapy was replaced with artemether-lumefantrine (Barnes, Durrheim et 
al. 2005), and in Thailand with the introduction of artesunate-mefloquine (Nosten, van Vugt et 
al. 2000). In both places, the cure rates increased and malaria transmission decreased and in 
Thailand there was an increase in the sensitivity of the parasite to mefloquine (Brockman, Price 
et al. 2000). 
However, there can be conflict between different policy goals. For example the desire to 
minimise morbidity and mortality now, by maximising access to drugs needs, to be balanced 
against limiting their current use, in order to decrease the development of drug resistance. 
Prioritising the former over the latter may result in a lower burden of disease for the current 
generation at the expense of future generations. 
1.2.7. Antimalarial drug policy - the current situation 
Malaria experts first publicly warned of the impending disaster due to antimalarial drug 
resistance in the late 1990s (Marsh 1998; White, Nosten et al. 1999). In April 2000, more than 
20 African heads of state met in Abuja, Nigeria and called on the world community to allocate 
at least US$1 billion per year towards reaching the Roll Back Malaria (RBM) target of halving 
malaria deaths by 2010. The following year, the WHO recommended the use of artemisinin- 
based combination therapies (ACTs) for the first-line treatment of uncomplicated P. falciparum. 
The four recommended treatments were artemether-lumefantrine (Coartem®), artesunate- 
mefloquine, artesunate-SP and artesunate-amodiaquine (WHO 2001a). However, initial 
scientific opinion was divided and the response from national governments and international 
donor organisations was slow. Most countries continued to recommend either chloroquine or 
SP, despite clear evidence that they were no longer effective (EANMAT 2006) and that their 
continued use was resulting in a relentless rise in morbidity, mortality and economic cost 
(Watkins, Kokwaro et al. 2004). 
In the last two years, there has been a considerable change in momentum. ACT is now 
generally acknowledged to be the treatment of first choice and countries are increasingly 
changing their national antimalarial drug policies to one of the recommended ACTs. In part, 
this acceleration can be credited to the vocal advocates who challenged the WHO and GFATM 
into action, in an exchange of letters in the Lancet (Nafo-Traore 2004; Nantulya and Liden 
2004; Watkins, Kokwaro et al. 2004). Further weight was added to argument for change by the 
Institute of Medicine report "Saving lives, buying time: Economics of malaria drug in an age of 
resistance". The report unequivocally supports of the urgent and wide scale deployment of 
ACTs. Moreover its central recommendation is for a "sustained global subsidy of artemisinins 
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co-formulated with other anti-malarial drugs" at an estimated annual cost of $500 million 
(Arrow, K. J., Panosian, C. et al. 2004). 
Currently, out of 43 countries in Africa, 14 countries have deployed an ACT (four with 
artemether-lumefantrine and 10 with artesunate-SP or artesunate-amodiaquine). Another 19 
countries have committed to but not yet implemented a switch to an ACT. In Asia, ACTs have 
officially been deployed for several years in Cambodia, Thailand and Vietnam, artesunate- 
mefloquine in the case of the first two countries and dihyroartemisinin-piperaquine, in the latter. 
Other countries are planning to switch (Bangladesh, Bhutan, Indonesia and Myanmar), or have 
deployed ACTs in some areas (India and China). However chloroquine and SP continue to be 
used either alone or in combination elsewhere. In the Americas, six out of 11 countries with P. 
falciparum, have officially switched to an ACT (WHO 2006b). The Global Fund is responsible 
for funding much of this change and has committed to help purchase 264 million doses of ACTs 
(GFATM 2006). 
However serious concerns remain around the implementation of ACTs (Bloland, Ettling et al. 
2000; Whitty, Allan et al. 2004; Mutabingwa 2005a). The high cost of the drugs remains a 
central issue, as they are clearly unaffordable to the vast majority of those at risk and are likely 
to continue to be so for some time. ACTs will therefore need to be provided for free or very 
cheaply and this requires a significant and sustained financial commitment from donors. 
National governments worry about sustainability, and both they and donors have to weigh up 
the relative cost and benefit of implementing ACTs, compared to other health and non-health 
related interventions. Many of the doubts centre on the actual effectiveness of ACTs when they 
are implemented in "real-life", where infrastructures are poor, access to health care is low and 
there is widespread inappropriate use of antimalarial drugs. In particular, there are concerns 
about poor adherence leading to the use of artemisinins on their own and the potentially 
disastrous consequences in terms of drug resistance arising to the artemisinin derivatives. This 
has recently led WHO to demand an immediate halt to the use of artemisinins on their own 
(WHO 2006c). Whether or not the use of ACTs should be limited to biologically confirmed 
malaria, targeted to specific at-risk groups, such as children, or used for "home-treatment" 
remains controversial (D'Alessandro, Talisuna et al. 2005). Finally, a considerable source of the 
benefit of ACTs in low-transmission areas is their ability to reduce malaria transmission and 
drug resistance. Enthusiasm for their deployment in high transmission settings is therefore 
tempered by the expectation that these consequences are less likely to occur in these settings. 
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1.3. Cambodia 
1.3.1. General background 
Cambodia lies in the Mekong delta region bordered by Thailand, Lao PDR, Vietnam and the 
Gulf of Thailand, covering an area of 181,040km2. The total population is approximately 13.5 
million (MoH 2003). The majority of the population are Khmer, with the ethnic minority 
population concentrated in the two remote Northeast provinces of Rattanakiri and Mondulkiri. 
Most of the population (84.3%) live in rural areas, mainly concentrated around the capital, 
Phnom Penh and to a lesser extent the provinces bordering Thailand. The population is very 
young, with nearly half the population under 15 years. Average household size is 5.2 people per 
household (NIS 1999). Following the Khmer Rouge's (1975-1979), forced move of city 
dwellers to the countryside and the years of ensuing conflict, there has been a long history of 
population movement10. In recent years, in response to a relative over-population of the central 
plains area, families have been moving into the sparsely inhabited forested areas that were 
previously dangerous and inaccessible because of conflicts, poor roads and unexploded 
landmines. 
Cambodia has only recently begun to recover from its turbulent past. The economy is now 
growing fast, with an annual gross domestic product (GDP) growth rate of around 5-6%. In 
2001-2002 the GDP was around $4 billion or US$278 per capita (World Bank 2002). However, 
of this some US$400 million or US$30 per capita was from foreign aid, accounting for 12% of 
the GDP (UNDP 2002) and Cambodia still remains amongst the poorest countries in the world, 
ranking 130`h out of 173 in the Human Development Index (UNDP 2002). Next to the Lao 
PDR, it is the poorest country in Southeast Asia. Of note is the low life expectancy (average 
57.4 years), high child and infant mortality rate (124 and 95 per 1000 live births respectively) 
and high maternal mortality (440 per 100,000 live births) (UNDP 2002). In 2002 it was 
estimated that 36% of the population lived below the national poverty line. In rural areas only 
11% of the adults were in paid employment and the average monthly household expenditure 
was $75, of which 6.6% was on medical care (NIS 1999). Further details of Cambodia's socio- 
economic status are provided in Annex 2. 
1.3.2. The healthcare system 
Following the abolition of modern medicine and the murder of most health workers during the 
rule of the Khmer Rouge, the existing health system was developed by a Vietnamese-led 
administration and a handful of non-governmental organisations (NGOs). In 1989, as socialist 
countries withdrew support and political and economic liberalisation evolved, increasing 
international aid flowed into the country and with it, an attempt to reform the structure of the 
10 32% of the population report to having being born in a place different from their current residence. 
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health system (Lanjouw, Macrae et al. 1999; Hill 2000). In the last few years, decentralisation 
has taken place with financial and management responsibilities devolved to the provincial health 
departments and operational districts. However, significant problems with delivery and access 
remain, exacerbated by poor infrastructures and inadequate salaries. Only 4% of the health 
budget is spent on salaries and the average health worker earns US$15-20 per month (MoH 
2001). 
The government health budget (recurrent costs) for 2001 was US$ $37.4 million (10% of the 
total government budget), representing a per capita allocation of $3.1 per person". In addition, 
Cambodia receives $25-30 million per annum from donors (WHO, World Bank, DFID, USAID, 
EC) (Grose, Sorya et al. 2002) and has been allocated substantial funding from the GFATM - 
almost US$40 million for HIV/AIDS, $26 million for TB and $10 million for malaria. 
1.3.3. Malaria in Cambodia 
Malaria reportedly accounts for 7% of admissions and 3% of outpatient attendances, with rates 
varying significantly between provinces (Figure 1-4). Based on official statistics, in 2003, there 
were 71,258 confirmed cases of malaria of which 63,739 were due to P. falciparum, and 492 
deaths (MoH 2001). Annual incidence has generally been falling since 1997 although the rate in 
2003 represented an increase from the previous two years (Figure A4-1). As the vast majority 
of Cambodians seek treatment in the informal sector, these numbers significantly underestimate 
the true burden of disease. 
1.3.3.1. Epidemiology 
Cambodia is generally flat in the centre with forest-covered mountains in the north, west and 
east. Between 35% to 63 % of the land mass is covered by thick forest and jungle (Hong 2004), 
the main breeding sites for the main malaria vectors, Anopheles nsinimus and Anopheles dirus. 
The climate is generally warm and humid throughout the year with an annual mean temperature 
of around 25°C, rising to the low 30s just before the rainy season. This occurs between mid- 
May to mid-September with a drier season from November to March. The transmission of 
malaria is largely determined by the proximity of humans to forest and is highly seasonal, 
peaking at the beginning of the rainy season. 
About two million of the population are considered "at-risk" of malaria and fall roughly into 
three categories12. The first group comprises the ethnic minority families living in thickly 
forested villages in Mondulkiri and Rattanakiri (approximately 350,000). The second and 
largest group comprises approximately 1.7 million temporary forest migrants -a heterogenous 
group of mainly adults, mainly men, who travel into the forest for work. The group includes 
Although in 1998 only one third of the then US$1.53 per inhabitant per year was actually disbursed. 12 There appears to be some confusion with regards to numbers and percentage of at-risk population. 
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hunters, gatherers, woodcutters, gem miners and soldiers. The third risk group comprises 
returning refugees and new migrants from lowland areas, settling in forested ex-Khmer Rouge 
areas (approximately 150,000) (CNM 2001). 
1.3.3.2. Malaria control 
Malaria control continues to be a vertically controlled programme run by the National Centre of 
Entomology, Parasitology and Malaria control (or "the National Malaria Centre"). The 
programme is responsible for making and implementing antimalarial drug policy and for vector 
control through the provision of insecticide treated nets (ITNs) and insecticides, the training and 
supervision of peripheral health staff, public health education and operational research. The 
malaria control programme has a reputation in Cambodia as being relatively well organised and 
has been heavily dependent on external agencies for financial and technical support. Key 
players have included the WHO, the World Bank, the European Commission - Cambodia 
Malaria Control Project (EC-CMCP), the UK Department for International Development and 
Medecins sans Frontieres (MSF). The malaria control programme successfully applied for 
US$10 million worth of funding from the GFATM for the provision of ACTs through village 
malaria workers, the expansion of the social marketing of ACTs and increasing the coverage of 
ITNs. 
Like elsewhere in the Mekong region, antimalarial drug resistance is one of the major problems 
for malaria control. In vivo studies have been carried out since 1983 and the antimalarial drug 
policy has been changed a number of times in response to increasing drug resistance, firstly to 
chloroquine, followed by SP and mefloquine. This is described in Table 1-2. Drug resistance 
has traditionally been worse on the Cambodia-Thai border and better in the east (Figure 1-5). 
This is due to a number of factors, the most important being the mobility of the population in 
the former where the at-risk population is mainly temporary forest migrants and new settlers13. 
This compares to the east, where the at-risk population is mainly isolated ethnic minorities. 
Because of the difference in level of drug resistance, a differential antimalarial drug policy was 
in place until 2000. 
In addition to antimalarial drug resistance, there are number of other interlinked challenges 
facing the control programme. Firstly the population affected by malaria is particularly difficult 
to access: not only are they in the remotest areas, but they are either highly mobile or from 
ethnic minorities who do not speak or understand Khmer. Secondly, because the formal 
healthcare infrastructure is weak, the majority (80-90%) of patients seek treatment in the 
unregulated informal sector (Bury 1999a; NIS 2001; Brown, Montavy et a). 2002). These 
" It is likely that another important contributory factor is the addition of chloroquine to salt in Pailin in 
the Southwest in the 1960s. 
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informal (or "private") sector providers range from village vendors, who sell everyday goods 
such as cigarettes and simple drugs, to trained health workers in larger towns. The latter are a 
heterogeneous group composed of individuals who received training in the refugee camps or 
from the Khmer Rouge; as well as pharmacists, nurses and doctors who are also officially 
employed in the formal (or "public") sector (WHO 1996). There is little government control of 
the informal sector, limiting the impact of any change in treatment policy. Fake antimalarial 
drugs are widely available, with potentially disastrous consequences to patients (Rozendaal 
2001). Finally, both in public health facilities and in the informal sector, rates of biological 
diagnosis are low leading to the widespread misuse of antimalarial drugs. 
1.3.3.3. Antimalarial drug policy 
In response to the growing problem of antimalarial drug resistance, Cambodia changed its 
antimalarial drug policy to artesunate and mefloquine in 2000, and in doing so was hailed as the 
first country to make the switch to an ACT (WHO 2002). The rapidity of this change, to what 
was seen as the ideal "evidence-based" choice, was facilitated by a number of factors including 
most importantly, strong advocacy and financial support from WHO. Although a differential 
policy depending on region was considered, a national policy was chosen because of logistic 
reasons, because artesunate was already widely available and because international donors were 
willing to bear the costs of such a strategy. This change was accompanied by a number of 
highly innovative strategies including: 
  The local blister-packaging of the combination into three age-group packages, to 
encourage provider and patient adherence and to aid product recognition and ensure 
consistent drug quality (See Annex 4 for details of age-weight groupings). 
  The social marketing of blister-packaged artesunate and mefloauine as "Malimarine®" in 
the private sector at a subsidised price 
 A publicity campaign to raise awareness about fake antimalarial drugs 
  The promotion of the use of the rapid diagnostic test, in both the public and private 
sector. 
In addition, there were a number of specific interventions aimed at increasing access to 
diagnosis and treatment, namely a malaria outreach programme in Anlong Veng district 
supported by MSF, and the training of village malaria workers (VMVs) in Rattanakiri and Ko 
Kong. 
However, the actual impact of the policy change and individual strategies was uncertain. 
Although there was a decrease in the number of reported cases in 2001 (Figure A4-1), there had 
already been a decreasing trend since 1997. However these numbers only reflect the use of 
public health facilities, and do not accurately reflect actual incidence rates. There were also 
39 
little data available even from the public health sector on whether patients were in fact receiving 
the first-line therapy and whether treatment had been preceded by biological diagnosis. There 
was therefore no indication of the success of the programme, either in terms of process 
indicators or outcome indicators. This was unfortunate as Cambodia was at the forefront of a 
global change in antimalarial drug policy and such information would have been useful for other 
countries that were earlier in the process of change. 
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Figure 1-4: Official incidence of malaria by geographical distribution (2001) 
Cambodia 
med maWda 11)ei 10001.2000 
Source: www. wpro. int/themes focuses 
Figure 1-5: Resistance to chloroquine, SP and mefloquine in Cambodia in 1991 
(See Annex 3 for description of the WHO criteria for in-vivo studies of antimalarial drug 
resistance) 
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1.4. Summary 
Antimalarial drug resistance is contributing to an enormous burden of disease in some of the 
world's poorest communities and yet there are tools available to help combat it. Foremost 
amongst these is the use of ACTs. However, these drugs are relatively expensive and there are 
complex decisions to be made regarding choice of drug, timing of switch, subsidies, targeting 
and access to treatment. The future costs and benefits are uncertain and not easy to predict. An 
economic analysis that incorporates the important biological and economic factors could be 
useful in elucidating these difficult policy choices. In addition documentation of the experience 
of a country such as Cambodia, which has implemented ACTs in difficult settings, may be 
helpful for other similar countries and for exploring the value of such an analysis in the "real 
world". 
1.5. Outline of thesis 
This thesis has nine further chapters. In Chapter 2a review of the literature is presented, 
focusing on the economic evaluation of antimalarial drugs and the modelling of antimalarial 
drug resistance. Chapter 3 describes the aims, objectives and conceptual framework of the 
study, and introduces the methodologies used in the thesis. The development of the bio- 
economic model, which forms the core of the study, is then presented in Chapter 4. The next 
three chapters describe the collection of data required for application of the model to realistic 
scenarios. This starts with Chapter 5, a systematic review of the literature of adherence to 
antimalarial drugs. In Chapter 6 and Chapter 7 the collection and analysis of empirical data in 
Cambodia are described, starting with the costing of some of the implementation strategies for 
ACT (Chapter 6) and followed by a presentation of the community based survey of antimalarial 
drug usage and treatment seeking behaviour (Chapter 7). In Chapter 8 the results are provided 
from running the bio-economic model for a low transmission setting with input parameters for a 
number of policy relevant scenarios. The chapter culminates in an application of the model to 
Cambodia using the results of the primary data collection. In chapter 9, the first of two 
discussion chapters, the strengths and limitations of the study are discussed followed by a 
summary of the results from the data collection and a detailed discussion of the results from the 
modelling. The final chapter discusses the implications for policy and future research arising 
from the findings of the study. 
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CHAPTER 2 
LITERATURE REVIEW 
In this chapter, a review of the relevant literature is presented. The first section focuses on 
economic analyses and starts with an overview of economic evaluations followed by a review of 
those focusing on antimalarial drugs and antimicrobial drug resistance. The second section 
focuses on the literature of the modelling of antimalarial drug resistance. An overview of the 
epidemiological models of malaria is first provided and is followed by a review of the key 
papers on the modelling of antimalarial drug resistance. 
The literature on economic evaluations of antimalarial drugs and on the modelling of 
antimalarial drug resistance was searched using PubMed® and the bibliographies of reviews 
and relevant papers. Terms used in the initial search included combinations of the terms: 
"malaria" or "antimalarial"; "economic or "cost"; "drug resistance" and "model". 
2.1 Economic evaluations 
2.1.1 Definition and type of evaluation 
Economic evaluation can be broadly defined as the comparative analyses of alternative courses 
of action in terms of both their cost and consequences. The types of costs and consequences 
relevant to the economic evaluation of health programmes are described by Drummond et al. 
and are shown in Table A-5.1 in the annex (Drummond, Stoddart et al. 1987). There are 
different types of analysis and some disagreement about the terminology, but the important 
difference between them lies in the way the outcomes are measured and this in turn is 
determined by the objective of the analysis, the perspective taken and the audience to whom it is 
directed. The most commonly used technique in health care is the cost-effectiveness analysis 
(CEA), where the outcome is measured in units of health, such as cases prevented or disability 
adjusted life years (DALYs) averted. 
The DALYs caused by a disease consist of the sum of years of life lost (YLL) and the "years of 
life lived with disability" and as a single measure the DALY attempts to capture both mortality 
and morbidity. The "years of life lived with disability" are calculated based on weights ranging 
from zero (for full health) to one (death) and are available from the Global Burden of Disease 
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study (Murray and Lopez 1996). The DALY can be used to compare interventions across the 
health sector and allows benefits in the future and benefits to people other than the patient 
(externalities) to be measured. Although there are methodological problems in its use (Anand 
and Hanson 1997; Arnesen and Nord 2000; Reidpath, Allotey et al. 2003), the DALY is 
increasingly accepted as a means of comparing the cost-effectiveness of interventions especially 
in developing countries (Adam, Lim et al. 2005; Baltussen, Floyd et al. 2005; Edejer, Aikins et 
at. 2005; Hogan, Baltussen et at. 2005; Morel, Lauer et al. 2005). 
There is no firm cut-off point to define whether an intervention is cost-effective or not, as this 
depends on the perspective of the analysis and resources available. As a guide to decision 
making, in 1996, a WHO Ad Hoc Committee recommended that for low-income countries with 
a gross domestic product (GDP) per capita of less than $765 (in 1996 dollars), interventions that 
cost $25 or less per DALY averted could be considered "highly attractive". Interventions 
costing $150 or less were considered "attractive" (WHO 1996a). More recently interventions 
costing less than three times the GDP per capita for each DALY averted have been defined as 
"good value for money" (WHO 2001b) or "cost-effective" (WHO 2002b), and those costing less 
than the GDP capita as "very cost-effective" (WHO 2002b). 
Outcomes can also be measured in monetary units in terms of total monetary benefits or cost 
savings. Such analyses are termed cost-benefit analyses (CBA). Although there are difficulties 
associated with attaching monetary values to health outcomes, CBAs do allow comparison 
between health and non-health related spending. Cost utility analyses (CUA), where the 
outcome is usually measured in quality-adjusted-life-years, and cost minimisation analyses, 
where the outcome is assumed to be the identical, are less common in the developing country 
literature. 
2.1.2 The theoretical basis 
There is no single theoretical framework underlying all economic evaluations. The original 
justification for cost-benefit analysis was provided by Paretian welfare economics. Welfare 
economics embodies certain value judgements, specifically that social welfare should comprise 
individuals' welfare and that individuals should be considered the best source of information for 
their own welfare. The Pareto principles are based on these foundations. The first principle is 
of "actual Pareto improvement" where a policy makes everyone better off and no one worse off. 
The second principle is of "potential Pareto improvement", where a policy creates winners and 
losers in welfare but the gainers have the potential to compensate the losers and overall there is 
a gain in social welfare. Because the compensation does not actually have to be paid, problems 
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with distributional equity can arise (Drummond, Stoddart et al. 1987). Cost-benefit analysis can 
be justified as the application of this principle. However, because of both practical and 
theoretical constraints - including difficulties in measuring peoples' health in monetary terms 
and the lack of a universally acceptable human welfare measure -a pragmatic approach using 
non-monetary outcomes, i. e. a cost-effectiveness analysis, is more often used. The theoretical 
basis for CEAs and CUAs tends to be more rooted in a 'decision-making' philosophy 
(Drummond, Stoddart et al. 1987). Because CEAs do not necessarily adhere to the Paretian 
principles, the technique has been criticised for not being able to handle questions of allocative 
efficiency (Donaldson, Currie et al. 2002). 
The approach used in undertaking an economic evaluation depends on the aim and theoretical 
basis of the analysis and the data available. Traditionally, approaches have been divided into 
predictive modelling approaches or evaluations performed alongside clinical trials, 
retrospectively or prospectively. However, this division is argued to be redundant as in reality 
most economic evaluations are a synthesis of both trial evidence and modelling with few 
evaluation drawing solely from one approach (Brennan and Akehurst 2000). 
Modelling plays an integral role in most economic evaluations but particularly when there is 
significant uncertainty and where events in the future are being predicted. Models are a way of 
representing the complexity of the real world in a more simple and comprehensible form to 
better understand the way a system works or to predict effects. Typically such models are 
mathematical representations of quantitative relationship between the variables and may be 
deterministic or stochastic. 
2.1.3 The role of models in economic evaluation 
Broadly the roles and applications of modelling in health economics can be identified through a 
number of overlapping perspectives. These applications and their associated problems are 
summarised below (Brennan and Akehurst 2000). 
Extending results from a single trial 
Often clinical trials are not designed to capture the appropriate policy relevant costs and 
outcomes. Therefore models are used to extrapolate outcome and to ýnnvert disease-specific 
outcome into general health outcome measures (e. g. quality-adjusted-life-years). Whilst this is 
a well-established means of bridging the gap between data from randomised control trials 
(RCTs) and policy needs, there is a danger of trying to compensate for inadequate data 
collection with extrapolation models (Sheldon 1996). 
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Combining multiple sources of evidence to answer policy questions 
As one study on its own is unlikely to have all the information needed to inform policy, results 
from other studies often need to be incorporated. This includes the linking of intermediate 
clinical endpoints from clinical trials to final outcomes from databases as well as the synthesis 
of head-to-head comparisons where relevant trials do not exist (Buxton, Drummond et al. 1997). 
The disadvantages of this approach include the possibility that the intermediate outcomes may 
not be valid proxy measures of the final outcomes and there are concerns that these `meta- 
analyses' suffer from clinical heteroRP^Pitand-bias (Sheldon 1996). 
Generalisingresults, from one specific context 
This can be broadly categorised into generalising from clinical trials to practical settings and 
generalising from one setting to another (Buxton, Drummond et al. 1997). 
Modelling to inform research strategy and design 
This is one of the key roles of modelling used by both government agencies and pharmaceutical 
companies. This can help to generate hypotheses that can be tested by trials and to decide on 
the key outcome variables to be measured. By quantifying the potential added value of the 
information, models can help inform research priorities and design issues. 
Modelling uncertainties in the knowledge base 
All economic evaluations have some degree of uncertainty that should be explored by 
modelling, usually in the form of a sensitivity analysis (Briggs 2000). 
Additional values of modelling 
In addition to its primary role, there are other benefits to modelling. As a communication tool, 
models are explicit and therefore provide a framework for consensus and a tool for 
dissemination once a policy is made. In addition they are valuable for conceptualising problems 
in order to identify key variables and to postulate the relationship between them. 
2.1.4 Types of models 
The modelling techniques traditionally used in economic evaluation have been decision-analytic 
models and Markov chain models. However for practical purposes, a combination of 
techniques and adaptations are often used. 
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2.1.4.1. Decision-analytic models 
These are based on the construction of a decision-tree, a graphical representation of probable 
pathways and consequences. The advantages are that they are simple to construct, they separate 
fact from value, they can include data from different sources and it is easy to identify what 
information is needed and where data are missing. The main disadvantages are that they can 
quickly become unwieldy conceptually and practically, that they use average values and that 
they are static. They are also said to be prone to errors of logic and structure (Sonnenberg, 
Roberts et al. 1994) and are therefore most appropriate for short time periods and for well- 
defined specific decisions. 
2.1.4.2. Markov chain models 
These attempt to overcome the static nature of decision-tree models by introducing feedback 
loops and the ability to change th pbabilities of ey; jAs Occurring ov r +ime. They are 
therefore useful when there is a relatively long time frame, when the time-dependant nature of 
the events needs to be considered (Sonnenberg and Beck 1993; Briggs and Sculpher 1998). The 
main disadvantage is that they require a strict assumption of zer memory so that the probability 
of mov0ing_frorry , 
ll t4tej, (i, Xher_is. indep_etnt of how that health state was reached 
or how long it was in existence for. This is a potential disadvantage of using this approach for 
the modelling of antimicrobial resistance (Smith, Coast et al. 2000a). 
2.1.4.3. Monte Carlo (Stochastic) Simulation 
Monte Carlo simulations have increasingly been used for conducting sen 'tivi analyses 
(Goodman, Coleman et al. 2001). This involves programming a computer to run a model 
several hundred or thousand times in which parameters ma be input at random from a pre- 
specified probability distribution. The underlying model is usually bas on a decision-trees or 
Markov chains. This results in an average predicted value with confidence intervals and allows 
a more robust prediction of likely outcomes. 
2.1.4.4 Other modelling approaches based on decision trees and Markov chains 
Both decision-tree models and Markov chain models are based on populations and therefore do 
not allow heterogeneity between individuals to affect model outcomes. In addition Markov 
chains make the assumption of "zero memory". With the advent of advanced computational 
ability, it is now possible to programme computers to track individuals through different health 
states, assigning them various attributes and recording their individual histories. The advantage 
of such models is that they allow complex and dynamic systems to be modelled, however the 
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resulting complexity can make them opaque and they require a significant input of time and 
resources. 
2.1.4.5. Mathematical models 
Although mathematics is at the core of all modelling, mathematical modelling as applied to 
solve epidemiological problems, macroeconomic and some microeconomic questions, implies 
the use of differential equations. These equations are programmed into a computer and then 
solved for a given input of data. The advantage of mathematical modelling is its great 
flexibility and the ability to handle complex interrelationships. The disadvantage is that the 
models can be highly complicated and therefore difficult to interpret and use. Recent 
macroeconomic models have demonstrated the wider economic implications of malaria (Gallup 
and Sachs 2001) and to more fully capture the economic benefits of averting infectious disease 
in children through immunisations (Bloom, Canning et al. 2005). With reference to their place 
in the modelling of resistance, Smith et al. comment that: 
"It is possible that the mathematical approach may be adapted or built upon in 
developing a cost model for the economic impact of resistance in terms of emergence 
and spread within populations. An alternative is for mathematical models of 
epidemiology of emergence and spread of resistance to be used to generate data to input 
into one of the other forms of model which may be applied to the economics of 
resistance. " (Smith, Coast et al. 2000a) 
2.1.5 General problems with economic models 
As well as d' vanta es mentioned with specific methodologies, there are problems inherent to 
any modelling approach. These range from the initial selection of data, which may be 
inappropriate or biased, through concerns with extrapolation and generalising, to overall doubts 
about the lack of transparency and vali itv of the app=h. Some of this concern arises from a 
fundamental discomfort with attempts to quantify human health. However, as argued by 
Williams, in the absence of a perfect measure, there is still a desire to improve peoples' health 
and therefore it is still necessary to measure and aggregate health. He identifies this process, 
clarity and explicitness as a means to allaying some of the criticisms (Williams 1995). 
2.1.6 Validation of economic models 
Ideally models should be validated either by cross validation against the results of other models 
or by comparing predicted results with real outcomes (Buxton, Drummond et al. 1997; Brennan 
and Akehurst 2000). The model should match the result of the source data to ensure internal 
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validity and predictions should agree with non-source data. Other means of increasing the 
validity of economic evaluations and the models used in them include making them transparent 
and explicitly exploring uncertainty. Validity is assisted if there is expert concurrence that the 
right factors have been chosen and that the relationships intuitively make sense. Finally they 
should be presented in a way that is as simple as possible but not over-simplified. 
2.2 Economics and malaria 
2.2.1 The economic burden of disease 
The human cost of malaria is high. In a recent study on the cause of 0.6 million annual global 
deaths of children under the age of five, malaria ranked 4t' after neonatal causes, pneumonia and 
diarrhoea, causing 8% of deaths overall (Bryce, Boschi-Pinto et al. 2005). In endemic African 
countries, malaria accounts for 25-35% of all outpatient visits, 20-45% of hospital admissions 
and 15-35% of hospital deaths (WHO 2005b). Malaria was estimated to be the 8`h largest 
contributor to DALYs lost worldwide and 2nd in Africa (WHO 2002b). In addition to the direct 
costs due to malaria, there are also the indirect costs due to the loss of productivity and 
schooling. Beyond this, the presence of malaria in societies has had a fundamental influence on 
their economic development that can only be appreciated from a macroeconomics perspective 
(Gallup and Sachs 2001; Sachs and Malaney 2002). 
In recognition of the magnitude of the burden, many studies have attempted to quantify it in 
economic terms. This body of literature has recently been the subject of a number of reviews 
(Chima, Goodman et al. 2003; Malaney 2003; Arrow, Panosian et al. 2004) and is summarised 
here in brief. In this section all costs have been converted to US$2002 to aid comparison. 
2.2.1.1. Macroeconomic studies 
Malaria and poverty are inextricably linked through multiple relationships. Where the burden of 
disease is the highest, economic development is lowest. In order to quantify this relationship, 
Sachs et al. recently analysed cross-country datasets of malaria and economic indices. Malaria 
burden was estimated using a "malaria index" derived from the fractional land mass with 
endemic malaria, the population estimates and the risk of P. falciparur malaria. They 
estimated that the average-per-capita gross domestic product (GDP) of malaria-endemic 
countries in 1995 was about one-fifth as much as the average across the rest of the non- 
malarious world. Between 1965 and 1990, annual economic growth in malaria endemic 
countries averaged 1.3% less than countries without malaria in terms of per-capita GDP, 
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controlling for other standard growth determinants. A 10% reduction in malaria was associated 
with a 0.3% higher growth rate. The association therefore is clearly significant and the authors 
detail a number of mechanisms through which t is in may operate These include effects on 
fertility, population growth, savings, investment, worker productivity, absenteeism, missed 
schooling, premature mortality and medical costs (Gallup and Sachs 2001; Sachs and Malaney 
2002). A similar study was conducted by McCarthy to explore the impact of malaria on average 
per capita growth rate between 1983 and 1997 and using malaria incidence as the indicator of 
malaria burden. A significant negative association between malaria and economic growth was 
also found in this study although the impact was smaller than in. the Gallup and Sachs study, 
averaging a 0.55% lower growth rate due to malaria. in sub-Saharir (McCarthy, Wolf et 
al. 2000). 
2.2.1.2. Microeconomic studies 
Most microeconomic studies that attempt to capture the cost of malaria use a "human capital" 
approach in which the costs borne by providers and privately by households are aggregated. The 
direct cost of treating or preventing malaria includes money spent on drugs, diagnosis, transport, 
consultation and bed nets. The indirect costs represent the loss of income due to lost days of 
productivity and are discussed later 14. 
Direct costs to households of malaria-related treatment include out-of-pocket expenditure for 
consultation fees, drugs, transport and the cost of subsistence at distant health facilities. 
Estimates vary significantly between settings depending on epidemiological and socio- 
economic factors, illness-related beliefs and methodology. Estimates of monthly per capita 
expenditure on malaria treatment in Africa range from $0.33 and $4.19. This is equivalent to 
$2.03 and $28.08 per householdlChima, Goodman et al. 2003). The available evidence 
suggests that spending on malaria treatment i highly regressive For example, in Malawi, it 
was estimated that the direct cost of malaria treatment amounted to 28% of household income in 
very poor households and 2% amongst others (Ettling, McFarland et a). 1994). Direct costs of 
prevention include the cost of bed nets and different types of mosquito repe]]ents. Estimates of 
monthly expenditure range between $0.05 and $2,27 per capita, equivalent to between $0.26 
and $16 per household (Chima, Goodman et a). 2003). In their review, the authors note that 
most estimates have been based on household studies that report expenditure within the 
previous month and therefore do not reflect the variation in spending through the y ar. 
", 
--- r, -ý -, 
14 The human capital theory regards investment in human health as akin to investment in physical assets 
with the benefits measured in increased output in the economy. 
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There are few data on the direct costs to the government of malaria prevention and treatment. 
This is in part because costs are borne both by vertical malaria control programmes, such as the 
cost of provision and distribution of bed nets, and also by the general health service who fund 
the outpatient and inpatient treatment of malaria. These treatment costs should ideally be based 
on estimates of the number of patients seeking care for suspected malaria and the unit costs of 
treatment. Both the number of patients and the unit costs vary significantly between studies. 
The number of patients mainly depends on transmission intensity and the unit cost on the health 
care setting, age of patient, severity of disease and methodology. Estimates for the cost of 
outpatient consultations vary from $0.44 (Jackson, Sleigh et al. 2002) to over $12 (Goodman, 
Coleman et al. 2000). Estimates of the cost of an inpatient admission vary from $4.60 to $277.5 
per admission (Goodman, Coleman et at. 2000), with the average length of stay being around 
four to five days (Ettling, Thimasarn et al. 1991; Goodman, Coleman et al. 2000). 
Estimates of the indirect cost of malaria based on the human capital approach attempt to value 
the loss in economic output as a result of ill health. Most studies are based on the wage-rate 
method, which multiplies estimates of the time lost by sick individuals and their carers, by some 
monetary value for that lost time, to represent lost productivity. However, there is considerable 
variation in estimating both of these elements leading to an enormous variation in actual 
estimates (Attanayake, Fox-Rushby et al. 2000). Average estimates for number of days of lost 
productivity for an adult range from one to five days but in some studies go up much higher to 
as much as 18 days (Jackson, Sleigh et al. 2002; Chima, Goodman et al. 2003). 
Some studies include additional morbidity costs and most studies do not include the cost of 
mortality in terms of lifetime income foregone. There are also significant differences in the 
definitions of the economically active workforce; the value of the marginal product of labour; 
the value given to carers' time; whether or not lower levels of activity are allowed for; and 
seasonal variation in productivity. In addition, there are difficulties in capturing the complexity 
of the effect of illness in one individual on other members of the household and community 
(Sauerborn, Adams et al. 1996). In their review of studies in Africa, Chima et al. found that 
estimates varied for indirect costs ranged from $0.73 per case in children under 10 years in 
Malawi, to $24.8 for an adult episode in Ethiopia (Chima, Goodman et al. 2003). 
The total economic cost of malaria, estimated by adding together the direct and indirect costs, 
has been estimated in a number of studies. At a household level, the total annual cost was 
estimated to be equivalent to 32% of household income in very low income households in 
Malawi (Ettling, McFarland et al. 1994). From the perspective of both the household and the 
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government, the mean total per capita cost per malaria episode was estimated at US$4.18 in 
Rwanda and US$1.67 in Burkina Faso (including indirect mortality costs). In Rwanda, direct 
costs made up 22%, indirect morbidity costs 20% and indirect mortality costs 58%. In Burkina 
Faso, direct costs accounted for 23%, indirect morbidity costs 9% and mortality costs 69% 
(Ettling and Shepard 1991; Sauerborn, Shepard et al. 1991). 
Shepherd et at. attempted to bring together data from these two studies and from studies in Chad 
and Congo, in order to estimate the overall cost of malaria morbidity and mortality in Africa 
(Shepard, Ettling et al. 1991). They estimated that in 1987 the total cost of malaria was $10.63 
per capita - $1.98 in direct costs and $8.65 in indirect costs (2002 prices). This led to a total 
cost of over $1 billion for sub-Saharan Africa or 0.6% of GDP. They predicted that due to 
projected increases in population, malaria incidence and the cost of antimalarials, this would 
rise to 1% of GDP by 1996. 
Another approach to assessing the burden of malaria is to assess how much individuals are 
willing to pay to avoid malaria. The "willingness to pay" or "contingent valuation" approach 
was originally used to estimate the value of goods and services to consumers (Donaldson 1990). 
There are a number of studies of "willingness to pay" in the context of malaria, mostly limited 
to patient's willingness to pay for insecticide treated nets (Onwujekwe, Chima et al. 2001; 
Sauerborn, Gbangou et al. 2005) with one published study on malaria vaccines (Sauerborn, 
Gbangou et al. 2005). 
Finally household datasets can be used to explore the impact of malaria on households through 
econometric methods. For example Laxminarayan conducted an empirical study in Vietnam, in 
which household consumption data was compared to malaria incidence data. He found that a 
60% reduction in malaria cases was associated with a 1.8% increase in household consumption. 
When this was extrapolated up to the national level, he estimated that this translated into an 
aggregate benefit of US$183 million per year (Laxminarayan 2004b). 
2.2.2 Economic evaluations of antimalarial treatment 
In framing the thesis within the context of these analyses, it is useful to start with the framework 
provided by Phillips et al (Phillips, Mills et al. 1993) This specifies the application of cost- 
effectiveness analysis in malaria control depending on objectives and choices (See Table A5-2). 
Within this framework, the study is mainly concerned with objectives III (The choice of first- 
line treatment) and IV (The choice of implementation strategy). 
53 
An extensive review of the literature on the economic analysis of malaria control, by Goodman 
et al. in 2000, identified only one CEA and one CBA on the case management of uncomplicated 
malaria. Since then, a number of other studies have been published. In most studies, 
antimalarial drug resistance plays a part by influencing the effectiveness of one of the drug 
choices. These studies have either been based on facility-based data, predictive modelling or a 
mixture of both. 
Sudre et al. used a probability-based decision-tree analysis and mortality estimates based on a 
Delphi survey to compare the cost-effectiveness of chloroquine, amodiaquine and SP for the 
treatment of children in sub-Saharan Africa, at different levels of chloroquine resistance (Sudre, 
Breman et al. 1992). Only the cost of the drugs was considered, with the SP costing 1.4 and 1.7 
fold more than chloroquine1s and outcomes were measured in cost per death averted. Adherence 
was shown to be a key determinant of the cost-effectiveness. Assuming 80% adherence to 
chloroquine and amodiaquine, and 95% to SP, they found that SP was more cost-effective than 
chloroquine in terms of cost per death averted when the level of ßIII resistance to chloroquine 
was over 14%. At this level of adherence, 34% of deaths were associated with poor adherence. 
By increasing adherence to chloroquine to 100%, the threshold at which SP was mnrP r. nct 
effective than c oroquine was increased to 330%. If the value of a death prevented was assumed 
to be less than US$2.38 (in 1992 US$), then SP was more cost-effective than chloroquine even 
in the absence of drug resistance. 
Schapira et al. also used a modelling approach to predict the optimal time of switching drugs 
through a series of four increasingly costly first-line drugs (chloroquine - $0.03, SP -$0.05, 
mefloquine -$0.60 and then halofantrine - $1.75) in a 27-year period (Schapira, Beales et a]. 
1993). The proportion of treatment failures was assumed to grow exponentially at 11% per 
annum for each drug from the time of introduction. With deaths valued at US$800 (in 1993), the 
minimum economic costs were achieved when chloroquine was used for five years 
(corresponding to a resistance level 42% , SP and mefloquine 
for 10 years, then halofantrine 
for two years. 
In a review on making antimalarial drug policy in the presence of drug resistance, Phillips and 
Phillips-Howard illuminated the important factors that need to be considered in the process. 
These include the relative costs of first-line drugs, the costs and accuracy of diagnosis, and the 
cost of the drugs relative to the "cost of failure" (Phillips and Phillips-Howard 1996). 
15 For 100,000 episodes the costs were assumed to be US$1,812 for chloroquine, US$2,622 for SP and 
US$3,044 for amodiaquine (in 1992). 
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The last issue - the importance of the cost of treatment failure relative to the incremental cost of 
drugs - was illustrated in a post-hoc hospital based study in India and a CEA from South Africa. 
In the hospital-based study, Gogtay et a]. compared the total expenditure (direct and indirect 
costs) of patients who had received either chloroquine or mefloquine as first-line treatment 
during a clinical trial (Gogtay, Kadam et al. 2003). The cost of mefloquine per patient was 12- 
fold higher than chloroquine (120 versus 10 rupees), however only 15 out of 76 patients treated 
with chloroquine were completely cured compared to all 55 patients treated with mefloquine. 
As a result, it was found that the total expenditure on patients who fail chloroquine would 
exceed the excess expenditure on mefloquine when the RII and RIII resistance to chloroquine 
exceeded 9%. 
Wilkins et al. analysed the cost-effectiveness of SP compared to chloroquine as first-line 
treatment for P. falciparum malaria in Mpumulanga, South Africa, from the perspective of the 
public health care provider (Wilkins, Folb et al. 2002). A "resistance variable" (R) described 
the proportion of patients who returned for treatment following treatment failure with the first- 
line drug. This was derived from a "probability of drug resistance" based on the proportion of 
RI, RII and RIII resistance from in vivo studies and the likelihood that patients would return for 
treatment. This probability of drug resistance to chloroquine was assumed to be 48%, and to SP 
5.5%, giving R values of 0.335 and 0.039 respectively. Based on local cost data, the direct 
provider costs of first-line treatment and subsequent recrudescent and severe infections were 
used to compare the two drug alternatives. SP was found to have an average cost-effectiveness 
ratio of 4.83 compared to chloroquine, despite being almost 20 fold more costly (US$4.02 
versus $0.22 in 1997). 
Agnamey et al. in Senegal explored the importance of diagnosis in determining the cost- 
effectiveness of different strategies including the use of an ACT (Agnamey, Brasseur et al. 
2005). The direct costs of malaria diagnosis and treatment were compared between a policy of 
presumptive treatment with oral chloroquine or intramuscular quinine and a switch to 
artesunate-amodiaquine (AS-AQ) based on biological confirmation. The average slide 
positivity rate was 34-44% and the cost of diagnosis by microscopy was US$0.3 and US$ 1.0 by 
rapid diagnostic test (RDT). The assumed failure rates were 50% for chloroquine and 5% for 
both quinine and AS-AQ. They found that the single most important determinant of cost saving 
was the switch from clinical to parasitological diagnosis and that even with RDT diagnosis, AS- 
reduced overall costs by 22% compared to use of chloroquine presumptively. AQ 
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With the increasing number of countries starting to switch to an ACT, there are a growing 
number of economic evaluations estimating the cost of switching to ACTs and their cost- 
effectiveness following implementation. 
Snow et al. estimated the total drug cost of providing ACTs for malaria case management in 
Africa, based on national surveys and population projections. Assuming the current practice in 
which a large number of non-malarial fevers are treated empirically as malaria, they calculated 
that the annual cost of ACTs would be between U$1.6 billion and 3.4 billion (Snow, Eckert et 
al. 2003). 
Estimates of the "willingness to pay" for ACTs was assessed, using a bidding-game technique 
in a recent study in Tanzania. Mothers whose children had been recruited into a clinical trial of 
different ACTs were interviewed about their willingness to pay for the drugs, two weeks after 
treatment. The authors found that mothers were willing to pay significantly more for the more 
effective ACTs than for the ineffective amodiaquine. This was between $0.65 - 0.75 for 
artemether-lumefantrine or artesunate-SP compared to US$0.47 for amodiaquine alone. 
Interestingly, there was no association between willingness to pay and socio-economic status 
(Wiseman, Onwujekwe et al. 2005). 
Muheki et al. undertook an economic evaluation of the change of first-line treatment in 
KwaZulu-Natal (KZN) in South Africa from SP to artemether-lumefantrine (AL) (Muheki, 
McIntyre et al. 2004). It showed that treatment with AL at US$3.24 per adult dose was not only 
more cost-effective than SP monotherapy at US$1.65, but also resulted in substantial cost 
savings. They estimated that the average cost per life saved with AL was US$18 compared to 
$158 with SP. Cost-savings for the sub-district (population not stated) were estimated to total 
US$201,065 ($115,801 from outpatients and $85,254 from inpatients). The evaluation was 
performed from the perspective of the government provider, which in South Africa reflects the 
reality of a well performing public health sector from which most patients receive treatment. 
In the studies presented thus far, the level of drug resistance has either been fixed or assumed to 
grow at a fixed rate independent of the actual drug. Therefore the actual effects of different 
drugs on the development of drug resistance itself have not been explored. In addition, the 
effects of drug resistance have been measured in terms of costs to the individual patient and 
provider, but not as a negative "externality". In economic terms, externalities are the effects felt 
on the overall welfare of a community, rather than the individual consumer (or patient) and their 
supplier (or provider) (Coast, Smith et al. 1998). The prevention of the development of drug 
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resistance and reduction of disease transmission are both positive externalities. As both are 
important in the rationale for switching to ACTs in the treatment of malaria, it is essential that 
they are incorporated into any long-term economic evaluations of ACTs. 
Goodman et at. explored the effect of drug choice on the dynamics of resistance in a model 
examining the optimal time to switch first-line drug from chloroquine to SP, within a 10-year 
time frame (Goodman, Coleman et al. 2001). Drug resistance to SP was assumed to grow twice 
as fast as resistance to chloroquine, which was assumed to grow exponentially between 7-15% 
per year. The approach placed a decision-tree based model into a dynamic framework with 
Monte-Carlo simulations to explore uncertainty. Outcomes were expressed as disability adjusted 
life years (DALYs) averted. The cost of SP was assumed to be only slightly higher than 
chloroquine and, as in the model by Sudre et at., it was assumed that adherence and therefore 
the cure rate was higher with SP. Therefore an immediate switch to SP from chloroquine was 
more cost-effective than continuing with chloroquine, if drug resistance was not considered. 
However, if the development of drug resistance was incorporated, then it was more cost- 
effective to use chloroquine for some years and then to switch to SP. The actual timing of 
switch was dependant primarily on the relative growth rates of resistance, the coverage rates, the 
time frame and the discount rate used. If 
_the 
starting level of resistance to chloroquine was 
20%, then the optimal time of switch was at four yearsLusiný a 10- ear time frame. It was 
noted that there is a trade-off between the cost-effectiveness in the long-term and higher rates of 
mortality in the short and medium term. 
In a related report, the authors extended the analysis to compare the cost-effectiveness of the 
ACT of artesunate and SP with the continued use of SP on its own, varying the growth rate of 
drug resistance to SP in both scenarios. They found that in a high transmission setting, if using 
the ACT reduced the growth rate of resistance to SP by greater than 58% compared to the 
continued use on its own, then the cost-effectiveness would be under $25 per DALY. In low 
transmission areas, the intervention was less cost-effective, with a reduction in the growth in 
resistance to SP of at least 47% being required, to be reasonably certain of a cost-effectiveness 
ratio less than $150 per DALY. In their discussion they note the importance of the coverage 
and adherence rates in affecting results (Goodman, Coleman et al. 2000). In a later paper, the 
model is used to undertake a threshold analysis of ACTs versus monotherapy. It was found that 
ACTs were more than 95% likely to be cost-effective (at a threshold of US$150 per DALY 
averted) except when a short (five-year) time frame was used and when the initial resistance to 
the monotherapy was less than 20% (Coleman, Morel et al. 2004). 
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In a more recent study, Morel et al. used the WHO approach of a generalised framework to 
compare the relative cost-effectiveness of implementing combinations of interventions for 
prevention or treatment of malaria, taking into consideration interaction between different 
interventions. This included the cost-effectiveness of chloroquine, SP, non artemisinin-based 
combinations and ACTs as first-line treatment. Each drug was assigned different cure rates 
based on expected levels of adherence and different starting levels of drug resistance and linear 
growth rates. A 10-year time- frame was used and effectiveness was expressed in terms of a 
reduction in incidence, a reduction in case fatality rates and DALYs averted. They found that of 
all single interventions, first-line treatment with ACT at high (>80%) rates of coverage was the 
most cost-effective overall. They estimated that the incremental cost-effectiveness of ACT at 
85% coverage in Africa D region was $9, and $10 at 95% coverage, and $12 at 95% coverage in 
Africa E region16 (Morel, Lauer et al. 2005). 
Although these models did allow resistance to spread at different rates with different drugs or 
drug combinations, they did not incorporate a number of important aspects of the epidemiology 
including host immunity and the effect of drug resistance on transmission intensity. In an 
attempt to incorporate some of these factors, Laxminarayan (Laxminarayan 2004a), proposed a 
model based on a basic compartment model of malaria transmission described by Koella 
(Koella 1991). In this model, the spread of drug resistance was dictated by the ratio of 
reproductive numbers, based on the relative duration of resistant and susceptible infections and 
the proportion of infections treated. Patients not treated with the drug in question were assumed 
to receive another effective drug. The model was used to compare the cost of illness resulting 
from a switch from chloroquine monotherapy to a non-chloroquine containing ACT, with and 
without an intermediate step through SP monotherapy. The results suggested that the cost of 
illness generally decreased with increasing coveragewith-ACTs, whether or not there was an 
rintermediate 
switch to SP. It also suggested that an intermediate switch to SP was less costly in 
certain circumstances, in particular when only a short time horizon (five years) was considered 
and at the extremes of coverage rates. Though useful for its qualitative findings, the model did 
not incorporate some biological and economic factors important for the realistic predictive 
modelling of drug resistance and combination therapy. In particular immunity was treated 
unrealistically as a binary phenomenon and the transmission of malaria was not made explicit. 
In economic terms, neither clinical outcomes nor treatment failures were included. 
16 Afr D countries are mainly in West Africa and Afr E countries mainly in East and Southern Africa. 
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In the Institute of Medicine report "Saving Lives, Buying Time" (Arrow, Panosian et at. 2004), 
the findings of Laxminarayan's model were discussed. In addition, the model by Goodman et 
al. was adapted to compare no treatment versus treatment with an ACT, with and without rapid 
diagnostic test (RDT) diagnosis. The cost of an ACT is assumed to be US$1 for an adult and 
US$0.50 for a child and the cost of an RDT, US$0.50. The proportion of patients who actually 
have malaria was assumed to be 45%. Treatment with ACT was found to be very cost-effective 
for the treatment of children under the age of five years, whether treatment is presumptive or 
given only to those with a positive RDT result - US$8 ne D ATV averted,, and I6.2_ 
respectively. The cost per life saved was calculated to be US$209 or US$171 respectively. For 
the treatment of older children and adults, the costs per DALY averted were much less - ILSS- 
t and US$81.61 with an RDT. 
In order to explore other possible approaches to incorporating antimalarial drug resistance into 
an economic evaluation, the literature on economics of antimicrobial drug resistance was 
reviewed. 
2.2.3 Economics of antimicrobial resistance 
For over 20 years there has been rising global concern about anti-microbial resistance (AMR). 
Across the industrialised world, methicillin resistant staphylococcus aureus (MRSA) infections 
and other hospital acquired multi-drug resistant bacterial infections have reached the top of the 
political agenda (Batty 2005; White and Carvel 2005). Much less is known about the problem 
of antibiotic resistance in developing countries. However a recently published review of the 
literature shows that the most common pathogens are becoming increasing resistant to the most 
commonly available antibiotics (Okeke, Laxminarayan et al. 2005). Despite this, relatively little 
has yet been published on the impact of interventions against antimicrobial resistance (Smith, 
Coast et al. 2000; Wilton, Smith et al. 2002; Okeke, Klugman et al. 2005). Since the literature 
has recently been extensively reviewed, only the relevant findings will be summarised here. 
2.2.3.1. Interventions to control antimicrobial drug resistance 
From the earlier reviews, it was suggested from the available studies involving combination 
therapies (none of which were antimalarials), that the use of combination drugs did generally 
show an effect on AMR. However it was noted that the duration of this effect was unknown. 
The overall conclusions of the reviews were that most of the studies were from the developed 
world, were hospital-based and inadequately measured the impact of interventions in terms of 
costs. The authors identify four further areas for research: the need for more effectiveness data, 
the need for "macro" level studies rather than studies based on the "closed hospital 
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environment"; studies in developing countries; and studies that examine cost implications 
(Smith, Coast et al. 2000; Wilton, Smith et al. 2002). 
The more recent review focuses on the evidence from developing countries (Okeke, Klugman et 
al. 2005). In addition to the use of combination therapies, the authors suggest that antimicrobial 
cycling may have a place in antimicrobial strategy. The argument is largely based on evidence 
from the studies of antimalarials which have shown that cessation of the use of chloroquine in 
some well-controlled settings has resulted in a return of susceptibility in the parasite population 
(Kublin, Cortese et al. 2003). 
As found in the previous reviews, although there was evidence that strategies aimed at 
modifying prescribing practice through training and guidelines could be effective, there was 
little evidence on the outcome in terms of the level of drug resistance. Recognising that in 
developing countries, the public health care infrastructure is often weak and the role of informal 
providers important, the authors also explored a number of other interventions. These included 
improving patient adherence, improving the drug supply, eliminating the availability of 
substandard and counterfeit drugs and improving the surveillance of antimicrobial drug 
resistance. The authors concluded that although data are lacking, especially on the cost- 
effectiveness of different interventions, based on the available information there are a number of 
feasible interventions that should be prioritised. 
2.2.3.2. Methodological issues 
The possible reasons for the failure to consider drug resistance in economic evaluations 
comparing management strategies of infectious disease was first approached by Coast et al. 
(Coast, Smith et al. 1996). The authors explore why this is the case, despite the fact that drug 
resistance is an important social externality. They identify the implicit assumptions that are 
made in ignoring AMR" and conclude that the exclusion is due to practical difficulties in 
measurement rather than based on methodological justification. Noting the diffuse and 
uncertain nature of the problem, and the fact that decisions regarding the choice of antibiotic 
therapy are usually made at the level of individual doctors and patients, they queried whether 
the inclusion of drug resistance in economic evaluations could in fact lead to a policy response. 
The difficulties in dealing with antimicrobial resistance in economic evaluation, and the 
possible policy responses were explored further in a later paper (Coast, Smith et al. 1998). The 
17 These include assumptions that either the absolute costs of AMR are too small to be considered; or that 
the future costs are too small in current values, either due to "time preference", or due to uncertainty 
about future costs. 
60 
authors identify important aspects of AMR which make it particularly challenging - mainly the 
intergenerational and interregional nature of the problem as well as the inherent uncertainties 
involved. The latter include not only uncertainties surrounding the biology of drug resistance 
and effectiveness of controls, but also uncertainties regarding the future development of new 
drugs and more diverse issues such as international travel, co-morbidity and economic growth. 
Drawing from the area of environmental economics in which there is more experience with 
dealing with externalities, such as pollution, three policy options are proposed - regulation, 
permits and charges. Each have their pros and cons but all seek to limit the use of antimicrobials 
based on the assumption that this would lead to a reduction in resistance and an overall positive 
effect on society as a whole. 
In a more recent paper, the authors discuss four key difficulties with evaluations incorporating 
AMR: diffuse impacts, comparing current and future impacts, uncertainty and difficulties in 
measurement and valuation (Coast, Smith et al. 2002). They note these difficulties result in a 
bias towards undertaking studies of interventions with short time horizons, in closed 
environments and where the spread rather than the emergence of drug resistance is targeted. In 
view of these uncertainties, they explore some other possible approaches to dealing with the 
emergence of drug resistance. Drawing from the natural resources literature, the idea of 
considering antibiotics as a non-renewable resource is explored. Given the uncertain but 
catastrophic nature of the emergence of drug resistance, it is possible to regard policies 
undertaken now to reduce the risk of resistance, as a form of insurance. Their recommendations 
for future research include focusing on modelling, in particular combining economic and 
epidemiological aspects as a means of evaluating different policy responses to drug resistance. 
The importance of considering the macroeconomic impact of antimicrobial resistance was 
recently explored by Smith et al (Smith, Yago et al. 2005). Using a static, closed-economy, 
competitive equilibrium model, the impact of methicillin-resistant staphylococcus aureus 
(MRSA) on 10 sectors of the UK economy is described. The key finding is that the impact of 
MRSA acting through higher healthcare costs is proportionately smaller in terms of adverse 
macroeconomic impacts compared to the impact of MRSA acting through labour quantity and 
productivity. An MRSA level of 40% was estimated to increase the government transfers to 
households by between 0.7% and 2.8%, unemployment by between 4 and 18% and lead to the 
loss of GDP of 0.4% to 1.6% (equivalent to £3-11 billion in monetary terms). The authors note 
the complementary nature of the "macro" and "micro" approaches and conclude that the former 
is dependant on the latter for data on the long-term impact of resistance in large-scale settings. 
In particular they identify the need for epidemiological studies of the factors affecting drug 
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resistance and studies that elucidate the relationship between drug resistance and health 
outcomes. 
The literature on the modelling of antimalarial drug is therefore now explored. 
2.3 Mathematical models of malaria 
Models of drug resistance have traditionally come from either an epidemiological perspective, 
which analyses the infected hosts, or a population genetics perspective, which analyses 
individual genes or clones. 
2.3.1 Mathematical modelling of infectious disease epidemiology 
"Epidemiology is the study of the spread of disease in space and time, with the objective of 
tracing the factors that are responsible for, or contribute to their occurrence" (Diekmann and 
Heesterbeek 2000). The founding father of modern epidemic theory is probably Sir Ronald 
Ross who first attempted to provide a quantitative understanding of the dynamics of malaria 
transmission and later extended this to develop a general theory of disease transmission. Thus 
the history of the mathematical modelling of infectious disease is closely entwined with the 
modelling of malaria transmission. 
Before focusing on the modelling of malaria specifically, it is useful to review steps involved in 
infectious disease models. An exhaustive list was drawn up by Habbema et al after their 
experience of the development of large micro-simulation models for the control of infectious 
diseases, with the aim of providing a tool for use by policy makers and programme makers 
(Habbema, De Vlas et al. 1996). Although they emphasize that the whole process highly 
iterative and may take years, it is a useful framework in which to situate this current study 
(Figure 2-1). 
2.3.2 Modelling malaria transmission 
The cornerstone to any infectious disease model is the basic reproductive rate, R0, which is 
essentially the average number of successful offspring that a parasite is intrinsically capable of 
producing or the average number of secondary infectious cases resulting from each infectious 
case in a totally susceptible population. Clearly for infections to spread, the Ro must be greater 
than one. Generally, once an individual is infected, they are no longer susceptible, thereby 
decreasing the pool of susceptible hosts. Eventually an equilibrium may be reached when the 
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rate of susceptible hosts becoming infected is balanced by the appearance of newly susceptible 
hosts (for example through birth or the loss of immunity). In other words, each infection will on 
average produce exactly one secondary infection and the Ro =1. 
Figure 2-1: Steps in the development and use of models 
Identify the question 
Identify existing knowledge 
Choose the model structure 
Choose the model type I 
I Model quantification 
Model validation 
I Prediction and optimisation I 
I Decision-making j 
Model transfer 
Source: Habbema, de Was et al. 1996 
The early models by Ross were essentially compartment models in which changes in the density 
of susceptible and infected people, and susceptible and infected mosquitoes, were described by 
a number of differential equations (Ross 1911). In the early 1950s, Macdonald refined the 
models by focusing on the interpretation and estimation of parameters (Macdonald 1957). 
Subsequent models of malaria transmission have largely been based on the "Macdonald-Ross 
model" with refinements aimed at improving the realism of the model. Early adaptations 
focused on the effect of immunity. In the original model, the simplest assumption was made 
about immunity - that on recovery from first exposure an individual acquires sterile immunity 
for life, similar to the simple compartment models of viral infections. This resulted in estimates 
of the duration of infection being much too long, up to 30 years! 
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In Dietz's and related models, humans are divided into a relatively non-immune group with a 
slow recovery rate and more immune group with a fast recovery rate and lower chance of 
detection (Dietz, Molineaux et al. 1974). There is a fixed rate of transition from slow recovery 
to fast recovery class. Infection induces immunity by increasing the threshold level of 
parasitaemia necessary of acute episode. The parameter estimates were largely based on the 
results of the Garki project, an extensive study of malaria in Nigeria. Unsurprisingly there was 
therefore a good fit between the model and actual estimates (Molineaux, Storey et al. 1980). 
One of the main limitations with the model was that it did not address all aspects of immunity. 
Aron and May attempted to address the problem of immunity directly by introducing three 
classes of individuals. susceptibles, infecteds and immunes (Aron and May 1982). Immunity 
was assumed to last for some fixed period of time in the absence of re-exposure and infection 
was assumed to occur at a fixed rate per capita. 
However, the categorisation of the host into three categories still lacked realism and the 
constraints of using a compartment-based model were made clear. As remarked by Anderson 
and May: 
"These observations combine to suggest that an accurate mathematical description will 
need to abandon the compartmental or prevalence based structure of conventional 
microparasite models and move toward a more detailed description of the growth and 
decay of parasite abundance within individuals. " (Anderson and May, 1991, p 417) 
In addition, none of these models deal specifically with the competition between two parasite 
populations, in order to explore the phenomenon of the spread of drug resistance. This was 
undertaken recently by Koella and Antia. This model is based on the traditional compartment 
model of malaria transmission with modifications to incorporate competing drug sensitive and 
drug resistant parasite populations, which are assigned different basic reproductive rates (Figure 
2-2) (Koella and Antia 2003). The parasite with the higher basic reproductive number R0, 
drives the number of susceptible hosts below the threshold density necessary to maintain the 
parasite with the lower basic reproductive number. A "cost of resistance" (or "fitness cost") is 
incorporated, which describes the reduced reproductive capacity and therefore transmission 
intensity of resistant parasites compared to sensitive parasites in the absence of drug treatment. 
In this paper, an arbitrary value of five is used. 
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Figure 2-2: Schematic diagram of Koella's model of malaria transmission adapted to 
incorporated resistant and sensitive parasites 
Infectious- infected- 
sensitive 
susceptrule 
Infectious- 
resistent 
Source: Koella and Antia 2003 
By varying proportions of infections which are treated, they explore the effect of drug treatment 
and observe that there is a threshold level of drug use below which resistance cannot spread and 
above which resistance spreads and eventually becomes fixed. This threshold level is 
determined by the duration of infection in treated sensitive infections and by the "cost of 
resistance". They also find that by allowing super-infection of hosts with both types of 
parasites, both parasite populations can coexist even in the absence of treatment under some 
conditions. Finally, they observe that the migration of mosquitoes from an area of malaria 
treatment to an untreated area can swamp the local effects of selection. Whilst the model is 
informative in exploring the factors affecting the spread of resistant infections in relation to 
sensitive infections, it is based on little empirical data and does not incorporate a number of 
important factors including pharmacokinetics, pharmacodynamics, clinical outcomes and most 
importantly host immunity. In addition, transmission is assumed to occur at a fixed rate so that 
drug resistance and treatment has no feedback effect on transmission intensity. In order to use 
the model in economic analysis, Laxminarayan adapted an earlier model by Koella and in doing 
so addresses some of the limitations (Laxminarayan 2004a). However, as discussed in the 
previous section, as a basic model, it lacks realism and a more comprehensive model is required. 
2.3.3 Modelling antimalarial drug resistance 
The development of drug resistance requires the initial emergence of a de novo genetic mutation 
and its subsequent survival and spread. In order for drug resistance to emerge, first a genetic 
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event18 that confers antimalarial drug resistance has to spontaneously occur de novo in a single 
parasite, independently of any drug. Mutation frequencies vary depending on the drug, because 
individual drug targets in the parasite differ in their vulnerability to mutations. Based on in 
vitro studies of atovaquone (Rathod, McErlean et al. 1997) and the DHFR mutation in SP 
(Paget-McNicol and Saul 2001), estimates for the frequency at which mutations occur vary from 
one in 105 to 2.5 in 109. Estimates calculated from observations from in vivo studies and from 
retrospective calculations are significantly lower (White and Pongtavornpinyo 2003). 
In humans, infections become microscopically detectable at a density of about 50 parasites/µl of 
blood. This corresponds to a total of between 108 and 109 parasites in an adult. In this context, 
it can be seen that if the in vitro estimates are accurate, the occurrence of the mutations 
themselves are probably not that rare. It can also be appreciated that the higher the parasite 
density in an individual, the more likely it is that they will harbour a mutant parasite. Therefore 
it is a non-immune patient who remains untreated and develops a high parasitaemia that has the 
highest chance of being the source of a new mutant (White and Pongtavornpinyo 2003). 
From field evidence, it has now become apparent that the actual emergence of a resistant 
infection is an extremely rare event and that most of the antimalarial drug resistance in existence 
today is the results of spread of a few original mutants. It is also clear that these mutants arose 
in low transmission areas and spread to high transmission areas. It is likely that the rarity of 
emergence reflects the infrequency at which spontaneous mutation that do arise, actually 
manage to survive and multiply at the expense of non-mutants within the initial host, to reach 
sufficient density of gametocytes in order to infect an inoculating mosquito (Hastings 2004). 
Models have been extensively used to examine the factors affecting the spread of resistance 
through the parasite population. There has been particular interest in exploring the effect of 
transmission intensity, clonal multiplicity and drug pressure on the evolution of drug resistance. 
In a pioneering work by Curtis and Otoo, a deterministic compartmental model was used to 
study the spread of drug resistance in a population where two drugs were used in sequence or in 
combination (Curtis and Otoo 1986). Their findings suggested that the use of combinations was 
advantageous provided that the resistance genes were rare, that free recombination could occur 
between them and that only a small proportion (<20%) of the parasite population remained 
untreated. Subsequent models which have used different approaches have confirmed that using 
18 Although the genetic event can be an amplification or mutation, for simplicity it will be referred to as a 
mutation. 
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drugs in combination is likely to slow the development of drug resistance (Mackinnon and 
Hastings 1998; Hastings and D'Alessandro 2000). 
In the model by Curtis and Otoo it was also predicted that drug resistance is more likely to 
evolve in low transmission areas. Modelling by Dye and Williams suggests that recombination 
between different parasite clones in multiclonal infections is more likely to result in outbreeding 
resistance, especially when resistance is determined by two or more genes which are initially 
both rare and subject to low selection pressure (Dye and Williams 1997). Emergence should 
therefore be less likely to occur in high transmission areas where superinfection is more likely. 
However other mathematical models have predicted that resistance would be more likely to 
survive and spread in areas of high transmission (Mackinnon 1997; Mackinnon and Hastings 
1998). In Mackinnon's earlier model, branching theory was used to examine the probability of 
survival of one- and two- locus new mutants as a function of drug pressure, transmission rate 
and fitness cost. Crucially, it was unrealistically assumed that the frequency of treatment is 
independent of transmission rate. Therefore in high transmission settings not only did new 
resistant mutants have a greater chance of being transmitted, but they were as likely as in low 
transmitting settings to be subjected to selection by drugs. In the later model, the positive force 
of effective selection on the parasite population is modelled against the negative force of 
recombination. The results suggest that high transmission rates promote the spread of drug 
resistance (Mackinnon and Hastings 1998). 
Hastings explained these discrepancies by comparing the implicit assumptions made by the 
analysts about whether host immunity was clone specific or generalised (Hastings 1997). He 
argues that in models which analyse individual genes or clones, there is an implicit assumption 
of specific clonal immunity and that this results in predictions that the evolution of resistance 
tends to be faster in low xransmission areas where the chance of recombination is less. Models 
that analyse infected hosts are more likely to make the implicit assumption that immunity is 
generalised and may conclude that evolution is more rapid at low or high infection levels 
depending on the choice of parameters. 
Hasting and D'Alessandro explore this further in a model of the evolution of drug resistance in 
which they examine the effect of clonal multiplicity, intrahost dynamics and starting frequency 
(Hastings and D'Alessandro 2000). Making assumptions of complete independence and 
complete non-independence of transmission of malaria clones from the same host, they suggest 
that as clone multiplicity increases, so does the recombination rate between resistant and 
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susceptible forms, with a corresponding decrease in the probability that resistance will be 
retained. Therefore the increasing number of clones seen in higher transmission areas slows the 
spread of resistance. 
Talisuna et al. used empirical data to described the relationship between chloroquine resistance, 
as measured by the frequency of pfcrt-76 and pfmdr-86 mutants, and transmission intensity, as 
measured by prevalence, in six Ugandan populations (Talisuna, Erhart et al. 2005). They found 
that the frequency of the resistant pfcrt-76 mutant was universally high (86 to 100%). However 
the frequency of the resistant pfmdr-86 mutant appeared to be higher at the extremes of 
transmission for that study. They provide an eloquent explanation for this observation in terms 
of the interplay of factors affecting the spread of drug resistance. In brief, in a high 
transmission setting, immunity results in lower parasite mass and decreased drug pressure. It is 
also associated with increased parasite diversity. As a result of the latter, there is increased 
sexual recombination, which leads to a break down in mutant parasites but also leads to a 
boosting of intrahost dynamics which can contribute to the selection of mutant parasites. 
Gatton et al. focused on the relationship in the rate at which mutants arise, that var gene switch 
rate, the host antibody response and the timing of drug treatment (Gatton, Hogarth et al. 2001) 
and predicted that drug resistance is more likely to be initiated in a malaria-naive host compared 
to someone who is relatively immune. 
A number of models have focused on pharmacokinetics and the development of drug resistance. 
By incorporating an intermediate partially-resistant class of parasites, Hastings et al. were able 
to describe the importance of long elimination half-life in selecting for resistance. They 
emphasize the difficult policy dilemma which requires the balancing of minimizing the risk of 
the development of resistance by minimizing drug usage against the benefit of having drugs 
readily available (Hastings, Watkins et al. 2002). 
The disadvantage of these models based on population genetics is that the consequences of 
different epidemiological circumstances cannot be examined. Ideally therefore, both the 
epidemiological and genetic models should be merged. This has been attempted in a number of 
models (Cross and Singer 1991; Dye 1991). 
Cross and Singer describe a closed model in which the infected human and mosquito 
populations are each identified by a log(tolerable dose) distribution of the parasites they are 
harbouring (Cross and Singer 1991). The human population is stratified into three age groups 
68 
with different durations of untreated infections and different levels of parasite density and 
therefore infectivity. The human and mosquito populations are exposed to each other on a daily 
basis resulting in a transformation of the distribution depending on a number of factors 
including infectivity and biting rate. The log(tolerable dose) distribution of parasites in humans 
is affected by drug treatment which acts by clearing or reducing parasite density depending on 
drug resistance. The model was calibrated with field data of pyrimethamine resistance in 
Tanzania. The important qualitative conclusion was that to maximize the length of time that an 
anti-malarial is effective in a community under holoendemic conditions, the curative doses 
should be administered to 25% or less of the infected population - poising an interesting ethical 
dilemma. The main disadvantages of this model are that immunity in the human population 
remains static and the effect of combination therapy is not incorporated, aspects that the authors 
suggest as priorities for future research. 
2.4 Conclusions 
From the literature reviewed in this chapter, it is clear that there are significant gaps in both the 
economic literature and the literature of malaria modelling with regards to the study of the 
economic impact of drug resistance and of drug policy options. The review of the literature on 
economic evaluations provided a framework for the analysis and clarified the possible 
approaches in this study. With a couple of notable exceptions, most economic evaluations of 
antimalarial treatment have taken a traditional microeconomic approach in which drug 
resistance has either been ignored or has been incorporated as a fixed phenomenon. The 
literature on the economics of antimicrobial resistance has also had limited reference to the 
study of antimalarials in community settings, with most focused on the use of antibiotics in 
hospital settings in developed countries. Macroeconomic analyses of the economic impact of 
malaria and of antimicrobial drug resistance highlight the importance of taking a broader 
societal view. However the accuracy of these analyses are dependent on the quality of 
information produced from "micro" economic studies which in turn are dependent on biological 
models of disease transmission. 
Reviewing the literature on the modelling of malaria transmission and drug resistance revealed 
the limitations of existing models. Although different approaches address different factors 
affecting disease transmission and the evolution of drug resistance, none of them incorporate 
them all. Epidemiological models, based on Ross and Macdonald's original model of malaria 
transmission, have focused on the dynamics of transmission between the human and mosquito 
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population where the implications of host immunity on the density and dynamics of the parasite 
population have not been realistically incorporated. Population genetic models have focused on 
the factors affecting the evolution of resistance in the parasites population but have also either 
ignored host immunity or treated it unrealistically and have not included other important 
behavioural, clinical and drug-related factors. 
There is therefore a clear need for a new model of antimalarial drug resistance, one that can be 
easily placed in an economic framework and that is as biologically accurate as possible. In 
particular the model needs to track both the human and the parasite populations and to 
incorporate immunity, drug characteristics and human behavioural factors. The realism of such 
a model depends on an extensive amount of empirical data, obtained mainly from secondary 
sources in order to reflect a range of settings. The literature reviewed in the process of 
developing the model, and the data extracted, is covered mainly within Chapters 4 and 5 and in 
table format in Annex 6. 
70 
CHAPTER 3 
AIMS, OBJECTIVES AND METHODOLOGY 
This chapter summarises the aims and objectives of the thesis and outlines the methodologies 
used. The overall approach and the economic analytic framework is first described, followed by 
a brief description of the methods used to achieve the objectives. More detailed descriptions of 
the methods are provided in the separate chapters with additional information in the annexes. 
3.1. Aims and objectives 
Aims 
The overarching aim is to conduct an economic analysis of combination therapy for the 
treatment of malaria in order to contribute to the current debate on the role of combination 
therapy in malaria control policy. There are two main elements to this study: the development 
of a bio-economic model of transmission and antimalarial drug resistance, and the collection of 
model parameters. 
Objectives 
(1) To develop a comprehensive bio-economic model of antimalarial drug resistance and 
combination therapy. 
(2) To collect and synthesize secondary data for such a model. 
(3) To collect and analyse primary data on the implementation of artemisinin-based 
combination therapy (ACT) from Cambodia, for input into the model. 
(4) To use the model in a low transmission context to predict the cost-effectiveness of 
ACTs under different conditions. 
(5) To discuss the implications for antimalarial drug policy based on these findings. 
3.2. Overall approach and study framework 
As discussed in the previous chapters, it is clear that despite significant changes in global 
antimalarial drug policy, uncertainty still exists on the benefits of switching and when and how 
to switch from monotherapy to an ACT. 
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There are a number of ways of dealing with this uncertainty. There is the "natural experiment 
approach" in which ACTs are introduced in only a few controlled settings and the impact on 
transmission and drug resistance is closely observed. However, this is clearly not feasible as 
there is an urgent need to act now. 
An alternative approach, and the one proposed here, is to use what information there is available 
to produce a model to predict what will happen in the future, given certain assumptions. In the 
process, the assumptions are made explicit, the gaps in knowledge are revealed and, if 
necessary, primary data obtained. Models have increasingly been used to help explore policy 
options where risks and benefit outcomes will be incurred in the future and where there are 
inherent uncertainties. They are ideally suited to exploring both biological and economic 
influences on outcomes. Moreover, models can be used to produce the estimates of the cost- 
effectiveness of policy options, which are now accepted to be a vital input to decision making in 
the health sector. 
As explored in the literature review, static economic models of malaria, which do not capture 
the change in disease transmission or antimalarial drug resistance, ignore the externality benefits 
and importance of both the reduction in the number of cases and prolonging the useful life of 
antimalarial drugs. The development of sound economic analysis is dependent on the robustness 
of the underlying biological model of malaria that predicts these changes. Although there have 
been a number of mathematical models of malaria and antimalarial drug resistance, none have 
comprehensively incorporated all the relevant biological and economic factors. 
It is the aim of this thesis to develop such a model. Critical steps in this process have been, 
firstly, the elucidation of the individual steps involved, defining these as "parameters" and 
determining their relationship to each other within the model. Finally, primary and secondary 
data needed to be gathered, to support the actual value inputs in the model. It was felt that 
producing such a comprehensive database of values would also be useful to others who wish to 
develop alternative models. During this process, gaps in knowledge were made apparent and 
decisions were made on how they should be handled. In general, the resulting uncertainties 
were incorporated into the model with the aim of testing them with sensitivity analysis. 
However, there were gaps that were thought likely to have a significant impact on the model 
outcomes and where it was possible to obtain primary data from the field. One such gap that 
emerged early on in the process pertained to the actual pattern of drug usage once ACTs were 
deployed, in terms of coverage rates and adherence. As it was possible to collect the 
information from Cambodia, the first country to switch to an ACT, this became an important 
part of the thesis. 
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The intensity of malaria transmission in Cambodia is generally low and therefore this work 
mainly focuses on low transmission settings. The model was run to illustrate how it functions 
and to explore the spread of drug resistance and the effect of ACTs, using inputs for different 
scenarios in a low transmission setting. However the model can be applied high transmission 
settings and this is illustrated in Annex 10. 
Table 3-1 shows the relationship between objectives and methods and Figure 3-1 describes the 
study framework. 
3.3. Economic analysis - Conceptual framework 
The primary purpose of the thesis was to produce a model that could be used to perform an 
economic analysis and to generate outcomes of direct policy relevance. The development of the 
biological model was therefore underpinned by the economic framework in which it was 
situated. 
Several guidelines on the application of economic evaluation in the health field have been 
published (Drummond et al 1993; Drummond and Jefferson 1996; Tan-Torres Edejer 2003; 
Weinstein 1996). There is broad agreement on most of the important aspects of analysis, and in 
this thesis, they have been followed as far as possible. However, there are still some areas of 
controversy, for example in the handling of DALYs, and where these are relevant the 
alternatives and choices are discussed here. 
In presenting an economic analysis it is important to state, at the outset, a framework that 
includes the perspective taken, the intended audience, geographical boundary, time-frame, 
outcomes and alternatives. As the intention was to develop a model that could be used to 
answer different questions, some of the specifics are left to be defined when the model is 
applied to particular scenarios in the results chapter (Chapter 8). 
3.3.1. Goals and perspective 
The overall goal of antimalarial drug policy is assumed to be a reduction in morbidity and 
mortality. This includes a reduction in the morbidity and mortality occurring in the future as a 
result of the reduction in drug resistance. The audience for this analysis is chiefly policymakers 
and malaria programme managers. 
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The potential benefits can be categorised into three separate policy desirable outcomes: 1) 
effective patient cure, 2) preventing the emergence and spread of resistance, which benefits 
future generations (a positive externality), and 3) in low transmission areas, reducing 
transmission which reduces the incidence of malaria and benefits the public, both now and in 
the future (a positive externality). 
The analysis is undertaken from a societal perspective, including that of the patient, because in 
the treatment of malaria, most of the cost of illness has traditionally fallen on patients and their 
families rather than the government, because most treatments are not obtained in the public 
sector. However, it has now been generally accepted that if the more expensive ACTs are to be 
used, then they must be highly subsidised or made free, shifting the cost of illness from patients 
to governments and donors. 
To try to dissect out who benefits and when, and who pays, the outcomes for the economic 
model are expressed in terms of current and future malaria cases and therapeutic failures, and 
the associated costs and cost savings. Costs and benefits to current and future patients are 
therefore considered as well as the costs to the government implicitly including donors. These 
include all the treatment costs associated with both the initial malaria infection and subsequent 
treatment for recrudescent and severe infections. 
3.3.2. Time-frame and population 
The actual time-frame over which costs and effects are considered is a critical part of the 
analysis as much of the benefit is expected to be reaped in the future, in terms of fewer cases 
and reduced drug resistance. Therefore, the time-frame of the analysis is allowed to vary in 
order to explore questions such as the length of time a policy needs to run before it starts 
becoming cost-effective, and at which time point it is most cost-effective to switch from a 
cheaper failing drug to a more expensive combination therapy. 
The population included in the analysis are all people living in a single geographical region with 
uniform malaria transmission, healthcare delivery and treatment seeking behaviour. This can be 
a whole region, country or specific area within a country. Key characteristics of the population 
that are assumed to affect the outcome of any policy change are the level of transmission and 
the proportion of patients who are likely to be covered by any change in drug policy. These 
parameters therefore form an integral part of the biological and the combined bio-economic 
model. 
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3.3.3. Costs 
The costs included and measured must be relevant to the objectives of the study. In this case, 
the focus is the incremental health impact of switching to a combination therapy. Given the 
importance of high coverage, the analysis is done with and without additional interventions to 
increase coverage. In addition, the overall cost of treating malaria, inclusive of treatment 
failures, is important. Therefore, the types of costs presented in this thesis are, firstly, the net 
incremental cost of the first-line drug inclusive of any delivery costs and, secondly, the total 
cost of treating malaria. 
Incremental costs consist of the costs that would be incurred based on the new resources needed 
to deploy combination therapy. In this case, for the cost-effectiveness analysis the incremental 
costs comprise the cost of drugs and of any interventions to increase coverage. The other costs 
of treatment such as the cost of consultation and diagnosis c- t. includedas i+'c assumed h at 
these would be incurred irrespective of the choice of drug. The costs of the policy change 
process itself are also not included as it is assumed that these would be incurred independent of 
the drug choice. 
In order to capture the consequences of antimalarial resistance in monetary terms, the total costs 
(direct and indirect) of malaria illness, to providers and patients, are considered. In this case 
average recurrent and capital costs are used, as there is an expectation that in the long term, 
treatment resources saved by the health sector and patients can be relocated away from malaria 
treatment. Details are provided in the next chapter. 
3.3.4. Outcomes 
In order to reflect the priorities of the audience for whom this analysis is intended, a number of 
different outcomes are presented. For affected communities and those involved specifically in 
malaria control, the cost per case of severe malariaýLClýýth averted ic_mnc+ relP a For policy 
makers involved in making allocative funding decisions across the health sector and who have a 
longer term outlook, the cost per DALY averted is used. Finally, for policy makers at this level 
and above, the monetary implications of different alternatives are included. 
3.3.4.1. Number of clinical cases 
In a low transmission area, using any effective drug should reduce the malaria incidence 
because people who are treated for malaria do not continue to be parasitaemic and therefore do 
not transmit malaria. Using combinations that contain an artemisinin derivative has the potential 
to reduce transmission further, because of their specific effect on gametocytaemia. This 
reduction in the number of clinical cases in the future is therefore an externality benefit. In high 
transmission areas, effective treatment is not expected to reduce malaria incidence, as only a 
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small proportion of those who are parasitaemic take any treatment, as immunity is higher and 
many people are parasitaemic but not symptomatic. 
3.3.4.2. Number of treatment failures 
Where levels of resistance to the current drug are already high, switching to ACT's or any 
effective drug reduces the number of treatment failures. Thus, in the short term (<5 years), the 
number of failures simply reflects the efficacy of the drug. In the long term, the continued 
effectiveness of the drug reflects how efficiently the development of resistance has been delayed 
by using ACT's. Therefore, treatment failures averted in the future reflect the externality benefit 
of controlling drug resistance. 
3.3.4.3. The consequences of treatment failure 
In itself, "treatment failure" has limited usefulness as an outcome measure in terms of policy 
relevance. To make this a more tangible concept, there is a need to estimate the clinical and 
economic consequences of the treatment failures. In other words, in order to quantify the "cost 
of resistance" there is a need to estimate the consequences and costs of treatment failure in 
terms of repeated or more expensive second-line drugs and their administration (parenterally 
rather than orally), prolonged illness, hospitalization, severe disease, death and lost productivity. 
Estimates of the likelihood that a patient who fails treatment will go on to develop severe 
malaria, and the likelihood of death, are therefore required, as are the associated costs as 
discussed above. 
3.3.4.4. Total costs 
As discussed above, in order to compare the cost-benefit of different strategies in monetary 
terms, the total costs of malaria, including the costs of first-line treatment and the subsequent 
cost of treating recrudescent infections and severe malaria, need to be considered. In this 
analysis, both the direct costs of treatment and the total costs inclusive of indirect costs are 
shown. 
3.3.4.5. DALYs 
Effectiveness is also expressed in terms of DALYs based on the number and age of averted 
deaths and the disability weights and durations assigned to uncomplicated and severe infections. 
This is discussed in more detail in the next chapter. 
3.3.5. Comparators 
The selection of alternative scenarios is an important step in setting up the economic analysis. 
In traditional cost-effectiveness analyses where two different treatment choices are being 
compared, the choice of comparator is reasonably straightforward. However, in this case, the 
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aim was to develop a generic model, which can be used to explore different scenarios. In this 
case, the base-case comparator is the continued use of a monotherapy and the alternatives are 
the switch to a combination therapy under different conditions. 
3.4. The development of the bio-economic model 
The biological model attempts to incorporate all the factors considered relevant to the 
development of drug resistance. These factors include host immunity, vectorial factors, drug 
characteristics and human behaviour. As discussed Chapter 1, drug resistance essentially 
develops in at least two distinct phases: firstly the "de novel" emergence of a resistant infection 
and then the spread of this infection through the population. In this thesis, only the spread of 
antimalarial drug resistance is explored. Emergence of drug resistance is a stochastic process 
and there is much more uncertainty involved in predicting its occurrence. It therefore requires 
modelling separately, and whilst this is now being undertaken with the aim of eventually 
interlinking it with the "spread" presented here, it was beyond the scope of this thesis. 
Consequently, the full benefits of ACT are not incorporated in this current model. 
The biological model evolved from a simple binary probabilistic model to an iterative dynamic 
model in which the total number of people and the age structure of the population remains fixed 
but other key features such as number of infections, level of resistance and cure rate are allowed 
to vary according to the outputs of the previous iteration. A cartoon of the model is illustrated 
in Figure 3-2. 
Essentially, this is a deterministic age-stratified population-based model that keeps track of the 
number and type of infections in humans and of parasites. The type of infections are monitored 
in terms of whether or not they are sensitive or resistant to a given drug (Drug A). At the 
beginning of each model iteration, a certain proportion of humans in each age group are infected 
by malaria, depending on their level of immunity and the transmission intensity. The outcomes 
of these infections, in turn, depend on whether they are resistant, whether and what type of 
treatment is received and the level of human immunity. The outcomes at the end of each 
iteration are the number and type of human infections, the number and type of parasites, and the 
level of drug resistance. The number of parasites determines the number of gametocytes, which 
in turn determines the infectiousness of humans to mosquitoes and therefore the transmission 
intensity in the next iteration. Input parameters and the costs of drugs, diagnosis and other 
treatment costs are varied in order to explore different scenarios. 
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Figure 3-2: Schematic diagram of one iteration of the model 
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One of the key steps in the development of the model was the description of the chain of events 
leading from a person getting malaria to receiving treatment and the consequent outcomes in 
terms of cure/failure, transmission and the development of resistance. This was necessary in 
order to elucidate the parameters and define the relationships between them. This was an 
iterative process so that as the model was being developed, it would become apparent which 
data were necessary. Conversely, new data could be found which would inforrn the 
development of the model. This chain of events is simplified and shown in Table 3-2. For most 
of the parameters, data were gathered from published sources and put in a collated table format 
(Annex 6). Data on drug usage was thought to be particularly important and was systematically 
reviewed and is presented separately. Some gaps in the data became apparent early on, in 
particular information on the actual implementation of ACTs and the level of expected coverage 
and adherence. The primary collection of this data was therefore undertaken in Cambodia. 
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3.6. Primary data collection in Cambodia 
Cambodia was the first country to switch to ACTs, and in making the change, also utilised a 
number of innovative strategies to improve coverage and adherence. An ideal opportunity was 
therefore presented to collect primary data on the implementation of ACT, the results of which 
would be useful both for the purpose of this model and also as a documentation of the 
experience for the information of other countries considering a switch in policy. 
A costing study of the drugs, including the cost of pre-packaging and delivery interventions, and 
a cross-sectional household survey, were therefore undertaken. The latter took place in villages 
with and without interventions to improve access to diagnosis and treatment through village 
malaria workers or outreach clinics. Households were screened for individuals who had had an 
episode of malaria-like illness in the last three weeks. or ouse os of were me ue, an 
interview was undertaken and questionnaires completed. This consisted of a household 
component capturing information about socioeconomic status and an individual component. 
The latter documented detailed information on treatment seeking behaviour and drug taking 
behaviour for the recent febrile illness. In addition to the questionnaire, a drug board for 
identifying drugs was used and blood was taken for microscopy and rapid diagnostic testing 
(RDTs). 
3.7. Running the model 
When the model had reached a stage at which it was felt sufficiently robust to use, it was run 
with different input parameters in order to explore the spread of drug resistance and the impact 
of combination therapy, under different scenarios. 
For each scenario, the main biological model was run for 12 years, with the initial two years 
being the time taken for the model to reach a "steady state", giving a time-frame of 10 years for 
actual comparison between scenarios. Selected outputs were then placed in clinical outcome 
and costs "sub-models" in order to generate outcomes in terms of actual number of cases of 
severe malaria, deaths, DALYs and costs. 
Running the model therefore entailed three steps: 
1) For each scenario, assigning values for the biological model and running this for 12 
years. 
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2) Placing the outputs from the biological model into the clinical outcomes model in order 
to generate policy-relevant clinical outputs. 
3) Placing the outputs from the clinical outcomes model into an Excel®-based 
spreadsheet. For each scenario, this results in the generation of the predicted levels of 
resistance, number of cases, failures, severe malaria and deaths, and costs. The results 
of these scenarios are then compared in a final spreadsheet in which cumulative costs, 
effects and cost-effectiveness ratios are calculated. 
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CHAPTER 4 
DEVELOPMENT OF A BIO-ECONOMIC MODEL 
4.1 Introduction 
In this chapter the development of the model is discussed. Firstly, there is a description of the 
overall structure, explaining how the core biological model and the behavioural and cost sub- 
models are integrated. The second section is devoted to the development of the biological 
model starting with a brief outline of its evolution, followed by a description of the model 
structure with a detailed explanation of the underlying concepts and data used. The third 
section describes how behavioural and economic sub-models were developed and integrated 
with the biological model. The chapter ends with a summary of the assumptions made. Annex 
6 contains the parameter estimates. 
4.2 The overall structure of the bio-economic model 
Central to the overall bio-economic model is a dynamic biological model of malaria 
epidemiology, which describes the transmission of drug-resistant parasites through human hosts 
via the mosquito vector. It attempts to incorporate the vector, parasite, drug and human factors 
likely to affect malaria transmission and the spread of drug resistance. Linked to this core 
model are three sub-models based on simple decision trees that form the user-end of the model, 
which allow the integration of operational and behavioural factors and costs that enable 
economic analyses to be undertaken. The first sub-model - the behaviour sub-model - 
calculates the coverage rate and nahen adh rne rates to monotherapy -a jld. 
dwg_combi+iatiei 
therapy according to whether patients seek treatment in the formal or informal sector. Based on 
this combined adherence rate, a maximum failure rate for each drug is assigned according to 
drug type and whether or not the infection is "drug resistant". These maximum failure rates and 
the coverage rate are then used as inputs into the biological model. The second sub-model - the 
severe outcomes sub-model - calculates the annual number of severe malaria cases and deaths 
based on annual number of cases, treatment failures, and level of drug resistance output from 
the model. The final sub-model - the cost-effectiveness sub-model - introduces the cost of 
drugs, other illness costs and the costs of implementation strategies and uses the outputs from 
all three models to calculate the costs and cost-effectiveness of different scenarios. The 
relationship between these components is illustrated in Figure 4.1. 
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4.3 The core biological model 
4.3.1 An outline of the preceding models 
The biological model was developed in the following steps, going from an initial simple 
exploration of the effect of immunity on the emergence and spread of resistance, "Model I ", to 
a sophisticated model which attempts to incorporate all known factors affecting the 
development of antimalarial drug resistance in "Model 3". In models 1 and 2, many of the key 
concepts in the final model were developed. However, because these earlier models were 
developed separately from the economic analysis and were superseded by model 3, only the 
latter model is described in detail. A table summarising the progressive sophistication of the 
models is shown below (Table 4-1). 
Model I was a simple closed model, which explored how the spread of rate of resistance was 
affected by varying the relative reproductive advantage of resistant over sensitive infections and 
by varying the level of immunity in infected humans. Immunity was treated unrealistically, as a 
binary factor where hosts are either completely immune and therefore do not receive treatment, 
or they are completely non-immune in which case they do receive treatment. _ 
It was a static 
model, in which the output was the proportion of resistant infections out of a fixed total number 
of infections, and therefore effects on transmission and the actual number of infections could 
not be explored. In addition, the ability to explore the effect of different treatment options was 
limited. It was therefore not a suitable model upon which to base an expanded policy-relevant 
model. 
Model 2 was a population-based dynamic model exploring the emergence and spread of 
resistance where immunity was incorporated as a function of age and was allowed to affect 
parasite density as well as the proportion of symptomatic and therefore treated infections. 
Immunity was represented more realistically as a continuous function based on age-stratified 
rates of severe malte (Yeung, Pongtavornpinyo et al. 2004). The emergence of drug resistance 
was incorporated simplistically by assigning every infection a fixed, albeit very small, 
probability of being a new resistant mutant infection. As the model ran, the immunity of the 
`_ population was allowed to change 
in response to the change in transmission intensity. The 
output at the end of each annual iteration was the absolute number of infections, as well as the 
proportion of infections that were resistant. These values change from iteration to iteration 
according to the relative "reproductive rates" assigned to sensitive and resistant infections. 
These "reproductive rates" were simplified terms that encompassed a number of steps involved 
in human to mosquito to human transmission with vector factors being assumed to remain 
constant. In attempting to use the model to predict absolute numbers of infections year to year, 
it was found that this oversimplification of transmission proved problematic, especially in high 
transmission areas. In addition, because of the simplistic detenninistic handling of the 
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emergence of drug resistance, there was an unrealistic constantly accumulating proportion of 
drug resistance. 
In order to address some of the limitations of the second model, a third and final model was 
developed. In this model transmission is dealt with explicitly, with infectiousness based on the 
actual number and distribution of gametocytes through the human population and the 
incorporation of vector dynamics. In addition, durations of infection, which were ignored in the 
previous model, are incorporated and more facets of immunity are included and are described 
by separate immunity functions. In addition to the outputs in model 2, the numbers of cured and 
recrudescent infections, and the age groups in which they occur, are also produced. The 
emergence of drug resistance is separated from the spread in order to focus on the latter, as it 
was not possible to model both within the given time constraints and because it was felt that 
there were more data available to create a reliable model of the spread of resistance. 
The remainder of this thesis relates only to the third and final model. 
Table 4-1: Summary of the refinements of the biological models, from model I to model 3 
Model 
1 2 3 
Emergence of resistance included 0 0 
Spread of resistance under drug pressure 
Output as total number of infections 0 
Immunity as a simple binary phenomenon 0 0 
Immunity as a continuous phenomenon with multiple effects 0 0 
Recrudescent infection included 0 0 
Integration of cure rates within biological model 0 0 
Infectiousness quantified as gametocyte carriage 0 0 
Feedback loop between transmission intensity and immunity 0 
Duration of infection included 0 0 
Iteration frequency Yearly Daily 
Vector factors dynamic included 0 0 
Migration allowed 0 0 
Seasonality allowed 0 0 
Effects of chemoprophylaxis allowed 0 0 
Different characteristics of drugs included 0 
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4.3.2 Computer programming 
The biological models and severe outcomes model were programmed and run in S-plus® 
(version 7). The decision-trees and calculations of coverage and cure rates based on patient 
treatment-seeking and adherence behaviour were performed in Excel®, with the inputs being 
fed into the biological model. The cost-effectiveness sub-model was also undertaken in Excel® 
by cutting and pasting spreadsheets produced in S-plus®. 
4.3.3 A general description of the core biological model 
As explained earlier, the biological model is primarily a dynamic model of malaria transmission 
and the spread of drug resistance. The model iterates by the day. The main body of the model 
is deterministic except for the introduction of new ("migrant") infections, which is allowed to 
vary stochastically daily". The model involves, firstly, the introduction of malaria infections 
into a non-immune human population, which is stratified by age and where treatment of a fixed 
proportion of the population is with a monotherapv (drug _A). -. 
This model is initially run with no 
resistance, until a stable level of transmission and human immunity is reached, q process `that 
was found to take approximately two years. At this point, infections that are resistant to drug A 
are introduced at a user-defined starting level of resistance. A change in drug policy can be 
made from the onotherapy to a combination therapy (drug AB or BC) at any time22. This is 
shown schematically in Figure 4-2. This is a population-based model; therefore outcomes and 
changes are observed at the level of age-stratified groups and not in individuals, and the 
population in any one age-group is assumed to be homogenous. The total population and the 
age-structure are assumed to remain fixed. This means that the influx into the population in 
terms of births and immigrants is assumed to be balanced by the efflux out, in terms of deaths, 
due to malaria and other causes, and migrants. 
Key inputs into the model include vector factors, drug characteristics, human behaviour factors 
(such as time-to-treatment and the proportion taking combination therapy versus monotherapy), 
treatment failure rates and costs. The model can then be used to compare alternative policies in 
different epidemiological settings by varying any of the input parameters and comparing the 
outcomes over the desired time period. 
2' The sensitivity analysis, done by WP, was also stochastic, using Monte Carlo simulations. 
22 The model also allows resistance to drug B or drug BC to be introduced at any time. 
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4.3.4 One iteration of the biological model 
The model starts with a population of humans stratified by agc. A specified number of new 
patent or transmissible infections are introduced into this population. For the vcry first iteration 
this number of infections is specified as an input value. Thereafter, the number of new 
infections is determined by the infectiousness of the population based on the previous iteration, 
as described later. The actual distribution of patent infections through the age groups is 
determined by the susceptibility to infection, which depends on the level of itt11uuuty. In the 
model, the level of immunity is expressed through the use of "immunity functions" which 
describe the relationship between age, transmission intensity and different facets of immunity. 
These are central to the model and are described in more detail later. This initial step is 
illustrated in Figure 4-3. 
At this stage. an additional refinement to the model accommodates the possibility that sonic 
people, when bitten by a mosquito, will have recently taken antimalarial treatment for a fever 
presumed to be malaria ("presumptive therapy") and this exerts a selective pressure that results 
in a fixed proportion of the potentially patent sensitive infections being extinguished. 
Figure 4-3: Introduction of patent infections into first iteration of model 
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Not all patent infections in humans will be symptomatic, as "anti-toxic" immuni _ allows 
immune patients to tolerate parasitacmias without apparent cf t-nicrcforc, in high 
transmission settings the majority of infections, especially in adults, will be sub-clinical. This is 
important to capture accurately in the modelling of drug resistance, as it is patients who are 
symptomatic and take antimalarials who contribute to the drug pressure that selects for resistant 
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infections. In this model, the proportion of patent infections that are symptomatic depends on 
age and transmission intensity as determined by the immunity function based on age-stratified 
likelihood of clinical malaria (Figure 4-4). 
Figure 4-4: Determination of likelihood of symptoms by age 
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Most symptomatic patients seek treatment sooner or later, depending on accessibility to 
treatment. In this model, it is assumed that the likelihood of seeking treatment and time to 
receiving treatment is independent of age and both these values are assi ned at the beginning of 
a simulation. In reality, patients take a variety of antimalarial drugs and drug combinations, and 
both the tNpe and timing of treatment, may be dependent on age. However, for the purpose of 
this model, they are allowed to receive either a combination therapy (drug AB) or a 
monotherapy (drug A), and the proportion receiving combination therapy is termed the 
- -------- -- --- - "coverage rate" and is varied as an input value (Figure 4-5). 
The model is initially run without drug resistance in order to allow malaria transmission to reach 
a steady state. Infections that are resistant to drug A are introduced into the population as a 
proportion of the number of new infections. Resistant infections are more likely to recrudesce 
than sensitive infections if treated with a failing drug, and it is this that is the main driver of the 
spread of drug resistance. Resistance to other drugs can also be introduced later. 
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Untreated infections resolve after a certain amount of time, depending on the level of immunity. 
Treated infections may either be completely cured or may recrudesce if treatment is 
unsuccessful. The likelihood of recrudescence also depends on patient immunity, as well as the 
type of treatment, whether or not the infection is sensitive to the treatment received and the level 
of patient adherence to therapy. In this analysis, the first three factors are used to determine the 
maximum failure rate expected in youngest "non-immune" hosts, and this is input into the 
model at the beginning of a simulation. The additional effect of immunity in clearing infection 
in the older age groups is affected in the model through the use of an immunity function based 
on age-stratified severe malaria. 
In order to allow the impact of change of treatment on cure rates to feed back into the 
transmission of malaria and the spread of drug resistance, the parasite population is tracked 
concurrently with infections. This allows the infectiousness of the human population to be 
estimated at each iteration, based on the number and distribution of gametocytes, the infectious 
form of the malaria parasite. The number of gametocytes is, in turn, determined by the number 
of asexual parasites and the rate at which they switch to gametocytes - the Gametocyte 
Switching Rate (GSR). The infectiousness of the human population is then used to work out the 
infectivity of humans to mosquitoes. This level of infectivity and the input characteristics of the 
vector population are used to calculate the inoculation rate for the next iteration. The input 
vector characteristics can be varied to simulate different transmission intensities. This therefore 
closes the loop and begins the next iteration, as illustrated in Figure 3-2. 
A further refinement of the model allows new infections to be introduced into the human 
population each day, either every day throughout the year or for a specified period. It can be 
used to represent the daily introduction of new infections by a group of infected "migrants" and 
is programmed to vary stochastically to introduce some heterogeneity in transmission into the 
model. Alternatively, it can be used to simulate the phenomenon observed in some low 
transmission settings where infections that have remained sub-patent during a dry season re- 
emerge in a subsequent year. 
At the end of each daily iteration, the model outputs the total and age-group stratified number of 
patent infections, treated infections, cured and recrudescent infections, taking into account both 
new infections and pre-existing infections. These are summed over a year to produce annual 
age-stratified incidence and point-prevalence rates. 
A data-frame of these outputs is then used in the sub-models to calculate annual and cumulative 
numbers of severe malaria, deaths, DALYs and costs. 
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4.4 Parameter estimates 
A large number of data were required at various stages in the development of the model. The 
process of developing the model, identifying what data were needed, and obtaining and 
transforming data, was iterative. There was a substantial amount of data that were useful in 
informing the development of the model but where actual values could not be used directly. 
The data that were collected and used are presented in table format in Annex 6 and are cross- 
referenced in the text in parentheses. 
4.4.1 Uses of data 
Data were applied in a number of ways: 
Development of the overall framework. For example, early on, evidence suggesting that 
the development of resistance was highly dependent on immunity ensured that this formed 
a core part of the model structure. 
" Input values. The data were used to guide the values of inputs used in the base-case 
scenario and to determine the range and distribution of values to be used in the sensitivity 
analysis. For example, drug prices are known fairly precisely whereas the data on duration 
of infection in the immune individual are less certain and estimates covered a wide range. 
" Relationship between parameters. Most often this was in the form of the likelihood of a 
given outcome; for example, the likelihood that a symptomatic patient would receive 
treatment or that a patient with severe malaria would die. 
" Construction of immunity profiles. Immunity functions were constructed and extensively 
used in the model. Their construction required age-stratified data on malaria parasite 
density, morbidity and mortality from different transmission settings. 
" Validating the model. The model produced outputs that could be validated against existing 
data, which had not been used directly in constructing the model. These data were 
therefore useful for checking whether the model outputs were within reasonable limits and 
refining the model. For example, the rich data from Senegal were used to check that in 
high transmission intensity areas, the model predicted the number of clinical attacks 
correctly (Trape, Rogier et al. 1994). 
" Scenario analysis. Where basic data are available from one particular setting, this can be 
substituted and the model adapted in order to make predictions relevant to that setting 
under different intervention scenarios. This was applied to data from Cambodia. 
4.4.2 Sources of data 
Several approaches were taken to obtain parameter estimates. The available scientific literature 
was initially searched electronically using PubMed®. Bibliographies of relevant papers and 
reviews were searched for literature missed in the original search and for unpublished sources. 
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In addition, archived papers, pre-dating electronic bibliographies, were obtained from personal 
collections. Experts in the field provided an invaluable source of unpublished data or raw data, 
especially for use in the construction of the immunity functions. In addition, where data were 
insufficient or unobtainable, expert opinion was sought; for example, for estimates of the failure 
rates for untreated symptomatic infections. In the case of data on the implementation of ACTs, 
primary data on costs, coverage and adherence were collected in Cambodia. 
4.5 Details of the biological model 
4.5.1 Measuring parasites 
Background 
One of the most important characteristics of this model is that it handles malaria like a "macro" 
parasite by quantifying the density of infection in the human host. This is important in the 
modelling of malaria epidemiology and antimalarial drug resistance for a number of reasons. It 
is the distribution and density of infections in humans that determines both morbidity and 
infectiousness (Anderson and May 1991). In addition, the in-vivo effect of drugs on parasite 
density can be measured, creating the unique ability to quantify the pharmacodynamic 
properties of drugs on parasites (White 1997). 
Modelling 
The model is based on parasite biomass in terms of number of parasites per person, whereas 
most data available in the literature refer to parasite density in terms of parasites per gl of blood. 
Therefore, the biomass of human infections was calculated using data on estimated blood 
volume per kilogramme (kg) of body weight and the estimated weight-for-age (M1 and M2). In 
fact, the blood volume/kg changes vary by age (from 80 to 70m1/kg) and the weight-for-g gJ 
a population depends on a number of factors includin race and nutrition. 
4.5.2 Infections in the human host 
Background 
The meaning of "infection" is not straightforward in malaria, as the relationships between 
receiving a potentially infectious bite (being "inoculated"), developing a detectable 
parasitaemia, developing symptoms and transmitting to other people ("infectious") are not 
fixed. A patient may receive an infectious bite after which the parasite may or may not multiply 
and the resulting parasitaemia may or may not be "patent" and may or may not be associated 
with symptoms. It is therefore important to define what is meant by infection depending on the 
perspective and outcome of interest. 
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From the perspective of the patient and health worker, an infection is relevant if it causes 
symptoms for which a patient might seek treatment. Symptomatic infections also matter from a 
public health perspective as whether or not patients are treated successfully has implications in 
terms of both transmission and the development of drug resistance. However, infections that do 
not cause clinical symptoms may still be transmissible or "patent" and are therefore important 
from a public health perspective. As we are interested in transmission, drug resistance and 
clinical outcomes, the model handles "patent", "symptomatic" and "treated" infections. 
Patent infections are those where the asexual parasite density is high enough to generate enough 
--ý ' gametocytes to cause a transmissible infection in a biting mosquito. Normally, in order for a 
mosquito to develop a transmissible infection it must take up at least one female and one male 
gametocyte in one blood meal. Because in human infections with malaria, there are normally 
four females for one male (Smalley and Sinden 1977; Smalley and Sinden 1977; Robert, 
Sokhna et al. 2003), the mosquito must take up on average five gametocytes in one meal. One 
blood meal is usually 2-3µl. Therefore, the density must be on average at least three per pl 
equivalent to a total parasite biomass of approximately 107 parasites in an adult23. 
Modelling 
For the purpose of this model, the equivalent of 10' parasites in an adult is therefore considered 
to be the minimum parasite density for patent infections. This works out to be around the 
parasite density that can be detected by light microscopy, which is fortuitous in our 
interpretation of field data, as it allows us to assume that all detectable parasitaemias from 
cross-sectional prevalence studies are potentially transmissible and therefore to use such data 
directly. 
All uninfected humans have an equal chance of being inoculated by an infective mosquito but 
whether or not the inoculation results in a "patent" infection is dependent on the immunity 
profile based on the age-stratified susceptibility of infection. This is discussed later in the 
section on immunity. 
Like other models of malaria transmission, we do not consider super-infection (Hastings 1997; 
Koella and Antia 2003). Therefore, only non-infected humans are susceptible, and while 
tau' ` infected, another infection is not allowed. 
23 There is some evidence to suggest that the gametocyte density picked by a mosquito from a skin 
capillary may not reflect that in a blood smear and that the ratio of gametocyte may vary according to 
drug treatment, but for this model these are ignored. There must also be an absence of factors which 
inhibit the development of viable sporozoites in the mosquito. 
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Individuals who have sub-patent infections where the parasite density is less than the detectable 
limit are assumed to have a low enough transmission potential that their contribution to the 
overall infectiousness of the population can be ignored. However, in reality there is some 
evidence that in low transmission settings, chronic low-density infections may survive through 
the dry season and be an important source of new infections at the beginning of the next high 
transmission season. As discussed later, the model allows for this phenomenon to be simulated. 
4.5.3 Period of chemoprophylaxis 
Background 
At any point in time, a certain proportion of the human population will have detectable levels of 
antimalarial drugs in their blood stream as a result of having taken antimalarial drugs, for 
example a recent episode of fever. A few of these will have a high enough drug concentration 
to inhibit the growth of sensitive parasites emerging from the liver 10 days after inoculation, 
effectively providing patients with chemoprophylaxis and exerting drug pressure that favours 
the selection of resistant parasites. Drugs with long half-lives, such as mefloquine, are 
particularly vulnerable to this type of drug pressure. As parasites become increasingly more 
resistant, they are able to tolerate and survive through higher levels of drug. In addition, the 
likelihood that a new infection becomes established in the presence of presumptive therapy is 
dependent on the amount of drug taken, the half-life of the drug, the time elapsed since being 
taken and the degree of drug resistance of the parasite. 
The likelihood that individuals will take antimalarial drugs in the absence of infection depends 
on epidemiological and behavioural factors. It is particularly high where the population 
habitually treat any fever with antimalarial drugs and historically during programmes of mass 
drug administration. In high transmission areas, it has been estimated that some 40% of 
children receive antimalarial treatment prior to seeking treatment at a clinic (Nshakira, 
Kristensen et al. 2002) and that 24% of children with fever in the community had received an 
antimalarial in the previous two weeks (Talisuna, Langi et al. 2002). A recent study by Eriksen 
et al. in Tanzania found that 18% of children in the community had detectable levels of 
sulfadoxine in their blood (Eriksen, Nsimba et al. 2005). 
Modelling 
In order to incorporate this phenomenon into the model, we simplified this relationship so that 
humans either have an inhibitory level of drug A in their blood or not, and if they do then 
potentially patent "sensitive" infections are extinguished whereas "resistant" infections survive. 
The value input into the model is the fixed proportion of the potentially patent sensitive 
infections that are extinguished before the infection reaches In the base-case scenario this is 
assumed to be 10% of the population (M 10). 
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4.5.4 Symptomatic infections 
Background 
Patients with patent infections may be asymptomatic or may develop fever and other symptoms 
depending on their age, parasite density and level of immunity. For non-immune patients, 
nearly all patent parasitaemia result in symptoms. Estimates range from 84-100% from studies 
based on adults and children in low transmission settings (Luxemburger, Thwai et al. 1996; 
Barnes 2003) and 95% in adult malaria therapy patients (Ciuca, Ballif et al. 1934). 
Numerous studies have attempted to establish the relationship between fever, age, immunity and 
parasite density. A number of studies have found that there is a significant negative correlation 
between age and pyrogenic density (Petersen, Hogh et al. 1991; Cox, Kum et al. 1994). In 
Senegal, the age dependent threshold parasitaemia was five times higher for a one year old than 
in a 60 year old (Rogier, Commenges et al. 1996). Petersen and colleagues suggested that this 
indicated there was no evidence of a separate "anti-disease immunity" independent of 
parasitological immunity, arguing that immunity results in less parasites and as a consequence 
less severe symptoms (Petersen, Hogh et al. 1991). / 
Modelling 
In this model the proportion of patent infections in each age group that manifest 
symptomatically is determined by the immunity profile based on age-stratified prevalence of 
clinical malaria (Im 1 and Im6)). An alternative approach would have first determined the 
parasite density of infections and then used a parasite-density dependent "pyrogenic threshold" 
to determine the number of symptomatic and asymptomatic infections. However, this was not 
undertaken for two reasons. Firstly, as described above, the exact relationship between age, 
immunity and pyrogenic threshold is still uncertain. Secondly, this is a population-based model 
in which each age group is assigned an average parasite density. Therefore, in age groups 
where the average parasite density falls below the pyrogenic threshold, all individuals in that 
age group would be assumed to be asymptomatic and vice versa. To enable this approach to be 
taken, the model would need to be adapted so that each age group was assigned a parasite_ 
density profile rather than an average parasite density, and then determining a pyrogenic 
threshold for each group dependent on the parasite density and possibly transmission intensity. 
4.5.5 Parasite growth and maximum parasite density 
Background 
Humans with previous and sustained exposure to malaria develop an anti-parasitic immunity 
that enables them to control the level of parasitaemia and to clear parasites without treatment. 
Therefore, in high transmission settings, the mean parasite density falls with age (Trape, Rogier 
et al. 1994; Akim, Drakeley et al. 2000). Patients without such immunity are more likely to 
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develop higher density infections and to take longer to clear their infections without treatment. 
In reality, once the parasite density reaches a certain threshold that causes symptoms, they are 
likely to seek treatment that modifies the duration of infection. 
The parasite multiplication rate prior to treatment is approximately eight-fold (90% CI, 5-12.3) 
per 48-hour cycle (Simpson, Aarons et al. 2002). The maximum parasite density in a non- 
immune host can reach almost 107/µl. The relative parasite density in asymptomatic infections 
varies in relation to symptomatic infections from 0.01-0.03 in Vanuatu (Maitland, Williams et 
al. 1996) to 0.55 in Mali (Sagara, Sangare et al. 2002) and 0.7 in adults in Ghana (Owusu- 
Agyei, Koram et al. 2001). 
Modelling 
The parasite density in all infections is allowed to increase at the same rate of one log every 2 
days (M9). However, the maximum density that they are allowed to reach is higher in 
symptomatic infections, which occur in relatively non-immune patients, compared to 
asymptomatic infections. The actual value for each age group is determined by an immunity 
function derived from age-stratified parasite density (Immunity Function 3 (Im3)) as described 
later. At the start of the model the maximum parasite biomass in the non-immune symptomatic 
infections is assumed to be equivalent to 1012 in adults. The parasite mass in asymptomatic 
infections is assumed to be 0.5 relative to that in symptomatic infections (Al). 
For symptomatic infections, it is assumed that patients become symptomatic when they reach 
this maximum parasitaemia. The length of time from this point to when they receive treatment 
depends on a number of factors including the patients' access to treatment and is varied as an 
input factor (S3). During this time, it is assumed that the parasite density remains at the 
maximum parasite density. 
4.5.6 Likelihood of treatment 
Background 
The likelihood that patients with symptomatic malaria receive antimalarial treatment depends on 
their treatment-seeking behaviour and access to antimalarial drugs. There is a substantial 
literature on the subject, including a review by McCombie (McCombie 1996) which suggested 
that although estimates varied substantially, the majority of patients seek treatment outside the 
home (>90%). This is corroborated by subsequent studies (Munguti 1998; Nuwaha 2002; 
Eriksen, Nsimba et al. 2005) which have found rates of 84-96%. However, the percentage 
actually receiving antimalarial treatment may be slightly less at around 80% (Espino and 
Manderson 2000; Deressa, Ali et al. 2003). 
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Modelling 
The likelihood of treatment is an input variable into the model and is termed the "treatment 
rate". The base-case scenario is given a value of 0.95 (S 1). 
The actual drugs that patients receive depend on a number of factors including whether they 
receive treatment in the formal or informal sector and the current recommendations. For 
simplification in the biological model, patients are allowed to either receive combination 
therapy (drug AB) or monotherapy (drug A), and the proportion that receives combination 
therapy is termed the "coverage rate" 24. The coverage rate is an aggregate value, calculated 
separately using simple decision-tree based models as described later in this chapter. 
4.5.7 "Migrant" or dormant infections 
Background 
In areas where the level of local transmission is low, infected immigrants from high 
transmission areas can be important in the maintenance of malaria infection in the population 
(Craig, Kleinschmidt et al. 2004; Zhou, Sirichaisinthop et al. 2005). In other areas where 
transmission is highly seasonal, there is evidence that infections in humans can remain at a sub- 
patent level through the dry season to become reactivated at the beginning of the next wet 
season. Such infections may therefore be an important reservoir of infections, enabling 
transmission to continue year to year (Roper, Elhassan et al. 1996; Babiker 1998). 
Modelling 
The model allows the possibility of introducing new infections either at a constant rate or over a 
specified number of days. Introducing infections at a constant rate can be considered to 
represent the inward migration of an infected population. The size and the characteristics of this 
sub-population can be adjusted so that when introduced, they have a different immunity profile 
and level of resistance from the main population. When the model was run to simulate low 
transmission settings, it was found that these "new" infections were important for the 
maintenance of infection in a population. Without them, it was possible to eradicate malaria in 
certain situations. Although not the focus of this thesis, this is an interesting finding and may be 
explored further using the model. In the base-case scenario, it is assumed that rate of 
introduction of migrant infections is around 5% of the population per year. This is allowed to 
vary from 3 to 7% of the population on a daily basis. 
24 In reality, patients receive any number of different drugs and combinations but this was too complex to 
be modelled. 
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4.5.8 Duration of infection 
Background 
The duration of parasitaemia in the human host is important in determining infectiousness - the 
longer an individual carries a patent parasitaemia, the longer they are potentially infectious to 
mosquitoes2S. Duration is influenced by the maximum density of parasites attained and the rate 
at which they are cleared from the blood, which both depend on host immunity and drug 
treatment. The effect of immunity on the duration of infection is uncertain. It is likely that 
duration of infection is reduced by immunity and this has been assumed by most mathematical 
models (Molineaux, Storey et al. 1980; Cross and Singer 1991). 
Few data are available for the duration of untreated infections, and estimates vary widely. This 
is because, for obvious ethical reasons, one cannot nowadays observe the natural course of 
infection in symptomatic patients without terminating the infection. However, estimates are 
available from the early observational studies of malaria therapy in adult patients with 
neurosyphillis and more recent longitudinal studies on asymptomatic infections. 
In an early study on malaria therapy patients, Eyles and Young estimated the average duration 
of an initial infection to be 121 days (s. d. 9 days). In a more recent retrospective analysis of 
similar data, the duration of primary treated infections varied from 79 to 132 days depending on 
parasite strain and from 89 to 185 days in infections that remained untreated (Collins and 
Jeffery 1999). 
In more recent years, molecular techniques have been used to detect persistence of 
parasitaemias that are undetectable by microscopy. In Sudan, in an area of highly seasonal 
malaria transmission, it was shown that multiclonal infections could be maintained throughout 
the dry season and into the next wet season (Babiker 1998; Babiker, Abdel-Muhsin et al. 1998). 
These would be supplanted by a novel genotype when transmission restarted. Franks et at. 
longitudinally studied 143 newborns in coastal Ghana, with monthly blood tests for the first two 
years of life, and found a median duration of an asymptomatic infection was less than four 
weeks and the longest period of continuous infection was 64 weeks. However, the transmission 
intensity was moderately high (5-10 infectious bites/year) and the duration of infection would 
have been influenced by immunity derived in-utero (Franks, Koram et at, 2001). But the 
problem with using the molecular-based data in the model is that because the infections are 
25 There is a difference between the "duration of infection" and the duration of illness experienced by 
patients. Duration of illness is important from the patient's perspective, both in terms of morbidity and 
costs in terms of days of lost productivity. The duration of illness is generally shorter than the duration of 
infection as symptoms are only experienced when a certain level of parasitaemia is reached. Average 
durations of symptomatic uncomplicated and severe episodes of malaria are used in the calculation of the 
cost of illness. 
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undetectable by light microscopy, they do not fall into our category of "patent" infections and 413- 
k are not considered transmissible. 
Modelling 
At a population level, the daily rates at which different infections are cleared from the human 
population are calculated as the inverse of the duration in days. This overall rate of conversion 
of "infecteds" to "non-infecteds" represents the population recovery rate. 
To describe the relationship between age and duration of infection, the immunity function based 
on age-stratified parasite density (Immunity Function 3 (Im3)) was used with specification of 
the maximum durations of treated and untreated infections in the non-immune host. 
The maximum duration of treated infections varies within the model according to the parasite 
reduction ratios for each drug (Im8). These were obtained from work by White and are based on 
the parasite clearance times provided in clinical trials (White 1997). This is described in more 
detail in the section on drug characteristics. 
For the purpose of the model, the maximum duration of an untreated infection is assumed to be 
80 days (Im7). This "untreated" group is predominantly made up of "immune" patients. 
However, for model simplicity and because of the lack of data, symptomatic non-immune 
patients were placed in the same group. 
4.5.9 Immunity 
Background 
Immunity clearly plays a central role in malaria epidemiology and in the development of 
antimalarial drug resistance. Immunity to malaria is acquired slowly following repeat and 
sustained infection. However, few individuals ever become completely immune and malaria 
infection continues throughout life despite repeated inoculation, with adults in high transmission 
areas tolerating a low-density parasitaemia without symptoms (a phenomenon known 
"premunition"). The level of immunity attained depends on a number of factors including the 
pattern of exposure, natural maturation of the immune system, parasite variability and variation 
between individuals and ethnic groups. 
As mentioned earlier, two main facets of immunity have been recognized: "clinical" or anti- 
toxic immunity, which acts to ameliorate the exhibition and severity of clinical symptoms, and 
anti-parasite immunity, which limits parasite numbers, replication and burden in the human 
host. These facets can be further broken down into the following: 
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" Reduction in host susceptibility to infection; 
" Reduction of the level of parasitaemia in infected patients; 
" Reduction in likelihood of fever and other symptoms in infected patients; 
" Reduction in the therapeutic failure rate for all levels of antimalarial drug resistance; 
" Reduction in severe disease and mortality. 
The relationship between age and frequency of infection and the rate of acquisition of immunity 
is complex and has not been clearly defined. From the neurosyphillis studies, adult patients 
developed both anti-parasitic and clinical immunity after one infection (Collins and Jeffery 
1999). However, the different facets of immunity appeared to be acquired at different rates at 
different transmission intensity. 
!, c- 
In high transmission settings, infants young children are particularly susceptible to severe 
and fatal malaria (Marsh 1992). Clinical immunity is gradually acquired through childhood 
(Rogier and Trape 1993) and this manifests as lower rates of disease and decreased severity of 
disease despite parasitaemia. Therefore adults are much less likely to develop infections (Beier 
et al 1994), to develop high parasitaemias (Beadle, McElroy et al. 1995) and to present with 
clinical symptoms (Bloland, Boriga et al. 1999; Owusu-Agyei, Koram et al. 2001). Infants in 
their first six months of life appear to be relatively protected against infection and severe 
clinical episodes of malaria (Kitua, Smith et al. 1996) due to acquired immunity from their 
mothers in-utero (Edozien, Gilles et al. 1962). 
Anti-parasite immunity which results in eliminating parasites or limiting their replication and 
burden also increases with age (Rogier, Commenges et al. 1996). The peak in age-stratified 
prevalence appears to occur later than the peak in incidence of clinical attacks (Smith, Genton et 
al. 1994). However, there is some evidence that of the two components only anti-parasite 
immunity plays a major role as age increases and not "anti-toxic" (clinical) immunity (Petersen, 
Hogh et al. 1991; Rogier and Trape 1993). 
At low transmission intensities, older children and adults have little immunity. There is some 
evidence that in epidemic situations, adults may be even more susceptible to infection and 
severe disease. Baird found that the prevalence of parasitaemia soon after onset of exposure 
was similar in non-immune migrants adults compared to children (Baird 1998) and that the risk 
of severe malaria was almost 2.7 times higher (95% CI=1.8-4.2) (Baird, Masbar et at. 1998). 
Similarly, Soni and Gouws found that the odds ratio for severe malaria in those over 12 years 
compared to under 12 years was 4.8 in the KwaZulu-Natal (Soni and Gouws 1996). 
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At intermediate levels of transmission, the relationship between transmission intensity and the 
epidemiology of severe malaria is therefore not straightforward. As the entomological 
inoculation rate (EIR) falls below 10 to 20 infective bites per year, the incidence of clinical 
malaria episodes and paediatric severe malaria appears to be higher than at higher levels of 
transmission intensity (Marsh and Snow 1999), and there is a shift from severe malarial disease 
in children younger than five years toward severe disease in older age groups (Snow, Omumbo 
et al. 1997). 
However, it has been widely observed that age is an important risk factor for treatment failure 
(Fontanet and Walker 1993; Dorsey, Kamya et al. 2000). In Uganda, children under the age of 
five years were found to be 3.4 times (95% CI = 1.8-6.3) more likely to be unsuccessfully 
treated with chloroquine than older patients (Dorsey, Kamya et al. 2000) and to require fewer 
dhfr/dhps mutations for treatment failure with SP (Staedke, Sendagire et al. 2004). 
The effect of immunity of infectiousness - i. e. the existence of transmission-blocking immunity 
- is still uncertain. There is some evidence that there is a specific immunity that results 
in the 
suppression of gametocyte production independent of the number of asexual parasites (Baird, 
Jones et al. 1991; Bousema, Gouagna eta]. 2004). 
Loss of exposure results in loss of immunity over a period of time that varies from host to host 
and depending on the type of immunity. African expatriates lose some immunity over two to 
three years while remaining protected from severe disease (Carter and Mendis 2002). 
Modelling 
Unfortunately there is no ex-vivo correlate for immunity against malaria, meaning that there is 
no single blood test that accurately reflects the level of functional immunity. However, it is 
possible to measure some of the effects that immunity has on clinically relevant outcomes. 
Therefore, by mathematically describing the relationship between age, transmission intensity 
and these outcomes, the resulting functions could be used in the model as proxy measures of 
immunity. The three functions for which sufficient data were obtained are: 
" Likelihood of symptomatic malaria (Immunity Function 1) 
" Mean parasite density (Immunity Function 2) 
" Likelihood of severe malaria (Immunity Function 3) 
These immune functions took the form of multiple regressions using EIR and age as 
independent variables. Detailed information on the sources of the original data, the functions 
and graphs themselves can be found in Annex 7. 
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These three immunity functions were used directly in the model and were also used as proxies 
for the other facets of immunity for which there were insufficient data. It is assumed that 
immunity does not have any specific effect on the infectiousness of gametocytes_- that is, there 
is no transmission-blocking immunity - due to the uncertainty in the data. 
The immune function described the change in an outcome with age but not the actual outcome 
itself. In order to generate actual values, the functions were "zeroed" by specifying the value in 
the youngest (under one year old) age group, who were assumed to be the most "non-immune". 
The facets of immunity, the immune function and data on which they are based are shown in 
Table 4-2. Where the functions are incorporated into the model is illustrated in Figure 4-6 and 
the facets and functions are discussed below. 
Host susceptibility 
Host susceptibility determines the likelihood that an inoculation results in a patent infection in a 
human. This cannot be measured directly and therefore the function based on age-stratified 
parasite density (Immune Function 2) is used as a proxy. This assumes that the anti-parasite 
immunity limiting the number of parasites in patent infections is similar to the immunity that 
eradicates parasites so that patency is never reached. 
The maximum likelihood of infection in the non-immune host is specified at the beginning of 
the model and the immune function is then used to describe the likelihood of infection in other 
age groups. From experiments on non-immune volunteers, it is apparent that several infective 
bites are required to get reliable infection (Peters, Fowler et at. 2002), showing that 
susceptibility to any single bite is below one. From a study on malaria therapy patients, Ciuca 
observed that after a single inoculation 75% of patients developed symptomatic parasitaemias 
and 4% developed asymptomatic parasitaemias (Ciuca, Ballif et al. 1934). A value of 0.8 was 
therefore used as the model input for the maximum likelihood of host susceptibility in the base- 
case scenario (Im4). 
Likelihood of symptomatic infection 
In order to answer the question "given a patent parasitaemia (of any level), what is the 
likelihood of clinical symptoms? ", individual level-data were required. Authors were therefore 
contacted directly and four data sets were obtained which contained adequate and comparable 
data on age-stratified parasitaemia and clinical outcomes16. 
26 As mentioned in the methods section, it was done this way round, rather than first determining the 
distribution and level of parasitaemia in each age group then separating asymptomatic from symptomatic 
cases, because in this population-based model it would have meant whole age groups either being 
symptomatic or not. 
105 
The best fit was with a bi-exponential non-linear regression model and the resulting function 
(Immunity Function 1) is used directly in the model to determine the proportion of patent 
infections in each age group that are symptomatic. The maximum likelihood that a patient with 
a patent parasitaemia is symptomatic in a non-immune host is specified as an input parameter 
and in the base-case scenario was assumed to be 0.8 (Im6). 
Parasite density 
Immunity Function 2 is based on the age-stratified parasite density at different transmission 
intensities. Eight sets of age-stratified cross-sectional data were obtained. The data from 
Thailand, Laos and two areas in Kenya were in the form of patient-level raw data and the 
remaining four sets of data were in the form of mean age-stratified densities. As the model 
tracked actual parasite numbers rather than density, the mean age-stratified parasite biomass 
was calculated27. It was assumed that the detectable limit in all studies was 20 parasites/µl 
(parameter M8) and the average blood volume was 75ml of blood per kg of body weight (M2). 
A number of non-linear regression models were fitted onto the data with the best fit being 
described by a two-term exponential decay function with an interaction term. This function is 
used directly in the model to calculate the parasite density in each group. The function is also 
used to as a proxy measure of the effect of immunity on host susceptibility and duration of 
infection. 
Duration of treatment 
It was assumed that the mechanism of host immunity that limits parasite density is the same as 
the mechanism that clears existing parasites. Therefore, the immunity function based on 
parasite density was also chosen to describe the relationship between duration and immunity. 
The maximum durations of different types of untreated infections and minimum parasite 
reduction ratios in treated infections are therefore assigned as input parameters (Im7 and Im8). 
Likelihood of treatment failure 
Age-stratified data on treatment failure are not widely available but obviously form a key 
component of the model. Fortunately, data suggest that in a low transmission setting the 
relationship between age and treatment failure rate is very similar to the relationship between 
age and severe malaria. It is therefore assumed that the immune mechanism protecting a human 
from developing severe malaria is the same or very similar to that which clears infection. 
Therefore, the immune function based on the age-stratified likelihood of severe malaria 
27 Where raw data were used, this was calculated using the mean log (parasite density). 
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(Immunity Function 3) is used in the model to determine the effect of age and transmission 
intensity on the likelihood of treatment failure. The "maximum failure rate for a non-immune 
patient' is specified depending on treatment type. drug resistance and level of patient adherence 
to therapy (Table A6-14). During the running of the model, the actual value used for a given 
age group is determined by the immunity function relative to this maximum rate. 
Likelihood of severe malaria 
The data used in order to construct the immunity function based on age-stratified severe malaria 
came from prospectively recorded paediatric admissions with severe malaria from five discrete 
communities in The Gambia and Kenya (Snow. Omumbo et al. 1997). and from one study on 
adults and children in Thailand (Luxemburger, Ricci et al. 1997). 
A number of non-linear regression models were fitted onto the data with the best fit being 
described by a two-term exponential decay function. This function is used in the severe 
outcomes sub-model to describe the likelihood of severe malaria in the absence of drug 
resistance after specifying the maximum likelihood in a non-immune host. The increase in 
likelihood of severe malaria due to increasing drug resistance is then calculated. It is also used 
as a proxy for the effect of immunity on clinical failure based on evidence that there is a similar 
relationship between age and the two outcomes in a low transmission setting. 
Figure 4-6: Schematic diagram of where immunity influences age-stratified likelihoods in the 
biological model. 
0 
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Table 4-2: Facets of immunity and data used in model 
Facet of Explanation Age and EIR Immunity Parameter for 
immunity stratified data function "zeroing" 
used in immunity (Im) immunity 
function function 
Reduction in Reduction of the Mean parasite Im 2 Maximum 
"Susceptibility" probability that an density susceptibility of a 
inoculation becomes non-immune host 
a detectable and 
viable infection (pre- 
erythrocytic or liver 
sta e munity) 
Reduction in Reduction in the Mean parasite Im 2 Maximum 
maximum probability that density parasite density 
parasite density viable merozoites in non-immune 
released from the host 
liver will multiply 
during the blood 
stage of infection to 
reach high densities 
Reduction in Increased rate of Mean parasite Im 2 Maximum 
duration of clearance of parasites density durations of 
infection different types of 
infection in non- 
immune host 
Reduction in Reduction in the Likelihood of Im 1 Maximum 
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clearance of 
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4.5.10 Gametocytes and infectiousness 
Background 
Gametocytes are the entity responsible for transmitting malaria from humans to mosquitoes. 
One of the key characteristics of this model is that by quantifying infectiousness in terms of 
gametocyte carriage, the details of transmission are handled explicitly. It is known that 
recrudescent infections are associated with a higher gametocyte density, with important 
consequences for the spread of drug resistance (Price, Nosten et al. 1999; Sowunmi and Fateye 
2003; Suputtamongkol, Chindarat et al. 2003). Drug treatment and drug efficacy affect the 
gametocyte density by decreasing the asexual parasite density. Drugs can also alter the rate at 
which asexual parasites switch to gametocytes, the "gametocyte switching rate (GSR)" and, in 
some instances, can have a direct effect on the gametocytes (Price, Nosten et al. 1999; 
Suputtamongkol, Chindarat et al. 2003; Pukrittayakamee, Chotivanich et al. 2004). Other 
factors which have been associated with gametocyte carriage include age, asexual parasite 
density (Akim, Drakeley et al. 2000), duration of illness, anaemia and gametocytaemia prior to 
treatment (Price, Nosten et al. 1999). However, our understanding of the gametocyte dynamics 
and infectiousness is still incomplete. 
Gametocytes take about 10 days to mature before they are infectious. Estimates for gametocyte 
circulation time vary from 3.4 days (Smalley and Sinden 1977) to 7.4 days (Eichner, Diebner et 
al. 2001), depending on underlying assumptions about gametocyte survival. 
Thomson, under the direction of Ronald Ross, compared the density of asexual parasites and 
gametocytes (known as "crescents") in partially immune and non-immune patients over time 
(Thomson 1911). In the former, an average of 172,300 asexual parasites/mm3 produced 3,343 
crescents per/mm3, giving a ratio of 52 parasites to one crescent. In the latter, the findings were 
724,000 asexual parasites to 1,354 crescents, giving a ratio of 535 to one. Almost 100 years 
later, Eichner et al. fitted a dynamic model to individual data from adult malaria-therapy 
patients, taking into account the gametocyte life-cycle. The authors estimated average 
conversion probabilities of between 0.0039 and 0.0068 (mean 0.0064) (Eichner, Diebner et al. 
2001). 
Modelling 
The infectiousness of humans is determined by the density of and duration that mature 
gametocytes remain in circulation, and can be expressed as the Area Under the Curve of time 
versus gametocyte density (AUCgam) as shown in Figure 4-7. This, in turn, is dependent on 
the number of asexual parasites, the GSR and the duration that mature gametocytes remain in 
circulation. The number of asexual parasites on any one day is dependent on the number of 
infected individuals, their age-stratified parasite density and the rate at which infections are 
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cleared (the population recovery rate). This process is shown schematically in Figure 4-8. In 
the model, gametocyte half-life was assumed to be 2.4 days (M7). The actual parameter input 
for the model for asymptomatic (untreated) infections is given as a value relative to the GSR of 
infections treated with the monotherapy and the base-case scenario is set at one (A2). 
Figure 4-7: Course of parasite and gametocti'te density in a single infection 
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4.5.11 Infectivity to mosquitoes 
Background 
The likelihood that a mosquito will develop a transmissible infection following a bite on an 
infected human generally increases in relation to the gametocyte density of the human host 
(Jeffery and Eyles 1955; Drakeley, Secka et al. 1999; Bonnet, Gouagna et al. 2000). There is 
some evidence that children who are carrying gametocytes are more attractive to mosquitoes 
than those who are not (Lacroix, Mukabana et al. 2005) but this is not a consistent finding 
(Burkot, Narara et al. 1989; Ferguson and Read 2004). Other factors may affect the infectivity 
of humans to mosquitoes but these have not been fully elucidated. 
Modelling 
It is assumed that all humans are equally attractive to biting mosquitoes and that the infectivity 
to mosquitoes is determined solely by the gametocyte density in humans (V2). In order to 
calculate this relationship in this model, an exponential model was fitted to data from a study by 
Jeffrey and Eyles, where mosquitoes were fed on blood from patients infected with different 
strains of P. falciparum (Jeffery and Eyles 1955). This function is used at each iteration to 
calculate mosquito infectivity and is shown in Annex 7. 
4.5.12 Vectorial dynamics and inoculations from mosquitoes to humans 
Background 
The intensity of malaria transmission from mosquitoes to humans is usually expressed as an 
annual Entomological Inoculation Rate (EIR). The EIR is determined by the infectiousness of 
the human population and by vectorial characteristics, namely mosquito density, their biting 
behaviour and how long they survive. These vectorial characteristics are captured in the 
"Vectorial Capacity" or "VC", which is influenced by many factors including temperature, 
humidity, rainfall, ecology, mosquito species and vector control. Estimates in low transmission 
settings for An. dirus range from 0.009-0.428 in Laos (Toma, Miyagi et al. 2002) to 0.48-1.28 
in Thailand (Rosenberg, Andre et al. 1990); for An. Minimus, 0.048-0.186 in Laos (Toma, 
Miyagi et al. 2002); and for An. Arabiensls, 0.34-1.42 in Tanzania (Ijumba, Mosha et al. 2002). 
In high transmission settings, levels up to 15 of have been recorded (Garrett-Jones and Shidrawi 
1969). 
Modelling 
The daily EIR determines the inoculation rate of mosquitoes to humans at the beginning of each 
iteration and can be expressed as: 
EIR=VCxPxi 
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where P is the proportion of the human population who are infected and i is the probability that 
a mosquito feeds on an infected human. 
The value for VC is an input parameter and is chosen to reflect high or low transmission 
intensity (V 1). The model also allows for data on the component parts of the VC to be fed into 
the model to enable the. exploration of vector dynamics, in particular the daily survival rate of 
mosquitoes (Smith and McKenzie 2004). It can be programmed to fluctuate from month to 
month in order to reflect seasonal changes that might be observed (V4 and V5) (Prakash, 
Bhattacharyya et al. 2001). In the base-case scenario, a value of 0.1 is used for the vectorial 
capacity and it is assumed that transmission is constant throughout the year. 
4.5.13 Drug characteristics 
Background 
The biological characteristics of drugs are described in terms of their pharmacokinetic and 
pharmacodynamics properties. Pharmacokinetics refers to how drugs are affected by humans, 
that is, their absorption, metabolism, distribution and excretion. Pharmacodynamics refers to 
how the drug affects its target. 
The most important pharmacokinetic property of antimalarial drugs is how long they remain in 
the blood stream, as expressed by the drug half-life. This determines the frequency and duration 
of drug administration and also the likelihood that new infections will be exposed to inhibitory 
drug levels from the prior consumption of an antimalarial drug. The former is important in 
influencing the likelihood of patient adherence and the latter has important implications for the 
development of drug resistance. Artemisinins have the shortest half-life, of an hour or less, and 
chloroquine and mefloquine have the longest half-lives, of several weeks. Other drugs such as 
pyrimethamine and quinine lie in between with half-lives of several days. 
Another important pharmacokinetic property of drugs is whether or not they are water-soluble. 
If they are not, for example lumefantrine, their absorption is dependent on concurrent 
consumption of fat in the diet, which affects their effectiveness outside of clinical trial 
conditions. 
The pharmacodynamics effect of antimalarial drugs is to kill malarial parasites. Different drugs 
have different levels of killing ability and target different stages of the parasite life cycle. The 
killing ability can be expressed as the maximum parasite reduction ratio (PRRRwhich is the 
fixed proportion of the parasite mass, which is removed per two-day life cycle. This varies 
from a parasite reduction ratio of 10-fold for the antibiotics such as tetracycline, to over 10,000- 
fold for artemisinin derivatives. Adult patients with acute malaria have up to 10t2 parasites 
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circulating in their blood. Therefore, even with a 10,000-fold reduction in each cycle, the 
complete eradication of the parasite load requires at least three cycles or six days, and 
therapeutic drug levels need to be present for four cycles to ensure cure (White 1997). 
The stages of the parasite life cycle that are vulnerable to drug attack are important in 
determining the range of effectiveness of the drug. Drugs that prevent the maturation of asexual 
forms to schizonts decrease sequestration and are therefore useful for treating severe malaria. 
Drugs that inhibit the development of gametocytes can help to decrease transmission. 
Artemisinins have the broadest stage-specificity of all antimalarial drugs, preventing the 
maturation of asexual forms to both schizonts and gametocytes. Their inhibitory effect on the 
production of gametocytes has important implications in terms of transmissibility, especially in 
low transmission settings (Chen, Li et al. 1994; Price, Nosten et al. 1996; Pukrittayakamee, 
Chotivanich et al. 2004). In contrast, other studies show increased carriage of gametocytes 
following treatment, especially with SP (von Seidlein, Drakeley et al. 2001; Sowunmi and 
Fateye 2003) and possibly chloroquine. 
Modelling 
The characteristics that can be varied in order to explore the affects of different drug choices on 
model outcomes are: the parasite reduction ratio (PRR), the gametocyte switching rate, the 
failure rates and the cost. 
The PRR is altered to reflect the rapidity of drug action, which effects the duration of treated 
infections. It is dependent on the type of drug and drug resistance. In the base-case scenario, the 
PRR in sensitive infections treated with monotherapy (SP or mefloquine) is 1,000-fold 
reduction in parasite mass per 48 hours and is reduced to 100-fold in resistant infections. The 
PRR in infections treated with an ACT is assumed to be 50,000 to reflect the rapid efficacy of 
the artemisinin component (Im8). ý"ý 
The GSR is varied to simulate the effect that drugs have on the production of gametocytes. 
These were estimated from clinical studies reporting data on the density of asexual parasite and 
gametocytes densities before and after treatment with different drugs. It was assumed that the 
GSR was reflected by the change in gametocyte density after treatment relative to the pre- 
treatment asexual parasite density. In the base-case scenario, the values used were 0.003 for the 
monotherapy and 0.0009 for ACTs (S4) (Price, Nosten et at. 1996; Robert, Awono-Ambene et 
al. 2000; von Seidlein, Drakeley et al. 2001). 
The failure rate with different drugs is varied by altering the maximum likelihood of cure in 
non-immune hosts depending on the resistance and adherence, as discussed below. Finally, the 
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cost of the drugs is varied in the costs model, so that the cost-effectiveness of different drugs 
and drug combinations can be explored. 
4.5.14 Drug resistance 
Background 
For most drugs, drug resistance is acquired in a step-wise fashion so that as a parasite acquires 
an increasing number of resistant mutations, the rate at which they are cleared by the drug 
decreases. Clinically, this results in longer parasite clearance times, an increased likelihood of 
recrudescence and a decrease in the time to recrudescence, until eventually there is no initial 
reduction in parasites at all, as if the infection is untreated. This results in an increased 
likelihood of severe malaria and death. Epidemiologically, this results in a shift from RI type 
failures to RII and RIII type failures, with the changes first occurring in children and pregnant 
women due to their relative lack of immunity. These different aspects of drug resistance are 
illustrated in Table 4-3. 
Table 4-3: Aspects and manifestations of drug resistance 
Aspect of drug resistance Manifestation of increasing drug resistance 
Genotype Increase in number of resistance mutants per resistant infection 
Clinical outcome (phenotype) " Increase in parasite and fever clearance time 
" Increase in likelihood of treatment failure 
" Decrease in time to recrudescence 
" Increase in likelihood of severe infection and death 
Epidemiology (model " Increase in proportion of population carrying resistant 
outcomes) mutants 
" Shift from RI through to RIII type failures 
" Increasing incidence of severe infections, especially in 
young children and pregnant women 
Modelling 
For the purpose of the model, the most important relationships to define are the relationships 
between genotypic resistance and clinical outcomes in terms of treatment failure and severe 
malaria. For simplicity, the duration of infections and the time to recrudescence are fixed 29. 
There were several possible approaches for handling the relationship between drug resistance 
and treatment failure and severity of disease in the model. The first, and most realistic, would 
have been to increase genotypic resistance in a step-wise fashion and to link this to a step-wise 
change in clinical outcomes, in particular failure rate and severity of illness. 
Z$ Although, on a population level, because the same factors increase both duration and likelihood of 
failure, an increasing number of failures is associated with an increase in the duration of the initial 
infection. 
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In an early model, this was attempted by creating an intermediate state of drug resistance 
between fully sensitive and fully resistant - termed "partial resistance". Clinical outcomes were 
expressed as complete cure, complete failure and "intermediate failure". However, as the model 
grew in complexity it became apparent that tracking three levels of resistance in both the human 
infection and parasite population was too unwieldy and that this was not a practical approach. 
Therefore, an alternative approach was required, which assumed that resistance was a binary 
phenomenon of either "resistant" or "sensitive" infections. 
The challenge was, therefore, how to link the likelihood of failure, a continuous phenomenon, to 
"drug resistance" as a binary phenomenon. One possible approach was to modify the structure 
of the biological model so that the failure rate did actually change as the proportion of resistant 
infections increased. This would have meant that although on an individual level, parasites 
were either resistant or not, at a population level, as the number of infections with "final 
mutant" increased, the consequence of the increasing number of "partially resistant" infections 
would be reflected in an increasing failure rate. This complexity could not be incorporated into 
the biological model but was applied to the proportion of recrudescent infections resulting in 
severe malaria in the "severe outcomes" model, and has therefore resulted in one of the key 
clinical consequences of drug resistance being shown as a continuous phenomenon. 
Within the biological model, the likelihood of treatment failure therefore had to be treated as a 
binary phenomenon and the failure rate resulting from the single genetic event conferring "drug 
resistance" had to be defined. This genetic event could have been chosen to represent an initial 
or intermediate step in the series of genetic events that lead to complete treatment failure. 
However, this would have been an arbitrary level and difficult to interpret. This genetic event 
was therefore assumed to be the "final step" conferring complete drug resistance and resulting 
in a recrudescence rate equivalent to that of an untreated symptomatic patient. 
4.5.15 Failure rates 
Background 
The likelihood that an infection recrudesces depends on whether it is treated, the efficacy of the 
drug, whether or not the infection is sensitive to the drug, and the level of host immunity. These 
have been discussed in detail in the sections on immunity and drug resistance. 
Modelling 
To describe the relationship between immunity and treatment failure, the immunity function 
based on the age-stratified risk of severe malaria (Immunity Function 3) is used, as explained 
earlier. In order to obtain the actual treatment failure rate for each age group, the relationship 
between drug resistance and the maximum failure rates in a non-immune host had to be defined, 
115 
depending on type of infection and treatment. This results in six possible resistance/treatment 
type scenarios: 
Sensitive to both A and B: treated with A --º Maximum failure rate I 
Sensitive to both A and B: treated with AB --º Maximum failure rate 2 
Resistant to A/ Sensitive to B: treated with A -+ Maximum failure rat 
Resistant to A/ Sensitive to B: treated with AB --º Maximum failure rate 4 
Resistant to both A and B: treated with A --> Maximum failure rate© 
Resistant to both A and B: treated with AB --ý Maximum failure rate 
& 
However, it is assumed that infections that are only treated with the drugs to which they are 
resistant are essentially. untreated and therefore have a fixed maximum failure rate. The 
maximum failure rates 3,5 and 6 are therefore assumed to be all the same. The cure rates of 
infections sensitive to monotherapy and combination therapy depend on the efficacy of the 
drugs and are reflected in different failure rates (Maximum failure rates I and 2 respectively). If 
an infection, which is resistant to drug A but sensitive to drug B, is treated with a combination 
therapy of AB, it is much more likely to be cured than if treated with drug A alone. However, it 
is still compromised by the resistance to drug A, and therefore the failure rate is higher than in 
infections with a parasite sensitive to drug A or infections treated with drug BC. In the base- 
case scenario, it is assumed that the monotherapy is mefloquine (drug A) and that the 
combination therapy is mefloquine and artesunate (drug AB). 
The other key determinant of failure is whether patients take a sufficient amount of the drug at 
frequent enough doses and for long enough duration in order to reduce the level of parasitaemia 
sufficiently for the remaining parasites to be cleared by host immunity. Patient adherence is 
therefore taken into account when calculating the input value used for the maximum failure rate 
in a non-immune host. This is explained in detail in a later section. 
4.5.16 Characteristics of recrudescent infections io 
Background 
Recrudescent infections are important not only because of the associated morbidity and costs 
but because they are the main source of the spread of resistance. Infections recrudesce because 
the infecting parasite is resistant to the treatment used or because of inadequate dose or duration 
of an efficacious drug, or both. Infections that recrudesce once are more likely than initial 
infections to recrudesce again, resulting in several recrudescent peaks separated by periods 
without detectable parasitaemia (Collins and Jeffery 1999). 
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Recrudescent infections tend to have a lower parasite density but relatively more gametocytes 
than initial infections and are potentially more infectious than initial infections (Handunnetti, 
Gunewardena et al. 1996; Sowunmi and Fateye 2003). Suputtamongkol et al. suggest a relative 
risk of developing gametocytaemia of 49.8 (Cl 14.4-171.9) and 39.8 (CI 9.1-173.4) in patients 
with recrudescence and re-infection compared with patients who are cured (Suputtamongkol, 
Chindarat et al. 2003). Price et al. found that patents who had a recrudescent infection had an 
adjusted odds ratio (AOR) of 2.3 of being gametocytaemic after adjusting for asexual parasite 
density (Price, Nosten et al. 1996). Sowunmi compared primary with recrudescent infections 
following chloroquine treatment in children in Nigeria. Expressing the gametocytes load as the 
Area Under the Curve of time versus gametocyte density (AUCgam), sensitive infections were 
found to have an AUCgam approximately 14 times higher for sensitive compared to resistant 
infections (Sowunmi and Fateye 2003) (R1). Drakeley found that infections which recrudesced 
following chloroquine treatment were 11 times more likely to result in transmissible infections 
in membrane-fed mosquitoes than those that were successfully treated (Drakeley, Jawara et al. 
2004). 
Modelling 
The course of asexual parasitaemia and gametocytaemia is illustrated in Figure 4-9. For model 
simplicity, multiple recrudescence peaks are treated as one long recrudescence and the total 
duration, the parasite density and gametocyte switching rates are determined so that the 
resulting area under the time/gametocyte density curve is equivalent to multiple recrudescent 
peaks. 
In the base-case scenario, the parasite density of recrudescent infection relative to initial 
infections is assumed to be 0.5 'o (R2) and the GSR is assumed to be 20- 
fold that of initial infections (R3). The time interval between initial and recrudescent infections 
input into the model is the time interval between disappearance of parasites in the initial and 
reappearance of parasites in recrudescent infections, and was assumed to be 14 days (R5). This 
is based on the mean "time to recrudescence" which is the time between and first- and second- 
line treatments. This varies depending on drug half-life, with an overall mean of 24 days (95% 
CI 21-27) (Stepniewska, Taylor et a). 2004). 
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Figure 4-9: Schematic diagram of the course of parasituemia and gametocl'taemia during the 
course of a recrudescent infection. Note that the y-axis uses a logarithmic . scale; the relbre 
gametocytes during recrudescence add little to the total gametocyte mass until they reach a 
density of above 1x107 /41. For cured infections only, the asexual parasites in the. first peak (ie 
above the minimum level ofpatency) are assumed to produce gametocytes. 
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4.5.17 Time intervals 
The model iterates by the day; however, some processes take days, weeks or months and 
therefore the appropriate input values for a particular iteration are not based on the output from 
the immediately preceding iteration, but from an iteration some time previously. These time- 
intervals include the interval between inoculation and infectiousness and the interval between a 
change in transmission intensity and the change in immunity profile of the population. 
The time taken for patent infections in one iteration to be translated into potential new infections 
is the time it takes for the malaria parasite to complete its asexual period in humans and its 
sexual period in mosquitoes. The asexual period in humans refers to the period from initial 
inoculation of sporozoites from an infected mosquito into a human host to the time when that 
host is infectious to a biting mosquito. This is equivalent to the pre-patent period (M5) plus the 
time to gametocyte maturation (M6) and is around 20 days. The sexual cycle in the mosquito 
refers to the time from the mosquito taking up gametocytes in a blood meal to the point when it 
is ready to transmit sporozoites to a susceptible human - this is around 12 days (V3). "ý 
As explained earlier, as transmission intensity changes, so does the level of immunity of the 
human population. Obviously, this does not occur immediately and is related to the rapidity of 
change and actual transmission intensity. However there is a lack of suitable data on which to 
base this estimate, therefore for simplicity, in the model immunity is updated every 90 days 
based on the mean transmission intensity in the previous 90 days. 
4.6 Sub-models 
4.6.1 Severe outcomes sub-model 
In order to estimate the "cost of resistance"29 it is necessary to extrapolate from "drug 
resistance" to the clinical and economic consequences in terms of prolonged and severe illness 
and deaths. Because these consequences do not affect transmission directly30, their calculation 
was done in a simple separate model as explained at the beginning of the chapter. 
Background 
Even in the absence of drug resistance, a certain proportion of malaria cases will progress to 
severe malaria and death. The likelihood of this occurring depends on age, immunity, access to 
29 The term "cost of resistance" in this case should not be confused with its other use to describe the 
"fitness cost" to a parasite of having a genetic mutation that confers resistance! 
30 However, in the model those patients more likely to develop severe malaria are also those more likely 
to have a higher parasite density and therefore be more infectious. 
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first-line treatment and treatment-seeking behaviour. In non-immune patients, the likelihood of 
severe malaria in treated symptomatic drug-sensitive infections is probably around 5% and of 
mortality around 0.2% (Luxemburger, Ricci et al. 1997). The mortality rate of severe malaria in 
non-immune adults in clinical trials is around 15-20% depending on the efficacy of the 
treatment (Newton, Angus et al. 2003; Dondorp, Nosten et al. 2005). 
The mortality of untreated malaria in non-immune patients is less certain. From observations of 
Europeans in Africa in the 19`x' century, the untreated mortality rate varied from 9.4 to 57% in 
French troops in Senegal from 1819-1831 (Curtin 1994). Sudre et al. used the Delphi method to 
gather expert opinion on the effect of resistance on case fatality rate (CFR). For children under 
two years old, estimates ranged from between 0.00045 and 0.007 in those with RI resistance to 
between 0.02 and 0.05 in for those with RIII resistance in a high transmission setting (Sudre, 
Breman et al. 1990). Brinkman, in a review of epidemiological studies in Africa, estimated that 
the CFR was between two and 24% depending on age and drug resistance (Brinkmann and 
Brinkmann 1991). 
Modelling 
It is assumed that as the proportion of drug resistant infections rises, there is a sigmoid 
relationship with the likelihood of severe infection or death. This is because when the 
proportion of infections that carry resistant genotypes is low, the intensity of resistance is also 
low, resulting mainly in recrudescent infections. However, as drug resistance rises, the time to 
recrudescence decreases until it is as if the initial infection is untreated. As a result, once this 
threshold occurs, there is an exponential increase in the rate of severe infections and death. 
There is therefore a fixed likelihood of severe malaria in a treated infection (initial or 
recrudescent) in a symptomatic host. This is the "baseline" likelihood of severe malaria, and 
referred to as p("baseline" severe) in Figure 4-10. Those that are symptomatic but untreated are 
much more likely to develop severe malaria and are assigned a maximum likelihood of severe 
infection - p(maximum severe). The effect of immunity on these likelihoods is estimated by 
using the immune function based on severe malaria (Immunity Function 3). It is assumed that 
once a patient develops severe malaria, the likelihood of death is fixed and there is no additional 
effect of immunity". 
To incorporate the increased likelihood of severe malaria in those who are drug resistant, there 
is an additional risk on top of the "baseline" likelihood for recrudescence infections. This 
probability increases according to the level of drug resistance in the population and reaches a 
maximum at 100% resistance, at which point it is assumed that the treatment is useless and the 
31 The CFR of malaria infections of course still varies by age because severe malaria varies by age 
according to immunity. 
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mortality rate is equivalent to an untreated symptomatic infection. The overall likelihood of 
severe infection for recrudescence is expressed as p(severe if recrudesce). This relationship is 
assumed to be a sigmoid relationship and is described by Equation 1-1 and illustrated in Figure 
4-11. 
Equation 1-1: y=Ymin+ ((Ymax * X°) / (XI +(X5o)) 4) 
where y= likelihood that recrudescent infection would become severe, x= level of resistance, 
Ym; n is the likelihood of severity with no resistance, Yn, is the likelihood of severity with 100% 
resistance, a gives the slope of the curve and X50 is the level of resistance at which the 
likelihood of severity is half the maximum. 
The data on which the estimates were based are shown in the parameters tables and can be seen 
to vary widely depending on location, definition and methodology. In the base-case scenario, 
the maximum likelihood of developing severe malaria for a non-immune treated infection is 
estimated at 5% and the untreated infection at 15%, with a mortality rate of severe malaria of 
15% (01,02 and 03). 
4.6.2 Behaviour sub-model 
4.6.2.1. Coverage 
Background 
The coverage rate is important as it has obvious cost implications and is assumed to have major 
implications on effectiveness in terms of clinical cure and drug resistance. In many settings the 
majority of patients seek treatment in the informal sector, where prescribing practices often 
differ from the public sector32. Many patients do not receive the correct treatment, let alone the 
correct dose or drugs of good quality. A significant proportion of patients who receive 
treatment may not actually have malaria. The latter is important because of the cost of 
unnecessary treatments and because the number of people exposed to the risk of adverse events 
is increased. These practical concerns have been a major deterrent to changing first-line drug 
policy to ACTS. Although data were available on the coverage rate and adherence rate to the 
older monotherapies, there was little data on ACTs. 
32 The terms "public" and "formal" sector are used interchangeably to mean providers who have received 
some formal training for the treatment of malaria and who are funded by the government. This includes 
the outreach workers and village malaria worker discussed later. The terms "private" and "informal" 
sector are also used interchangeably to denote all other providers of healthcare. 
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Figure 4-10: Diagram illustrating severe cases as a consequence of initial infections and 
recrudescent infections 
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Figure 4-11: Diagram showing the sigmoid relationship between resistance and severe 
malaria or mortality 
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Modelling 
In the biological model, the "coverage rate" is the likelihood that treated patients receive the 
combination therapy (drug AB or drug BC). It is assumed that all those not treated with the 
combination are treated with the monotherapy (drug A). In the base-case scenario, it is assumed 
that all treatments are received in the public sector where only good quality drugs are available, 
and that they are both correctly prescribed by the health worker and correctly adhered to by the 
patient. However, this is unrealistic. Whether or not patients receive the correct first-line 
therapy requires a number of steps. For simplicity, these individual steps are not included in the 
biological model. Instead the "coverage rate" is considered as an aggregate parameter based on 
the choice of provider and likelihood of receiving diagnosis and combination therapy from 
different providers. These calculations are performed outside the biological model in a simple 
decision-tree "behaviour" sub-model. This allows the calculation of treatment rates, coverage 
rates and adherence rates, given inputs of the proportion of patients going to the private and 
public sector (B1) and the likelihood that they will receive a monotherapy or combination 
therapy (B2). The decision-tree on which these calculations were based is illustrated in Figure 
4-12. In this way, the costs and effect of implementing changes to the coverage rate can be 
explored. For example, if an intervention to provide combination therapy through village 
malaria workers results in a higher coverage rate, then the cost of the intervention and the 
effects in terms of cure rates and drug resistance can be estimated. 
4.6.2.2. Adherence 
The likelihood that a patient will receive the correct dose and be adherent to therapy is also 
dependent on the provider. To allow for this, an extra level of branches is added to the 
"behaviour" decision-tree model (Figure 4-12). The likely adherence rates to the monotherapy 
and combination therapy in the informal and formal sector are input along with the estimated 
maximum failure rates dependent on drug resistance. The resulting aggregate maximum failure 
rates are then used as the inputs into the biological model. This allows examination of the effect 
of shifting treatment provision from the informal to the formal sector on treatment failure, 
transmission and clinical outcomes. 
As mentioned earlier, the two main factors affecting treatment failure rate are drug resistance 
and adherence. Unfortunately, there are very little quantitative data linking adherence rates to 
cure rates. Further, the relationship is not simple or linear and depends on the pharmacokinetics 
and pharmacodynamics of the drug and how the drug is taken in terms of frequency and dosing. 
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Because this is an important relationship in the model, estimates were made based on the 
following approach: 
" What is the known or estimated adherence rate to different antimalarial drugs? 
" If not adherent, how is the drug most likely to be taken (e. g. a duration of three instead 
of seven days for quinine) 
" What is the likely cure rate given the non-adherent behaviour if the infection is a) 
sensitive or b) resistant? 
Some data on the last question could be estimated quite well for some drugs where clinical trials 
have been carried out on different dosing regimes, for example mefloquine. A large number of 
clinical trials of antimalarial drugs were reviewed in order to gather the available information on 
failure rates associated with fewer or lower doses than currently recommended. This was 
entered into an Excel® database and cross-checked with a systematic review of antimalarial 
trials by Dr Hla Myint (Myint, Tipmanee et al. 2004). In addition, a systematic review of 
studies of adherence to antimalarials was also undertaken and is presented in the next chapter. 
Where data were not available, estimates were based on expert opinion and estimated from 
available data and the known properties of the drugs. The result, of this exercise are 
summarised in Table A6-14 in the Annex. 
4.6.3 Cost-effectiveness sub-model 
The annual outputs from the biological model and severe outcomes model are placed in an 
Excel®-based model in order to calculate DALYs and costs. The results from two or more 
different scenarios can then be compared in order to examine the relative costs and cost- 
effectiveness of different policies or implementation strategies. 
4.6.3.1. First-line drug cost and cost of improving access 
The annual cost of first-line drugs is obtained by attaching the cost of the monotherapy or 
combination therapy (inclusive of packaging, freight and wastage) to the annual number of new 
cases treated with those drugs and according to three age groups33. The incremental cost of 
drugs is the numerator used in the calculation of the cost-effectiveness ratios. In the scenarios 
in which interventions to improve access to diagnosis and treatment are introduced, the 
incremental cost also includes the cost of the interventions. This consists of the annual fixed 
cost and the variable costs that depend on the number of patients seen and treated, and comprise 
33 For pre-packaged artesunate and mefloquine in Cambodia, the cost of different age-group packages was 
used. Otherwise the cost of drugs was assumed to be 50% and 25% that of adults for the 6-12 year old 
and the <6 year old categories respectively. 
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the cost of rapid diagnostic tests, in addition to the costs of antimalarial drugs. This is explained 
further in Chapter 6. 
4.6.3.2. Total cost of malaria treatment 
The total costs of malaria include the costs of the initial infection and the costs of treatment 
failure in terms of the recrudescent infections and severe infections. In the base-case scenario, it 
is assumed that all malaria cases go a public health facility for the initial, recrudescent and 
severe infections. 
For patients, the main direct costs are of transport for the patient and carer to the health facility 
and for food and other consumables during their time at the health facility (UC2). For severe 
infections, the average in-patient stay was estimated to be five days (IC3). Although user fees 
are often charged, as this does not represent a net change in overall "societal" costs, for 
simplicity, it is assumed that the cost of consultations is borne by the provider. 
For the provider, the cost of the outpatient treatment of the initial infection includes the cost of 
consultation (UCl) and microscopic diagnosis (UC5), in addition to the cost of the first-line 
drug. It is assumed that uncomplicated recrudescent cases are treated as outpatients and the 
costs include the cost of more costly second-line drugs. F^ or swere infections, it is assumed thaw 
patients require five days in-patient treatment and receive three days of parenteral quinine, four 
cost of investigations, consumables the hotel costs of staying in hospital based on the 
In addition, the total costs inclusive of the indirect costs are also estimated - although as noted 
previously, indirect costs are notoriously difficult to estimate reliably. In this analysis, it was 
assumed that the total number of lost days of productivity (inclusive of carers' loss) was five 
days for uncomplicated episodes (PC1) and 10 days for severe episodes (PC2). The loss was 
assumed to be the same whether the patient was a child or an adult, based on the assumption 
that an adult would not be able to work while looking after a sick child. The daily loss of 
income was estimated at US$1.5 based on the daily labourer's wage in Cambodia (PC3). 
The costs and benefits to private, or "informal", sector providers are not included as this was 
felt to fall beyond the scope of this analysis. However, where the informal sector is an 
important source of malaria treatment, the successful implementation of drug policy is 
dependent on involving them in the process. This requires an understanding of the sector and 
implementing strategies that will impact on their prescribing behaviour, for example subsidising 
the cost of drugs and rapid diagnostic tests. Thus, it is an important area for future analysis and 
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average cost per in-patient day (IC6). The cost of death per se is not included. 
the overall model structure has been developed to enable the incorporation of costs and benefits 
to the informal sector in later analysis. 
4.6.3.3. DALYs 
Effectiveness is also expressed in terms of Disability Adjusted Life Years (DALYs) averted. In 
this analysis, the years of life lost were based on the life expectancy tables for West Africa, 
which are typical of developing countries34, and disability weights were taken from the Global 
Burden of Disease study (Murray and Lopez 1996). Initial and recrudescent infections were 
assigned a weight of 0.211, with an average duration of 0.01 years. Neurological sequelae were 
given a weighting of 0.473 if untreated and 0.436 if treated, with an average duration of 35.4 
years. The likelihood of neurological sequelae for severe malaria was assumed to be 0.0093. 
This was based on the likelihood that severe malaria is associated with cerebral malaria and the 
likelihood that cerebral malaria would result in neurological sequelae. However, estimates of 
the frequency, duration and severity of different types of neurological sequelae vary 
enormously. Although effects of low birth weight, chronic anaemia and effect on co-morbidity 
were not included, which therefore results in an underestimate of the actual burden of disease, 
by far the largest contribution to DALYs in malaria are the childhood deaths (Snow, Korenromp 
et al. 2004). 
DALYs were discounted at a rate of 3% to aid comparison with other studies in the field 
(Goodman, Coleman et al. 2001). This was varied to 0% in the sensitivity analysis. This results 
in health benefits in the future accounting for less than those occurring currently, although this 
has been criticised as being inequitable. This is particularly the case in an analysis such as 
antimalarial resistance where the major effects of an intervention are expected in the future 
(Coast, Smith et al. 1996). However, this has now become accepted as standard practice in 
economic evaluations. Age weighting of DALYs has been advocated by some authors (Murray 
and Lopez 1996). This is where more weight is given to the years lived between the ages of 9 
and 54 years than those outside of this range in an effort to capture some value of the notion of 
"productive years". This remains controversial and, counter-intuitively, actually results in more 
importance being placed on deaths occurring in the 0-27 age group than in the 9-54 age group 
(Barendregt, Bonneux et al. 1996). In addition, weighting would not be expected to make any 
difference to the cost-effectiveness in the analysis and therefore was not incorporated in the 
base-case scenario, but was explored in the sensitivity analysis 
34 West Africa was chosen rather than the table available for Cambodia because the values were very 
similar but were not available down to one-year age groups for the latter. 
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4.7 Assumptions 
Although a more comprehensive model than previous models of antimalarial resistance, as in 
any model there was a trade-off between realism and simplicity and a number of assumptions 
were made, many of which are unlikely to make a material difference to the outcomes of the 
model. The important assumptions are described below, with a more detailed discussion on the 
possible implications for policy and future research in the final chapter. 
The population of humans was fixed in total number and in age-structure over time. Therefore, 
it was assumed that the number, age and level of immunity of humans that entered (as births or 
in-migrations) balanced those that exited (as deaths or out-migrations). Although immunity 
varied by age group, some other characteristics were assumed not to be affected by age, in 
particular the likelihood of inoculation, the likelihood and type of treatment, adherence to 
treatment and death in the case of severe malaria. In addition, within each age group the 
population was homogenous, so variations between individuals and groups were not allowed. 
Therefore, the effect of individual differences in immunity and of differences in immunity 
between ethnic groups or due to genetic differences such as sickle cell trait, could not be 
explored. 
The vector population was also assumed to be homogenous, although monthly vectorial 
capacity was allowed to vary to simulate seasonal changes. 
In terms of human immunity, it was assumed that there was no refractory period, thus patients 
could receive a new infection at any time after being cured of an infection. However, once 
infected, it was assumed that further infection was not possible - that is, that there was no super- 
infection - and all infections were therefore single clonal. Clearly, the use of the immunity 
functions themselves is based on the assumption that they accurately represent the relationship 
between age and EIR and the intermediate outcomes in the model. Children aged one year or 
less were the least immune, although it is known that in high transmission settings infants under 
six months are afforded some protection from the in-utero transfer of maternal antibodies. 
However, attempting to incorporate this into the immunity functions was not possible and it is 
unlikely to make a material difference to the overall results. It was also assumed that there was 
no specific transmission-blocking immunity. 
If infections were treated, there were only two treatment choices, the monotherapy or 
combination therapy, and if infections were not treated then the human hosts were assumed to 
have the same immune characteristics as immune non-symptomatic individuals. 
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Like most other models, a number of simplifying assumptions were made about drug resistance 
and treatment failure. It was assumed that resistance was a binary phenomenon and that 
complete drug resistance that rendered a drug completely ine f vt e wa le 
r genetic event. It was also assumed that there was no fitness disadvantage of being a resistant 
mutant and there was no cross-resistance between drugs. It was assumed that treatment failures 
are uniform in character and consist of a recrudescent infection that becomes detectable 14 days 
after the initial infection. 
The model does not take into account var switching which would act to decrease the 
susceptibility of parasite infections to clearance by the human immune system (Peters, Fowler et 
al. 2002). 
Finally, in the cost-effectiveness modelling, it was assumed that the cost of drugs were the same 
whether or not patient was adherent to therapy. However, this could be varied in the sensitivity 
analysis if necessary. 
4.8 Summary 
In summary, this is a deterministic, age-stratified, population-based, dynamic bio-economic 
model of the spread of antimalarial drug resistance in the human and parasite population. It 
iterates on a daily basis and incorporates a large number of factors that are thought to be 
important in the transmission of drug resistance. In addition to epidemiological factors such as 
vectorial capacity and the potential for seasonality, which allow the spread of drug resistance in 
different transmission settings to be explored, it has at its core the effect of human immunity 
and treatment on the outcome of potential infections, both in terms of clinical failure and 
infectiousness. This feeds back into the model to ensure that changes to either are reflected in 
the future in terms of transmission intensity and the spread of drug resistance. It incorporates 
drug characteristics including rapidity of action and effect on gametocytes, and also takes into 
account the possible effect on drug resistance of chemoprophylaxis due to prior exposure to an 
antimalarial drug. The model was developed within an economic framework with an intention 
of being able to generate tangible clinical and economic outcome to help address policy-relevant 
questions using data such as coverage rates, failure rates, rates of adherence, cost of drugs and 
interventions to maximise access. As these data were clearly important in determining the 
outcomes of the model, the comprehensive collection of secondary, and in the case of coverage 
and adherence rates to artemisinin-based combination therapy - primary, data was made a 
priority and is covered in the next three chapters. 
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CHAPTER 5 
SYSTEMATIC LITERATURE REVIEW: 
ADHERENCE TO ANTIMALARIAL DRUGS35 
The objectives of this review are to summarise the current knowledge on adherence, the 
effectiveness of interventions to improve antimalarial drug usage, and the effects of patient 
adherence on therapeutic response. 
5.1. Material and methods 
5.1.1. Search strategy 
The medical literature was searched using PubMed under the following terms ("malaria" OR 
"antimalarial") AND ("compliance" or "adherence" or "prescri* or" or "drug usage"). Studies 
in all languages were considered. 
The bibliographies from studies and reviews were then searched manually for relevant 
references. In addition, the International Network for Rational Use of Drugs (INRUD) database 
was screened for unpublished work and a further search was carried out using the ScirusTm 
search engine, which combines Medline and Embase and also searches websites for unpublished 
material. Finally, we solicited materials of interest from individuals known to be active in the 
field. 
5.1.2. Criteria for inclusion 
Studies that were clearly irrelevant were first discarded. The remaining studies were examined 
for information about use and/or effect of antimalarial drugs in the treatment (not prophylaxis) 
of malaria. These were included for further analysis if they fulfilled the following criteria: 
" Studies with original quantitative data on patient "adherence" to a prescribed 
regime of antimalarials or comparing "self-treatment" with recommendations. 
" Studies of interventions to improve antimalarial usage where patient or carer 
behaviour were assessed. 
35 Published as Yeung S., White N. J. (2005). How do patients use antimalarial drug? A review of the 
evidence. Trop Med Int Health 10(2): 121-138. 
130 
" Clinical trials reporting objective measure(s) of effectiveness of unsupervised 
treatment either in comparison with supervised treatment or with an assessment 
of adherence. 
The following categories of study were excluded: 
" Studies conducted in populations in which malaria is not endemic. 
" Studies/reviews on chemoprophylaxis or mass treatment. 
" Clinical trials with no data on effectiveness of unsupervised treatment or patient 
adherence. 
" Studies of knowledge, perceptions or behaviour with no quantitative data on 
drug usage for specific and recent illness episodes. 
" General reviews with no original data. 
Two reviewers undertook the initial search and sorting independently. Where there was 
discordance over whether or not a paper should be included in the review, this was resolved 
through discussion. 
5.2. Results 
5.2.1. Studies identified 
The initial search using PubMed resulted in 1292 hits. Many of these studies were irrelevant, 
referring to the use of antimalarials or antibiotics in the treatment of non-malaria conditions 
such as the quinine for leg cramps or cardiac arrhythmias, chloroquine for the treatment of 
rheumatoid arthritis, or dapsone for leprosy. There were also a large number of articles of 
general travel advice, adverse effects of antimalarials and general reviews. 
The search of bibliographies, hand searching journals and personal communication resulted in 
eight additional studies. Finally only 24 studies that fulfilled the inclusion criteria were 
identified. Of the excluded studies, two thirds were on chemoprophylaxis or mass treatment, 6% 
were clinical trials (often of short course regimens in which adherence was mentioned but not 
measured), and 7% were reviews about adherence that did not contain any original data. The 
remaining 8% of the studies were an assortment of studies on economics, treatment seeking and 
diagnosis. The result of the search process is shown in Figure 5.1. 
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Figure 5-1: Result of literature search 
Pubmed search 
("malaria" OR "antimalarial") AND 
("compliance" OR "adherence" OR "prescri*) 
NOT "cytoadherence" 
N=1292 
Discard irrelevant studies 
N= 187 
Sort studies according to 
inclusion and exclusion criteria 
N=16 
Additional search (Scirus® 
Included studies N=8 search engine, bibliographies 
N=24 and personal communication) 
5.2.2. Types of study 
The search captured a wide variety of studies, which for ease of description are presented as 
follows: 
(1) Descriptive studies of "How do patients actually take antimalarial drugs? " 
a. When they are prescribed by a trained provider 
b. When bought in the community 
(2) Intervention studies which looked at "How can drug usage be improved? " 
(3) Clinical outcome studies which examined "Does non-adherence matter? " 
Of the 24 studies, there were eight "purely descriptive" studies (four clinic based and four 
community based), nine "interventions" studies and seven "outcome" studies. There was 
obvious overlap between these categories in that intervention studies and some clinical outcome 
studies included descriptions how drugs were used by patients. 
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5.2.3. Study populations 
Thirteen studies were undertaken in Africa, nine in Asia and two in South America. Of the 13 
studies in Africa, 10 were on children only and three were on both adults and children. In Asia, 
four of the eight studies were on adults only and the other four on both adults and children. 
Both studies in South America included adults and children. 
5.2.4. Definitions 
By default, the definition of malaria differed by the location and type of study so that in all the 
community based studies the diagnosis of malaria was self-defined whereas in most clinic-based 
studies, diagnosis was confirmed biologically. 
There was wide variation in definitions for the terms "home or self-treatment", "compliance" 
and "adherence" which reflected the range of study approaches and methodologies. The terms 
"home treatment" or "self treatment" imply that treatment was obtained without consultation 
with a formal sector provider, however studies differed in whether treatment from private 
providers was included or not. 
A wide range of definitions of full adherence, non-adherence, under- and overdosing were used, 
with a minority of studies using detailed definitions of adherence that included dose, duration 
and frequency (Yepez, Zambrano et al. 2000; Ansah, Gyapong et al. 2001; Depoortere, 
Guthmann et al. 2003). Definitions such as "bought and used full course" were not uncommon 
and even where doses were specified, the criteria for adherence differed from study to study. 
However, the implications of failing to take one of the 70 tablets in an adult course of treatment 
with quinine and tetracycline are considerably different to those of not taking one of the three 
tablets in a treatment with SP, or one of the five tablets in a mefloquine treatment. Clearly there 
is a considerable subjective element to both the definition and its assessment. For the purpose of 
comparing different studies in this review, a standardised operational definition of "full 
adherence" was used and the term "compliance" was replaced by the currently more acceptable 
term, "adherence". This meant that the antimalarial was taken at a dose and duration that was 
considered to be within a range that would result in the same efficacy as the recommended 
regime. As few studies reported the actual frequency of administration, this was not included in 
the definition. Where the authors themselves had used a similar definition, their categorisation 
was used directly. In other cases, the data reported were used to obtain the best estimate e. g. if 
the only data available was on "non-adherence" defined as "failing to take the full course" then 
it was assumed that everyone else was " adherent". 
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5.2.5. Measurement of drug usage or adherence 
Patient drug usage can be assessed by a number of means including self- or carer report, pill 
counts or container inspection, electronic counters and blood or urine drug assays. 
5.2.5.1 Drug assays 
Drug assays were used in six studies, either as the sole measure of adherence (Na-Bangchang et 
al. 1997; Shwe et al. 1998) or as a supplement to reported behaviour and container inspection 
(Qingjun, Jihui et al. 1998; Marsh, Mutemi et al. 1999; Kofoed, Lopez et al. 2003; Fogg, 
Bajunirwe et al. 2004). 
Blood mefloquine levels on day 2 were used to assess adherence to a two-day course of 
artemether and mefloquine in Thailand. Patients were considered fully adherent if the 
mefloquine level was within or above the 95% confidence interval of the same regime 
supervised. Using this definition, 87% of patients were considered fully adherent, 11.3% were 
partially adherent, and 2% had undetectable levels (Na-Bangchang, Congpuong et al. 1997). 
In another study of adherence to a five-day regime of artesunate with mefloquine, one tablet 
each of chloroquine and quinine were added to the blister-packages of artesunate and 
mefloquine on day 3 and day 5, respectively. The presence of both chloroquine and quinine in 
the urine was taken to mean full adherence and was reported to be 99.5% (Shwe et al. 1998). 
The other studies mainly relied on drug histories with or without tablet inspection and 
selectively used drug assays to complement or validate this information. 
In the study of adherence to artemether-lumefantrine in Uganda, adherence was assessed by 
interview and inspection of the blister-package, and this was compared to plasma levels of 
lumefantrine on day 4. Although levels were lower in the non-adherent patients than in the 
adherent patients, this difference did not reach significance (Fogg, Bajunirwe et a1.2004). 
Marsh et al. found that blood chloroquine levels in children whose carer reported full adherence 
to a 25mg/kg dose taken unsupervised at home, were not significantly different from levels in 
children who had received 25mg/kg under supervision (Marsh V. M. et al. 2004). A similar 
finding, suggesting that carers' reports of adherence were reliable was reported by Kofoed et at. 
who found that the median day 7 chloroquine levels in children w lose mot ers had retained 
empty medicine bags did not differ significantly from those who had thrown them away (546 
i1/1 versus 644 nmol/1 respectively, P>0,05) (Kofoed, 
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Comparability between drug assays and self-reported adherence in adults was also found in the 
study by Qingjun et al.. In this two-phase study adherence to blister-packaged chloroquine and 
primaquine was reported to be 97% both when assessed by self-report in one set of patients and 
when assessed by the presence of urinary phenobarbital, which had been added to the blister- 
packages as a marker drug, in another set of patients (Qingjun, Jihui et al. 1998). 
5.2.5.2. Other measures 
In the remaining studies, adherence was measured using drug histories with or without pill- 
counting or container inspection and in one study was not assessed at all, being purely a 
comparative study of effectiveness of drugs taken with and without supervision (Smithuis et al. 
2003). 
Several studies also included qualitative assessments such as focus group discussions and key 
informant interviews to validate the results of household surveys (Marsh, Mutemi et al. 1999; 
Ansah, Gyapong et al. 2001; Yeboah-Antwi, Gyapong et al. 2001; Reilley, Abeyasinghe et al. 
2002). 
5.2.6. Adherence to clinic-prescribed antimalarial drugs 
Thirteen studies gave details of adherence to antimalarial drug regimes prescribed in clinics 
prior to any intervention either as purely descriptive studies (n=3), as a baseline in intervention 
studies (n=5) or as part of a clinical effectiveness study (n=5). These results are pooled and 
discussed by drug regime. 
5.2.6.1. Chloroquine 
Three studies which reported adherence to three-day chloroquine regime using syrup in children 
prior to any intervention, all showed poor levels of adherence of 33-42% (Ansah et at. 2001 
(Ansah, Gyapong et al. 2001; Okonkwo, Akpala et al. 2001; Yeboah-Antwi, Gyapong et al. 
2001) although one further study suggested no difference in chloroquine levels between 
supervised and non-supervised patients (Kofoed, Lopez et al. 2003). Overdosing was reported 
to be around 40% for a three-day regime (Nshakira, Kristensen et al. 2002), and I% in the single 
study of a one-day regime (Deming et al. 1989). 
5.2.6.2. Chloroquine and primaquine 
Interestingly, despite generally longer and more complicated regimes, clinic based studies of 
adherence to chloroquine and primaquine conducted in Asia and South America showed 
generally higher levels of adherence. Thus, adherence rates varied from 58% to a three-day 
course of chloroquine and seven-day course of primaquine in Ecuador (Yepez, Zambrano et al. 
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2000), to 82% to a three-day course of chloroquine and eight-day course of primaquine in a 
study in Sri Lanka (Reilley, Abeyasinghe et al. 2002). 
5.2.6.3. Quinine and tetracycline or doxycycline 
Only one study, by Fungladda et al., documented adherence to a seven-day regime of quinine 
(three doses/day) and tetracycline (two doses/day). Self-reported adherence was surprisingly 
high at 72% (Fungladda, Honrado et al. 1998). One further study reported adherence levels of 
84%, but did not differentiate between the three-day chloroquine and 14-day primaquine regime 
for vivax malaria and the seven-day quinine and doxycycline regime for falciparum malaria and 
suffered from potential recall bias as patients reported on their last malarial episodes, some of 
which had occurred more than two years earlier (Duarte & Gyorkos 2003). 
5.2.6.4. Artemisinin monotherapies and combination therapies 
The study by Fungladda also reported adherence levels of 98% to a five-day artesunate 
monotherapy regimen. Other studies reported adherence to three-day artemisinin combination 
therapies with mefloquine or SP and co-formulated with lumefantrine. When mefloquine 
tablets were not provided together at the same time and place, very few (<5%) patients 
reportedly bought and took both components (Shwe, Lwin et at. 1998). Much better levels of 
adherence were reported when both component drugs were provided together, with adherence 
levels of 78% for a three-day course of artesunate and SP in Zambia (Depoortere, Guthmann et 
al. 2003) and 87% for a two-day course of artesunate and mefloquine in Thailand (Na- 
Bangchang, Congpuong et al. 1997). In an excellent study in Uganda which used self-report, 
pill counting and blood drug levels, adherence to a three-day course of co-formulated 
artemether-lumefantrine (Co-artem(D) was reported to be even higher at 90-93%, even though 
twice daily dosing was required (Fogg, Bajunirwe et at. 2004). 
5.2.7. Antimalarial drug usage in the community 
Seven studies described use of antimalarial drugs for treatment of malaria-like illness in the 
community. Of these three were purely descriptive studies (Table 5-1 and 5-2) and four were 
from the pre-intervention phase of intervention studies (Table 5-3). Five of the studies 
documented the use of chloroquine use in Africa. For a standard three-day course the median 
reported correct usage was around one third (Thera, D'Alessandro et al. 2000; Nshakira, 
Kristensen et al. 2002), with a wide range from less than 10% (Marsh, Mutemi et al. 1999) to 
68% (Krause and Sauerborn 2000). However the settings and methodologies varied 
considerably. In particular the type of provider accessed by the study populations differed 
considerably. For example in the study in Mali, even though only 8% of respondents sought 
treatment at health centres, over half of the remainder obtained their treatments through 
pharmacies or drug shops linked to health centres where they were more likely to receive 
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antimalarials at the correct dose. This compares to the two studies by Marsh et at., where the 
main source of treatment was small general shops with untrained shopkeepers where the type 
and duration of treatment is largely determined by the client's ability to pay. The relatively high 
adherence rate from the Burkina Faso study may be explained in part by the fact that follow-up 
was conducted mid-way through the treatment course rather than after completion. In addition 
the results represent only the small proportion of clients who were successfully followed-up. 
Even when compared to a recommended one-dose regime of chioroquine, only 29% reportedly 
took the right dose. Overdosing rates were similar to those in the clinic based studies (Marsh, 
Mutemi et al. 1999; Thera, D'Alessandro et at. 2000). 
The two remaining community based studies were conducted in Cambodia, the first in 1998 
when the recommended treatment was seven days of quinine (three doses/day) and tetracycline 
(two doses/day). Only one to 10% of those who bought quinine and tetracycline, bought and 
used the full course (Denis 1998). In the second study in 2002, of those who took the new 
recommended first-line therapy of blister-packaged artesunate and mefloquine, over 77% were 
adherent (i. e. completed the blister-package over three days). However, less than 10% of the 
^ respondents actually received the recommended therapy in the first place and that artesunate 
monotherapy in inadequate doses was one of the most popular options (Yeung, Socheat et at. 
004). 
5.2.8. Interventions to improve adherence 
Table 5-3 and 5-4 summarise the four community-based and five clinic-based studies that 
assessed interventions aimed at improving patient drug usage. In all studies the authors found 
that at least one intervention had a significant effect in improving patient drug usage. 
Of the clinic based studies, four were randomised control trials (RCTs), three based on 3-day 
chloroquine treatment in African children, examining the effect of packaging (Yeboah-Antwi, 
Gyapong et al. 2001), formulation (Ansah, Gyapong et al. 2001), and patient or carer education 
(Okonkwo, Akpala et at. 2001) and one RCT of blister-packaging of chloroquine and 
primaquine in China. All the community based studies were of a pre- and post- intervention 
observational study design except one in which two types of study design were used (Sirima, 
Konate et al. 2003). 
5.2.8.1. Clinic based interventions 
Drug formulation and packaging 
For children, adherence to chloroquine in tablet form was found to be significantly better than 
syrup in two RCTs (Ansah, Gyapong et al. 2001; Yeboah-Antwi, Gyapong et al. 2001). Pre- 
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packaging drugs in age-specific quantities, resulted in a reported increase in adherence of about 
20%, from 33% to 54% for syrup and from 61% to 80% for tablets (Yeboah-Antwi, Gyapong et 
al. 2001). 
Only one study directly compared the effectiveness of blister-packaging with conventional 
dispensing. In this RCT, Qingjun et al., showed that adherence to a regime of chloroquine 
(three days) with primaquine (eight days) for the treatment of P. vivax infections, was already 
high (81-83%) when provided in traditional paper envelopes from clinics (Qingjun, Jihui et al. 
1998). By replacing this with blister-packaging, adherence was reported to increase to 97%. 
Although one other study did report remarkably high levels of adherence (99.5%) to a blister- 
packaged five-day regime of artesunate with either mefloquine or a placebo (Shwe, Lwin et al. 
1998), the non-intervention group were not even provided with the drugs concurrently and were 
expected to go to a different outlet in order to obtain the mefloquine. 
Patient/carer information and education-clinic 
One study, an RCT, specifically studied the effectiveness of instructions for carers on the 
correct use of drugs; this was for the use of chloroquine syrup in children in Nigeria (Okonkwo, 
Akpala et al. 2001). At baseline, with no intervention, adherence was only 37%. With pictorial 
instructions alone, this increased significantly to 52% and with both pictorial and verbal 
instructions adherence increased further to 73%. 
5.2.8.2. Community based interventions 
Behaviour change communication 
In Kenya a pilot programme was undertaken during which drug vendors were trained to treat 
childhood fevers with chloroquine and provided with age-specific dosing charts. Pre- and post- 
intervention assessments showed that the number of childhood fevers treated with chloroquine 
increased and in those who received it, adherence to the correct age-specific dose increased 
from 4% to 75% and correct duration from 23% to 47% (Marsh, Mutetui et al. 1999). 
Following a switch in national drug policy to SP (which has the advantage of a single dose) and 
the further scaling up of this programme, this improvement in drug usage has been sustained 
(Marsh, Mutemi et al. 2004). 
Community education appeared to improve drug usage in a pre- and post-intervention 
observational study in Cambodia at a time when the recommended regime was quinine and 
tetracycline (Q+T) for seven days (Denis 1998). In villages with posters only, adherence in 
those who bought Q+T reportedly increased from one to 15% and the proportion of patients 
buying Q+T increased from 47 to 54%. In villages using both videos and poster the 
corresponding increases were from 10 to 38% and 57 to 74%. The evaluation was only 
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conducted immediately before and after the 10-week intervention, and so the long-term impact 
of the campaign in unknown. 
Clinical outcomes and interventions 
Four of the clinic based studies reported some measure of outcome. However because follow- 
up was very short and relied on carer reports and was unlikely to identify most recrudescent 
infections, it is not possible to comment accurately on the relationship between interventions to 
improve adherence and clinical outcomes from the data presented. These reported "recovery 
rates" were uniformly high and did not differ significantly between groups. 
In the community based study (Sirima, Konate et al. 2003) in BurkinIFaso, the measure of 
clinical outcome was the incidence of probable severe malaria. The intervention was a 
community malaria control programme which involved a number of integrated strategies 
including the training of community health workers and providing them with pre-packaged 
antimalarial drugs (PPAM). Unfortunately, no pre-intervention data are presented, however, 
post-intervention, the incidence of probable severe malaria in children who had received PPAM 
for a malaria-like episode was reported to be 5%, compared to 11% for those who had not 
(adjusted odds ratio of 0.47 (95% CI 0.35,0.64; P<0.0001). Interestingly, receiving the incorrect 
age-specific package or taking incorrect duration was not shown to make any difference to the 
outcome (P=0.64 and P=0.23 respectively). 
5.2.8.3. Cost of interventions 
Some information on the cost of interventions was available from six studies. Only one study 
on pre-packaging of chloroquine gave detailed financial and economic costs from both the 
government and caregivers perspective (Ansah, Gyapong et al. 2001). 
Cost of pre-packaged drugs was also reported in the study by (Yeboah-Antwi, Gyapong et al. 
2001), who found that the average cost to the patient who received treatment in intervention 
dispensaries (with pre-packaging) was almost half that in non-intervention dispensaries 
(US$0.38 versus US$0.72). From the patients perspective, Sirima found that if patients bought 
pre-packaged antimalarial drugs (PPAM) from the community health worker (CHW), the cost 
of treatment was US$0.05-0.12 compare to the standard practice of buying 20 tablets each of 
chloroquine and paracetemol for US$0.70 (Sirima, Konate et al. 2003). However, Yeboah- 
Antwi et al. noted that some patients preferred to have extra medication in order to treat future 
episodes, and it may be that some would be willing to pay more for this option. In the study by 
Okonkwo inserting a pictorial insert added US$0.01 to the mean cost of a bottle of syrup 
(US$0.30) (Okonkwo, Akpala et al. 2001). 
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From the private vendors' perspective, treating childhood fevers with chloroquine as well as 
antipyretics increased the mean cost per treatment from US$0.15 to US$0.21 and this increased 
profitability was perceived as a benefit by the vendors (Marsh, Mutemi et al. 1999). 
5.2.9. How much does adherence affect clinical outcome? 
Seven clinic-based studies reported parasitological outcome in relation to unsupervised or non- 
adherent antimalarial drug taking. Only one of these studies was conducted in Africa (using 
chloroquine in children) (Kofoed, Lopez et al. 2003). There were three RCTs comparing 
supervised versus unsupervised treatment, one RCT comparing the outcome of different drug 
regimens both given unsupervised (effectiveness), two observational follow-up studies relating 
patient adherence to outcome, and one longitudinal cohort study relating adherence with therapy 
to subsequent incidence of malaria attacks (Table 5-5). 
5.2.9.1. Chloroquine 
There was one RCT of supervised versus unsupervised treatment with chloroquine in children in 
Guinea-Bissau in 1996 (Kofoed, Lopez et al. 2003), where the cumulative failure rate up to day 
35 was high in both the unsupervised group (47%) and in the supervised group (36%) 
(Cumulative relative risk =1.26; 95% CI 0.76-2.10, Logrank test, P=0.37). Day 7 chloroquine 
levels were not significantly different between the two groups. 
5.2.9.2. Chloroquine and primaquine 
In Ecuador, Yepez et al. compared 14-day cure rates in self-reporting non-adherent and adherent 
patients. For patients who were adherent to the three-day course of both drugs for falciparum 
malaria, cure in adherent patients was 90% compared to non-adherent patients in which it was 
69%; adherence was reported to be 74%. For patients with vivax malaria for whom 
recommended treatment consisted of three days of chloroquine and seven days of primaquine, 
adherence was significantly lower at 58%. Cure rates were "high" in both adherent and non- 
adherent groups at 100% and 94% respectively, however with only 14 days of follow-up, few 
failures would have been detected. 
Adherence and outcome with chloroquine and primaquine (14 days) treatment of P. vivax 
infection was also studied in Brazil (Duarte and Gyorkos 2003). Patients in the community 
were asked when they had received their last treatment for vivax or falciparum malaria infection 
and whether they completed the course. They were then followed-up to record the incidence of 
malaria episodes. Unfortunately the results for patients treated for vivax malaria are not 
presented separately from those who were treated for falciparum malaria, who should have 
received quinine for three days and doxycycline for seven days. Overall, the authors conclude 
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that poor adherence was an important predictor of subsequent malaria episodes, but only in 
individuals who were "less immune". 
5.2.9.3. Quinine and tetracycline 
In a comparative trial of the effectiveness of five-day artesunate monotherapy and seven-day 
quinine and tetracycline in Thailand (Fungladda, Honrado et al. 1998), "cure rates" were 
assessed very early, at the end of the treatment (i. e. days 5 and 7 respectively). The cure rate to 
the quinine and tetracycline regime was reported to be 77% in the 53 out of 60 (88%) patients 
followed up. Adherence was reported to be 72% with cure rates of 73% in the non-adherent and 
79% in the adherent group. 
5.2.9.4. Artemisinin derivative monotherapy 
In the other arm of the Fungladda et al. study, the five-day "cure rate" to artesunate 
monotherapy was reported to be 100% in the 61 out of 77 (79%) patients followed up. 
Adherence to this regimen was reported to be 98.4%. 
Efficacy and effectiveness were compared with five-day regimens of either artesunate or 
artemisinin monotherapy in Vietnam (Le, Pham et al. 1999). With artemisinin, the 14-day 
parasitological cure rate in the supervised "efficacy" group was reported to be 100%, 
significantly higher than the unsupervised "effectiveness" group, in which it was 83.3%. With 
artesunate a difference was not seen; corresponding values were 100% and 97.1%, respectively. 
However treatment groups were small and again follow-up was too short at only 14 days, which 
is insufficient to define the true treatment failure rate. 
5.2.9.5. Artesunate and mefloquine 
Fortunately the most rigorous "outcome" study may also have the most relevance to countries 
contemplating a switch in drug policy to ACTs. In this health centre based RCT in Myanmar 
(Smithuis, van de Broek et al. 2003), four artesunate and mefloquine regimes were compared 
including a supervised and unsupervised regime of artesunate 4mg/kg/day for three days and 
mefloquine 25mg/kg, where the only dose to be supervised was the first day's dose of 
artesunate. After 42 days of follow-up, there were no recrudescences in the 177 patients who 
received the three-day regime under supervision and only seven (polymerase chain reaction 
(PCR) confirmed) recrudescences in the 180 unsupervised patients, giving a cure rate with 
unsupervised treatment of 96% (95% CI: 93 to 99%). Although this difference was significant, 
unsupervised treatment was still extremely effective. 
The effectiveness of a two-day course of artesunate and mefloquine was also studied by Na- 
Bangchang. However, only 43% of the patients were followed up to day 42. The cure rate 
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reported for these patients was high (92.6%), and thought to be similar to the 96.4% cure rate 
reported with supervised treatment in a previous efficacy studies at the same site (Na- 
Bangchang, Congpuong et al. 1997). 
5.3. Discussion 
In recent years there has been considerable interest and concern in translating antimalarial 
efficacy (documented usually with observed treatment in randomised controlled trials) into 
effectiveness, when these drugs are taken unsupervised in "real life" settings in malaria-affected 
communities. The importance of understanding how antimalarial drugs are used in the 
community, how their use might be improved, and the effect on clinical outcome are reflected in 
the growing number of studies in this area. Of all the studies reviewed, all except one were 
published in the last 10 years, and 13 were reported in the last five years. The utility and quality 
of studies has improved with more recent publications, reflected as clearer definitions of 
adherence, an increasing number of randomised control trials, and longer periods of follow-up 
for patients in effectiveness trials. However, the overall quality and quantity of information 
available to date is still seriously inadequate and results are so variable that it certainly does not 
justify generalisations on how good or bad adherence is to currently available drugs in different 
settings. 
There are a number of limitations to this review. Although the search strategy involved more 
than one electronic database and personal communications, it is possible that we failed to 
identify studies that would have fulfilled the inclusion criteria. We did not include unpublished 
work such as project reports, theses, and local surveys, although a substantial amount of 
information is available from these sources, because we could not be sure of either the 
completeness of the search or the quality of the data. The review was limited to studies that 
provided quantitative information related to the use of antimalarial drugs by patients for specific 
episodes of malaria. We did not attempt to include studies of treatment seeking behaviour, 
qualitative studies, or evaluations of provider behaviour. These studies contribute greatly to our 
understanding of the factors underlying the drug usage behaviour of patients. These include 
assessment of socio-economic factors (Kaewsonthi and Harding 1986; Snow, Peshu et al. 1992; 
Molyneux, Mung'Ala-Odera et al. 1999; Biritwum, Welbeck et al. 2000; Kaurat 2001), the 
prescribing behaviour of providers in the public and private sector (Ndumbe 1989; Feller- 
Dansokho, Ki-Zerbo et al. 1994; Ofori-Adjei and Arhinful 1996; Ongore and Nyabola 1996; 
Sharma, Gupta et al. 1996; Yousif and Adeel 2000; Font, Alonso et al. 2001; Rowe, Onikpo et 
al. 2001; Agyepong, Ansah et al. 2002), and the underlying community beliefs and attitudes 
(Ahorlu, Dunyo et al. 1997; Miguel, Tallo et al. 1999; Williams, Kachur et al. 1999; Baume, 
Helitzer et al. 2000; Tarimo, Lwihula et al. 2000; Kilian, Tindyebwa et al. 2003). Without such 
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an understanding, attempts to influence behaviour are unlikely to succeed. Nor, did we include 
community or informal provider intervention studies that did not include information on patient 
drug usage. As a result, a number of studies with useful information for the implementation of 
such programmes were excluded (Kafle, Gartoulla et al. 1992; Oshiname and Brieger 1992; 
Kidane and Morrow 2000; Tavrow, Shabahang et al. 2003). Of particular note are the studies of 
retailer training in Nepal by Kafle et al. and Kidane and Morrow's RCT in Ethiopia where 
mothers were taught to recognise and treat malaria and were supplied with chloroquine, 
resulting in a significant reduction in under-five mortality. 
Despite the limitations and the disparity in locations, study designs, drug regimens, and health 
environments, it is still possible to draw some broad conclusions from the studies in this review. 
As might be expected, descriptive community based studies indicated generally low levels of 
conformity to national recommendations for malaria treatment. This is unsurprising as 
treatments are often bought over the counter from untrained shopkeepers where the choice of 
drug and amount purchased are limited by the cost of the drugs and the training of the provider. 
However, when patients were given free drugs at the correct dose by a trained health provider, 
levels of adherence were much higher, especially if careful verbal instructions had been given. 
Patient adherence to a recommended drug regime represents the final step in a pathway from 
first developing symptoms to receiving curative treatment (Krause & Sauerborn 2000) and the 
problem of patients not taking drugs as recommended, may be more a result of the patient not 
having access to affordable treatments and not receiving the correct instructions rather than 
"patient non-adherence" per se (Nshakira et at 2002) (Kofoed et at 2003). Identifying where 
problems lie in this complex pathway is important so that interventions to improve drug usage 
can be tailored accordingly. 
It is generally assumed that adherence to antimalarial regimens is inversely proportional to the 
duration of treatment and the frequency of dosing, although there are few data to support this. 
Certainly the treatment of malaria (between one to seven days) cannot be compared with the 
treatment of HIV (lifelong with poorly tolerated drugs) or tuberculosis (six months). Seven day 
regimens with quinine, a generally poorly tolerated drug, are generally considered to be poorly 
adhered to - although this has not been well documented. Although adherence with unobserved 
three-day regimens is likely to be less than single dose treatments, the very limited available 
data suggested that with attention to patient or care education and packaging, cure rates 
approached those with observed treatment. 
There appears to be a trend towards higher rates of adherence to drug regimes known to be 
efficacious than those that are ineffective. In particular, evidence in this review and other 
studies in South Africa and Laos (Dr K Barnes and Dr Mayxay, personal communication) 
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suggest high levels of adherence and effectiveness to 3-day regimes of artemisinin combinations 
which are known to be both very well tolerated and highly effective (Price, van Vugt et al. 
1999; McGready, Cho et al. 2001) compared to the three-day regime of chloroquine which is 
increasingly ineffective. This finding should help allay fears that the rapidity of action of ACTs 
would actually encourage poor adherence. 
Although there are significant logistic constraints to improving antimalarial drug usage, the 
limited interventions studies presented here, suggest that there are a number of simple practical 
interventions both at the community level and clinic level which are effective. This includes 
making sure that patients and carers understand both how and why drugs should be taken 
correctly and providing patients with pre-packaged drugs (Ross-Dengan, Laing et al. 2003). 
However, in order to improve community drug usage both for malaria and other common 
diseases, the most effective approach is an integrated one in which affordable diagnosis and 
effective treatment are made accessible, community awareness is raised, and health care 
providers are trained and supported appropriately. 
In terms of the relationship between actual antimalarial drug-taking and clinical outcome, the 
data were sparse. Despite this, the effects of incomplete adherence were most evident where the 
antimalarial used was relatively ineffective. This is related to the shape of the dose-response 
curve as shown in Figure 5-2. Poor adherence reduces the dose taken and therefore increases 
the chance of therapeutic failure if the dose is reduced to the steep part of the dose-response 
curve. The closer the dose is to the steep part of this curve the greater is the reduction in cure 
rate with incomplete treatment. Thus as cure rates with observed treatment fall, the greater is 
the effect of poor adherence on treatment outcomes. As cure rates fall further the differences 
reduce again. 
Highly efficacious treatments are more likely to be adhered to, and if they are not, the 
consequences in terms of efficacy are less, than with poorly efficacious treatments. Where an 
effective antimalarial is used or the patient is partly "immune", unsupervised treatment or 
incomplete adherence usually still results in a good outcome in terms of clinical cure. However, 
there are two caveats to interpreting these data. Firstly, nearly all of the "outcome" studies were 
facility-based where drugs are prescribed by trained staff and the "non-adherence" is probably 
less extreme than the "non-adherent" behaviour in the informal sector. Secondly, these studies 
only measured clinical outcomes (and often with inadequate follow-up) and did not assess the 
negative impact of poor adherence on the development of antimalarial resistance. 
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Figure 5-2: The relationship between dosing (dose and duration of dosing) and therapeutic 
response to antimalarial drug treatment in sensitive (green) and resistant (red) infections. 
Treatment failures result from resistance (shaded area). 
100% 
istant 
Cure rate 
Dose 
The relationship between drug usage and antimalarial drug resistance has not been well 
characterised. Partially effective treatment which results in recrudescence of the infection 
encourages the selection of resistance (White 2004). Taking little or no drug does not select for 
resistance (but will not cure the illness either! ). Where resistance to the recommended 
antimalarial regime is high, the first-line drug is by definition ineffective, and so it is entirely 
rational for the patient or carer to choose not to use the drug or to use if for a short time before 
looking for a more effective alternative. This may reinforce the behaviour of trying out many 
different drugs for short durations, and is most likely to reduce trust in that medicine, the 
dispensing healthcare provider, and the health care system. Strategies to improve delivery and 
adherence are likely to have e limited effectiveness if ineffective drugs are used and the 
poor results from such studies hould not deter deployment of effective antimalarials. 
Interpretation and judgement of the community's drug usage behaviour must be done in light of 
the known efficacy of the recommended regime. 
The review revealed other gaps in knowledge and areas in which future studies could be 
improved. Community drug usage studies are constrained by not knowing whether a patient 
actually had malaria or not and therefore whether the choice of treatment was in fact 
appropriate. Microscopy at time of interview is not useful, as patients who genuinely may have 
had malaria will often have undetectable parasitaemias soon after starting treatment. The wider 
user of rapid diagnostic tests both operationally and for research purposes, especially in low 
transmission areas may be one approach to addressing this problem. 
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There were wide discrepancies in the definition and measurement of "adherence". A patient 
may not take the regimen exactly as prescribed, but still receive adequate treatment. Clearer 
definitions of adherence in terms of dose, duration and frequency would greatly assist 
interpretation and comparison across studies. Although the results of studies in this review 
(Qingjun, Jihui et al. 1998; Marsh, Mutemi et al. 1999; Kofoed, Lopez et al. 2003) suggest that 
in these settings carer or self-reported drug histories were reliable, other studies have shown that 
they can be subject to bias and error (Nwanyanwu, Redd et al. 1996). More studies which 
validated drug histories would be reassuring. Use of modern population pharmacokinetic 
approaches would considerably improve drug concentration interpretation in adherence studies 
(Simpson, Aarons et al. 2001). 
There is inadequate information on the clinical outcome when antimalarial drug are used outside 
of controlled clinical environments, therefore more effectiveness studies are needed. But these 
will be of limited use unless the follow-up is for sufficient duration to detect treatment failures 
(i. e. > 28 days). The majority of studies in Africa were on chloroquine use in children (often 
where the drug was failing) whilst studies of ACTs and other drugs were largely performed in 
Asia and South America. As the majority of the world's malaria occurs in Africa, where 
countries are increasingly switching to combination treatments, there is a need to document how 
well the drug is being used by both adults and children in the community and how effectively 
specific interventions can improve drug usage and therapeutic outcome in these settings. This 
includes evaluation of the effectiveness of strategies such as the use of rectal artemisinins in 
children, the blister-packaging of tablets, co-formulations, and working with the informal sector 
to improve diagnosis and treatment. Finally future intervention studies should include more 
information on costs and how they are calculated in order for policy makers to make informed 
decisions around policy change and implementation. 
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CHAPTER 6 
PRIMARY DATA COLLECTION IN CAMBODIA: COSTING STUDY 
From early on in this study it was apparent that there was a lack of data on the actual 
implementation of ACTs, the adherence and coverage rates and the costs in trying improve 
either or both. In this and the next chapter the primary data collection that took place in 
Cambodia is described and the results presented. The chapter starts with a background section 
describing the key components of the implementation of ACT in Cambodia including blister- 
packaging, rapid diagnostic tests (RDTs) and delivery through village malaria volunteers 
(VMVs) and outreach. The cost methodology for each strategy is then presented followed by 
the results. 
6.1 Specific aims 
The aim of the costing study was to estimate the provider costs of interventions involved in the 
implementation of "Early Diagnosis and Appropriate Treatment" (EDAT) with artesunate and 
mefloquine to obtain the appropriate input values to assess the cost-effectiveness of introducing 
ACTs. These included the incremental cost of commercially available blister-packaged ACT, 
RDTs and the cost of delivery with VMVs and outreach clinics. 
6.2 Background 
6.2.1 Blister-packaged artesunate and mefloquine 
When Cambodia became the first country to switch to an ACT for the first-line treatment of P. 
falciparum malaria in 2000, it was clear that there were a number of obstacles to successful 
implementation. These included the unavailability of co-formulated or blister-packaged ACTs, ý /) 0<-2 
the low utilisation of public health facilities; the high usage of antimalarials without biologica-iý. 
J 
confirmation of malaria; and the wide-spread avai ai ity of fake artesunate and mefloquine. In 
order to address these problems, the change in policy was accompanied by a number of 
innovative strategies. 
Initially the artesunate and mefloquine were distributed and prescribed separately. However the 
dosing regime is relatively complicated and it was recognised early on that there would be 
problems with ensuring that the drugs were correctly prescribed by health providers, and 
153 
correctly taken by patients. In addition, in view of the problem with fake drugs, it was felt that 
pre-packaging drugs would also enable both patients and health workers to be assured of the 
drug quality. 
However, at the time there were no local pharmaceutical companies with the capacity to 
produce blister-packages. Therefore a decision was made by the National Malaria Centre 
(CNM) with the support of WHO, to pre-package the drugs themselves. A room in the Central 
Medical Stores building was extensively renovated, including the installation of specialist air- 
conditioning and ventilation; the separation of packaging and storage rooms; and the 
construction of a special staff toilet. New packaging and printing machines were purchased and 
staff were given the appropriate training. 
Artesunate and meflo uiq ine table&ereboughtseparately and then pre-packaged together into 
three different age-packages: for children aged from 6-11 years, 12-15 years and adults (See 
Annex 4 for details). Packages for the public sector ("A+M") were packaged simply with a 
warning of "not for sale". In recognition that the majority of patients would continue to seek 
treatment in the private sector, the two older age group regimes were also packaged for sale in 
the private sector ("Malarine") in more attractive packaging (Figure 6-1). These were marketed 
in the private sector through a social marketing initiative that was initially piloted in two 
districts, and then was launched nationwide in March 2003. 
The local blister packing of the ACT was only ever intended as an interim measure until 
commercially produced ACT became available or until local production of the blister-packages 
could be taken over by a more appropriate organization. The process is now being contracted 
out to the Food and Drugs Administration (FDA) who have established a blister-packaging 
facility. 
The original system was reported to have a capacity of up to 2,500 tablets per day but actual 
maximum technical efficiency was estimated at 2,000 tablets/day or 40,000 blisters per month. 
In reality only 56,794 packages were officially produced in 2001 (CNM 2001). Once the 
production is taken over by the FDA, the maximum technical efficiency is more likely to be 
reached. 
6.2.2 Rapid diagnostic tests (RDTs) 
One of the keystones to the EDAT approach was the provision of accurate biological diagnosis 
to replace the inaccuracies of clinical diagnosis. The broad intention was to ensure that patients 
with malaria-like symptoms, who did not have access to microscopic diagnosis, should receive 
diagnosis by an RDT prior to receiving antimalarial treatment. Paracheck®, a P. falciparum - 
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Figure 6-1: The blister packaged A +M4 and Malarine® 
Figure 6-2: The Paracheck k rapid diagnostic test 
I ;s 
specific RDT (Figure 6-2), was introduced with the intention that it should be used in health 
centres without microscopes and also in the private sector alongside Malarine®. However, 
actual implementation was patchy, and there was a lack of information on the extent to which 
the RDTs were actually being used in the either sector. To add to the confusion, a shipment of 
Optimal®, an RDT which can detect non falciparum malaria, also started to be distributed36. 
However initial problems with quality as a result of deterioration during storage in field 
conditions resulted in haphazard introduction and use. 
6.2.3 Interventions to improve access to early diagnosis and appropriate treatment 
In addition to the change in national policy, there were a number of initiatives aimed at 
increasing access to early diagnosis and treatment at the village level including Malaria 
Outreach Teams in Anlong Veng district and VMVs in Rattanakiri and Ko Kong provinces. 
These are described below. 
6.2.3.1. Outreach clinics 
The malaria outreach activities in Anlong Veng District, Oddor Meanchey province were set-up, 
run and funded by Mddecins Sans Frontieres (MSF) as part of their programme of support in 
that area. The area is in the Northwest of Cambodia, heavily forested and had remained a 
Khmer Rouge (KR) stronghold until 1999 and therefore lacked government-supported health 
facilities. MSF first arrived in 1998 and took over the running of the previously KR-run Anlong 
Veng Health Centre37 in 1999. 
The collapse of KR power resulted in an influx of non-immune migrants from all over 
Cambodia who came in search of farmland and to collect forest products. The population of the 
district estimated by MSF in 2001 was 19,029 in 64 settlements (Goubert L, personal 
communication)38. This figure is continuously changing as new settlements appear and 
sometimes "older" ones disappear in response to local political problems, superstitions or 
rumours of new roads being built. 
One of the major health problems as new settlers moved into areas was an epidemic of malaria. 
Between May and August of 1999, in the health centre alone, there were over 2000 confirmed 
malaria cases, 400 hospitalisations and 18 deaths with malaria accounting for one third of all 
outpatient and two thirds of all inpatient cases (Van Engelgem 2001). 
36 The current recommendation is for Optimal® be used in health centres without microscopes and for 
Paracheck® to be used by VMVs and for outreach activities. 3' Anlong Veng health centre is classified as a "Health centre with beds" and is the only bedded health 
facility in the district. It actually functions somewhere between a health centre and a hospital. 
38 There was no census data available as the area had been under KR control during the time of the 
census. 
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At the time, the national antimalarial guidelines for uncomplicated P. falciparunr malaria in that 
area was single dose mefloquine, and for complicated malaria, quinine and tetracycline. In 
response to the epidemic and the known problem of drug resistance, MSF switched first-line 
treatment to an ACT of artesunate and mefloquine (A+M). A malaria control project was also 
set up with a core component being malaria "outreach" clinics. These consisted of teams of two 
people who went out each day from the health centre to the settlements, in order to diagnose and 
treat malaria using RDTs and A+M. There were initially two teams, expanding to four teams 
with the aim of visiting each settlement once or twice per week depending on population 
movement, road conditions and information about suspected malaria outbreaks. 
6.2.3.2. Village Malaria Volunteers (VMVs) 
The first experience of using village malaria volunteers in Cambodia came from a community 
based trial for insecticide treated bed nets (ITNs) in 30 villages in Rattanakiri in the Northeast of 
the country in 2001. This is a remote heavily forested area, sparsely populated by ethnic 
minorities with low access to any kind of health service. Malaria transmission is high with 
prevalence rates of 5 and 57% (Sochantha, Hewitt et al. 2005). The trial aimed to assess the 
impact of ITNs by comparing P. falciparum prevalence rates in intervention versus control 
villages. However, in order to address ethical concerns about having an exposed group without 
any interventions, village malaria volunteers (VMV) were introduced in all villages. The 
VMVs were trained to perform RDTs on any villagers suspected of having malaria and to 
provide treatment as per the national guidelines. They were supervised and re-supplied monthly 
by the provincial malaria staff. The resulting data from this passive surveillance system 
exposed the scale of the problem of malaria in these communities and demonstrated that VMVs 
provided a practical means of access to biological diagnosis and appropriate treatment. A 
further piloting project was therefore undertaken in 10 ethnic Khmer villages in Ko Kong 
province in the South (Sedano 2002). A grant application was successfully made to the Global 
Fund to expand the VMV programme to 300 villages in 10 provinces and is now in the process 
of being implemented (Cambodia Coordinating Committee 2002). 
6.3 Methods 
The costing in this chapter was performed from the perspective of the provider. The household 
costs of treating malaria were obtained during the community based study described in the next 
chapter. Throughout this chapter, capital costs are annualised at a rate of 3% and all costs 
converted into US$200239. 
39 US$1= 3900 Cambodian riel 
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6.3.1 Cost of blister-packaged artesunate and mefloquine 
The cost of the blister-packaged drugs was separated into capital costs and recurrent costs. 
Costs were obtained from receipts and where these were not available, from estimates by the 
WHO and CNM staff. 
The capital costs included were: the building renovations ($20,000), the blister-packaging and 
printing machinery ($40,000), and the consultancies and training ($15,000). The useful life of 
these inputs was assumed to be five years. The costs involved in the decision-making process 
were not included. These discussions were mainly carried out by e-mail and telephone 
conversations between WHO staff and experts but were considered a routine part of their work 
and a reliable estimate of the time and money allocatable specifically to blister-packaging was 
not available. 
The recurrent costs were separated into fixed and variable costs. The fixed costs were the 
overhead costs for electricity, water and building maintenance ($1,600/month) and staff salaries 
and wages. The staff consisted of a pharmacist ($800/month), a maintenance technician 
($200/month) and 12 machine operators who were paid a daily wage of $12.50 per working day. 
Actual expenditure on salaries was not available but according to the administrator, all operators 
were paid to work full-time. The average monthly earnings in the manufacturing industry in 
Cambodia were approximately $195 ($ 228 for men and $161 for women), giving an estimated 
total monthly payout of $2,340 per month for labour. 
The cost of packaging and drugs are shown in Table 6-1 and Table 6-2. At the time of the 
analysis, 50mg tablets of artesunate were being used for all products except adult Malarine® 
where the 200mg tablets were used instead, partly to ensure differentiation of the product inside 
the packaging from A+M, in order to discourage leakage of the latter into the informal sector. 
The choice of drug varied over time according to the availability and cost of different products. 
Table 6-1: Cost ofpackaging4° 
Cost per blister US$ 
Aluminium foil 0.0267 
PVC 0.0115 
Individual boxes 0.0340 
Large boxes (for 100 individual boxes) 0.0048 
Ink for rintin on box 0.0020 
Package insert 0.0010 
40 The cost of the aluminium foil and PVC included freight and storage. Other products were available 
locally and the cost is the price paid inclusive of delivery and storage. 
a' Although the printing costs for the Malarine® products was higher than A+M because of the amount of 
coloured ink used, only an average cost of ink was available 
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Table 6-2: Cost of antimalarial drugs 
Cost per tablet S$ 
Meflo uine 250mg Me ha® 0.3696 
Artesunate 50mg (Gui Lind 0.0725 
Artesunate 200mg Me ha ® 0.3323 
6.3.2 Cost of rapid diagnostic tests 
The data on the costs of the tests, and the training and supervision of healthcare staff were 
obtained from the CNM. In addition information was obtained on the rate of positive tests 
under routine use. This is necessary as the cost-effectiveness of the RDTs themselves and of 
ACTs depends on the relative costs of the tests and drugs, the likelihood that a febrile illness is 
truly due to malaria, and the cost of drugs used when the diagnosis is negative for malaria. The 
cost of the tests are shown with and without the inclusion of the training and supervision costs. 
6.3.3 Costing interventions to increase access 
The costs of the delivery interventions consisted of variable costs and fixed costs. The latter 
included the capital costs and recurrent costs of the intervention. These were divided into 
staffing; transport; computers and other equipment; and office overheads. Fixed costs were 
estimated with and without the inclusion of the start-up costs and the cost of project co- 
ordinators, in order to facilitate comparison with other settings. The variable co w rP tho&a-, 
directly associated with diagnosing and treating patients with malaria and essential__ y ýd 
the costs of RDTs and drugs as calculated above. In addition, in order to take into account the 
cost of performing tests on patients who presented with malaria-like symptoms but did not have 
malaria, data on the proportion of tests taken which were positive were also noted. 
The costing of these two interventions was carried out separately. Detailed information was 
available for the year 2001 from the expenditure accounts, budgets, logbooks and reports from 
the MSF outreach programme and an ingredients approach was therefore used. Actual cost data 
from the project were used where possible and in particular for the vehicles and computers. 
Costing of the VMV intervention was based on the budget granted by the GFATM. 
The level of activity in terms of number of suspected malaria patients tested and number of 
patients with P. 
, 
falciparur malaria treated was gathered from the statistics kept from the two 
projects in order to estimate the cost per case seen and treated for each intervention. 
42 Including 5% wastage and 3% freight. 
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6.3.3.1. Outreach clinics 
Start-up costs 
Start-up costs were based on discussions with project staff and involved estimates of the time 
and resources spent in the months leading up to the launch of the project. It was estimated that 
the project co-ordinator spent about three months in preparation, at which time it took up about 
80% of his time. During the month preceding the launch the supervisor (80% allocation) was 
recruited and the lab technician became involved in assessing different RDT (20% allocation). 
Salary, transport and overhead costs were allocated accordingly. 
Staffing 
The staff directly involved in the outreach activities in 2001 consisted of four, six and then eight 
outreach workers, a local supervisor, a local laboratory technician and an expatriate project co- 
ordinator. Outreach workers each spent on average two or three days per week on outreach. 
They were officially ministry of health (MOH) employees from whom they received a salary of 
$8.20 per month but they also received a salary supplement from MSF (average $17.50 per 
month) and a per diem for each day of outreach work. The per diem paid out from MSF was $2 
(of which half went to the worker and half went into a common staff fund). For the cost 
analysis the actual cost paid out monthly by MSF was used. 
Both the supervisor and laboratory technician were MSF employees receiving a monthly salary 
of $250. The supervisor was dedicated to the malaria control activities in Anlong Veng and 
estimated that 60% of his time was spent on outreach activities, mainly collecting and entering 
data, organising supplies and repairs and direct supervision of the outreach teams. The 
laboratory technician was mainly occupied with providing microscopic diagnosis for inpatients 
and outpatients but also provided training and quality control for the RDTs and estimated that 
about 10% of his time was spent on outreach activities. 
The expatriate project co-ordinator was based in Siem Riep town and was responsible for 
overseeing the established Anlong Veng malaria control project, setting up new projects 
elsewhere and liaising with central headquarters in Phnom Penh. In addition to a monthly salary 
of $380, there were costs associated with housing and a malaria project driver. The proportion 
of the co-ordinators time dedicated to the outreach activities in Anlong Veng was estimated at 
20% and was allocated accordingly. 
Other staff indirectly involved included the MSF medical co-ordinator and assistant co- 
ordinator and the support staff in the Siem Riep office and the Phnom Penh headquarters. Data 
on these costs were only available as part of the gross cost of operating and staffing costs at 
these two levels. These costs were not included in the costing as they are very context specific. 
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Table 6-3: Cost of staffing for the outreach intervention 
Staff Monthly Additional costs % allocated to 
salary outreach 
S$ 
Outreach workers (x643 ) 25.70 US$2/day per diem for each 100% 
outreach day worked 
Supervisor 250 - 60% 
Laboratory technician 250 - 10% 
Expatriate project co- 380 Housing, food, air tickets 20% 
ordinator (approximately US$750/month) 
Project driver 225 20% 
Vehicles 
The annual costs of the vehicles consisted of maintenance and fuel taken from receipts plus the 
capital cost of the vehicles assuming a useful life of five years for motorcycles and six years for 
the car44. The eight motorcycles were bought locally at an average price of $1,400. Total 
annual cost for maintenance was $1796 and for fuel, $428. There was also a Toyota Hilux car 
used by the project co-ordinator for other business and therefore 20% of the costs associated 
with the car and driver were allocated to outreach. The capital cost of the car was $27,300, 
inclusive of freight and radio equipment and the annual cost of maintenance and fuel was 
$2,380. 
Equipment and office overheads 
The other capital costs were for a laptop computer (US$2,000), motorcycle helmets, weighing 
scales and bags. These were assumed to have a useful life of five years. The cost of office 
overheads were estimated for the MSF office in Anlong Veng where the malaria project had 
desk space in a building built by MSF next to the health centre. The accounts did not 
differentiate between the costs of the health centre and the office cost; however it was estimated 
that about 10% of the costs of maintenance and electricity to the health centre and 20% of the 
office related to outreach activities. This worked out to approximately $20 per month. 
6.3.3.2. Village malaria volunteers 
Start up costs 
The start up costs that were budgeted for in the first year included the cost of initial training, 
monthly meetings with the newly trained VMVs and an initial screening survey. The latter 
involved visiting villages in the 10 provinces to choose the 300 villages with the highest 
proportion of children with palpable spleens (the "spleen rate") as an indication of malaria 
prevalence. Each province was estimated to take about 10 days to cover and involved three 
43 Four workers from January to March (three months), six workers from April to August (four months) 
and then eight workers (four months). 44 Based on estimates provided by the logistics co-ordinator. 
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CNM staff (with a per diem of $30) and their transport costs to and around the province at 
$500/province and two provincial health staff (with a per diem of $20) and their transport costs 
at $300/province. The initial training involved ten two-day courses for 10 health staff from 
each of the 10 provinces and 25 separate four-day training courses for the 20 VMVs (at a per 
diem of $5/day). Training materials were estimated to cost $5 per provincial health staff and 
$10 per VMV. Total transport costs were estimated at $80 and $100 for the provincial staff and 
VMV training sessions respectively and refreshments $1 per person per day. 
Stang 
The budget for the salary of the project co-ordinator was $ 24,000 per annum. The other costs 
were associated with the supervision, monitoring and evaluation and were estimated at $30,000 
per year. This was to cover the per diems of two teams of two CNM staff employed to 
supervise the project, with an aim of visiting each village twice each year, taking about 100 days 
working days at $20 per diem. At the provincial level, support was budgeted for monthly 
meetings (nine per year) between provincial health staff and VMVs with per diems of $5 and $2 
respectively. In addition salary support was budgeted for local monthly data collection, data 
entry and reporting of data. 
Vehicle and transport costs 
The project budgeted for the purchase of four new 4-wheel drive vehicles and 10 motorcycles. 
The cost of maintaining the vehicles was estimated at a total of $5,000 per year for the first two 
years and then $10,000 per year thereafter. In addition there were transport costs associated 
with monitoring and supervision activities. 
Other costs 
The other costs included the capital costs of two computers and annual administrative costs 
estimated at $10,000 per year. The office overheads in the CNM headquarters in Phnom Penh 
were not estimated. 
6.4 Results 
6.4.1 Blister-packaging and drugs 
The results of the costing of the blister-packaging are shown in Table 6-4. It can be seen that 
the total costs inclusive of capital costs of the blister-packaged drugs were between $2.60 for the 
package for the A+M2 and $3.77 for A+M4. The cost of MaIarine® was slightly more than 
A+M4 because of the higher cost of the artesunate used. The cost of packaging material was 
$0.089 per package for all packages and at actual productivity, salary and overhead costs per 
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package were $0.338 and $0.706 respectively, resulting in a total packag p ckaae of 
$1.133! If production were increased to 80% of the potential capacity, then packaging costs 
would be reduced more than 5-fold to $0.188, resulting in the cost of A+M2 and A+M4 being 
considerably lower, at $1.42 and $2.59 respectively. Figure 6-3 shows that when the costs of 
the product are broken down, at the current level of productivity, the drug costs only accounted 
for 45% and 62% of the cost of A+M4 and A+M2 respectively, compared to 83% and 90% at 
the anticipated level of productivity. 
Table 6-4: Cost of blister packaged artesunate and mefloquine 
Drug package Actual cost Potential cost 
(at 9.5% productivity) at 80% productivity) 
Recurrent Recurrent and Recurrent Recurrent and 
costs capital costs costs capital costs 
A+M2 2.307 2.595 1.386 1.420 
(Art 50mg x6+ Mef 250m x 2) 
A+M3* 2.894 3.182 1.973 2.007 
(Art 50mg x9+ Mef 250mg x 3) 
A+M4 3.480 3.769 2.560 2.594 
(Art 50mg x 12 + Mef 250m x4 
Malarine® (adult) 3.608 3.896 2.688 2.722 
(Art 200m x3+ Mef 250mg x 4) 
*Same cost for Malarine junior ® 
Figure 6-3: Breakdown in costs of blister packaged drugs 
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The basic cost of RDTs inclusive of freight, storage and wastage was $0_83 for Paracheck(k) and 
$2.75 for Optimal®. When used in the health centres, the cost of training and supervision of 
health centre staff added an additional $0.12 to each R1)'l' assuming that a health centre 
performed an average of 200 tests per year. 
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6.4.3 Interventions to improve access 
Table 6-5 and Table 6-6 summarise the results of the cost analysis for the MSF malaria outreach 
project and the VMV scheme. 
Table 6-5: Summary of the annual fixed costs of the outreach and VMV interventions 
Cost S$ 
Outreach VMV 
Basic annual running costs 
(without expatriate co-ordinator) 
Salary 5,422 20,270 
Transport 2,224 37 850 
Other (equipment, overheads) 739 10,738 
Sub-total 8 385 68 858 
Additional costs 
Cost of ex atriate co-ordinator 4,643 24,000 
Initial start-up cost 4,710 40,000 
Total annual cost 13 89S 100,243 
Table 6-6: Estimated activity and fixed cost of interventions per capita, per patient seen and 
ner nation/ trog! J 
Outreach VMV (based on 
estimates from 
ilot ro'ect 
Population 19,029 100,000 
Number seen 3,152 57,360 
Number P. alci arum cases treated 658 13,407 
P. alci arum positive rate 20.9% 23.4% 
Basic annual fixed cost*/ca ita $0.44 $0.69 
Basic annual fixed cost*/patient seen $2.66 $1.20 
Basic annual fixed cost*/positive case $12.74 $5.14 
Total annual fixed cost/capita $0.73 $1.00 
Total annual fixed cost/ patient seen $4.41 $1.75 
Total annual fixed cost/ positive case $21.12 $7.48 
(*Without start-up and co-ordinator costs) 
6.4.4 Inputs for modelling 
The costs obtained from this analysis were used as inputs into the model. In the base-case 
scenario the cost of the drugs based on the cost of monotherapy and ACT are assumed to be the 
cost of mefloquine and blister-packaged artesunate and mefloquine. For mefloquine 
monotherapy the cost is $1.11 for an adult cost, $0.56 for a child aged six to twelve years and 
$0.28 for a child aged one to five years. The age-grouping of the blister-packages did not match 
the age-grouping used in the model. For the purpose of the model it was assumed that those 
above twelve years received A+M4 (aimed at those 15 years and above), at $3.77 per course. 
Children aged six to 12 years were assumed to receive A+M2 (aimed at children aged six to ten 
164 
years), at $2.60 per course. Children aged five years and under were suppose to receive five 
days of rectal artesunate (or artemether) suppositories and mefloquine but in reality, usually 
received artesunate tablets with or without mefloquine from blister-packages. The cost of five 
suppositories and one tablet of mefloquine at $2.40 was similar to the cost of A+M2 and in the 
model the cost input for the ACT in this age group was assumed to be $2.60. 
For the cost of the intervention to improve access the basic fixed annual costs were used, 
exclusive of the cost of the expatriate co-ordinator and the start-up costs as it was felt that these 
costs are highly context specific making it difficult to generalise to other settings. The actual 
annual fixed costs used in the base-case scenarios with a population of 10,000 was therefore 
$4406 for outreach and $6886 for the VMV scheme. The variable costs were the costs of the 
drugs and the RDTs as described above. 
The costing of the blister-packaged drugs shows that at 
an adult course of 
level of productivity in 2001, 
is compares with $2.40, the 
current price of artemether-lumefantrine (Co-artem®) supplied by Novartis to WHO). By 
increasing the productivity, the cost of A+M4 can be lowered to almost the same as artemether- 
lumefantrine. 
From the cost analysis of the interventions, it can be seen that the basic per capita running costs 
of the schemes was estimated to be around $0.44 from outreach and $0.69 for the VMV scheme. 
Inclusion of the cost of a project co-ordinator and (20% allocation for the outreach project and 
full-time for the VMV scheme) and annualised start-up costs increased this to $0.73 and $1.00 
respectively. 
Although the fixed cost per capita of outreach is less than that of the VMV scheme, the costs per 
case tested and per positive case treated are almost double. This is because the prevalence of 
malaria was higher in the area covered by the VMV scheme in Rattanakiri from where the 
estimates for the projected number of visits and cases came. It is also probably because the 
VMVs were more convenient and accessible than outreach and were more often consulted. It is 
estimated that over half the population are likely to visit th M` ia year compared to fewer 
than 20% in the area covered by outreach. 
However, as explained earlier, the populations covered by these two interventions was quite 
different and it is unlikely that VMVs would have operated successfully in the Anlong Veng 
district. It can therefore not be assumed that VMVs are the more cost-effective option in all 
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6.5 Discussion 
settings. Nonetheless the cost of the outreach programme, at $12.74 per positive case, appeared 
to be considerably more than that estimated by Ettling et al. for a similar intervention in Mae 
Sot, Thailand, where diagnosis was by microscopy and treatment was with a single dose of 
mefloquine (Ettling, Thimasarn et al. 1991). Despite the slide positivity rate in Thailand being 
only 5%, the average institutional cost per positive case was $2.57 (90 baht) and $0.13 (4.4 
baht) per smear45. The community cost inclusive of the indirect costs of lost earnings, was 
$0.06 (2.26 baht) per positive case. In terms of institutional costs alone adding a mobile clinic 
in addition to a central clinic was less cost-effective, in terms of costs per positive case treated, 
than adding a peripheral clinic, partly because the slide positivity rate was higher (17.5%) in the 
latter. 
There have been a number of other descriptive studies of village malaria volunteers, however in 
most, costing data were not available. One cost-minimization analysis was performed on a small 
community based intervention in Brazil. Volunteer bar owners in a remote mining town were 
trained to use the ParaSight-F® test (a similar test to Paracheck®) to diagnose malaria and to 
treat positive cases with mefloquine monotherapy. The study compared the direct costs (patient 
and provider) incurred with the intervention compared to the costs prior to the intervention, 
when the main source of treatment was the government clinic and hospital located 32 km away. 
It was found that net savings were $60,900 or $81 per person per year46 (Cunha, Piovesan-Alves 
et al. 2001; Pang and Piovesan-Alves 2001). 
However there are little published data that includes both the costs and the effect of these 
interventions from the community perspective. In the next chapter the treatment seeking and 
drug usage behaviour in areas with and without VMVs and outreach clinics is compared. 
45 $US1 (2002) = 35 baht (1990). 46 They also established from interviewing, that the average willingness to pay for RDT diagnosis alone 
was $5.60 (average monthly income of $250). 
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CHAPTER 7 
PRIMARY DATA COLLECTION IN CAMBODIA: 
COMMUNITY-BASED STUDY OF 
TREATMENT SEEKING BEHAVIOUR AND DRUG USAGE 
In this chapter, the specific aims of a community-based study on treatment seeking behaviour 
and antimalarial drug usage are presented. This starts with the aims of the study and is followed 
by the methods used, results and discussion of the findings. For the purpose of the model, it 
was important to have data on adherence to ACTs and the coverage rate with the policy 
following a switch from monotherapy. Cambodia had been commended for its early switch to 
ACTs, however there was no reliable documentation of this process or its success in terms of 
whether or not patients with malaria actually received the recommended drugs or took them 
correctly. It was therefore decided that it would be useful to collect data to assess the coverage 
and adherence rates to ACTs, with and without interventions to improve access. Not only 
would this serve to fill gaps in the data needed to apply the model, but it would also serve as a 
useful resource for other countries earlier on in the process of changing policy. 
7.1 Specific aims 
The aims of this community-based study were: 
1) To document the coverage rate of the new antimalarial drug policy i. e. the proportion of 
people with malaria-like symptoms who received a biological diagnosis and the 
proportion who received artesunate and mefloquine for P. falciparum malaria. 
2) To quantify the effectiveness of providing outreach clinics and village malaria 
volunteers in increasing coverage of the policy. 
3) To measure the adherence to artesunate and mefloquine (A+M) when given in an 
operational setting. 
4) To obtain the household costs of treating malaria. 
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7.2 Methods 
7.2.1 Study design 
This was a cross-sectional household survey carried out in three different types of intervention 
areas: with village malaria vo unt e-r (VMVs), outreach clinics and no specific interventions. 
In addition to household and individual questionnaires, a drug board for identifying drugs was 
used and blood was taken from a finger-prick for rapid diagnostic testing (RDT) of 
P. falciparum malaria. RDTs were performed in an effort to estimate very approximately, the 
proportion of respondents who actually had P. falciparum malaria in the previous two weeks. 
This relies on one of the usually unwanted characteristics of tests based on Histidine Rich 
Protein 2, (HRP2) which is that it persists in the majority of treated cases for at least two weeks 
following effective treatment47 (Mayxay, Pukrittayakamee et al. 2001). 
7.2.2 Sample size calculation 
From the preparatory work it was estimated that the presence of outreach and VMVs increased 
coverage of biological diagnosis and ACTs by at least 60%. A sample size of 200 people in 
each group was therefore chosen, which had a 90% probability of detecting a difference in 
coverage or adherence rates in two groups of 60% and 75% at the 5% level on a two-sided test. 
In the event, due to problems in the intervention area with VMVs and generally lower than 
expected levels of malaria, it was not possible to achieve samples of 200 in the intervention 
groups. However the differences between intervention areas were large enough to infer 
significance for most key outcomes. 
7.2.3 Site selection 
Sample selection was pragmatic because the main purpose was to describe the behaviour of 
people with malaria and to include areas in which the interventions were carried out. The 
district of Anlong Veng, which was covered by the outreach programme, was therefore 
purposefully selected as were the 10 villages in the Ko Kong VMV pilot project. The latter was 
selected rather than the villages with VMVs in Rattanakiri for a number of reasons. Ko Kong is 
ethnically Khmer whereas the population in Rattanakiri is from many different ethnic minority 
groups, which are culturally and linguistically distinct from the majority Khmer population. 
This would have made the conduct of the household survey very difficult and the results could 
not be extrapolated to elsewhere in Cambodia. In addition a qualitative and quantitative study 
of treatment seeking behaviour had recently been conducted in villages in the province (Brown, 
Montavy et al. 2002). 
47 61% in uncomplicated malaria and 89% in severe malaria. 
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Villages in the Sampalouen district, where Malarine, *- was being supplied directly to market 
retailers in a social marketing pilot project, were also selected. However, early on in the field 
work and subsequently in the initial data analysis it was apparent that Malarine® had ceased to 
be stocked by a number of the market retailers and had not penetrated into the villages, resulting 
in no difference between pilot and non-pilot areas and a subsequent absorption of these villages 
into the "non-intervention" group. The study sites are shown in Figure 7-1. A detailed 
description of the interventions was given in the previous chapter and a table comparing the 
characteristics of all areas is given in Table A9-1. 
Figure 7-1: Map of study sites in Cambodia. The orange dots identify the areas studied in 
this study. The red dots . are the areas covered by the national drug usage survey carried out 
in 2002. 
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Within single districts there were areas or villages severely affected by malaria and others that 
were completely malaria-free. Therefore, in the first instance, districts and health centre 
catchment areas within them were chosen that qualitatively most closely matched the 
intervention areas. This was done in terms of risk of malaria; ecology; access to roads, health 
centres and markets; and the socio-economic status of the communities in terms of livelihood, 
poverty and level of migration". Selection of villages took place at the health centre with the 
assistance of local health care staff (Figure 7-2). After identifying all the villages covered by 
the health centre, those in which no malaria cases had been seen or reported and those that were 
48 However this matching was not done with the intention of matched analysis. 
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deemed too dangerous (because of landmines or bandits) were excluded. The remaining 
villages were stratified into two groups according to accessibility. Villages were then randomly 
selected from each stratum49. Selected villages were visited one or two days prior to the day of 
the survey in order to inform and discuss the study with the local community. 
7.2.4 Screening of households 
On the day of the survey, all households in the selected villages were visited and if an adult was 
present, screened for inclusion. The inclusion criteria was anyone in the household who in the 
last three weeks had either taken an antimalarial drug or who had symptoms consistent with 
malaria50. Interviewers were instructed to return to empty households twice if possible, before 
recording them as absent. 
7.2.5 Questionnaire development and piloting 
Prior to the questionnaire, in-depth interviews were carried out with villagers, migrant workers, 
drug vendors, and private and public health centre staff. On the basis of this information and 
from previous surveys carried out in Cambodia (Bury 1999; 2000; Brown, Montavy et al. 2002), 
an instrument was developed, translated, back-translated, piloted in the field on three separate 
occasions and revised a number of times. 
7.2.6 The questionnaire 
The questionnaire had two modules: a household module and individual module. One 
household module was filled out for each included household. This contained questions on the 
household socio-economic status in order to explore whether this had any impact on treatment 
seeking behaviour. The individual module was filled out for each member of a household who 
fulfilled the inclusion criteria. This module included sections on the details of the illness 
episode, with questions on the most recent and preceding episodes of fever in an attempt to 
capture information about chronic infections and possible treatment failures. The questions were 
designed to capture some of the key indicators of antimalarial drug usage as shown in Table 7-1. 
Questions were asked about the illness itself; where treatments were sought; whether any 
diagnostic tests were undertaken; what kind of drugs were bought or prescribed; how exactly 
they were taken in terms of dose, frequency and duration; and how much they cost. The 
questionnaires are appended in Annex 8. 
49 In Sotnikum and Sampalouen districts there were insufficient numbers of malaria-affected villages 
within the official boundaries of the chosen health centre areas, therefore two villages from the 
neighbouring health centre area were selected. 50 This was defined as fever +/- headache +/- chills excluding other localizing infection e. g. bloody or 
profuse watery diarrhoea, or cough productive of coloured sputum as the predominant symptom. 
170 
D" 
0 
a "r 
0 
r 
dy 
ti 
4 
.a m H 
° 
it y 
> 
V 
U oU l P - 0 y 
°' 
¢ 
Z. 
W 
'O 
w 
. 
9 
N 
VII Q3 
M 
II II 
Ü y ý. Ü Ü y 
0 
vi 
0 
CC 
O 0 
bi) 
5 
' p°q 
C 
w 
C 
r: ' Cý U 
ý+ 
cd 
G 
+ U U 
Ü Pý Ü Ü Ü Ü Ü 
N N r N 
aO lz N O ý Olý O, % Oý CT Or c, e 
S S ° C 
U 
ý te 
R o2 
bA 
2 
bA 
°2 Ere, u 
Cy 
0) ens 
' 
°c 
' ýn r 
1a 
° 3 3'° b`2', E° * 
.ý 
VE 0E cry; E52 
9) a; ° um 
Ci. ° ° 0 0+ o= c 
A aE a, E a, E a3 
C ö Qý < 
U U 
y C 
U 
° m`0 ý :1 
m ä U ö 
r (L) 
u 
. U . C. 10 U ce 57 ý 
U 
ce y 3 le rA ýn 
0 le 
-0 
- 
,q `. ý o c°j 
0 0 3 
0 3 
to r v ö ' 
-C 1 
> ä 
ýä 
c 
c 'ý Co 
3 .ý 
ä 
.ý 
" ° ä--cc ý 4 92.9) o o v 
0U 
ý 
0 . 
rý3 0o 
ýb öý ö8y ö a: ö3 ö 
eý "Fw I 
.b y U b 
e 
C7 
E 
> 0 ° ö d 
8 
... Q o v 
.ö 
0) 
= 
QQi cli 'b 
ä 'U a) a0 
r 
A" 
Z 2 2ä 0 0E ö ä m 
Ö Ü Ö aUi Ur. -c 
0) 
N 
7.2.7 Drug identification board 
One of the key difficulties in community-based drug usage studies is the accurate identification 
of drugs. Patients and even providers may not know the name of the drugs in question. This is 
particularly a problem where mixtures of drugs are bought in unlabelled plastic bags, as they are 
in Cambodia (Figure 7-3). In order to assist in this identification process a drug identification 
folder was developed which aimed to enable patients to correctly identify drugs. This is 
illustrated in Figure 7-4. Patients were first asked to name the drugs they thought that they had 
been given, prior to being shown the drugs identification folder as a prompt to help them recall 
the identity of drugs they may have forgotten (Figure 7-5). 
7.2.8 Blood testing 
For each individual who fulfilled the inclusion criteria, blood was taken by finger prick for a 
RDT (Paracheck®) for P. falciparum malaria and was read at 15 minutes". If patients were 
symptomatic and RDT positive they were treated with artesunate and mefloquine according to 
national guidelines. 
7.2.9 Ethics and consent 
Ethical approval was granted by the Cambodian Ministry of Health, the research ethics 
committee of the London 'School of Hygiene and Tropical Medicine, and the research ethics 
committee of the Oxford Tropical Medicine Network. Informed consent was obtained from the 
community and individual participants (Annex 8). 
7.2.10 Data entry and analysis 
Data were double-entered into Epilnfo 2000, cleaned and analysed using STATAC (Version 8 
and 9). The STATA survey commands were used to adjust for stratification by intervention area 
and to adjust for clustering between individuals in the same village52. Observations were not 
weighted as there was no sampling within villages. Differences in proportions were tested for 
significance using the Pearson chi-squared statistic adjusted for the survey design. Regression 
models were used for multivariate analysis of variation in key outcomes using the STATA 
survey logistic (svy logistic) commands, which enable adjustments to be made for clustering and 
stratification. 
s' From patients who reported having taken mefloquine and 30 "controls", 200ul of blood was also 
collected onto filter paper and kept in a desiccated container. The intention was to later measure drug 
levels in order to estimate the actual amount of mefloquine taken by comparing with population 
pharmacokinetic data. In the event, due to the small numbers it was not feasible to carry out this part of 
the study. 
52 Clustering should normally have been taken into account in the sample size calculation, however the 
necessary information should be captured in the width of the confidence intervals (Smith & Bates 1992). 
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Figure 7-2: Identifying villages in the health centre catchment area 
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Figure 7.3: Packages of tablet mixtures. as commonly bou, ght_for the treatment of malaria 
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Figure 7.4: Drug identification board 
Figure 7.5: Sokhoe», one of the recc'urc h ilccictuntc intervirirhrl a re%pon lent 
7.3 General analytical approach and definitions 
7.3.1 General approach 
The first step in the analysis involved identifying the key indicators for each stage of the process 
leading up to the point where patients with malaria take the recommended antimalarial drugs in 
the recommended fashion. The indicators were chosen because they represent important steps 
in the process and are a specific measure of whether key objectives of improving malaria case 
management are being reached (Table 7-1). These were both process indicators, such as the 
proportion of cases seeking treatment from a trained provider, and outcome indicators, such as 
the proportion of patients diagnosed with P. falciparum malaria taking the first-line therapy. 
7.3.2 Provider type 
Providers were grouped into "formal" or trained provider (public, VMV, outreach) and informal 
providers (simple sellers, private health worker, other). As described in the background chapter, 
most of the population obtained treatment from the informal sector and this sector included a 
range of providers - from village vendors who sold simple drugs including antimalarials, to 
providers who either had or were perceived to have had some training in prescribing, including 
doctors, nurses and pharmacists and medical assistants trained by the Khmer Rouge or by NGOs 
in border camps. The Khmer term "phet" was used by villagers to describe those providers 
whom they perceived to have some relevant prescribing knowledge. This term was used in the 
questionnaire and is referred to as "private health workers" in this study. 
7.3.3 Drug categories 
To simplify the analysis of treatment types, drug treatments were grouped into mutually 
exclusive categories that were felt to be most informative and useful for comparing with 
recommendations. Thus, there were separate groups for treatments that contained combinations 
of artesunate with mefloquine, quinine with tetracycline and separate groups for chloroquine 
and for artemisinin derivatives alone and partnered with ineffective drugs. The latter group, 
where artemisinin derivatives are in effect used unprotected by a partner drug is important as 
their widespread misuse as a monotherapy in a short course is ineffective and theoretically 
increases the risk that resistance may arise. Where a treatment regime could belong to more 
than one group, it was grouped according to whether any of its components belonged to a 
recommended combination and if not, then by its most efficacious contents e. g. a mixture of 
artesunate, quinine and tetracycline was grouped as "quinine and tetracycline +/- other 
antimalarial" and the combination "artesunate plus tetracycline" was grouped as "artemisinin 
alone (without mefloquine) + other antimalarial". 
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7.3.4 Adherence 
Although correct duration, dose, frequency and timing may be important for effective treatment, 
in this survey duration of treatment was used as a proxy measure for adherence. This is due to 
the difficulty of determining with any accuracy, the dose and timing of treatment. In addition, 
the adequacy of treatment duration is particularly important in determining cure and decreasing 
the likelihood of resistance arising to the most efficacious and commonly used antimalarials 
(artemisinins and quinine) 53 
In order to define adherence, the duration of treatment taken was compared to the minimum 
recommended duration. For artemisinin derivatives without an effective partner drug, the most 
commonly available artesunate tablets are sold as a five-day regime and this is widely thought 
to be adequate. However, the evidence suggests that cure rates are lower (down to 72%) 
compared to a seven-day regime (cure rate >95) (Bunnag, Viravan et at. 1991a; Bunnag, 
Viravan et al. 1991b; Hassan Alin, Ashton et al. 1996)54. Therefore for monotherapy with an 
artemisinin derivative, adequate duration was assumed to be seven days. For simplicity, if the 
antimalarial drugs were taken for longer than the recommended duration, the respondent was 
regarded as "adherent" rather than creating an extra category for prolonged duration" 
7.3.5 Socio-economic status 
Households were defined as the number of people regularly living and eating together under one 
roof and often included more than one family. In order to compare the level of poverty between 
households within the sample, a poverty rank was established by performing a principal 
component analysis (PCA) on the socio-economic indicators collected in the survey. This 
method was chosen due to the problems associated with collecting reliable and meaningful 
household income or expenditure data and the acceptance of such an index as a reasonable 
measure of household wealth in similar settings (Filmer and Pritchett 2001). 
In brief, PCA is closely related to factor analysis and is a technique of data reduction where 
there is an attempt to explain the total variability of a large number of correlated variables 
through the weighted linear combinations of the original variables, known as "components". 
Thus the first principal component is the weighted linear combination that captures the largest 
s; From patients who reported having taken mefloquine and 30 "controls", 200µl of blood was also 
collected onto filter paper and kept in a desiccated container. The intention was to later measure drug 
levels in order to estimate the actual amount of mefloquine taken by comparing with population 
pharmacokinetic data. In the event, due to the small numbers it was not feasible to carry out this part of 
the study. 
'a Five days may be adequate if a higher dose is taken (Looareesuwan, Wilairatana et at. 1997). ss Although prolonged duration does has implications both for the patient in terms of adverse events, costs 
and possibly for the development of resistance due to the increased likelihood that malaria parasites from 
new infections are exposed to levels of drug in the bloodstream that inhibit the growth of sensitive 
parasites but not resistant ones. 
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amount of information common to all the variables. If each variable is a household asset or 
other indicator of wealth, then the principal component analysis produces a poverty index for 
each household (Pj) based on the formula; 
Pj=f1 x (ail-a1)/(S1)+ f2 x (a2-a2)/SZ... +fN X (; IN-aN)/(SN) 
Where f1 is the Eigenvalue or "scoring factor" for the first asset as determined by the procedure, 
a;, is the jth households' value for the first asset, and al and sl are the mean and standard 
deviation of the first asset variable over all households. Using this index each household is then 
ranked and assigned into quintiles. 
In this study information was collected on the following indicators: building material for the 
roof and walls; ownership of land, livestock, means of transport and telecommunications; source 
of water, years of schooling; and number of months of borrowing money for food. 
7.4 Results 
In this section the results are presented according to non-intervention and intervention areas. In 
order to compare the effect of the interventions and other factors on the key outcomes, 
multivariate regressions are also included where appropriate. The general characteristics of the 
sample are first described, followed by the findings from the household module of the 
questionnaire and then the findings from the individual module. Annex 9 contains additional 
tables. 
7.4.1 General characteristics 
In all, 1491 households in 23 settlements in six administrative districts were visited in the 
survey. The description of the sample resulting from the screening process is presented in Table 
7-2. Of the households visited, there was an adult present in 1143, which were therefore 
included in the screening, In 290 households, at least one person fulfilled the inclusion criteria 
resulting in a total of 361 individuals completing the individual questionnaire and being 
included in the analysis. Unfortunately the sample size from the VMV intervention area was 
small. This was due to unfortunate political reasons that necessitated the withdrawal of the 
ý-' survey from these villages early on in the study. In the majority (82%) of households only one 
person was included, in 35 (12%) two people, in 17 (6%) three people or more. 
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Table 7-2: Summary description of sample 
Overall Intervention area 
None Outreach VMV 
No. of districts 6 4 1 1 
No. of villages 23 14 7 2 
Total population of screened villages 10,120 8,325 1,401 394 
No. of households in screened villages 
(covered by intervention) 
2,093 1,767 252 74 
No. of households visited 1,491 1,185 232 74 
No. of households with adults present 
(% of those visited) 
1,143 (77%) 884 (75%) 198 (85%) 61(82%) 
No. of households included 
(as % of those screened) 
290 (25%) 208 (24%) 63(32%) 19(31%) 
No. of individuals included 361 251 88 22 
Mean age in years - 25.2 22.0 21.8 
% male 57% 58% 55% 
7.4.2 Results from the household module 
In total, 290 households were included in the analysis. Half the respondents of this part of the 
questionnaire were the head of the households (85% male), and a third were their spouses. 
Overall, 57% of households had been in-situ for less than five years, with marked difference 
between villages. The length of stay was noticeably short in Anlong Veng and Sampalouen 
districts, where around one third of households had been in-situ for less than a year (Table 7-3). 
Overall the mean number of people per household was 6.3, median six (range 1-25) with a 
median of three children (under the age of 12 years) per household. 
Table 7-3: Median duration of stay by district 
District 
(Intervention type) 
n Median 
duration in 
years 
(range) 
% of households 
who had been in- 
situ less than 1 
year n 
AnIong Veng (Outreach) 64 1(0.2-30) 33%(21) 
Chik Phat MV and non-intervention) 72 11 0.5-30 4% (3) 
Malai (Non-intervention) 36 6(0.3-30) 11%(4) 
Sampaleoun on-intervention 50 3 (0-25) 28%(14) 
Sotnikum on-intervention 25 25(2-57) 0 (0) 
Thmar Bang (Non-intervention) 39 3 0.5-6 3% (1) 
Total 286 4(0-57) 15%(43) 
7.4.2.1. Socio-economic status 
The population was predominantly farmers and many were very poor. Level of educational 
attainment was generally low, with 42% of the respondents reporting having had no schooling at 
all, giving a median of one and mean of 2.5 years of schooling overall. The median size of land 
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ownership was one hectare with one quarter of households being completely landless. This did 
not vary significantly by district (Table A-9.2). Although detailed information was collected on 
crop production, it proved difficult to analyse because of differences in measurements 
(descriptions in sackfuls but different size sacks) and areas where maize or beans were grown 
rather than rice. These data have therefore not been analysed. The number of months of food 
shortage, reflected by the borrowing of rice or money to buy rice, appeared to be more reliable. 
One third of the 264 respondents to the question of borrowing said that they had to borrow rice, 
or borrow money for rice in the last year (Table 7-4). Over one third reported that the food 
shortage lasted for more than half the year (Table A9-3). There was a significant difference 
between districts with over 40% of households in the two districts in Ko Kong (Chik Phat and 
Thmar Bang) reporting having to borrow, compared to only 10% in Malai (p=0.014). Most 
(86%) households received some form of income, the most common being selling forest-related 
products (33%) or working as hired labour (20%). 
Table 7-4: Proportion of households who had to borrow money last year 
District n % who have to borrow (n) 
Anlon Veng 62 36%(22) 
Chik Phat 66 42%(28) 
Malai 29 10% (3) 
Sampalouen 48 27%(13) 
Sotnikum 22 18% (4) 
Thmar Bang 37 3%(16) 
264 33%(86) 
p=0.014 
7.4.2.2. Poverty indicators 
Details are provided in the Tables A9-4 to A9-10, but in summary the findings confirmed that 
the level of poverty in the sampled population was high. Housing materials were of poor 
quality with 70% of roofs and over 40% of walls being made of leaves or bamboo, and the 
majority of households (85%) not owning any draft animals or any means of transport (66%). 
Access to clean water was poor with only 7% having access to water from a drilled well with 
most people relying on a dug well (72%) or surface water (21%). In terms of 
telecommunications, only 26% of households owned a radio and 64% owned neither a radio nor 
television. 
7.4.3 Individual data 
Altogether 361 individuals fulfilled the inclusion criteria. The median age was 22 years, with 
6% of the sample being five years or younger (Table A9.11). Of the sample, 57% were male. 
Age and sex distributions did not differ significantly between different intervention areas. 
179 
7.4.3.1. General description of illness 
Commonly reported symptoms included fever (97%), headache (85%) and chills (71%) with 
only two respondents reporting to have had convulsions. The median duration of fever was four 
days (range 1-60). Of the sample, 70% (254) reported having only one episode of fever in the 
previous two months, where an episode was described as a period of fever separated from a 
previous fever by more than three days. The remainder reported having had two episodes 
except for two individuals who had three episodes. 
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7.4.3.2. Treatment with modern drugs 
Modern drugs were taken by 85% of the respondents for the most recent episode of fever. 
Surprisingly, the treatment rate was significantly lower in the VMV area with only 14 out of the 
22 (63%) respondents reporting to have received modern treatment compared to 84% in 
outreach areas (x2 p=0.054). By univariate analysis the odds ratio (OR) of receiving modern 
drugs was 0.34 (95% CI 0.13 - 0.87) if in a VMV area and on multivariate analysis, this 
remained the only significant factor when adjusted for age, sex, distance from health centre, 
poverty and clustering in the survey design (Table 7-5). 
Table 7-5: Proportion and likelihood of receiving modern drugs for most recent episode of 
fever 
Intervention n % who received Odds ratio p Adjusted odds p 
modern (OR) ratio* (AOR) 
=361 treatment (n) (95% CI) 95% C 
None 251 85%(213) 1 - 1 
Outreach 88 84% (74) 1.03 (0.52- 0.09 0.70 (0.33-1.48) 0.34 
2.00) 
VMV 22 63% (14) - 0,34 (0.13- 0.02 0,28 (0.10-0.80) 0.03 
0.87) 
1 'Adjusted for sex, age (<6 and 6-14 years), distance from health centre (>2 hours by 
motorcycle), poverty rank (poorest 40% and richest 20%) and survey design. 
7.4.3.3. Timing of treatment 
Overall, the median time to modem treatment from the onset of symptoms was two days. 
"Delay in treatment" was defined as time to treatment of more than two days and was found to 
be significantly different between intervention areas. In non-intervention areas, the delay in 
treatment was 37% (107), compared to 25% (19/75) in outreach areas and 57% (8/14) (x2 
p=0.026) in VMV areas. When adjusted for clustering, this difference was no longer significant 
(p=0.1536). This suggests that clustering may have contributed to the significance of the result 
and that the sample may have been underpowered to detect the difference between intervention. 
By multivariate analysis the only factor to correlate with delay in treatment was age five years 
or under (OR 0.58,95% CI 0.35-0.98, p=0.044). 
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7.4.3.4. Number of treatments 
Altogether there were 466 treatment contacts in the previous two months, with 369 of those 
being for the most recent episode. The majority (78% of 298), of respondents only received one 
treatment for their most recent episode, 20% (60) received two treatments and 2% (6) received 
three. The likelihood of having more than one treatment did not differ between intervention 
areas (p=0.38). 
7.4.3.5. Source of treatment 
First provider 
In non-intervention areas, the single most common source of initial treatment was a "simple 
seller", accounting for 54% of first providers. This was followed by private health workers, 
either at the providers' place in 24%, or seen at the patient's home in 6%. This was 
significantly different by intervention such that in VMV areas 10 out of 14 (71 %) of cases first 
went to the VMV. However in the outreach area only 17% first went to the outreach team, the 
majority (63%) still choosing to go to a simple seller first (Table 7-6). 
Table 7-6: First source of treatment by intervention (n) 
Inter- n Simple Went to Public Private VMV Out- Tradi- Other 
vention seller private health health reach tional56 
health facility worker 
worker came to 
=317 home 
None 224 54% 24% 6% 6% 1% 0.5% 3% 6% 
(121) (54) (13) (13) (2) (1) (7) (13) 
Outreach 76 63% 7% 3% 1% 0 17% 0 8% 
(48) (5) (4) (1) (13) (6) 
VMV 17 12% 6% 0 0 71% 6% 0 6% 
(2 (1) (12) (1) 1 
Use offormal providers 
For the most recent episode, only 8% of cases in non-intervention areas who sought treatment 
received treatment at some time from a formal provider (as defined in the Methods section). 
This was much higher in both outreach villages (31%) and particularly VMV villages (93%) 
(p<0.001) (Table 7-7). Children under the age of 14 were three times more likely to be taken to 
see a formal provider, but neither distance from the nearest health centre, sex, or level of 
poverty made any difference (Table A9-12). 
56 Although a number is given for provider contacts which were considered "Traditional" this is likely to 
be an underestimate and limited to those cases where traditional remedies were sought from outside the 
household. In reality patients often used local remedies early on in an illness and often at the same time 
as modem medicines. These included drinking concoctions made from local plants, rubbing with coins or 
cupping. 
57 "Other" included the military, de-mining organisations and forest rangers. 
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Table 7-7: Proportion and likelihood of patients seen by a trained or `formal" provider for 
the most recent episode 
Intervention n % seen OR p AOR* p 
by (95% CI) (95% CI) 
formal 
(N=294) provider 
n 
None 206 8% 17 1 - 1 - Outreach 74 31% (23) 5.1 (2.5-10.0) <0.01 4.0 (1.2-13.2) 0.023 
VMV 14 93% (13) 144.5 (17.8- <0.01 147.5 (8.46- 002 
1173) 57 20.7 
*Adjusted for sex, age (<6 and 6-14 years), distance from health centre (>2 hours by 
motorcycle), poverty rank (poorest 40% and richest 20%) and study design. 
7.4.3.6. Diagnosis 
Overall rates of biological diagnosis were very low. Of the 251 respondents in non-intervention 
areas, only 17% of 251 reported having had a biological diagnosis for their most recent episode 
of illness. This was significantly higher in the areas with VMVs and outreach, at 63% (14/22) 
in the former and 35% (31/88) (p=0.009) in the latter. By univariate analysis the odds ratio of 
having a test were 8.5 (95% Cl 3.3-21.4) if the respondent was from a VMV area and 2.6 (95% 
CI 1.5-4.5) if they were from an outreach area (Table7-8). Adjusting for the same factors as 
described previously, the odds ratio of having a test was increased 11-fold in VMV areas and 
two-fold in outreach areas but adjustment for clustering reduced the level of significance, so that 
only the former reached significance. This reflects the amount of variance between villages 
with 2% of respondents from villages in Chik Phat reporting to having had a biological 
diagnosis compared to 46% in Malai (Table A9-13). Children aged six to 12 years were three 
times more likely to have a test (95% CI 1.1-7.8, p=0.035), however sex, distance from health 
centre and level of poverty did not have any effect (Table A9-14). 
Table 7-8: Proportion and likelihood of having a biological diagnosis for most recent episode 
of fever 
Intervention n % having OR p AOR* p 
biological 
diagnosis 
(N=361) (n) 
None 251 17%(42) 1 - 1 
Outreach 88 35%(31) 2.6 1.5-4.5 0.001 2.4 0.83-6.9 0.102 
VMV 22 63% (14) 8.5 3.3-21.4 0.00 10.7 4.7-24.3 <0.001 
*Adjusted for sex, age (<6 and 6-14 years), distance from health centre (>2 hours by 
motorcycle), poverty rank (poorest 40% and richest 20%) 
The difference seen in intervention areas is mainly explained by the fact that consultations with 
VM\T or outreach workers resulted in a biological test 96% and 94% of the time, respectively. 
This compares to around half the consultations in public health facilities (52%) and private 
health workers (42% to 52%) and only 3% when treatment was sought from the most popular 
source of treatment, the simple seller (Table 7-9). The type of test provided also varied 
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significantly by intervention area so that tests performed by VMV or outreach workers were 
reportedly always by RDT. In contrast, only 15-25% of tests by informal providers and 63% of 
tests at public health facilities reportedly included an RDT (Table 7-9). Overall, the test 
positive rate was 77% and was significantly lower. ((XL p: -: 0,009) if performed by RDT (67%) 
compared to microscopy only (88%). This difference is reflected in the decreased likelihood of 
having a positive test if performed by a VMV or an outreach worker. This is at least in part 
explained by the fact that Paracheck®, the RDT used, only detects P. falciparum malaria, 
whereas all species can be detected by microscopy. 
Table 7-9: Frequency of biological diagnosis by provider type (all contacts) 
Type of provider No. of 
contacts 
No. (% ) of contacts 
resulting in biological 
diagnosis (B) 
No. of RDTs 
(as % of B) 
No. of tests 
reported 
positive 
as%ofB 
Simple seller 232 8 (3.4%) 3 (37.5%) 4 (50.0%) 
Went to private health 
worker 
98 41(41.8%) 6 (14.6%) 36(87.8%) 
Public health facility 31 16(51.5%) 11(62.5%) 13 (81.3%) 
Private health worker 
came to home 
24 4 (16.7%) 1 (25.0%) 3 (75%) 
VMV 18 17(94.4%) 17(100%) 11(64.7%) 
Outreach 23 22 (95.7%) 22 (100%) 17 (77.3%) 
Other 26 4 (15.4%) 3 (75.0%) 3 (75.0%) 
Unknown 23 12 4 (33.0%) 6* (66.7%) 
Overall 452 124 (27.4%) 65 (52.4%) 93* (76.9%) 
*3 unknown results 
7.4.3.7. Drug treatment 
The common practice in the selling of drugs in Cambodia is for a selection of different coloured 
tablets and pills to be packaged together in little plastic bags or wrapped in paper, often one 
dose per packet (Figure7-3). In this study respondents reported receiving altogether 464 
treatments in the previous two months. Of these, 23% of treatments contained four or more 
different drugs with a mean and median of 2.6 and 2.0 respectively. Of these treatments 63% 
(296) were known to contain antimalarials, 13% possibly contained antimalarials ("unknown") 
and 23% did not. Overall the mean number of antimalarial drugs per treatment was one. 
There were at least 28 different combinations of antimalarials of which 15 contained an 
artemisinin derivative. These different combinations were placed into mutually exclusive 
groups for analysis (as described in the Methods). In non-intervention areas, the most 
commonly received treatment was one containing artesunate without mefloquine, which 
accounted for 40% of all treatments containing antimalarials. These treatments can be 
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effectively considered as artemisinin derivative "monotherapy" because even if they contained 
other antimalarial drugs, the latter were generally either ineffective against P. falciparur 
malaria (e. g. chloroquine) or taken for insufficient duration (e. g. quinine). The proportion of 
artemisinins derivatives that are taken as monotherapy rather than in effective combinations has 
grave implications for the potential development of drug resistance. In non-intervention areas 
this accounted for 78% (102/131) of all artemisinin derivative use whereas in outreach and 
VMV areas this was 36% (10/28) and 7% (1/14) respectively (Table 7-10). 
Table 7-10: Percentage of different antimalarial treatments received in the last two months, 
by intervention area (n) 
Treatments received in last 2 months Intervention 
None Outreach VMV 
Artesunate + mefloquine 
+/- other antimalarial) 
11.3% (29) 23.1% (18) 52.4% (13) 
Artemisinin derivative alone 16.7% (43) 7.7% (6) 0 
Artemisinin derivative with other drug_ 16.0% (41) 2.6% (2) 4.8% (1) 
Artesunate+ tetracycline 
+/- other antimalarial) 
7.0% (18) 2.6% (2) 0 
Chloro nine 14.8% (38) 26.9% (21) 0 
Chloro uine + tetracycline 4.3% (11) 5.1% (4) 0 
Other antimalarial combination 5,1% (13) 6.4% (5) 0 
Quinine +/- other antimalarial) 8.6% (22) 11.5% (9) 0 
Unknown 16.3% (42) 14.1% 11 . 3% (7) 
Total 257 78 21 
P<0.001 
In order to compare coverage with the first-line ACT, artesunate and mefloquine, information 
on antimalarial treatments taken for the most recent episode were compared (Table 7-11). In 
non-intervention areas only 8% of patients received artesunate and mefloquine compared to 
22% and 64% in outreach and VMV areas respectively (p<0.001). The adjusted odds ratio of 
receiving A+M was 2.7-fold higher in outreach areas and 7.7-fold higher in VMV areas. No 
other factor was significantly associated with a change in likelihood of receiving A+M (Table 
A9-I5). 
Table 7-11: Proportion and likelihood of treated patients receiving A+M for most recent 
enisode 
Intervention n 
=298 
% receiving 
A+M 
OR p AOR* (95% CI) p 
None 210 8% 17 
Outreach area 74 22%(16) 3.05 0.003 2.73 0.99-7.59 0.053 
VMV area 14 64% 9 9.53 0.000 7,72 1.84-28.2 0,007 
298 14%(42) 
* Adjusted for sex, age (<6 and 6-14 years), distance from neattn centre (>z hours by 
motorcycle), poverty rank (poorest 40% and richest 20%) and survey design. 
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7.4.3.8. Adherence 
Most antimalarial drugs were taken for a median of two to three days with a range of one to 14 
days (Table A9-16). Patient adherence to the recommended treatment regime was defined 
according to duration as explained in the methods section. This analysis was carried out on the 
most recent treatment, as this was less likely to be subject to recall bias than earlier treatment 
taking episodes. The results are summarised in Table 7-12. Adherence was noticeably better to 
the three-day regime of A+M than to the three-day regime of chloroquine (77% versus 35%). 
However when artemisinins were not taken as part of pre-packaged artesunate and mefloquine, 
adherence was poor with only 13-28% taking at least seven days of treatment. Adherence was 
even poorer with quinine-based regimes with none of those taking quinine and tetracycline 
taking it for the recommended seven days and only 13% taking quinine on its own for seven 
days or more. 
In order to compare adherence across interventions and to examine the factors affecting 
adherence, a binary variable of "adherent to treatment" or "not adherent" was created. In non- 
intervention areas adherence was 37% (80/218), in outreach areas 44% (34/78) and in VMV 
areas 90% (17/19). By univariate analysis the OR of being adherent was 15-fold greater in 
VMV areas (95% CI 3.3-65.1) but not sianificantly greater in outreach areas. By multivariate 
analysis adherence was not affected by age, sex, distance from closest public health facility, 
schooling or level of poverty. 
Of particular interest was the likelihood of adherence to A+M and whether this was affected by 
whom it was obtained from. The results are shown in Table 7-13. Unfortunately as only three 
patients obtained A+M from a public health facility the result is unlikely to be representative. 
However if A+M was obtained from a VMV or from the outreach team, adherence appeared to 
be better than if obtained in the informal sector. 
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Table 7-12: Adequate duration of treatment (for most recent treatment) 
Regime (recommended duration) n % achieving 
recommended 
durations 
A+M (+/- other antimalarial) 44 77% (34) 
3 days) 
Artemisinin alone 29 28% (8) 
Idays) 
Artemisinin with other drugs (including quinine) 31 13% (4) 
I days) 
Chloroquine (+/- tetracycline) 63 35% (22) 
(3 days) 
Quinine (+/- other excluding artemisinins) 24 13% (3) 
(7 days) 
Quinine + tetracycline (+/- other excluding artemisinins) 13 0 
(7 days) 
Overall 204 46% (94) 
r<u. uu i 
Table 7-13: Proportion "adherent" to artesunate and n: efloquine regime by type of provider 
Type of provider N % adherent (n) 
Public health facility 3 33% (1) 
VMV 13 85% (11) 
Outreach 15 87% (13) 
Informal provider 17 59% (10) 
48 73%(35) 
7.4.3.9. Rapid diagnostic test results 
Overall 355 study RDTs were performed at the time of interview, of which 28% were positive. 
There was no significant difference in positivity rate between intervention areas and non- 
intervention areas. There was however a significant difference within the non-intervention areas 
such that in Malai only one out of 44 people (2%) tested positive compared to 40 out of 91 
(44%) in Chik Phat, There was no significant difference in the result if the analysis was limited 
to the 215 who began treatment recently (in the last three weeks) and who therefore might have 
been expected to still be RDT positive had they been parasitaemic before starting treatment. By 
multivariate analysis, in the model adjusted for study design, the only factor significantly 
associated with an increased likelihood of having a positive RDT on the day of the study was 
being a child less than five years of age (AOR 2.5, CI 1.44 - 4.21, p<0.00 1). Being further than 
two hours by motorcycle from the nearest health centre halved te likelihood of a positive test. 
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Table 7-14: Likelihood of positive study RDT 
1ý 
P 
Variable** AOR (95% Cl) p 
Outreach area 1.62 (0.88-3,01) 0.12 
VMV area 1.06 (0.32-3.49) 0.92 
Did not receive A+M in last 2 
months 
1.95 (0.97-3.91) 0.06 
Did not receive any antimalarial 
received in last 2 months 
1.04 (0.54 -2.02) 0.90 
Female 1.26 (0.77-2.07) 0.36 
Child 6-14 2.46 (1.44-4.21) 0.00 
Child <6 0.64' 0.18-2.34 0.50 
Far 0.45 (0.26-0.79) 0.01 
Poorest 40% 1.20 (0.67-2.15) 0.54 
Richest 20% 1.14 (0.57-2.32) 0.71 
Number of obs=354 
* Adjusted for sex, age (<6 and 6-14 years), distance from health centre (>2 hours by 
motorcycle), poverty rank (poorest 40% and richest 20%) and study design. 
**Results in bold highlight variables that significantly affect the AOR. 
7.4.4 Patient costs 
The table below summarises the household costs for the most recent treatment. All costs have 
Intervention 
(n) 
Cost (US$) 
Drugs Travel Total including other 
costs58 
None Mean s. d. 3.24(6.23) 0,38 1.18 4.31(8.07) 
(205) Median (range) 0.88 (0- 41.0 0.00 0-11.1 1.28 0- 54.9 
Outreach Mean (s. d. ) 2.01 3.22 0.26 0.89 2.92 5.32 
(71) Median (range) 0.77 0- 17.9 0,00 (0-6.41) 0.90 0- 33.7) 
VMV Mean s. d. 0.52 1.28 0.00 0.68 1.37 
(16) Median (range) 0.00 (0-5.13) 0.00(0-0) 0.00 0-5.13 
been converted to US$ 2002 (US$=3900 Cambodian riel). 
Table 7-15: Costs for mo recent treatmep episodevention area 
Much of the difference in cost between intervention areas is explained by the difference in the 
cost of drugs from different types of providers and the proportion of treatments sought from 
each. Drugs from simple sellers and private providers, the most popular source of treatment in 
non-intervention areas, cost a median of $0.77 and $2.95 respectively. This compares with a 
median of zero from VMVs and $0.64 from outreach workers. As can be seen from Table 7-16 
there was a large variation in the cost of drugs ranging up to $41 from a private health worker. 
58 Other costs included food and drink. 
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Table 7-I6: Cast (1, " 1 nfdruoc (far mnct ro, 'on! lrnn! »nn, a! onlcnflol A ,t nrn. ý., I.. #.,.,. 
--7: > 
Provider n Median (Range) Mean (s. d. ) 
Simple seller 151 0.77 0- 12.82) 1.28 (1.86) 
Went to private 
health worker 
65 2.95 (0 - 41.03) 7.35 (9.56) 
Public 17 0.95 0-9.23 2.41 2.83 
Private health worker 
came to home 
15 6.44 (0.44 -15.38) 5.73 (4.23) 
VMV 12 0 (0-1.78) 0.23 (0.54) 
Outreach 18 0.64 0 -1.28 0.51 0.41 
Traditional 1 0.77 0.77 
Other 13 0 0-1.54 0.30 (0 - 0.57 Total 292 0.77 0- 41.03 2.79 5.51 
Cost of drugs 
Overall, households spent a median of $0.77 for A+M compared to a median of $2.05 for 
artemisinin derivatives without another antimalarial, and $1.67 for artemisinin derivates given 
in combination with another (non-mefloquine) antimalarial. Treatments that did not contain any 
antimalarial cost $0.38 and the most common non-artemisinin antimalarial treatments cost a 
median of $0.67 (for both chloroquine and/or tetracycline and quinine without tetracycline) 
(Table 7-17). 
Table 7-17: Cost of different treatments for most recent episode (US$) 
Treatment for most recent episode (n) Mean (s. d. ) Median (range) 
A+M +/- other antimalarial) (42) 2.00 3.27 0.77 (0 - 12.82) 
Artemisininalone (25) 5.00 7.35 2.05 0.38-26.7 
Artemisinin with other antimalarial 31 4.01 (7.04) 1.67 0.22 - 38.9 
Chloro uine and/or tetracycline 61 1.08 1.66 0.67 (0.11 - 11.11) 
Quinine +/- other antimalarial) (21) 2.15 3.70 0.67 0- 11.1) 
Quinine + tetracycline (+/- other antimalarial) 
(13) 
3.01 (4.65) 1.11 (0.35 - 17.3) 
Other antimalarial combination (6) 2.76 3.48 1.53 (0 - 9.23) 
No antimalarial (55) 0.76 0.94 0.38 0-4.44 
Unknown 36 7.43 9.9 3.59 0- 41.03 
Total (290) 2.79 5.5 0.77 0- 41.03 
In order to compare costs across interventions and to investigate factors other than intervention 
type that might influence costs to households, a binary indicator variable of "cost of treatment 
greater than $1" was created (Table 7-18). There was no difference by intervention area and 
increasing the threshold to $2. By multivariate analysis, only the level of poverty affected the 
likelihood of paying more than $1 for drugs with those in the poorest 40% being less likely than 
those in the middle 40% AOR 0.38,95% CI 0.21-0.68). 
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Table 7-18: Proportion and likelihood of spending greater than $1 treatments for malaria 
Interventions n % spending OR p AOR* p 
more than 
=298 $1 (n) 
None 210 52. %(110) 
Outreach 74 46% (34) 0.93 0.795 1.15 0.525 
(0.55-1.59) 0.63-2.12 
VMV 14 29%(4) 0.42 0.126 0.55 0.107 
(0.14-1.23) 0.16-1.85 
* Adjusted for sex, age (<6 and 6-14 years), distance from health centre (>2 hours by 
motorcycle), poverty rank (poorest 40% and richest 20%) and study design. 
7.4.5 Inputs for modelling 
The values for input into the model were estimated from the data collected. Most values could 
be used directly but for some estimates, adjustments had to be made, in particular to that the 
model tracked P. falciparum infected patients whereas the study was on patients with malaria- 
like symptoms. 
Treatment rate 
In this study, in the absence of interventions, the treatment rate for malaria-like symptoms was 
only 83%. However, as explained in the next chapter, for the purpose of the model, the 
treatment rate is assumed to be 95%. 
Formal or informal provider 
The type of provider determined the likelihood of receiving the ACT, likelihood of adherence 
and cost. In non-intervention areas, of those who received modern treatment, an estimated 8% 
were seen in public health facilities with the remainder being seen in the informal sector only 
(Table 7-7). Dues to the small sample size in the outreach and VMV areas and for ease of 
comparison, it is assumed this was the same proportion in intervention areas. It is therefore 
assumed that in outreach areas 23% were seen by outreach workers and in VMV areas 85% 
were seen by VMVs59. It is assumed that choice of provider is the same irrespective of whether 
the malaria-like illness is actually due to P. falciparum malaria or not. 
Likelihood of receiving combination therapy 
For the model, the likelihood that patients with P. falciparunr malaria receive the ACT needs to 
be known. From the survey it is not possible to know whether patients actually had P. 
falciparum malaria, except if treatment was sought from outreach workers or VMVs, where all 
patients were tested with an RDT and treated with A+M if positive. However for patients who 
went to the private sector it is only known that 8% received A+M. Therefore it is assumed that 
the likelihood of receiving A+M is independent of actual diagnosis and that the likelihood of 
59 the proportion seen in the formal sector as whole was 31 % in outreach and 93% in the VMV areas. 
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receiving A+M is 8%. In public health facilities, biological diagnosis is more likely, a choice of 
antimalarials are available and prescription of antimalarial drugs is presumably more rational. It 
is therefore assumed that patients who received chloroquine had non falciparur malaria and 
that those who did not receive an antimalarial did not have malaria. The coverage rate with 
A+M is therefore the proportion of those who received A+M over those who received any no- 
chloroquine antimalarial, which in this case was three out of seven (43%) in the public health, 
facilities (Table A9-17). 
Likelihood of adherence to A +M 
Adherence to A+M was estimated for the different providers but because the numbers were so 
small, an average was taken for all formal providers (public health facilities, VMV and 
outreach) and was estimated at 77%. In the private sector adherence to A+M was 59% (Table 
7-13). 
The model also required estimates of adherence to the monothera , drug A, which 
in this case 
was mefloquine. However, mefloquine was seldom prescribed or bought. Therefore for the 
purpose of the model it was assumed that adherence to the monotherapy would be same as that 
for the combination therapy in the formal sector. In the informal sector, because mefloquine is 
relatively expensive, it was assumed that adherence was an arbitrary 30%. The inputs are 
summarised in Table 7-19. 
Table 7-19: Parameter inputs for "behaviour" sub-model derived fron: results of the survey 
Scenario 
Input parameters for patients with No Change Change Change 
symptomatic malaria change to ACT to ACT + to ACT + 
outreach VMV 
Proportion receiving antimalarial treatment 95% 95% 95% 95% 
Proportion seeking treatment in health centre 8% 8% 8% 8% 
Proportion receiving ACT if seen in health 0% 43% 43% 43% 
centre 
Proportion seeking treatment from outreach or 0% 0% 24% 86% 
VMV 
Proportion receiving ACT if seen by outreach NA NA 100% 100% 
or VMV 
Proportion seeking treatment in formal sector 8% 8% 32% 94% 
(health centre, outreach or VMV) 
Proportion seeking treatment in informal sector 92% 92% 68% 6% 
Proportion receiving ACT if seen in informal 0% 8% 8% 8% 
sector 
Adherence rates: 
A+M (public sector) 80% 80% 80% 80% 
Mefloquine (public sector) 80% 80% 80% 80% 
A+M (informal sector) 59% 59% 59% 59% 
Meflo uine (informal sector 30% 30% 30% 30% 
190 
7.5 Discussion 
In this section the findings of the research are discussed and suggestions for further research 
specific to Cambodia made. The study's strengths and weaknesses and more general 
recommendations for policy and research are discussed in the final discussion chapter. 
This study documented for the first time the actual impact of the change in policy to ACTs in 
communities affected by malaria, and the impact of different delivery strategies in Cambodia. It 
was also unique for a study on treatment seeking for malaria, in attempting to explore the 
proportion of fever patients who actually had evidence of recent P. falciparum malaria, by 
carrying out a rapid diagnostic test at the time of the study. Although in practice there were 
problems with interpreting the results, as discussed below, the experience showed that with 
adaptation this approach may prove useful in future studies of treatment seeking for "malaria". 
The key findings in this study were that the coverage with both arms of the "Early Diagnosis 
and Appropriate Therapy" approach was low, but that significant improvements could be made 
with specific interventions to improve access to reliable diagnosis and free drugs. The other 
important finding was the widespread use of artemisinin derivatives without mefloquine - over 
78% or treatments containing artemisinins in non-intervention areas. 
In the absence of any intervention, only 17% of respondents received a biological diagnosis for 
the most recent episode of fever and only 11% received artesunate and mefloquine for malaria- 
like illnesses in the last two months. The results came as a surprise and disappointment as much 
work had gone into the changing of the policy and Cambodia was seen as an example of a 
country with an innovative policy (WHO 2002). In particular, there had been much optimism 
for the attempts to socially market Malarine®. However the finding in this study were later 
confirmed in a larger national antimalarial drug usage survey the following year in nine districts 
in which 1277 household respondents in 36 villages participated. The survey differed from this 
study in that districts did not have any special interventions to increase coverage60. In this 
national survey, only I1% of adults, 10% of children (five to 14 years) and only 2% of the 116 
children under five years received the recommended treatment (Duzey, Kim et at. 2003)61. An 
even higher proportion (92%) of treatments containing an artemisinin derivative were taken 
without mefloquine if they were not blister-packaged with mefloquine (Duzey, Kim et at. 2003). 
60 However half had purposively been selected as they were districts in which there were sentinel sites for 
the monitoring of drug resistance and therefore by implication had relatively well functioning health 
centres. 
61 Only two children received an artemisinin derivative as a suppository and only five received oral 
artesunate and mefloquine. 
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One of the reasons for the low coverage rate with A+M in Cambodia is that few treatments were 
obtained in public health facilities. In the thesis, in the absence of any interventions, only 8% of 
respondents sought treatment from a public health facility for the most recent episode of a 
malaria-like illness, with the most popular first source of treatment (56%) being untrained 
village providers. These findings are similar to rates found in other settings with poorly 
functioning health systems (Slutsker, Chitsulo et al. 1994; Ruebush, Kern et al. 1995; 
McCombie 2002; Williams and Jones 2004) and confirms previous reports in Cambodia. In 
other studies in Ko Kong, only 2 to 4% (Denis, Macdonald et al. 1994; Sedano 2002) of patients 
first sought treatment for malaria in the formal sector. In other areas rates of 7 and 26% have 
been described with the variation between villages being explained by proximity to roads and 
the nearest health centre (Bury 1999). In the national antimalarial drug usage survey in 2002, 
18% of first treatments were received from public or NGO facilities62 (Duzey, Kim et al. 2003). 
However, even in public health facilities, the treatment guidelines were often not followed. In 
2001, from the official statistics, 169,215 patients were treated for malaria in public health 
facilities of whom 32% received a biological diagnosis. Of those having a biological diagnosis, 
only 7% were by an RDT with an average positivity rate of 48%63 (range of 18-70% depending 
of the province) (Soley L, personal communication). Unfortunately, information about what 
treatments patients diagnosed with malaria actually received was not available and there was no 
accurate information on the distribution of drugs and RDTs in that year. However less than 
60,000 doses of pre-packaged A+M were produced (CNM 2001) and in the preceding year only 
21,850 doses of drug and 13,725 rapid diagnostic tests were distributed (CNM 2000). 
Therefore the low rates of biological diagnosis (52%) and use of the combination therapy in 
public health facilities found in this study are not surprising. From interviews with health centre 
staff it became apparent that they continued to stock and use the old drugs (quinine and '110- 
tetracycline) for the first-line treatment of P. falciparun: malaria. 
The low uptake of Malarine® in the informal sector was less surprising, but still disappointing, 
particularly in Sampalouen district where the pilot project had been ongoing for over a year. 
There are a possible number of explanations for this: low awareness of the policy by both 
patients and/or providers; low availability of the RDTs and A+M; unaffordability; or preference, 
based on some other factor such as familiarity of older drugs or fear of side effects64 
62 It was also noted that the likelihood of going to the public/NGO sector increased as more treatments 
were sought. 
63 The overall slide positive rate was 35%, of which 90% were P, falciparum, the remainder being mainly 
P, vivax. 
64Although the experience or fear of side effects with mefloquine was widely reported anecdotally, this 
was not confirmed in this study. Unlike foreigners taking mefloquine for chemoprophylaxis who mainly 
associate mefloquine with its much rarer neuropsychiatric side-effects, the main side-effects experienced 
in the local communities are nausea, vomiting and dizziness. However from the national survey the 
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The policy had been accompanied by an advertising campaign on the television and local radio, 
largely promoting the availability of Malarine® and dipsticks from private providers. At the 
end of the advertisements brief mention was made to the fact that both could be obtained free at 
health centres. It had been hoped that there would be sufficient financial incentive to encourage 
more patients to use the public health facilities rather than the private sector for their treatment 
and that patient demand would result in the provision of Malarine® in the informal sector. The 
poor uptake was due mainly to the one-year delay between the publicity campaign and the_, 
launching of the nationwide implementation. During this extended "pilot" phase, even interest 
from the 10 pilot market retailers waned and the product did not penetrate into the villages in 
the catchment area. It was during this period that this study was conducted and therefore the 
findings do not reflect the results of the full-scale implementation. However, the national 
antimalarial drug usage survey was carried out six months after the nationwide launch of the 
social marketing project. This confirmed that Malarine® was not penetrating into rural areas - 
none of the village providers stocked Malarine® compared to 40% of market providers65. It also 
showed low levels of awareness of the product and of the national antimalarial guidelines 
(Duzey, Kim et al. 2003). 
However, there was evidence of widespread leakage of blister-packaged A+M from the public 
sector into the private sector in both this study and the nationwide antimalarial survey. In the 
latter, blister-packaged A+M was found in over 30% of market providers and over 15% of 
village providers. The problems of low motivation and low pay amongst health staff in the 
periphery are well known and there are a number of initiatives aimed at addressing this. 
However, this will take some time and although the leakage is seen as a very serious problem, 
there is also a pragmatism, amongst certain donors and senior health officials, that recognises 
that it is preferable for patients with malaria to receive effective treatment and for some public 
money to go into the pockets of a few private individuals, than for patients to risk death from 
receiving inappropriate drugs in the informal sector. 
Previous studies (Rose, Dixon et al. 2002) have documented the severity of the problem of 
inappropriate drug usage in Phnom Penh in Cambodia. The problem of unnecessary infusions 
and injections is particularly worrying. Unfortunately in rural areas, where malaria is often 
perceived as a potentially life-threatening disease, some patients are willing to pay for more 
expensive treatment often including injections or infusions. Therefore a financial incentive 
exists for private health workers to make a diagnosis of malaria. There was evidence for this in 
following year, these side-effects did not occur more often with mefloquine than with other drugs and 
neither patients nor providers reported this as a common reason for not taking A+M. 
65 The provider arm of the study included 49 market-level facilities, 107 village-level facilities and 12 
public health facilities. 
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Malai district which recorded the highest rate of biological blood tests and the highest rate of 
positive tests and yet the lowest rate of positive study RDT tests. Interestingly we were told that 
a diagnosis of "Falciparum" would inevitably result in the prescription of parenteral drugs 
because the word sounds like "Svar" (monkey) "psi" (eat) "serum" (serum or intravenous 
fluids) in the Khmer language! 
The challenges in changing prescribing practice in the informal sector are considerable and 
make the alternative, of community based interventions, very attractive. It was clear from this 
study that the interventions to improve coverage were effective, in particular the VMV scheme. 
The likelihood of receiving a biological diagnosis was increased 11-fold and the likelihood of 
receiving A+M was increased eight-fold. The use of artemisinin derivative monotherapy was 
also much lower than in non-intervention areas. However there were some surprising results. 
In the VMV area a higher proportion of patients reported remaining untreated despite having 
had malaria-like symptoms and waited for longer before seeking treatment. This could be for a 
number of reasons. The presence of a VMV may have allowed them to risk waiting for longer 
to see how symptoms evolved before seeking treatment, assured that if they did have malaria 
they would receive the right treatment immediately, or patients may not have been able to find 
the VMV if they were in the field or elsewhere. 
Coverage was lower than anticipated with the outreach programme. From discussion with the 
villagers it was apparent that this was mainly an issue of time and convenience. For those that 
were close to roads, if they could afford the transport and drug costs, they preferred to go to buy 
drugs rather than wait for the outreach service to come to them, unless they knew that they were 
arriving in the next day or two. For the more remote and poor villages, they seemed to be more 
willing to wait. Unfortunately numbers were not big enough to test this hypothesis statistically. 
The two interventions cannot really be compared, as the contexts were very different. In Ko 
Kong, the communities had generally been in place for longer and there was a strong sense of 
community, which meant that there were willing volunteers. In Anlong Veng, much of the 
population had arrived recently from disparate locations and there was little connection between 
them. Individual households were struggling to survive, building themselves crude shelters and 
clearing land. It was therefore felt that there was little capacity or inclination for community 
volunteers. It may also be that there was a bias in the philosophy of the organisations involved 
that meant different systems were favoured. 
The rates of receiving any kind of modern treatment were generally lower than expected. 
However in non-intervention areas for those who did receive modern treatment, over 60% 
received treatment within two days of the onset of treatment. Reassuringly there appeared to be 
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some recognition that young children were particularly at risk of malaria, as they were 
significantly more likely to receive modern treatment within two days of symptoms and were 
three times more likely to be seen in the formal sector than older children and adults. They were 
also three times more likely to receive a biological diagnosis, but were no more likely to receive 
the recommended A+M than older age groups. 
Interestingly, data on drug costs suggested that households pay $0.5 to $2.60 with a median of 
$0.77 for antimalarial drugs and this was in fact the median costs paid for blister-packaged 
A+M. In general, there was a great deal of variation in the price paid for treatments with people 
paying up to $41 for a single course of treatment from a private provider. The median cost of a 
course of an artemisinin drug without another antimalarial appeared to be more than that if 
provided with another (non-mefloquine) antimalarial but with less variation (range $0.90-2.69) 
compared to $1.67 (range $0.77-5.13) respectively. This was because artesunate tablets, the 
most popular form of artemisinin derivative, were generally sold either in whole blister packets 
containing 12 artesunate tablets at a usual cost of around $2 per packet, or as a single tablet 
packaged with a number of other cheaper drugs such as paracetemol and chloroquine to 
constitute a single dose of treatment at a cost of about $0.25-0.50 per packet. For the latter, the 
number of doses of treatment bought would depend on a number of factors including how much 
the patient could afford and how ill they were. 
Of note the only variable with a significant correlation to the amount of money paid for 
treatment was poverty rank. This confirms previous findings of the relationship between 
poverty and treatment expenditure (Filmer, Giao et al. 2005) and adds weight to the argument 
that ACTs will need to be provided almost free if the biologically vulnerable (who are usually 
the most economically vulnerable) are to be reached (Arrow, Panosian et al. 2004). 
Reassuringly, the cost of treatments was cheaper in the formal sector compared to the informal 
sector66. Treatment from the VMVs was supposed to be provided free and the study suggested 
that usually this was the case, although there was evidence that occasionally small payments 
were made (maximum $0.54). In outreach areas the median cost of treatment from an outreach 
worker was reported to be $0.64 but ranged up to $5. I. This is concerning as the patients were 
only supposed to be charged up to a maximum of $0.75 depending on their means (as assessed 
informally by the outreach worker) and it was said that the majority of patients received their 
treatment for free. In contrast, treatment from a simple seller cost a median of $0.77 and from a 
private health worker $2.95 if the patient went to the health worker and $6.44 if the health 
worker came to the patient's house. 
66 This is similar to the findings in the national drug usage survey where the median cost was 8000 riel in 
the private sector (n=554) which was almost double the cost of public sources (4550 riel) (n=132). 
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The study revealed encouraging results with regard to adherence to the ACT. Of patients who 
did receive the blister-packaged artesunate and mefloquine, 77% reported to taking the whole 
package over 3 days and were therefore considered adherent. Although an attempt was made to 
differentiate between A+M that was blister-packaged and artesunate and mefloquine provided 
separately, there was no apparent difference in adherence. This is most likely due to the small 
sample size or failure to differentiate between the two. It may also be because there was no real 
difference or because when A+M was provided "separately" it was actually the blister-packaged 
A+M which had been re-packaged so that it was not recognizable as A+M67. In the national 
drug usage survey using similar criteria, adherence rates were between 73% for Malarine and 
97% for A+M, possibly reflecting that A+M was more likely to be obtained in the formal sector 
where it was provided free and by a trained provider (Duzey, Kim et al. 2003). The results 
compare favourably with clinic-based studies of adherence to artesunate and SP (Depoortere, 
Guthmann et al. 2004) and artemether-lumefantrine (Fogg, Bajunirwe et al. 2004) where rates of 
78% and 90-93% were reported respectively. The latter is co-formulated which ensures that 
both drugs are taken, but requires twice daily dosing, which is likely to decrease adherence in 
terms of frequency and overall dosing, making direct comparison difficult. 
7.5.1 Further research 
This study aimed at answering a number of questions: 1) What proportion of patients with 
malaria received a reliable diagnostic test and A+M? 2) How adherent were patients to A+M? 
and 3) How effective were outreach and VMVs in improving access to early diagnosis and 
appropriate treatment? Although all of these questions were answered to a certain extent, the 
process of undertaking this study and the finding themselves exposed areas where further 
research would be helpful. Further research specific to Cambodia are discussed here. More 
general recommendations for studies of antimalarial drug usage and treatment seeking 
behaviour are made in Chapter 5 and in Chapter 10. 
Given the size of the study, one of the main priorities was to validate the findings and attempt to 
quantify the extent of the problem nationally. In addition there was a lack of information on 
high-risk groups in particular pregnant women and children. As discussed earlier this in fact 
was achieved the following year (Duzey, Kim et al. 2003) using a simplified survey in nine 
districts across the country. 
67 There was evidence that this was done from inspecting some drug packages obtained from the private 
providers. This was also practised by one of the outreach workers who cut up the blisters and put each 
dose into a separate plastic bag, believing that it would easier to take. 
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As the study in this thesis purposefully focused on the behaviour of patients, only limited 
information was gathered from providers themselves. However providers in each village and 
town were visited and although the information has not been presented, it seems that there was a 
low level of awareness of the national antimalarial guidelines, and low availability of the ACT 
and RDTs. There was also widespread evidence of leakage of A+M and availability of fake 
artesunate. It was clear therefore that much more systematic information was required from the 
supply side of the antimalarial drug market, focusing on these issues. It would also be useful to 
explore attitudes and knowledge about the current policy and the willingness to participate in 
training and provision of malaria curative services. Fortunately, following this study, a number 
of other studies has been undertaken addressing some of these concerns. 
Finally, this was a quantitative survey, aimed at answering questions of the "How much" or 
"When" type rather than the "Whys? " and "Hows? ". It revealed substantial gaps in our 
understanding about why uptake of A+M and RDTs has been so low. More qualitative work 
will be essential in or er to un erstarr e perceptions, attitudes and reasons underlying 
patients' and p ovi(iPr-, 'bf--haviQur. if implementation strategies are to succeed. One particular 
area where there is little understanding is the acceptability of using rectal medication in 
children. The policy was introduced with limited consultation with health care workers and 
patients themselves and it would appear that there may be problems with acceptability. 
7.6 Conclusion 
This study has shown that the main challenge in changing to ACTs is ensuring adequate access 
to accurate diagnosis and ACTs in the poor rural areas where the community have limited 
access to any kind of health care. Adherence to the ACTs once received appears to be good if 
provided in blister-packaged doses. In order to improve access, the training of volunteers at the 
village level and provision of free RDTs and drugs certainly seems to be effective but may not 
be appropriate in all circumstances, and there may be a role for outreach teams in new 
settlements where there is much fluidity in the population movement and a lack of social 
cohesion. Visits may well need to be more frequent than once weekly, and even so patients are 
still likely to seek treatment from the private sector. However, low uptake of the socially 
marketed Malarine® was disannointing and_much more effort needs to be made in ensuring a 
higher level of awareness and availability of drugs. This will require both a greater 
understanding of how the market currently works and the costs patients are willing to pay. 
Successful implementation will probably require more direct communication with providers 
who, on the whole, did appear very willing to improve the quality of the service they provided 
to their clients. This has been successfully done in other countries both focusing on malaria 
(Marsh, Mutemi et al. 1999; Marsh, Mutemi et al. 2004) and other diseases (Luby, Zaidi et al. 
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2002). The latter is relevant in view of the limitations of focusing only on malaria diagnosis and 
treatment rather than the provision of a more holistic service. 
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CHAPTER 8 
MODELLING ANTIMALARIAL DRUG RESISTANCE AND 
ARTEMISININ-BASED COMBINATION THERAPY: 
RESULTS 
In Chapter 4, the model development and structure was described. In this chapter, the model is 
run to illustrate how it functions and is applied to explore the spread of drug resistance and the 
effect of combination therapy in a low transmission setting. 
8.1. Overview of the chapter 
The chapter starts with the presentation of results when the biological model is run to simulate a 
base-case scenario in which use of monotherapy is continued in a low transmission setting. 
This enables the detailed exploration of the outputs of the biological mode Ni terms ote 
spread of drug resistance, number of infections and recrudescent infections in a "no change" 
situation. These outputs are then fed into the sub-models to illustrate how these component 
models link together to produce outcomes in terms of severe malaria, deaths, disability-adjusted 
life years (DALYs) and costs. 
The model is then run to simulate the introduction of an artemisinin-based combination therapy 
(ACT) in presumably ideal conditions, where the switch from monotherapy is made early and 
the coverage rate with ACT is high. The results of comparing these first two scenarios are then 
presented and form the basis of the cost-effectiveness analysis of combination therapy. In the 
next section, the results of the sensitivity analysis are shown. Firstly, a brief summary of the 
extensive sensitivity analysis of the biological model undertaken by WP is presented, followed 
by sensitivity analysis of some of the parameters and assumptions used in the sub-models. 
Scenario analyses are then presented, of the cost, effect and cost-effectiveness of combination 
therapy compared to monotherapy in different circumstances. Finally, the chapter illustrates 
how the model might be applied to a real-life scenario to predict the cost-effectiveness of 
different interventions by using the data collected in Cambodia. This sequence of presentation 
of results is illustrated in Figure 8-1. 
Because the inter-relationships between the factors that influence transmission and drug 
resistance are complex, and this complexity is reflected in this model, the outcomes for a given 
set of inputs were not predictable and were often surprising. When such results were produced 
during the development of the model, they were occasionally due to errors in the model script 
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that had to be corrected. However once such errors had been ironed out, it was often in the 
investigation of these initially unexpected results, that the importance of certain factors and 
relationships emerged or assumptions that had been made in the modelling were uncovered. 
These discoveries would lead to refinements in the model, the gathering of more data or a note 
of the importance of specific assumptions made. 
Although not the focus in this thesis, the preliminary application of the model to a high 
transmission setting has also been undertaken and results provided in Annex 10. Specific 
comments are provided in the chapter text where the results are of interest. 
Figure 8-1: Sequence of presentation of results in this chapter 
Base-case scenario 
" Continued use of monotherapy (drug A) in a low transmission setting 
" Detailed exploration of outputs 
Comparison of base-case scenario with combination therapy (drug AB) 
" Annual outputs 
" Cumulative outputs 
" Cost-effectiveness 
Sensitivity and scenario analysis 
" Summary of sensitivity analysis of inputs into biological model 
" Sensitivity analysis of inputs into sub-models: 
o Likelihood of severe malaria and mortality 
o DALYs and discounting 
" Scenario analysis 
o Costs 
o Coverage 
o Timing of switch and choice of drug 
Application of model to Cambodian data 
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8.2. Presentation of results 
For each simulation of the biological model, a large amount of outputs are produced. The 
choice of which outputs to present, and how to present them, needs to reflect the requirements 
of the audience for whom the analysis is intended. Many of the outputs of the biological model 
are useful for problem shooting and in refining the model, and will be useful for further 
exploration of particular aspects of malaria transmission and resistance. However they are not 
of direct relevance to the economic analysis and are therefore not presented here. 
The purpose of this chapter is to focus on the outcomes most relevant to policy and to present 
them in a way that is accessible and potentially useful. Therefore, the choice of results included 
reflects an attempt to balance parsimony with sufficient information. The eventual choice is 
discussed and justified below: 
Annual versus cumulative results. Annual and cumulative results are both presented, as 
annual results show the change in outcomes over time, and the results cumulated over 
time capture the long-term costs and consequences. The latter can illustrate the 
importance of using a sufficiently long time-scale when the externality benefits of 
reducing resistance and transmission are to be considered. 
Incidence in terms of patent versus symptomatic or treated infections. Although the 
number of patent infections is important in terms of transmission, it is the numbers of 
symptomatic or treated infections that are more tangible, are routinely measured in 
studies and are directly associated with clinical outcomes and costs. In low transmission 
settings they are similar but there is considerable divergence in high transmission 
settings where immunity is high. The incidence of patent infections is therefore not 
presented. 
" Symptomatic infections versus treated infections. Both could have been presented but 
this was unnecessary as the model assumes that a fixed proportion of symptomatic 
infections are treated. In the base-case scenario, this proportion is fixed at 95% and 
only results of treated infections are presented as these are the ones for which costs of 
treatment are incurred. 
" Direct costs alone versus total costs inclusive of indirect costs. Direct costs are tangible 
and hold meaning for policy makers in terms of actual monetary value and are therefore 
shown throughout. Indirect costs are difficult to measure and value estimates vary 
widely depending on the setting and the methodology used. However they do attempt 
to capture the total cost of malaria and are therefore shown intermittently to emphasise 
the societal cost of drug resistance. 
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" Ideal versus realistic coverage rate with combination therapy. In basic comparison 
between monotherapy with combination therapy, an "ideal" coverage rate of 100% and 
a realistically more achievable rate of 80% are both shown. This is to make clear what 
is the maximum possible effect of combination therapy from a theoretical point of view 
as well as the effect that is practically more likely. Having illustrated the potential 
difference in outcomes, for clarity, the model was run with 100% ACT coverage 
thereafter except when coverage rates were varied from 10% to 100% in the scenario 
analysis. 
Discounted versus undiscounted future costs and benefits. As discussed in Chapter 3, 
costs and DALYs are discounted at a rate of 3% for comparability with other studies. 
Undiscounted costs and DALYs are tested in the sensitivity analysis. All costs are 
expressed in terms of US$ 2002. 
8.3. Base-case scenario - The continued use of monotherapy 
8.3.1. Results of the biological model 
The model was run with inputs for a "base-case scenario" in order to explore in detail the 
outcomes of the model and the relationships between different inputs, and as a reference case 
with which other scenarios could be compared. This base-case scenario is the continued use of 
monotherapy at a treatment rate of 95% in an area of relatively low transmission intensity with 
an entomological inoculation rate (EIR) of one or less68. Although, for this example it is 
assumed that the monotherapy (Drug A) is mefloquine, the values of the inputs would in fact be 
the same for SP. Later, this base-case scenario is compare& with a switch to a combination of 
artesunate with mefloquine69 (Drug AB). The characteristics assigned to both the monotherapy 
and combination therapy are shown in Table 8-1. 
The model was run for 12 years, with the first two years being the time to reach steady state 
without drug resistance. At this point resistance to drug A is introduced with a starting level of 
1% of patent infections. All the fixed model inputs are highlighted in the parameter tables in 
Annex 6. The values of the variable parameters used in the base-case scenario are shown in 
Table 8-2. A population size of 10,000 was used and the analysis was carried out using three 
age groups (<5 years, 5-12 years and >12 years). Although the analysis could have been 
undertaken with more age groups, it would have taken longer for the model to run, and would 
not have provided additional useful information for the purpose of this thesis. 
68 Although the WHO recommend the inclusion of a "null case" scenario, which in effect is the natural 
course of disease, we felt that it was more helpful to take as the base-case, the common scenario which is 
the continued use of monotherapy. 
69 The assumed dosages were: mefloquine at a single dose of 25mg/kg, and for combination therapy, 
artesunate at 4 mg/kg once daily for three days with mefloquine 25mg/kg in single dose on the first day. 
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Table 8-1: Characteristics of monotherapy (drug A) andACT (drug AB) 
Parameter Value in base- 
case scenario 
allure rat n the non-immune host if 
Sensitive to Drug A and treated with Drug A 10% 
Resistant to Drug A and treated with Drug A 95% 
Sensitive to Drug A and treated with Drug AB 3% 
Resistant to Drug A and treated with Drug AB 30% 
Minimum parasite reduction ratio with Drug A if sensitive to Drug A 1,000 
Minimum parasite reduction ratio with Drug A if resistant to Drug A 100 
Minimum parasite reduction ratio with Dru AB if sensitive to Drug A 50,000 
Minimum parasite reduction ratio with Drug AB if resistant to Drug A 50,000 
_Gametocyt 
e switching rate with Drug A 0.003 
_Gametocyt 
e switching rate with Drug AB 0.0009 
Cost of adult course of drugs : 
Drug A $1.11 
Drug AB $3.77 
Table 8-2: Values of variable parameters used in base-case scenario 
Parameter Value in base- 
case scenario 
Population size 10,000 
Number of age-groups 3 
Vectorial Capacity (giving an initial EIR of 1) 0.1 
Seasonal variation in transmission None 
Likelihood that symptomatic patient receives antimalarial treatment 95% 
Time delay before seeking treatment 1.2 days 
Coverage rate with combination therapy 0% 
Proportion of humans who have inhibitory concentrations of antimalarial 
drug in their blood 
10% 
New "migrant" infections as a proportion of the total human population 5% 
Time of undetectable parasitaemia between initial infections and 
recrudescence 
14 days 
Starting level of resistance to drug A 1% 
70 The cost of most drugs for children aged 6 to 12 years and 1 to 5 years was assumed to be 50% and 
25% of the cost of the adult course respectively. For artesunate and mefloquine the costs were based on 
the cost obtained for blister-packaged "A+Nf' in Cambodia with an adjustment for the difference in age 
grouping. 
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8.3.1.1. Drug resistance 
As shown Figure 8-2, in this scenario, resistance rises exponentially from 1%, at the time of 
introduction of drug resistance, to almost 100% in around six years, and stays at this level 
thereafter. This rapid increase in resistance until saturation point occurs in this scenario because 
it represents a low transmission setting, where adults as well as children are not immune and 
therefore most patent infections result in clinical symptoms for which treatment is taken. In this 
example, the treatment rate is assumed to be 95%, all of whom receive monotherapy and are 
compliant. This means that nearly all parasites are subject to the drug pressure that 
discriminates against sensitive organisms and allows resistant organisms to persist, causing 
recrudescent infections and therefore the increase in their relative infectiousness and an 
expansion in their numbers relative to their drug-sensitive counterparts. In high transmission 
settings a much smaller proportion of parasites are exposed to drug pressure and resistance 
therefore rises more slowly (Figure A10-1). 
Figure 8-2: Spread of drug resistance to drugA with continued use of drug A monotherapy 
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8.3.1.2. Recrudescent infections 
Figure 8-3a shows the total number of recrudescent infections. As expected, once steady state is 
reached and drug resistance is still low, there are few recrudescent infections in the first few 
years - less than 30 cases per year. As resistance rises, so does the number of recrudescent 
infections. After drug resistance reaches 100%, recrudescent infections also start to plateau at 
around 760 cases per year representing a 25-fold increase in incidence of recrudescent 
infections. 
The failure rates in the base-case scenario were chosen to reflect high levels of patient 
adherence to treatment. Therefore the maximum failure rate when a sensitive infection is treated 
is assumed to be 10% in the youngest age group. Older children and adults are assumed to 
acquire a degree of immunity that enables them to self-cure. Therefore, when we examine the 
age group in w is te recrudescent infections are occurring, it can seen that the youngest age 
group contribute the most to the total number of recrudescence infections (Figure 8-3b). 
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Figure 8-3: Recrudescent infections - a) Total number of cases h) By age group 
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b) Annual Incidence of recrudescent 
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It may appear to be unrealistic to allow the model to continue running without a change in 
therapy and one would hope that a switch to an efficacious therapy would occur much earlier. 
However, in reality resistance to chloroquine is known to have reached extremely high levels 
and yet the drug continues to be used. 
8.3.1.3. New infections 
The annual incidence of new patent and treated infections is shown in Figure 8-4. It can be seen 
that under these conditions, after reaching steady state, the incidence of patent infections 
initially remains steady at around 700 infections per year. Then about four years after the 
introduction of drug resistance, there is an exponential rise in the incidence of new infections. 
This is because with the increasing number of recrudescent infections, the infectiousness of the 
population increases. This increase appears to stabilize at around 3000 after another three years 
as resistance reaches a maximum and there is no possible further increase in recrudescent 
infections and therefore in infectiousness. In a low transmission intensity setting such as this, 
all age groups have low immunity therefore most patent infections manifest symptomatically 
and are treated. In a high transmission setting most patent infections are asymptomatic and 
remain untreated (Figure A10-2). 
Figure 8-4: Annual incidence of patent and treated infections (assuming that 95% of 
symptomatic infections are treated) 
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Breakdown of patent and treated infections by age groups is shown in the next figures. This 
shows that infections occur in all ages, including adults and is explained by the low level of 
acquired immunity and therefore susceptibility to infection throughout life. The absolute 
number of infections is greater in the adult age-group because this is numerically the largest 
group. There is an overlap in the two child age-groups because the size and immunity profiles 
result in a similar number of cases in these groups. In higher transmission intensities. only a 
small proportion of the patent infections are symptomatic and treated and the majority of 
infections would be expected to occur in the youngest age group (Figure A10-3). 
Figure 8-5 Annual incidence of a) patent and b) treated infections by age group 
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At an operational level, neither patients nor health workers routinely discriminate between 
"new" infections and recrudescent infections when patients present with a fever, unless little or 
no time has elapsed between a prior fever and the current presentation. Therefore, in the face of 
an increase in the number of clinical infections, it will not be apparent what proportion is due to 
recrudescence. Figure 8-6 illustrates how in this base-case scenario. although there is a 
dramatic rise in recrudescent infections, this is masked by the concurrent rise in new infections. 
Figure 8-6: Total number of patent infections showing the proportion due to recrudescent 
compared to new infections 
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8.3.2. Results of the sub-models 
8.3.2.1. Severe infections, and deaths 
In this section the outputs from the biological model are used in the clinical outcomes sub- 
model, to calculate the number of severe infections and deaths in each age group. In this base- 
case scenario, the inputs to make the calculations were as follows: 
" Likelihood of severe malaria in a treated symptomatic infection in a non-immune host, 
in the absence of drug resistanc (0.05). 5 1. 
" Likeliho of severe malaria in an untreated symptomatic infection, in a non-immune 
hos (0.15) is is the likelihood of severe malaria in symptomatic infections when 
drug resistance has reached 100% and the drug is considered completely ineffective. 
" The mortality rate was fixed in relation to the severe rate at 20%. 
Given these inputs, the number of severe patients by age group is generated, as shown in Figure 
8-7. Initially, when resistance is first introduced into the model at the end of year 2, the 
incidence of severe malaria and mortality is low, 33 severe cases and seven deaths, out of 
around 700 cases. As resistance rises, so does the likelihood of severe malaria and death so that 
when resistance to drug A has reached almost 100% six years later, the number of severe cases 
and deaths has gone up by seven-fold to 234 and 47 respectively. 
The increase in severe infections is due not only to the increase in recrudescent infections but 
also to the increased likelihood of developing severe malaria as drug resistance rises and 
because of the absolute increase in the number of new cases. 
In this setting adults contribute almost the same numbers of severe cases as the youngest age 
group. This is because although there are more infected adults than children, because adults are 
assumed to have a degree of clinical immunity, they are less likely to develop severe malaria. 
This is reflected in the case fatality rate which shows that the rate in the youngest age group is 
almost double that in adults. 
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Figure 8-7: Annual incidence of a) severe cases by age group, b) deaths and c) case fatality 
rate by age group 
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8.3.2.1. Costs 
In this section the costs in the base-case scenario are presented. As explained in the 
methodology section, costs are presented in a number of different ways to address the needs of 
different audiences. From the point of view of donors and malaria control programmes, it is 
mainly the incremental costs of combination therapy compared to monotherapy that are of 
interest. This includes the cost of drugs and any additional delivery costs. The cost of the 
monotherapy drug therefore forms the base cost with which the incremental cost of switching to 
combination therapy can be compared. It is this difference in drug costs that forms the 
numerator in the cost-effectiveness ratio in terms of the incremental cost per case, death or 
DALY averted. 
In order to quantify the benefits in monetary terms, the total cost of malaria to patients and 
providers is also calculated. In this base-case scenario it is assumed that all patients go to the 
formal sector. The direct costs to the provider of the initial infection include the costs of 
consultation and of diagnosis. The direct costs of treatment failures, borne by the provider are 
those associated with recrudescent and severe infections, which include the cost of 
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hospitalisation. The direct costs borne by households are therefore the cost of transport and 
food and other consumables. In addition they bear the indirect cost due to loss of productivity. 
For clarity, from hereafter in the presentation of the results, the first 2 years of the biological 
model simulations are not shown in the figures. This is because, during this time, the model is 
reaching a steady state in the absence of drug resistance and is the same for all scenarios. 
In the base-case scenario, the annual cost of drugs rises in line with the epidemic increase in 
new cases as shown in Figure 8-8a. After drug resistance reaches 100%, there is no further 
increase in the annual incidence of new cases and the cost of the first-line drug therefore also 
plateaus. On close inspection, the costs in fact appear to start to fall. This is because costs are 
discounted. 
Figure 8-8b shows the overall direct cost of treatment. It can be seen that initially the cost of 
treating new infections is higher than the cost of severe and recrudescent infections. However, 
the latter rises steeply with increasing drug resistance so that by year 3, the cost of treating 
recrudescent infections and severe infections is the same as the cost of treating new infections 
and thereafter exceeds it. Once drug resistance has reached these high levels, the cost of the 
first-line drug represents only a very small proportion of the overall direct treatment costs. In 
Figure 8-8c the total costs, inclusive of indirect costs, are presented. Taking a societal 
perspective, the incremental cost of drugs is comparatively insignificant in comparison to the 
total cost of treatment failure. 
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Figure 8-8: Annual costs in the base-case scenario (continued use of inonotherap)') 
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8.4. Monotherapy versus combination therapy 
In this section, the base-case scenario of the continued use of mefloquine (drug A) is compared 
to a switch to the ACT of blister-packaged artesunate and mefloquine (drug AB). It is assumed 
that the switch to combination therapy occurs when resistance to drug A is introduced at a level 
of 1%. It is also assumed that the switch is made instantaneously and that drug resistance to 
artesunate (drug B) does not arise. The results from scenarios with coverage rates of 100% and 
80% are both shown in order to compare an "ideal situation" with a more achievable coverage 
rate. 
8.4.1. Outcomes 
8.4.1.1. Drug resistance and number of infections 
In the base-case scenario we saw that the model predicts that once drug resistance is introduced, 
it spreads rapidly with the continued use of that drug on its own. The impact that combination 
therapy has on this rate of spread is one of the key model outcomes and is shown in Figure 8-9a. 
Figure 8-9: a) Resistance and b) Annual EIR with ACT compared to monotherapy 
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The results in this scenario suggest that when an ACT is deployed at 100% coverage, there is a 
dramatic slowing in the spread of resistance. Under the ideal conditions in this example, by year 
10 drug resistance to drug A has only reached 15%. However, under slightly more realistic 
conditions, with 80% coverage, the use of combination therapy appears to have much less effect 
on the spread of drug resistance to the monotherapy, so that by year 6 it has already reached 
20% and by year 10 it has reached 75%. The effect of different coverage rates is explored in 
more detail later in the scenario analysis. 
In a relatively low transmission setting such as this, it might be expected that widespread use of 
an efficacious therapy would result in a decrease in transmission intensity and a decrease in the 
number of new infections. This is confirmed in this analysis that suggests that a switch to the 
ACT does effectively prevent the epidemic increase in the incidence of malaria seen with the 
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continued use of monotherapy. At 80% ACT coverage, despite the rise in drug resistance. 
annual incidence remains low with around 700-750 infections per year (compared to 650-700 
with 100% coverage). This is because most resistant infections that are treated with the 
combination therapy are still cured, with a maximum failure rate of 30%. and because only 20% 
of resistant infections are exposed to monotherapy. Therefore. initially there is only a very 
small increase in recrudescent infections and infectiousness in the population (Figure 8-1 Ob). 
In these examples, the maintenance of infection in the population is largely due to the new 
"migrant" infections introduced from outside. This is allowed for because during the 
exploratory phase of running the model, it was found that in low transmission settings, a 
constant input of new infections was required in order to maintain transmission. The rate at 
which this was assumed to occur in these scenarios was varied stochastically between 3-7% of 
the total population per day. Although this may seem unrealistic, there is evidence that in areas 
of low transmission, migrants from high transmission settings or individuals travelling between 
areas of high transmission and low transmission are responsible for a significant proportion of 
infections (Gu, Killeen et al. 2003, Craig, Kleinschmidt et al. 2004; Zhou. Sirichaisinthop et al. 
2005). 
Figure 8-10: a) Number of new (treated) infections and b) recrudescent infections with 
combination therapy compared to monotherapy 
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In a high transmission setting, only a small proportion of patent infections are symptomatic and 
treated and altering their transmissibility would therefore be expected to have little impact on 
the overall transmission intensity (Figure A10-2) and less impact of clinical outcomes (Figure 
A10-4). Depending on the proportion of the human population with drug A presumptively and 
with inhibitory levels of the drug in their blood stream, resistance to drug A may, the 7 
introduction of ACT for the treatment of symptomatic infections may have little impact on the 
increase in drug resistance to drug A. 
/I/\-- ý ýy 
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8.4.1.2. Severe malaria and deaths 
The number of severe cases and deaths averted by the use of combination therapy compared to 
monotherapy directly reflects the reduction in the number of cases of recrudescent infections 
due to use of an increasingly failing drug. As shown in Figure 8-11, with 100% ACT, the 
number of severe cases and deaths remains at around 25 and five respectively with a case 
fatality rate of around 1%. With 80% coverage, the number of severe cases and deaths remains 
stable for the first eight years but then begins to rise, so that by the end of year 10 there are 
around 39 severe cases and eight deaths. 
Figure 8-11: Number of a) severe cases and b) deaths with combination therapy compared to 
monotherapy 
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8.4.2. Costs 
Figure 8-12 illustrates how the effects on clinical outcomes translate into costs. In the first 
figure, the annual cost of the first-line drugs is compared and shows that initially the annual 
drug costs of combination therapy exceed that of monotherapy. However, the use of ACT 
averts the epidemic increase in cases seen with the monotherapy and the associated increase in 
drug costs and therefore by year 5, the annual drug costs are lower in the ACT scenario. 
The next figure compares the total annual direct cost of malaria, including the costs of treating 
treatment failures and severe infections. It is only for the first two years, that the overall annual 
direct costs in the combination therapy scenario are greater than in the monotherapy scenario. 
After this. the costs in the monotherapy scenario increase rapidly whilst the costs in the 
combination therapy scenarios remain static. Thus, by year 10 they differ by almost five-fold 
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(Figure 8-12). In this example, the direct cost of treating severe malaria in an adult is assumed 
to be $61.19 and the cost of an adult course of combination therapy of artesunate and 
mefloquine is assumed to be $3.77 compared to $1.11 for mefloquine, i. e. an incremental cost 
of $2.69 per treatment. The incremental cost of treating one severe infection is therefore 
equivalent to the incremental cost of 23 treatments (61.19/2.69). Even in the absence of any 
effect on the incidence of malaria, switching to combination therapy is cost saving if it averts at 
least one in 23 severe infections. When the effects of ACT also include a reduction in the 
number of cases, as in this example, the threshold is lower. 
Figure 8-12: Annual direct costs of a) First-line drug alone" b) All direct treatment costs for 
malaria 
a) Annual first line drug costs b) Annual direct costs of malaria 
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Clearly the difference in the total direct cost between the monotherapy and combination therapy 
determines the threshold at which the latter becomes cost saving, if indeed it does at all. This is 
explored later in the scenario analysis. 
8.4.3. Cumulative results and time frames 
So far, the outcomes and costs have been expressed in terms of annual rates. This allows us to 
compare easily the relative changes over time between the alternatives. However, the 
presentation of results in this way does not easily allow for a comparative summary measure of 
costs and outcomes, which can be used to compare cost-effectiveness over different time 
frames. The changes in costs and outcomes over time are non-linear and taking a single annual 
measure at any particular time does not give any information about outcomes and costs prior to, 
or after this snapshot in time. Therefore for a given time period, in order to provide a summary 
measure and to compare cost-effectiveness. the total (i. c. annual cumulative) outcomes and 
costs in that period are compared. 
The small increase in drug costs at year 3 with 100% ACT coverage is because by chance there were 
more "migration" cases in that year. This is not apparent in the earlier figure because of the scale chosen. 
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The cumulative outcomes are shown in Figure 8-13 and in Table 8-3. Using a 10-year time 
frame, the cumulative number of new cases in the monotherapy scenario, is more than three 
times greater than in the combination therapy scenarios, and the cumulative number of severe 
infections, deaths and DALYs is almost seven times greater. 
Table 8-3 shows the cumulative costs of the first-line drugs alone. Unlike the comparison of 
annual costs, the cumulative cost of combination therapy remains more than that of 
monotherapy. However, the difference gradually decreases over time because of the larger 
number of doses needed in the monotherapy scenario, so that by year 10 the cumulative drug 
cost of combination therapy is $16,905 compared to $13,500 with monotherapy. 
When the cumulative overall direct costs of treating malaria (including the costs of recrudescent 
and severe infections) are considered, by the end of year 4, the cumulative cost of treatment in 
the monotherapy scenario exceeds that of combination therapy. By year 10 the direct costs are 
almost four times greater in the monotherapy scenario compared to combination therapy, at 
80% or 100% coverage. A similar pattern is seen when the total cumulative costs, inclusive of 
the indirect costs, are considered. 
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Figure 8-13: Cumulative results comparing outcomes with nionotherapi, compared to 
combination therapy 
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Figure 8-14: Cumulative cost offrst-line treatment 
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8.4.4. Cost-effectiveness 
So far, the benefit of using combination therapy has been expressed in monetary ternwý by 
attaching costs to the treatment of malaria including recrudescent and severe infections, so that 
the total costs of the alternatives could be compared. In this section, the cost-effectiveness of 
combination therapy is explored by comparing the incremental cost of' ACT to monotherapy, 
and the incremental effect in health outcomes in terms of cases, failures, deaths or DAI. Ys 
averted, using the cumulative results as explained above. The cumulative incremental cost- 
effectiveness at the end of one, five and 10 years is presented in the next set of' tables and 
figures, in order to explore the effect of the time frame of the analysis on the cost-el'f'ectivcness 
of 100% combination therapy. 
In each example, the numerator is the incremental cost of combination therapy compared to 
monotherapy and the denominators are the dif ercnt outcomes of interest. As discussed in the 
background, the perspective taken determines the choice of the outcome and time franc of' the 
analysis. From the perspective of the patient or their carer and the health-care worker, the 
interest is in the immediate outcome, and therefore the cost per cure or the cost per . severe 
outcome averted is appropriate. From the perspective of'the Ministry of' I lealth and donors, the 
cost-effectiveness compared to other health interventions will he relevant, in terms of the cost 
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per death or DALY averted. By taking a more tong-term perspective, all these outcomes 
capture the externality benefits due to delayed drug resistance and reduced transmission. 
Figure 8-15 and Table 8-3 show the change in cumulative incremental cost-effectiveness over 
time. It can be seen that the longer the time frame used, the more cost-effective ACT becomes. 
It can also be seen that most of the gain is seen in the first five years. This is because it is within 
this period that resistance to drug A rises rapidly when it continues to be used on its own, a rise 
that is avoided by the use of combination therapy. The use of ACT therefore averts the year-on- 
year increase in the consequences of drug resistance. By year 6, resistance saturates and there is 
no further increase in cases or failures. In this example, the cumulative incremental cost per 
DALY averted at one year is $129, at 5 years $4.7 and at 10 years $0.4. 
If the incremental cost of drugs is replaced by the incremental total costs as the numerator for 
the cost-effectiveness ratio, then ACT are clearly much more cost-effective than monotherapy 
even with a short time frame. After one year the total direct cost per DALY averted is $105.7 (- 
1383.5/129. one) and the total cost inclusive of indirect cost, per DALY averted is $70.7 
(925/129.1). By year 5, because the total costs are less in the ACT scenario compared to the 
monotherapy scenarios, ACTs are clearly dominant because they are both more effective and 
cost saving. 
Figure 8-15: Cumulative cost-effectiveness of combination therapy (at 100% coverage) 
compared to monotherapy over tim 
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8.5. Sensitivity analysis 
Sensitivity and scenario analysis were carried out to examine the effect of uncertainty of 
parameter inputs and the effects of varying inputs on the model outputs. The terms sensitivity 
analysis and scenario analysis are used to describe analyses that are undertaken with different 
objectives. The term "sensitivity analysis" is used to test the robustness of the model to 
uncertainties in the model inputs and assumptions within a range of possible values. The 
sensitivity analysis of the biological model was undertaken by WP, and a summary of the 
results is provided in Annex 11 and briefly discussed in the section below. In this thesis the 
focus of the sensitivity analysis is limited to uncertainties in the parameters and assumptions 
made in the sub-models. Scenario analysis, on the other hand, is used to describe the outcomes 
when the changes in the value of the inputs represent different settings or policy choices, for 
example a different choice of drug. The scenarios explored in the next section are: 
" Different costs 
" Different coverage rates with ACT 
" Switching from drug A to drug BC (instead of drug AB) at different levels of resistance to 
drug A 
" Cambodian scenarios with different delivery interventions 
8.5.1. Sensitivity analysis of the biological model 
The sensitivity analysis undertaken by WP involved 5000 simulations each for four scenarios, 
where the ACT was assumed to be drug AB: 
" Low transmission (mean vectorial capacity of 0.1) - Low ACT coverage (10%) 
" Low transmission (mean vectorial capacity of 0.1) - High ACT coverage (85%) 
" High transmission (mean vectorial capacity of 15) - Low ACT coverage (10%) 
" High transmission (mean vectorial capacity of 15) - High ACT coverage (85%) 
As one simulation of the model for 12 years takes 2'V2 hours to run, the sensitivity analysis 
required a large amount of time and computational resources. At the beginning of each 
simulation, values for all input parameters were randomly selected from a range of values with 
the probability of selection dependant on a defined distribution (e. g. uniform, normal or log 
normal). The results of the 5,000 simulations for each scenario were then analysed by partial 
rank correlation co-efficient analysis, which ranks the parameters in order of influence on 
different outcomes for the model at different time points. The model outcomes included were 
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the level of drug resistance, the prevalence of patent infections, the percentage of infections that 
recrudesce and the percentage of patent infections that are treated. For each outcome the 
average result in terms of mean and median and the degree of variability in terms of standard 
deviation were also output. The detailed table of results are in Annex 11. The results for a low 
transmission setting are summarised in Table 8-4 and discussed briefly here. 
For all model outcomes, the transmission intensity as measured by the vectorial capacity (VC) 
was the single most important parameter in determining the values at five and 10 years. For the 
level of drug resistance with the continued use of monotherapy, at 10 years, VC was the only 
parameter to which the model was sensitive. At five years the gametocyte switching rate, the 
proportion of the population with residual drug levels (i. e. chemoprophylaxis), and treatment 
rate were also important. With combination therapy, the coverage rate, the failure rate in 
infections resistant to drug A and treated with combination therapy relative to the failure rate 
with monotherapy, and the duration of untreated infections, were also important in determining 
the level of drug resistance reached. 
The prevalence of patent parasitaemia was sensitive mainly to the gametocyte-switching rate, 
the level of susceptibility to infection in a non-immune host and the proportion of the population 
with residual drug levels. The treatment rate and duration of untreated infection were also 
important in the combination therapy scenario. 
For the rate of recrudescent infections, unsurprisingly the failure rates in drug resistant 
infections treated with monotherapy and with combination therapy emerge as important 
parameters, as does the ACT coverage rate. 
This sensitivity analysis helps us to understand the relative influence of the values of different 
parameters on model outcomes, and may therefore indicate in reality what factors are most 
likely to influence the spread of drug resistance, clinical outcomes and the transmission of 
malaria. It also indicates the sensitivity of the model to parameters for which there is much 
uncertainty, and for which more accurate data are required before conclusions from the model 
can be made with more confidence. However, this sensitivity analysis does not tell us about the 
absolute relationships. Therefore it is not possible to say, for example, that an increase in a 
certain input by x% results in an increase in the rate of resistance by y%. This would be useful 
for specific parameters that represent factors that can be altered by interventions or for 
examining specific scenarios. This is done in the scenario analysis by taking the most policy 
relevant of these parameters, the ACT coverage rate, and varying it on its own to examine the 
effect on model outcomes. 
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Table 8-4: Summary of sensitivity analysis of biological model undertaken by Wr for a low 
transmission setting. The table shows parameters with the highest partial rank correlation 
coefficients of input parameters with actual values in brackets 
Output Monotherapy Combination therapy 
Drug " Vectorial capacity (0.7) " Vectorial capacity (0.6) 
resistance at " Treatment rate (0.2) " GSR for monotherapy (0.2) 
5 years " GSR for monotherapy (0.2) " Relative failure rate in drug resistant 
" Proportion with residual drug infection treated with ACT (0.2) 
(0.2) " Proportion with residual drug (0.2) 
" ACT coverage (-0.2) 
" Duration of untreated infections 
(-0.2) 
Drug " Vectorial capacity (0.3) " Vectorial capacity (0.6) 
resistance at " Proportion with residual drug (0.3) 
10 years " GSR for monotherapy (0.2) 
" Relative failure rate in drug resistant 
infection treated with ACT (0.2) 
" ACT coverage (-0.2) 
" Duration of untreated infections 
-0.2 
Prevalence of " Vectorial capacity (0.7) " Vectorial capacity (0.7) 
patent " Host susceptibility (0.2) " Host susceptibility (0.2) 
infections at " GSR for monotherapy (0.2) " GSR for monotherapy (0.2) 
5 years " Proportion with residual drug " Duration of untreated infections 
(0.2) (-0.2) 
" Treatment rate (-0.2) 
Prevalence of " Vectorial capacity (0.7) " Vectorial capacity (0.7) 
patent " Host susceptibility (0.2) " Host susceptibility (0.2) 
infections at " GSR for monotherapy (0.2) " GSR for monotherapy (0.2) 
10 years " Relative parasite density in un- " ACT coverage (-0.2) 
treated infections (0.2) 
" Relative parasite density in 
recrudescent infections (0.2) 
% " Vectorial capacity (0.7) " Vectorial capacity (0.4) 
recrudescence " Host susceptibility (0.2) " Relative failure rate in drug-resistant 
at 5 years " GSR for monotherapy (0.2) infection treated with ACT (0.4) 
" ACT coverage (-0.3) 
" Proportion of population with 
residual drug 0.2 
% " ACT coverage rate (-0.5) " Relative failure rate in drug-resistant 
recrudescence " Vectorial capacity (0.4) infection treated with ACT (0.6) 
at 10 years " Failure rate in drug-resistant " Vectorial capacity (0.4) 
infection treated with " ACT coverage rate (-0.3) 
monotherapy (0.4) 
% treated " Vectorial capacity (0.4) " Vectorial capacity (0.5) 
infections at " Treatment rate (0.4) " Treatment rate (0.5) 
5 years " GSR for monotherapy (0.2) 
% treated " Treatment rate (0.4) " Vectorial capacity (0.6) 
infections at " Vectorial capacity (0.3) " Treatment rate (0.4) 
10 years " GSR for monotherapy (0.2) 
GSR = Gametocyte Switching Rate 
222 
8.5.2. Sensitivity analysis of inputs for the sub-models 
The sensitivity analysis of the sub-models was undertaken to explore the effect of uncertainties 
in the parameters used to calculate severe malaria and mortality, and the effect of different 
assumptions about discounting and disability-adjusted life years (DALYs). A simple approach 
was taken, in which only the parameter under question was varied, keeping all other parameters 
unchanged. 
8.5.2.1. Severe malaria and mortality rates 
As discussed in the previous chapter, there was considerable uncertainty about the maximum 
likelihood of severe malaria in a non-immune host, with and without drug resistance, as well as 
the mortality rate of severe malaria. The minimum and maximum estimates obtained from 
literature were tested in the sensitivity analysis. The results suggest that the cost-effectiveness 
of combination therapy compared to monotherapy is not very sensitive to this uncertainty. The 
cost per DALY averted varies from $3.1 to $6.7 at five years and from $0.3 to $0.6 at 10 years 
(Table 8-5). 
8.5.2.2. DALYs and discounting 
In the base-case scenarios, costs and DALYs were discounted at 3%, and DALYs were not 
weighted for age. The effects of not discounting DALYs and of adding age weighting were 
therefore both explored (Table 8-6). Both changes result in a slight decrease in the cost per 
outcome averted making ACT more cost-effective. The effect of not discounting reflects the 
importance of the greater difference in outcomes between the two scenarios in later years. 
There is little effect of the discounting of costs on the cost-effectiveness of combination therapy 
so that at five years, the use of undiscounted cost results in a cost per DALY averted of $5.0 
compared to $4.7 and at 10 years, the cost per DALY averted remains at $0.4 whether or not 
costs are discounted. 
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8.6. Scenario analysis 
8.6.1. Different drug and treatment costs 
Estimates for costs vary widely from country to country and between different settings and 
institutions. In the baseline comparison, the drug costs were based on those in Cambodia, 
where the monotherapy was mefloquine and the combination therapy was blister- packaged 
artesunate and mefloquine. Mefloquine however, is relatively expensive compared to other 
drugs currently being used as a monotherapy and therefore the cost of the combination therapy 
was only 3.4 times greater than the monotherapy. In most other settings, the monotherapy is 
chloroquine or sulfadoxine-pyrimethamine (SP), which cost around $0.10 for an adult dose. 
Therefore, the difference in the cost of drugs was maximised, firstly, by using the highest 
estimated cost for the ACT of artesunate and mefloquine and the lowest estimated cost of 
mefloquine alone and secondly, by substituting the cost of SP and the combination of artesunate 
and SP, assuming that the outcomes are similar to the mefloquine and artesunate and 
mefloquine scenarios. The artesunate with SP combination was assumed to be the commercially 
available product and therefore the packaging costs were considerably lower, resulting in a 
lower incremental cost in switching from the monotherapy to the combination therapy. The cost 
of the artesunate with SP combination was assumed to be $1.39 for an adult course, which is 
14.5 times greater than the monotherapy. The cost of switching from SP to artemether- 
lumefantrine is explored later because this combination involves not only a difference in costs 
but in outcomes as well. 
In addition, the impact on total annual direct costs of different patient and provider costs of 
treatment was also explored, using minimum and maximum estimates. 
The results at 10 years are shown in Table 8-7. It can be seen, perhaps unexpectedly, that the 
cost-effectiveness of switching from the monotherapy to a combination therapy is not t; reatly 
affected by changing to the cost of SP and artesunate plus SP. This is because it is the absolute 
difference in cost between the monotherapy and combination that determines the incremental 
cost of the combination therapy and not the relative difference. In this case the absolute 
difference between the monotherapy and combination in the two scenarios is $2.69 for 
mefloquine versus artesunate plus mefloquine and $1.29 for SP versus artesunate plus SP. 
When this cost difference between the monotherapy and combination therapy is maximised to 
$5.55, that is 3.3 fold greater than in the base-case scenario, the cost-effectiveness falls12 by the 
same factor from $0.4 per DALY averted to $1.3 per DALY averted. 
72 For clarification an "increase" in cost-effectiveness implies that something becomes more cost- 
effective i. e. more favourable, and a "fall" in cost-effectiveness implies the reverse, 
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Varying the direct costs of malaria between minimum and maximum values results in the 
cumulative direct costs saved by using combination therapy varying from $22,182 to $264,586 
or $2.2 versus $264.6 per capita. This compares to cost-savings of $11.1 per capita using the 
baseline values. 
8.6.2. Coverage rates 
In the initial comparison between monotherapy and combination therapy, it was assumed that 
coverage with combination therapy was either 100% or 80%. In reality, the coverage rate is 
likely to be much lower but the impact that this will have on the effectiveness and cost- 
effectiveness of combination therapy is not known and difficult to predict intuitively. For 
example, it is not clear whether there are threshold coverage rates at which there are abrupt 
changes in effects. Therefore, in this section the results of a scenario analysis are presented in 
which the level of coverage with ACT (drug AB) is varied from 0 to 100% in 10% increm. 
8.6.2.1. Effects 
Figure 8-16 shows the change in outcomes in relation to the level of coverage with ACT. The 
graph of drug resistance suggests that when only low levels of coverage can be achieved, the 
introduction of combination therapy has little effect on the spread of resistance to drug A, and 
that it is not unless levels of over 80% are reached that there is any noticeable effect. However 
at these higher levels of coverage, small increments in the coverage with ACT has a significant 
effect on the rate of spread of resistance to drug A. Thus with a coverage rate of 90%, 
resistance reach 50°/ at year 10 compared to 15% at 100% coverage. 
However, when the effects on clinical outcomes are examined, a different pattern emerges. 
Even at low levels of coverage with combination therapy, there appears to be a noticeable 
impact on the incidence of malaria, recrudescent and severe infections and therefore deaths and 
DALYs. With a coverage rate of only 10%, there are 17% fewer new cases and 23% fewer 
recrudescent infections by year 10. 
The graphs indicate that the higher the level of ACT coverage achieved, the slower the rate of 
rise of these outcomes, and the lower the level at which they plateau when 100% resistance to 
drug A is reached. This is because once resistance saturates, there is no further increase in the 
failure rate for a given coverage rate and therefore the proportion of infections which fail 
remains fixed. 
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Figure 8-16: Effect of different coverage rates with ACT (drug AB) on resistance (to drug A) 
and outcomes 
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8.6.2.2. Costs 
In the comparison between monotherapy and ACT at 100% coverage, the annual drug costs of 
ACT were initially higher than with monotherapy, but by the end of vear 5, ýbecame cost 
saving when considering first-line drug costs alone. _ 
It can be seen from Figure 8-17, that as 
expected, for the first few years there is a direct relationship between the coverage rate achieved 
and the annual cost of the first-line drug. However, at lower coverage rates (below 60%) the 
incidence of new infections then starts to increase with the rise in drug resistance, resulting in an 
increase in the number of first-line drug doses. The rate which this occurs and the final level at 
which the annual incidence plateaus, is dependent on the coverage rate. As a result, by year 10, 
there is an inverse relationship between the coverage rate with ACT and the annual first-line 
drug cost. 
If the overall costs of treating malaria are considered instead, then clearly whether switching to 
combination therapy is cost saving or not, depends on the cost of treatment failure compared to 
the difference in cost between the monotherapy and combination therapy. In these scenarios, 
the monotherapy is assumed to be mefloquine at US$1.11 per adult dose, compared to $3.77 for 
the combination therapy of artesunate and mefloquine. The cost of an uncomplicated 
recrudescent infection is assumed to be US$4.80, and for a severe infection US$61.19 per adult. 
The number of recrudescent infections and severe infections therefore has a large impact on the 
total annual direct cost of treating malaria. In the first couple of years when drug resistance is 
similar under different coverage rates and there are few recrudescent infections, the total direct 
costs of treatment are directly related to the cost of first-line drugs and therefore the coverage 
rate with ACT. However, with time, the number of cases of treatment failure increases at a rate 
inversely related to the coverage rate with ACT. Therefore, in addition to the increased costs of 
first-line drugs, as described above, there is an increase in the total costs of treating recrudescent 
and severe cases. The total costs of continuing treatment with ACT are therefore rapidly 
exceeded by the total costs in the monotherapy scenarios at any rate of coverage. The higher 
the rate of coverage achieved, the greater the cost savings. Even with a coverage rate with ACT 
of 10% and by year 5, the annual savings with ACT are substantial - $30,852 with combination 
therapy compared to $37,793, a 22% reduction in cost. 
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Figure 8-17: Cost of first-line drugs and of total (direct) cost of ma 
recrudescent and severe infections by level of coverage with combination Cher, 
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8.6.2.3. Cumulative costs, effects and cost-effectiveness 
The incremental cost-effectiveness of moving from one coverage rate to another are presented 
in the next set of figures and tables. Two main observations can be made from Figure 8.18, 
which shows the relationship between cumulative effects and coverage. Firstly, as expected, 
there is an inverse relationship between cumulative effects and the coverage rate with ACT and 
this relationship becomes more marked with time. Secondly, at 10 years the relationship is 
steeper at lower coverage rates than at higher coverage rates. This means that there are 
decreasing returns to increasing coverage rates. 
As expected, initially, there is a positive relationship between the cumulative cost of first-line 
drugs and the coverage rate with ACT. However this relationship changes over time, and is 
most acute in the first five years becoming less pronounced thereafter. This is because the 
cumulative drug costs saved in the later years due to the fewer cases with ACT, make up for the 
cumulative higher costs due to the higher costs of drugs, in the earlier years (Figure 8-19). 
From the next set of figures (Figure 8-20), which show the change of cumulative cost- 
effectiveness over time, in terms of the ratio of cumulative costs to effects, a number of 
observations can be made. Firstly, even with a time frame of two years, the cost per DALY 
averted lies below $70, at any rate of coverage. Secondly, as observed in the base line 
comparison of monotherapy with ACT at full coverage, the cumulative cost-effectiveness at all 
coverage rates increases over time. Finally, using a two and five-year time frame, there is a 
positive relationship between coverage rate and the cumulative cost per effect, implying that 
there are decreasing returns in terms of cost-effectiveness, to increasing coverage rates. By 10 
years, coverage makes little difference to cumulative cost-effectiyenes so that cost per DALY 
averted ranges from $0.1 to $0.4, although there is a suggestion that optimal cost-effectiveness 
is achieved at a coverage rate of 50 to 60%. 
In order to show more clearly the change in cost-effectiveness in moving from one coverage 
rate to another, the relationship can also be compared using incremental cost-effectiveness (CE) 
planes. Figure 8-21 shows the cumulative incremental costs and DALYs averted, of ACT 
compared monotherapy at different coverage rates. These suggest that there are rapidly 
decreasing returns to achieving higher coverage rates above 50%, at both 5 and 10 years. 
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Figure 8-18: Graphs showing cumulative eýJictc bpp coverage rate and tine frame 
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Figure 8-18: Graphs showing cumulative effects by coverage rate and time frame 
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Figure 8-19: Graphs showing cumulative costs hy coverage rate' and tinier 
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Figure 8-20: Cumulative incremental cost-effectiveness in terms of cost of drugs per case 
averted and cost of drugs per DALY averted by coverage rate al years 2,5 and 10, 
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Figure 8-21: Cumulative cost-effectiveness planes showing effect of coverage rate with ACT 
compared to monotherapy on cumulative incremental cost of drugs compared to cumulative 
incremental DALYs averted 
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8.6.3. Choice of drug and timing of switch 
Decisions regarding which particular artemisinin-based combination therapy to switch to, and 
when to switch, are important in the process of making antimalarial drug policy. So far in this 
analysis, the comparison has been between the continued use of drug A. mefloquine, and a 
switch to drug AB, which involves the addition of artesunate to mefloquine. However, the ideal 
choice of combination therapy is one in which there is no resistance to either drug in the 
combination, such as artemether-lumefantrine, that is a switch from drug A to drug BC. The 
choice of drug also influences the timing of the switch. If a switch is being made to drug BC, 
abandoning drug A. there may be a preference for continuing to use the cheaper drug A on its 
own for as long as possible. On the other hand if the switch is being made to drug AB, then the 
incentive may be to prolong the life of drug A, for as much as possible, by using it in 
combination. In order to explore these options, the model was run with inputs to compare a 
switch from drug A to either drug AB or to drug BC. at 100% coverage. This entailed changing 
the drug characteristics for drug BC, so that unlike drug AB, if infections resistant to drug A are 
treated with drug BC, they behave in the same way as infections that are sensitive to drug A. It 
is assumed that resistance does not develop to drugs B or C during the course of the analysis. In 
addition, to explore the effect of delaying a switch to combination therapy, the level of 
resistance to drug A, at which the switch was made, was varied from one to 20%. 
8.6.3.1. Effects 
The impact of different policies on drug resistance is shown in Figure 8-22. Once a switch is 
made to drug BC, the level of resistance to drug A remains almost static''', unlike the switch to 
drug AB which is associated with a continued increase in resistance to drug A. 
Figure 8-22: Drug resistance to drug A comparing the effect of switching to drug AB versus 
drug BC at different levels of resistance to drug A 
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73 There is very small increase in resistance to drug A even after the switch to drug BC because the model 
assumes that there is still some presumptive use of drug A and therefore some drug pressure. 
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The next set of graphs (Figure 8-23) compare the incidence of new infections, recrudescent 
infections and severe infections. The most noticeable difference between the two combinations 
is in the incidence of recrudescent infections, a difference that increases over time. This is 
because although treatment with the addition of drug B to drug A is still very effective despite 
resistance to the latter, the drug resistance to drug A does compromise the efficacy of the 
combination and therefore the failure rate is slightly higher than with drug BC. Within the time 
frame of the analysis, however, there are only slightly more severe cases with drug AB than 
with drug BC and no difference in transmission intensity. If the analysis were continued for 
longer, as resistance continued to rise in the drug AB scenario, we would expect a larger 
difference to emerge between the two drug choices. 
8.6.3.2. Costs and cost-effectiveness 
In many settings, the monotherapy in question is often SP, and the actual choice is between 
switching from SP (drug A) to SP and artesunate (drug AB) or to artemether-lumefantrine (drug 
BC). There is a substantial difference in the cost of these combinations. The cost per adult 
course of these drugs is approximately $0.10, $1.39 and $2.40 respectively74. Therefore if only 
the short term, first-line drug costs are considered, the artesunate and SP choice is more 
attractive than artemether-lumefantrine Figure 8-24. In order to compare the cost-effectiveness 
of artesunate and SP with artemether-lumefantrine, the appropriate costs of drugs were 
substituted into the model. The results in terms of cumulative costs and cost-effectiveness are 
shown in Table 8-8 and Table 8-9. For clarity, only the costs of switching at 1% resistance to 
drug A are shown, but the results, when the switch is made at 20% resistance are also discussed 
with the tables of results shown in Annex 12. 
7 
Because neither combinations impact on the incidence of malaria the total annual drug costs of 
the combinations remain an order of magnitude greater than the continued use of SP and the 
annual drug costs of artemether-lumefantrine remain twice as high as the drug costs of 
artesunate with SP. However when the overall direct costs of malaria are examined, it can be 
seen that any difference between the ACT options is dwarfed by the annual cost savings 
compared to monotherapy, after the first few years. 
In terms of cumulative cost-effectiveness, at five years the cost per DALY averted under the 
artesunate-SP scenario is $2.3, compared to $4.2 with the artemethcr-lumcfantrine. At 10 years, 
the cost per DALY falls to $0.6 and $1.0 respectively. 
74 Cost of packaging at $0.21 per packet, cost of drugs for children aged 6-12 years and <6 years were 
estimated at 50% and 25% of adult course. The cost of drugs for treating recrudescent cases was assumed 
to be the same as the cost of the combination therapy. 
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Comparison of the effect of the timing of switch on cost-effectiveness suggests that the higher 
the level of resistance to drug A at which the switch is made, the less cost effective the switch, 
although the difference is very Thus, if the switch is made at 20% resistance to drug A 
rather than 1% resistance, there is slight decrease in the cumulative cost-effectiveness, so that 
the cost per DALY averted at five years is $3.0 and $5.0 for the artesunate-SP and artemether- 
lumefantrine scenarios, and $0.6 and $1.1 at 10 years, respectively. This is because, in the time 
it takes for resistance to increase from 1% to 20% resistance, the costs saved due to continuing 
to use a cheaper drug is proportionally less than the increase in recrudescent infections and 
severe infections. 
As resistance increases so does the incidence of recrudescent infections, severe infections and 
DALYs, so that at the higher the rate of resistance at which the switch is made, the greater the 
difference in these outcomes, before and after the switch. 
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Figure 8-23: Graphs comparing outcomes between switching from drug A to drug B(' (on the 
left) and to drug AB on (the right) at different levels of resistance to drug A 
a) Annual incidence of new infections (treated) b) Annual incidence of new infections (treated) 
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Figure 8-24: Annual cost of first-line drug and annual direct cost of treating malaria 
comparing monotherapy (drug A) to switching to drug AB or drug BC at different levels of 
drug resistance to drug A 
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8.7. Application of the model to Cambodian data 
8.7.1. Introduction 
For the purpose of illustration, the results up until now have been from an idealised setting in 
which the coverage rate to combination therapy has been assumed to be high, and the failure 
rates reflective of complete adherence to the antimalarial drugs taken. 
In this section, in order to evaluate how the model performs with realistic scenarios, it was run 
with data from Cambodia to assess the cost-effectiveness of switching to combination therapy 
with and without interventions aimed at increasing coverage. 
As described previously, use of the public sector has been very low in Cambodia, with the 
public sector delivering less than 10% of first-line treatments for malaria. In the informal 
sector, patients receive a wide variety of treatments for malaria, which rarely follow the national 
guidelines. In order to address this problem, a number of local interventions were introduced, to 
increase access to reliable diagnosis using rapid diagnostic tests (RDTs) and treatment with 
artesunate and mefloquine. The two main initiatives were an "outreach" service and village 
malaria volunteers (VMVs). 
The model was therefore run using the primary data collected in Cambodia presented in 
Chapters 6 and 7. The aim was to explore the effects, cost and cost-effectiveness of the change 
in policy to ACT in Cambodia and to predict the incremental cost and impact of adding the 
interventions to increase coverage. 
8.7.2. Inputs and parameterization 
In the methods chapter, the use of sub-models to calculate the coverage rate with ACT and 
failure rates based on actual real-life conditions was described. However, up until now, these 
have not been used, as it has been assumed that all patients received free and appropriate 
treatment in a public health facility following biological confirmation and that patients were all 
adherent to therapy. In reality, this is seldom the case, and the proportion of patients with 
malaria who receive the recommended drug and take the full course is far from optimal. There 
are a large number of steps required to reach the ideal state. For simplicity, these individual 
steps have been reduced to the choice of provider (formal or informal) and the impact that this 
choice has on coverage rates, adherence rates and costs. Attempting to increase the coverage 
rate with ACT by delivery strategies such as outreach clinics and VMVs increases the 
incremental cost of switching to ACT. In order to assess the impact this has on cost- 
effectiveness, this incremental cost is compared to the increase in effects. Because both of these 
delivery interventions involved the introduction of biological diagnosis with RDTs, this cost is 
also included in the analysis. Although the cost-effectiveness of diagnosis with RDTs is an 
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important issue, it is not dealt with specifically here as it lies outside the focus of this thesis and 
is being dealt with in detail by others (Goodman C, personal communication). 
The inputs derived from the drug usage survey were summarised in Section 6.4.4 and in Table 
7-19 in the previous chapters. The values used to calculate the maximum failure rates in the 
model in relation to the overall adherence rates are shown in Table 8-10 and the resulting inputs 
into the model are shown in Table 8-11 and are discussed below. 
8.7.2.1. Type of provider 
Where patients with malaria go for treatment determines the likelihood of them receiving 
combination therapy and therefore the "coverage rate" input into the biological model. All 
malaria patients seen by outreach workers and VMVs receive artesunate and mefloquine, but 
only 43% of those seen in a public health facility and 8% of those seen in the informal sector. 
The likelihood of adherence, and therefore cure, also depends on where treatment is obtained. 
Patients receiving treatment from VMVs or outreach workers are assumed to have the same 
likelihood of adherence as if they went to the public health facility. Therefore the value for the 
maximum failure rates that are input into the biological model vary according to the proportion 
of treatments sought in the formal sector compared to the informal sector and the associated 
adherence rates. The introduction of VMVs and outreach clinics is assumed to attract patients 
who would have otherwise sought treatment from the informal sector, and therefore leads to a 
marginal increase in treatments sought in the formal sector. In other words, the interventions do 
not substitute for the public heath facilities. 
Second-line treatment for recrudescent infections and treatment of severe infections are more 
likely to be obtained in public health facilities than are first line treatments for new infections. 
The actual proportion and the type of treatment received in different facilities depends on a 
number of different factors. However, for simplicity, in these scenarios, as in previous 
scenarios, it is assumed that all recrudescent and severe infections are treated in the public 
sector. Although this results in an underestimate of the cost of malaria to the patient and an 
overestimate in the cost of malaria to the provider, accurate data were not available. 
8.7.2.2. Costs 
If patients seek treatment in a public health facility, then the costs of consultation, diagnosis and 
treatment are assumed to be borne by the provider, whilst the patient bears the cost of transport, 
food and other consumables. If they seek treatment in the informal sector, then the patient bears 
all the costs. 
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In the "intervention" scenarios, in addition to the variable costs associated with the number and 
age of patients treated, there is an annual fixed cost of each intervention, All these costs are 
borne by the provider. The variable costs are the cost of the drugs and the cost of the RDTs, 
including the cost of the negative tests performed on patients who did not have malaria. To 
calculate the latter, based on the experience in Cambodia, it was assumed that the likelihood of 
a positive test was 25%, and therefore for every positive test, there were three "wasted" tests. 
This value is dependent on the prevalence of malaria and the treatment seeking behaviour of the 
population and can be varied depending on the setting. 
8.7.2.3. Level of drug resistance 
In Cambodia, the decision to switch to artesunate and mefloquine occurred when resistance to 
mefloquine was already well established in some parts of the country, However, it is of interest 
to explore the cost-effectiveness of ACTs in other similar settings where the level of resistance 
to the monotherapy is still low. Therefore the scenarios have been run with the switch being 
made at both 1% and 20% resistance to the monotherapy. 
8.7.2.4. Treatment rate and time to receiving treatment 
Although, treatment rates were around 85% in the primary data collection in Cambodia, a value 
of 95% is used in running the model foora 
number 
of reasons. Firstly, the model is structured 
1112 
with the assumption that malaria patients who are treated are relatively non-immune, and that 
those who are untreated are relatively immune. Therefore assigning non-immune symptomatic 
patients to the "untreated" group artificially increases the level of immunity of the population, 
with a potentially significant impact on the model outcomes. Secondly, as discussed previously, 
the result from the study in Cambodia does appear to be unusually low and the literature 
generally suggests higher treatment rates. 
It was also assumed that the time interval between the development of symptoms and receiving 
treatment was not affected by the interventions. This assumption was made in order to simplify 
comparison across different scenarios, and because the findings from the study did not suggest a 
consistent relationship-The sensitivity analysis of the biological model suggests that vary 
length of this time interval would not have made a significant difference to the outcome. 
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Table 8-10: Maximum failure rates input into sub-model to calculate overall failure rates 
Maximum failure rates in non-immune host If adherent If non- 
adherent 
Sensitive to meflo uine, treated with artesunate and meflo uine 2% 2% 
Resistant to meflo uine, treated with artesunate and meflo uine 20% 40% 
Sensitive to meflo nine, treated with meflo uine 5% 40% 
Resistant to meflo uine, treated with meflo uine 85% 85% 
Table 8-11: Calculated coverage rate and failure rates to monotherapy mefloquine (drug A) 
and the ACT, artesunate and mefoquine (drug AB) in non-immune host, as biological model 
inputs 
Scenarios 
Calculated inputs into biological model No Change Change Change 
change to ACT to ACT + to ACT + 
outreach VMV 
_Coverage 
rate with drug AB 0% 10% 32% 90% 
Overall maximum failure rates 
Sensitive to drug A, treated with drug A 28% 28% 24% 13% 
Resistant to drug A, treated with drug A 85% 85% 85% 85% 
Sensitive to drug A, treated with drug AB - 9% 7% 5% 
Resistant to drug A, treated with drug AB - 28% 26% 24% 
Ratio of maximum failure rate with drug AB 0.32 0.29 0.38 
compared to drug A for infections sensitive to 
drug A 
Ratio of maximum failure rate with drug AB 0.33 0.30 0.28 
compared to drug A for infections resistant to 
_drug 
A 
tý Cý 
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8.7.3. Results 
8.7.3.1. Effects 
In Cambodia, the introduction of ACT, without any delivery interventions to improve access, 
resulted in a coverage rate with ACT of only 10%. Unsurprisingly, the model suggests that this 
would have little effect on the spread of resistance over time (Figure 8-25). However, because 
treatment with the combination results in cure of infections, which would have failed with 
monotherapy, there is still an impact on the number of recrudescent infections and transmission, 
whether the switch is made at 1% or 20% resistance to mefloquine (Figure 8-25). With a five- 
year time frame, if the switch to ACT is made at 1% drug resistance, then compared to 
monotherapy there are 12% fewer cases, 26% fewer recrudescent infections and 22% fewer 
severe cases and deaths. If the switch is made at 20% resistance the impact is slightly less 
marked (8%, 19% and 17% respectively) but by 10 years there is little difference between the 
cumulative results of the two scenarios. For clarity only the results from a switch made at 1% 
resistance are described in detail hereafter. 
In Anlong Veng, the introduction of outreach increased the coverage rate with ACT to 32%. 
The model suggests that this incremental increase would have little effect on the spread of 
resistance but a significant effect on recrudescent infections, severe outcomes and transmission. 
Therefore, with a five-year time frame, if the switch to ACT is made at 1% resistance to 
mefloquine, the model predicts that compared to monotherapy there would be cumulatively 
23% fewer new cases, 57% fewer recrudescent cases and 39% fewer severe cases and deaths 
compared to the monotherapy scenario (Table 8-12). At 10 years, the difference is expected to 
have increased, so that there would be 40% fewer new cases, 61 % fewer recrudescent infections 
and 51% fewer severe cases and deaths (Table 8-13). 
The introduction of VMVs increased the coverage rate with ACT up to 90% and as expected, 
the model predicts that this would result in a substantial impact not only on recrudescent, severe 
infections and transmission, but also on the spread of resistance to mefloquine as well. Because 
of this, the increase in the number of cases that is seen in the other scenarios is not seen with the 
introduction of VMVs and the incidence rates remain stable for the 10 years of the analysis. 
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Figure 8-25: Annual outcomes predicted b3' model for Cambodian scenarios" 
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15 For clinical outcomes and DALYs. only the results for the scenarios at which a switch is made at P/o 
resistance to drug A are shown. The results for a switch at 20% are very similar and if included make the 
figures difficult to read. 
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8.7.3.2. Costs 
In terms of the annual drug cost to the provider over the 10-year period, the costs of switching 
to ACT without any delivery interventions is almost the same, or marginally lower, than the 
continued use of monotherapy (Figure 8-26 and Table 8-14). This is because although there is 
an incremental increase in the cost of drug per patient treated with ACT, there are fewer new 
cases overall than with monotherapy, and therefore the overall effect is that the drug costs 
remain almost the same. However, there is still a rise in the number of cases over time and 
therefore there is an increase in the cost of first-line drug. Most of this increase in cost is borne 
by patients, with the annual drug costs to patients doubling from around $800 per year in the 
first year, to $1,600 in year 10. 
The introduction of the two delivery interventions increases the provider cost of first-line 
treatment substantially. For outreach, the annual cost remains constant over the 10-year period 
at approximately $4,800 per year, and for VMVs, the annual costs falls, from approximately 
$10,000 to $7,800, if the switch is made at 1% resistance (Table 8-14). This compares to the 
annual costs of monotherapy or combination therapy, without any delivery intervention, which 
do rise over time but at year 10, only reach $345 and $326 per year respectively. 
However, as expected, substantial cost-savings are experienced by patients as a result of the 
introduction of outreach or VMVs. This is both because the cost per case is less, since patients 
do not have to pay for drugs or transport, but also because overall, there are fewer cases than in 
the non-intervention scenarios. This is especially the case with the high coverage rates reached 
with VMVs where costs remain constant so that by year 10 the annual direct cost to patients for 
first-line treatment (inclusive of transport and other costs of consultation) is still only $65. This 
represents only 1% of the total direct cost of first-line treatment. With the lower coverage rates 
achieved with outreach, on average, patients bear more of the treatment costs per case and there 
is a rise in the number of cases over time, so that by year 10, the total annual cost to patients is 
$824 per year or 15% of the total direct costs. This compares to $1,616 (84% of total costs) for 
introduction of ACT without any delivery intervention and $1,849 (83% of total costs) for the 
continued use of monotherapy. 
If the direct costs of malaria including the cost of severe and recrudescent infections are 
considered, then the broader economic impact of the different strategies can be appreciated. 
From Figure 8-26 it can be seen that initially, the annual direct costs of malaria directly reflect 
the provider and patient cost of first-line treatment. At the end of the first year, the costs are 
approximately $12,800 in the VMV scenario, $8,500 in the outreach scenario and $3,400 in the 
non-intervention scenarios, with either monotherapy or with ACT. The direct costs in the VMV 
scenario gradually fall over the years, whereas after a few years, the costs in the other scenarios 
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rise, mainly due to the rise in severe cases. These costs plateau after drug resistance to 
mefloquine reaches 100% at around year 8. In this analysis, the level at which they plateau 
results in the direct costs of all scenarios falling between $10,500 and 13,500, with the highest 
level being in the monotherapy scenario and the lowest level being in the combination therapy 
with VMV scenario. 
By considering the total costs, inclusive of the indirect cost of lost productivity borne by 
households, we can get some indication of the societal costs of malaria with the different 
strategies. From this perspective, it can be seen that, although the addition of delivery strategies 
results in the initial total costs being higher, this difference is relatively small compared to the 
initial difference in direct costs. Thus, initially in the absence of any delivery interventions, the 
total annual cost is approximately $10,000 (with or without a switch to ACT) and the addition 
of outreach and VMV brings these costs up to approximately $15,000 and $17,000 respectively. 
When annual indirect costs are taken into account, by the end of year 5, the VMV intervention 
becomes cost-saving relative to the outreach intervention, and the outreach intervention 
becomes cost-saving relative to the introduction of ACT without any delivery intervention. 
8.7.3.3. Cost-effectiveness 
In order to compare the cost-effectiveness of the different scenarios, the cumulative costs, 
effects and cost-effectiveness at five and 10 years are shown in Table 8-12 and Table 8-13 
respectively, and the cost-effectiveness (CE) planes are shown in Figure 8-27. The latter 
compares the incremental cost of the first-line drug including the cost of delivery intervention, 
with the incremental effect in terms of DALYs averted. 
Firstly, compared to the continued use of monotherapy, the introduction of ACT without 
delivery interventions is more effective and almost cost neutral and 4kereforr is therefore 
definitely cost-effective. Secondly, as observed previously, the cumulative cost-effectiveness of 
all interventions increases the longer the time frame used. Thirdly, the cost-effectiveness of 
outreach and VMVs is very similar so that at 10 years the cost per DALY averted is $16.2 with 
the outreach intervention and $19.3 with the VMV intervention. This results in the appearance 
of the CE plane, which shows a linear relationship in moving from the introduction of ACT 
without interventions, to the introduction of ACT with outreach, and then to the introduction of 
ACT with VMVs. 
Whether the policy is switched at 1% or 20% resistance to mefloquine has little effect on the 
costs, effects and cost-effectiveness because in this example, resistance rises to 20% by the end 
of year 3 and the avoidance of negative outcomes in the first couple of years is dwarfed by the 
magnitude of effects in later years. 
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Figure 8-26: Annual costs predicted by mode! for Cambodian scenarios(. switching at I% 
resistance) 
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Figure 8-27: CE planes comparing the incremental cost of first-line drug and delivery 
interventions with DAL Ys averted for the different Cambodian scenarios. The origin (or 
comparator) is the continued use of monotherapy 
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S. S. Summary 
In this chapter, the results from running the combined biological model and sub-models have 
been presented. The process of running the model showed that it was reasonably easy to apply 
and as hoped, could be adapted to explore the spread of drug resistance, malaria transmission 
and clinical outcomes in a wide range of scenarios. However it was also found that, because of 
the complexity of the model, it took a long time to run, with one scenario taking almost three 
hours. For the purpose of this thesis, the application of the model was focused on a low 
transmission setting, although a preliminary run of the model for a high transmission setting 
indicate that it will generate meaningful results. 
In the base-case scenario, with the continued use of monotherapy, the model predicts that 
resistance spreads very quickly, going from 1% to 100% in six years, and this is associated with 
a 25-fold increase in recrudescent infections. This results in a 4-fold increase in the annual 
incidence of new infections and seven-fold increase in the number of severe infections and 
deaths. Because of the lack of immunity in all of the population, nearly all patent infections are 
symptomatic and treated and adults account for a large proportion of new infections. However, 
adults are assumed to have slightly more clinical immunity against severe malaria, which results 
in children making up a larger proportion of the cases of severe malaria and deaths. 
The introduction of combination therapy with drug AB under ideal coverage (100%) or near 
ideal (80%) coverage results in a dramatic slowing in the spread of drug resistance and averts 
the rise in incidence of malaria and the consequences of treatment failure that are seen with the 
continued use of monotherapy. As a result, in these circumstances the introduction of ACT 
becomes cost saving within two years if the total annual direct costs of treating malaria are 
considered and within five years if the cost of the first-line drug alone is considered. The 
introduction of ACT is therefore clearly cost-effective with a cumulative cost per DALY 
averted of $4.7 using a five-year time frame and $0.4 with a 10-year time frame. 
The results of the biological model were subjected to a sensitivity analysis conducted by WP. 
This indicated that the outputs of the biological model are particularly sensitive to the vectorial 
capacity. In addition, in a low transmission setting, other important biological parameters to 
which the model is sensitive include host susceptibility, the gametocyte switching rate and the 
duration of untreated infections. The drug and behavioural related characteristics that are 
important are mainly the treatment rate, coverage rate with ACT, the failure rate of drug 
resistant infections and the proportion of the population with residual levels of antimalarial 
drugs in their blood. 
257 
The cost-effectiveness of combination therapy compared to monotherapy was also subjected to 
a sensitivity analysis of the clinical outcomes parameters used outside of the biological model 
and to the assumptions made about discounting and DALYs. This suggested that the cost- 
effectiveness ratio was not substantially altered by changes in the rates of severe malaria and 
mortality, the use of discounting or the handling of DALYs. 
In examining the effect of different drug costs on cost-effectiveness, the analysis clarified that it 
is the absolute difference in the cost between the monotherapy and the combinati n theraov that 
affects the incremental cost-effectiveness of combination therapy. Thus a switch from SP 
monotherapy to a combination of artesunate and SP is likely to be almost as cost-effective as a 
switch from mefloquine to artesunate and mefloquine. In order to compare this combination 
with artemether-lumefantrine, the model was run with changes in both the cost of drug and the 
characteristics assigned to the artemether-lumefantrine. The results suggest that at 100% 
coverage, and within the time frame of this analysis, the artesunate-SP combination remains 
both more cost-effectiý any mare cost-saving than the artemether-lumefantrine combination, 
although they are both very cost-effective, costing $2.3 per DALY averted and $4.2 per DALY 
averted respectively at five years, and $0.6 and $1.0 respectively at 10 years. If the scenarios 
were run fora longer period or at a lower coverage rate, we would expect artemether- 
lumefantrine to become more cost-effective relative to artesunate-SP. This is because SP 
resistance would continue to spread in the artesunate-SP scenario, resulting in an increasing 
number of negative outcomes, and an increase in incidence of new infections and therefore first- 
line drug costs. 
Achieving a high coverage rate with ACT (greater than 80%) was shown to be important in 
slowing down the spread of drug resistance to drug A, but is less important in terms of clinical 
outcomes and cost-effectiveness. Switching to ACT appears to be cost-effective at any level of 
ACT coverage, with the cumulative cost-effectiveness increasing with the length of time frame 
used. Therefore, even using a relatively short time frame of two years the r» nlative roct ner 
DALY averted, at any rate of coverage, is less than $60. This, is because, in addition to ACT 
Bing more efficacious, it has the externality benefit of reduced transmission resulting in fewer 
new cases. This in turn, leads to less potential for recrudescent infections, but in addition, leads 
to lower first-line drug costs thereby reducing the cost component of the cost-effectiveness 
ratio. Because the use of ACT is associated with a decrease in the first-line drug costs, ACT is 
actually cost saving relative to monotherapy after five years, even when the costs of severe and 
recrudescent infections are excluded. If these costs are included, then ACT becomes cost- 
saving within a shorter time frame. 
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The effect of the ACT coverage rate on the cost-effectiveness of combination therapy was 
explored further when the model was applied to the data collected in Cambodia, where the 
coverage rate was around 10%. Interventions to improve coverage add a considerable amount 
to the incremental cost of introducing ACT. Thus the implementation of an outreach service 
raised coverage to 32%, and resulted in increasing the cost of the first-line drug, inclusive of 
delivery costs, to $4,800 per annum. The implementation of village malaria volunteers initially 
costs $10,000 per annum, to raise coverage to 90%. This resulted in a cumulative cost per 
DALY at five years of between $48 for outreach and $68 for village malaria workers, if the 
switch is made when drug resistance to mefloquine is only 1%. At 10 years the cumulative cost 
per DALY is $16.2 and $19.3 respectively. Delaying the timing of the switch until resistance 
has reached 20% results in a slight decrease in cumulative cost-effectiveness, because resistance 
rises to this level in a short space of time. Thus, even with the additional costs required to 
increase coverage, the switch to combination therapy in these circumstance is still very cost 
effective. The additional resources required compared to the ideal scenarios mean that cost 
savings are less likely to occur. However, in this example, both interventions become cost 
saving by year 7 if only direct costs of malaria are considered, and by year 5 if indirect costs are 
also considered. 
As expected, very different results were obtained when the model was run to simulate a high 
transmission setting. Under the continued use of monotherapy, the model predicted that 
resistance to drug A ,, meads much more slowly than in a low transmission setting and that the 
use of combination therapy has much less e fect,; _In 
fact, in the combination therapy scenarios, 
if it is assumed that the proportion of the population who have inhibitory levels of drug A is the 
same in both settings, then the model predicts that resistance to drug A will spread faster in the 
high transmission setting. The model therefore predicts that the switch to combination therapy 
has less impact on clinical outcomes than in low transmission settings and no impact on malaria 
transmission. 
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CHAPTER 9 
DISCUSSION I: 
METHODOLOGICAL STRENGTHS AND WEAKNESSES 
AND DISCUSSION OF RESULTS 
The aim of this thesis was to produce a bio-economic model of the spread of antimalarial drug 
resistance, which could be applied to assess the cost-effectiveness of implementing ACT under 
different conditions and to collect the necessary data both to construct the model and to apply it 
to realistic situations. In this chapter the methodological strengths and limitations of the study 
are assessed and the research findings are summarised and discussed. In the next chapter the 
policy implications arising from the study are discussed and recommendations for further 
research are made. 
9.1 Methodological strengths and weaknesses 
9.1.1 Conceptual framework 
Strengths 
At the core of this thesis is an economic analysis of combination therapy in which the spread of 
antimalarial drug resistance plays the central role. Because of this, many of the difficulties 
associated with incorporating drug resistance into economic evaluations have been dealt with 
explicitly. These difficulties in the past have generally led to drug resistance being ignored in 
economic evaluations comparing management strategies of infectious disease (Coast, Smith et 
al. 1996; Coast, Smith et al. 1998). The problems such as the diffuse nature of the impact of 
drug resistance and the intergenerational nature of the externalities are implicitly dealt with 
because the model is population-based and constructed to measure the spread of drug resistance 
over time. In addition the effect of drug resistance on clinical outcomes and the long-term 
effect of the pattern of antimalarial consumption on drug resistance are elucidated. This study 
therefore takes a microeconomic approach. Although this means that the full impact of 
antimalarial drug resistance on the economy as a whole is not assessed, such a micro approach 
is essential for contributing to the accuracy of any macroeconomic analyses of antimalarial drug 
resistance (Smith, Yago et al. 2005). We know from macroeconomic studies of the impact of 
malaria (Sachs and Malaney 2002) and of antimicrobial drug resistance (Smith, Yago et al. 
2005), that the health-care related costs are dwarfed by the impact on national income and 
productivity. 
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Another strength of the approach taken in this study is that the resulting model can be 
generalised to different settings. As recommended by Gold in guidelines for maximising the 
generalisability of economic evaluations (Gold 1996), it assumes the inclusion of a reference 
case alternative where the option taken is of "doing nothing" (the continued use of 
monotherapy). In theory, the simulation of a hypothetical state of no interventions - the "null 
case" scenario - is also possible, as advocated in the WHO guidelines on generalised cost- 
effectiveness analysis (Murray, Evans et a1.2000), but was not done here. 
The development of the model was a multidisciplinary effort between a mathematician and 
myself. This did mean that at times the progression of the model was delayed whilst awaiting 
the collection or interpretation of data and conversely that the running of the full bio-economic 
model was dependent on the completion and correctness of the underlying biological model. 
However this collaborative approach was essential to ensure that the model was biologically 
plausible, and policy relevant as well as being mathematically correct, and its completion would 
not have been possible without both elements. 
Limitations 
There are two main limitations with the overall approach taken. Firstly, as mentioned this is 
fundamentally a microeconomic analysis and therefore the results presented here represent an 
underestimate of the negative impact of antimalarial drug resistance and the potential positive 
impact of combination therapy. Secondly, only the spread of drug resistance is considered and 
r 
not its emergence. This preference for studying the spread rather than the emergence of 
antimicrobial drug resistance has been previously noted and is largely to do with the degree of 
uncertainty in the latter (Coast, Smith et al. 2002). One of the main rationales for the 
introduction of ACT is that it will delay the emergence of drug resistance (White 1999; Hastings 
and D'Alessandro 2000). The results from this analysis therefore underestimate the overall 
potential benefit of introducing ACT. However a biological model of the emergence and 
survival of antimalarial drug resistance is currently underway. Ultimately this "emergence 
model" will be dovetailed into the "spread model" presented here, enabling a more complete 
economic evaluation of the cost-effectiveness of ACT. 
A third issue that may be considered a limitation is that this analysis focuses on antimalarial 
drugs and does not deal explicitly with other important aspects of malaria control, in particular 
vector control. Other studies have compared the cost-effectiveness of different malaria control 
strategies (Goodman, Coleman et at. 2000; Morel, Lauer et al. 2005). This model can, if 
necessary, be used to explore the implication of changes in vector dynamics and synergistic 
interactions resulting from integrating different strategies. 
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9.1.2 Primary data collection in Cambodia 
Strengths 
The main contribution of this study was that it was the first study to attempt to evaluate the 
implementation of a change in national antimalarial drug policy to an ACT. It was particularly 
useful because it included areas with delivery interventions aimed at increasing access to early 
diagnosis and treatment with ACT. The cost-effectiveness of these interventions could 
therefore be assessed not only in terms of increasing coverage but also in terms of effect on drug 
resistance and clinical outcomes by feeding data into the bio-economic model. Methodological 
advances of the study included the use of a drug identification board to assist the respondents in 
their recall of the medicines and the use of rapid diagnostic tests to indicate recent infection with 
P. falciparum. Although there are problems in the interpretation of the results of the latter, this 
appears to be the first time that they have been applied in the study of treatment seeking for 
"malaria" and may pave the way for further research on the definition of "malaria" and non- 
malarial illness. This may provide greater confidence on defining whether the treatment 
received by patients is appropriate or not. 
The questionnaire itself was comprehensive, generating a rich amount of data that included 
information on both treatment seeking and adherence as well as socio-economic status and 
household costs. The inclusion criteria was limited to those who had experienced a malaria-like 
illness in the last three weeks and the information was gathered about specific episodes rather 
than general behaviour. This helped to reduce recall bias and to aid in the accuracy of the data 
obtained, as recommended in McCombie's review of studies of malaria treatment seeking 
behaviour (McCombie 1996). 
This project was fortunate in having a research team that consisted of experienced and highly 
motivated research assistants all of whom had a background in health care and who were 
therefore able to seek clarification and to make appropriate explanations during the process of 
the interviews. It could be argued that this could have led to a bias by influencing respondents 
to answer in a particular way, for example to try to give what they thought were "correct" 
answers. This would have most likely lead to an overestimation of adherence and to have 
resulted in the cost estimates either being too high (if respondents thought that there was a 
possibility of compensation for the costs paid for treatment) or too low (if they were charged 
fees for supposedly free services and did not want to implicate the provider). There is also a 
danger that the research assistants may unwittingly influence the answers given, based on their 
medical knowledge. However the trade-off was that the quality of d as good and that th= 
was a high participation rate. The latter was probably due to a combination of factors including 
the fact that participation was perceived to be potentially beneficial, as it could result in a blood 
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test and if appropriate, anti-malarial treatment. This could have also led to some respondents to 
answer the screening questions positively in order to be included in the study. Although this 
would possibly reduce the reliability of the results, it is difficult to predict how this would have 
led to a systematic bias in individual responses. Reassuringly, the findings in this study were 
generally in keeping with other similar studies in Cambodia using lay people as research 
assistants and therefore substantial systematic bias is unlikely. 
Limitations 
The main limitations of the Cambodian survey are that the sample size was relatively small and 
that the sample selection was purposive up to the point of the health-centre catchment areas 
sampled. This was largely due to difficulties related to carrying out fieldwork in the remote 
areas in which malaria occurs. Many communities were located far from roads and reached 
only by motorcycle, ox-cart, canoe or by foot through dense forest. In order to capture malaria 
treatment seeking behaviour, the study was conducted during the wet season when road 
conditions were at their worst. In addition, in some areas there was a risk of unexploded 
landmines, which further limited access. The sample size from the VMV intervention area was 
particularly small, with only two villages included. For political reasons, the study had to be 
withdrawn early from the area. 
i0 
Uý1 
The main consequence of the small sample size is that some of the apparent differences between 
intervention and non-intervention areas failed to reach statistical significance, after adjusting for 
study design. This was particularly the case for outreach areas because although the sample size 
was larger than from the VMV areas, the differences were much less marked and therefore less 
often reached significance. The small sample size also meant that relatively few children and 
pregnant women were included. Of note was low numbers of children aged five years or 
younger. This in part reflects a difference in exposure, as children often stay behind in the 
village, whilst adults go to work in the forest where malaria transmission occurs. 
Although the sampling was purposive up to the health-centre catchment areas, the selection 
process should have ensured that the results were representative of those villages affected by 
malaria in those areas. Within each village, all households were seen. For a more widely 
representative sample, it may have been preferable to randomly select a proportion of 
households and to sample from more villages; however this was not possible within the time 
and resource available. Malaria transmission in Cambodia varies widely, and the sampling 
strategy chosen enabled us to collect useful data about treatment seeking behaviour for malaria 
in villages that were believed to have malaria transmission without wasting limited time and 
resources in villages with no malaria transmission. Although the results cannot therefore be 
extrapolated to the rest of the country, the areas were chosen by local experts to represent the 
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range of settings in which malaria is transmitted in Cambodia and the results were not dissimilar 
to the much larger, systematic survey that was carried out the following year (Duzey, Kim et al. 
2003), suggesting that the results were reasonably representative. 
A potential source of bias is that only the households in which an adult was present on the day 
of the interview were included. This could result in a bias towards villagers who tend to stay in 
the village and against those who worked and stayed in their "chamkars" - plots of farming land 
in the forest. The latter group are at the highest risk of being infected with malaria and may 
behave differently in relation to seeking and taking treatment. In order to avoid this problem, as 
far as possible, communities were forewarned of the day of the study. In addition, the timing of 
the study itself was at the beginning of the wet season, when planting had already taken place 
and harvesting was yet to happen, and therefore village occupancy was close to a maximum. 
In terms of the actual data collection, the questionnaire itself was initially quite difficult to 
administer, This was because it had been designed with the intention of capturing information 
on preceding episodes of fever as an indication of chronic, untreated infections or re-infections. 
The team of research assistants was small and highly motivated and were soon able to undertake 
the interview without problem. In addition, there were potential disadvantages of the drug 
identification board. Many drugs look alike and respondents may have had a tendency to 
positively identify drugs as one thing when in fact they may have taken a completely different 
but similar looking drug. 
The study had a number of other limitations which are general to studies of treatment seeking 
behaviour and adherence rather than specific to this particular one. 
As in other studies of "treatment seeking behaviour" for malaria, it is not actually known 
whether or not patients who sought and took treatment for malaria actually had malaria. 
As a 
consequence the appropriateness of their management is difficult to judge with any certainty. 
If 
they did not really have symptoms of malaria, then they may not have warranted a diagnostic 
test and should not have received A+M, in which case their management would, in fact, have 
been "appropriate". 
In order to go some way to addressing this problem, RDTs were utilised based on the evidence 
that the HRP2-based tests, such as Paracheck®, remain positive for a few weeks following 
treatment (Mayxay, Pukrittayakamee et al. 2001). However the likelihood of a test being 
positive is not only related to whether or not a patient had P. falciparun: malaria but also when 
they had it, the level of parasitaemia and the efficacy of the treatment taken. Therefore although 
the interpretation of a positive test was fairly straight-forward (i. e. the patient has or has had P. 
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falciparum malaria in the last few weeks), the interpretation of negative tests was more difficult. 
For example, a patient who had a low grade parasitaemia two weeks previously and had 
received a full course of A+M, could well be Paracheck® test negative by the time of the survey 
and would be impossible to differentiate from a patient who never had malaria. This difficulty 
in interpretation is highlighted by the finding that there were significant differences between 
intervention areas in the proportion of patients who had reportedly recently had a positive test 
and who were RDT test positive test on the day of the test. 
Adding blood tests to the study also added a potential bias. For ethical reasons, patients who 
were symptomatic and who tested positive were treated with A+M. This may have resulted in 
respondents tending to answer the screening questions positively in order that themselves or 
their children would be included in the study. To overcome this potential bias, currently ill 
patients could have been excluded. However it was felt that it was important to document the 
lack of access to effective treatment, which would be reflected in malaria patients who had 
ongoing symptoms for several days. Reassuringly comparison of these results with those of the 
national drug usage survey, where inclusion criteria were similar but blood tests were not 
performed, showed similar inclusion rates. 
However, as in all studies where data are based largely on self reporting, there still remains the 
problem of reporting bias. This was of particular concern for adherence as this was one of the 
main objects of the study. Attempts were therefore made to triangulate the self-reported data, 
firstly by asking respondents to produce the packaging and remaining medication and secondly 
by taking a small blood sample (200µl) on filter paper from patients who reported to having 
taken A+M, in order to establish the presence and quantity of mefloquine in their blood. The 
aim had been to compare the levels found with established population pharmacokinetic profiles 
in order to estimate the likelihood that an adequate dose had been taken. However because of 
the small number of respondents who reported to having taken mefloquine (n=44), it was not 
economically feasible to complete this part of the study. This reflects one of the other 
schallenges inherent in attempting to capture both treatment seeking behaviour and adherence to 
specific antimalarial treatments in one study. 
In order to specifically study adherence to A+M, other possible approaches would have been to 
identify patients who had been prescribed A+M and then to follow them up at home. However, 
if patients are informed that they will be followed-up at home, this may alter their behaviour so 
that they are more adherent than they would have been, had they not been aware of being 
observed (the "Hawthorne effect"). Providers may also behave differently, giving more 
information to patients to ensure that they understand how to take the drugs. Following-up 
patients without them having been informed is problematic both ethically and practically as 
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detailed descriptions of where they live are necessary in order to ensure successful follow-up. 
To validate the results in this study, the findings were compared to the results of the larger 
survey undertaken the following year. 
Like most other studies of community-based interventions, this was an observational study of 
interventions that had already been implemented. We do not therefore know what the patterns 
of behaviour were preceding the interventions and do not know how much of the observed 
differences between the three intervention "groups" were due to the interventions. However as 
far as possible, non-intervention areas were chosen to be comparable to the intervention areas in 
terms of accessibility to health centres and markets, size of villages and estimated malaria 
prevalence. 
9.1.3 Secondary data collection 
The process of collecting secondary data resulted in the production of a comprehensive data 
base of parameter estimates, which revealed important gaps in data that will be important to 
address with future research, if more accurate predictions of the impact of ACTs on antimalarial 
drug resistance and malaria transmission are to be realised. 
9.1.3.1. Review of antimalarial drug usage studies 
Strengths 
In Chapter 5, a review of antimalarial drug usage was presented, focusing on adherence to 
drugs, interventions to improve adherence and information linking clinical outcomes to the use 
of drugs outside of clinical trials. The main methodological strength of this part of the data 
collection was that the search of the literature and the inclusion and categorisation of the studies 
were performed systematically, resulting in a comprehensive review of the literature, allowing 
conclusions on the state of the available evidence to be made confidently. 
Limitations 
The limitations are mainly a result of the nature of the studies under review, in that the 
methodologies, settings and drug regimes varied greatly with studies being of poor quality, so 
that comparing and generalising from the studies was difficult. 
9.1.3.2. Other parameter estimates 
Strengths 
The rest of the parameter estimates were collated and presented in table format. The main 
methodological strength of this part of the study is that it covers a broad range of parameters 
important in the biology and economics of malaria and antimalarial drug resistance. Modelling 
is often criticised for being opaque and there is often an underlying suspicion that specific 
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values are selected in order to produce desirable results. Obtaining estimates from several 
sources of data and presenting them in table format makes the process of parameterization more 
transparent. The process revealed important gaps in the data and by sharing the tables with 
other groups (Dean Jamison, Ric Price, Karen Barnes), further information and feedback was 
obtained. Moreover, the tables proved to be a useful resource, enabling others to bypass the 
time- and resource- consuming step of collecting all the necessary data for modelling the 
biology and economics of antimalarial drug resistance. 
Limitations 
The main limitation of the parameter tables is that they contain only the parameters that are used 
in the construction of this particular model, and models that are structured differently may 
require different data, for example disaggregated data for vectorial capacity or similar data but 
measured or expressed differently. Another inevitable limitation of any collection of secondary 
data is that new data are continuously being generated and therefore the information requires 
regular updating. However, since the production of the earlier versions of the parameter tables, 
it has been relatively easy to locate and update parameters as new data emerge. 
9.1.4 Development of the bio-economic model 
Strengths 
This study has produced a new model of the spread of drug resistance designed to examine the 
effectiveness and cost-effectiveness of combination therapy in achieving better cure, delay in 
resistance and possible reduction in transmission in low transmission settings. It is a more 
comprehensive model than previous models, incorporating a wide number of factors including 
those related to the dynamics of malaria infection, host immunity, human behaviour, drug and 
vectorial characteristics. By integrating the costs of the drugs, delivery costs, cost of severe 
malaria and cost of interventions, the model can be used to compare the cost-effectiveness of 
different drug policies in different epidemiological settings. New approaches have been 
explored and an extensive amount of data incorporated resulting in a comprehensive model. Its 
application to a number of scenarios proved that it is usable and flexible enough to be adapted to 
answer a range of questions and to explore phenomena that could not previously have been 
explored using existing models. The interrelationships between factors are complex and the 
resulting outcomes are unpredictable. In creating the model a constant balance had to be struck 
between making the model realistic and avoiding it becoming overly cumbersome. The final 
product represents a compromise between reality and simplicity. 
Most previous economic analysis of antimalarial drugs have focused on the immediate benefits 
of using a more efficacious drug in affecting clinical cure in the face of drug resistant malaria 
(Sudre, Breman et al. 1992; Phillips and Phillips-Howard 1996; Wilkins, Folb et al. 2002; 
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Gogtay, Kadam et al. 2003; Muheki, McIntyre et al. 2004) but have disregarded the effect of 
changing therapy on the course of drug resistance itself. Where drug resistance has been 
included, it has been assumed to rise at a fixed rate irrespective of drug treatment (Schapira, 
Beales et al. 1993; Coleman, Morel et al. 2004; Morel, Lauer et al. 2005). However, these 
models have not allowed any feedback so that, for example, different patterns of drug usage on 
transmission and spread of resistance could not be explored. 
However, the potential for ACTs to delay the development of drug resistance has been one of 
the main rationales used in advocating the change in global drug policy from the use of single 
drugs. Therefore it is important that we have some indication of the size of this potential effect, 
and that an economic analysis of ACTs explicitly makes predictions of the effect on the 
evolution of drug resistance. For this a biological model of malaria drug resistance is required. 
Most existing models of antimalarial drug resistance have come from the perspective of 
population biology, where the emergence, survival and spread of a single resistance clone is 
tracked (Curtis and Otoo 1986; Dye and Williams 1997; Hastings 1997; Mackinnon 1997; 
Hastings and D'Alessandro 2000). These models have elucidated the important factors in the 
emergence and spread of resistance within the parasite population but do not tell us about the 
distribution and spread of infections through the human population and the effect of immunity 
and human behaviour. In contrast, epidemiological models focus on the infections in the human 
host and mosquito host. However until recently epidemiological models had not been used to 
explore drug resistance (Koella and Antia 2003). Laxminarayan based an economic analysis of 
switching from monotherapy to an ACT on such a model (Laxminarayan 2004a). However, 
like other epidemiological models a number of important factors were either not treated 
realistically or explicitly, including: immunity, clinical outcomes, infectiousness, 
pharmacokinetics and pharmacodynamics. 
Looking beyond the field of malaria did not prove fruitful in terms of models or approaches that 
could be adapted for use in this analysis. Most studies were based in hospitals, in developed 
country settings and dealt with anti-bacterial resistance (Wilton, Smith et al. 2002). There are 
many reasons why these are unsuitable for adaptation for an economic analysis of antimalarial 
drug resistance. These include basic biological differences between bacteria and plasmodium, 
including mode of transmission, the mechanism of how drug resistance evolves, the 
consequences of drug resistance, the long term carriage of infections and the role of host 
immunity. There are also differences in terms of the population and settings involved and the 
approaches to the control of drug resistance. 
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Therefore the development of this model represents a contribution to the field of malaria 
modelling and to the field of economic analysis of antimicrobial drug resistance. 
One of the central aims of the model was that it could be used to explore the effect of 
transmission intensities on outcomes. This was in order to address concerns about the extent to 
which the successful implementation of ACTs in low transmission settings could be replicated 
in high transmission settings (Bloland, Ettling et al. 2000). The transmission intensity is varied 
by setting the vectorial capacity at the beginning of a scenario to reflect a given transmission 
intensity. Feed-back is achieved by allowing the daily entomological inoculation rate (EIR) to 
vary during the running of the model according to the infectiousness of the population as 
expressed by gametocyte density in the human population. 
Had the aim of this model been limited to the exploration of the spread of resistance in a high 
transmission setting, then it would have sufficed to use differences in clinical outcomes 
themselves to describe different transmission intensities (Goodman, Coleman et al. 2000). In 
high transmission settings, disease incidence is unlikely to be affected by ACTS and the main 
outcome of interest is the cure rate and the effect on the spread of drug resistance. However, in 
low transmission settings, transmission intensity may vary considerably depending on a number 
of factors including drug resistance, vector control and climatic changes (Craig, Kleinschmidt et 
al. 2004a; Craig, Kleinschmidt et al. 2004b). This would be expected to have an impact on the 
immunity of the population and to feed-back to the incidence of new infections. These changes 
are not captured in models that do not incorporate immunity. 
The realistic modelling of immunity is therefore a unique and core part of this model. The 
effect of change of transmission intensity on different facets of immunity is manifest through 
"immunity functions" derived from EIR and age-stratified data on parasite density, symptomatic 
malaria and severe malaria. Moreover, using different clinical data to describe different 
"facets" of immunity adds an extra layer of sophistication to the model by simulating the 
differential rates of acquisition of different aspects of immunity. 
The other advantage of incorporating immunity into the model in this way is that it leads to the 
population being stratified by age. This allows the change of inputs on the outcomes in 
different age groups to be explored and means that if necessary inputs can vary by age. An 
example where this might be useful is in the targeting of combination therapy at children only. 
This model allows the introduction of new "migrant" or dorm infections. This is important 
in low transmission settings where infected migrants high transmission areas can be 
important in the maintenance of malaria infection in the population (Craig, Kleinschmidt et al. 
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2004a; Zhou, Sirichaisinthop et al. 2005). By allowing these "new infections" only to occur 
over a few months each year, the re-emergence of infections that have remained sub-patent over 
a dry season can also be simulated (Roper, Elhassan et al. 1996; Babiker 1998). 
Another unique feature of the model is that it allows for a certain proportion of the human 
population to have inhibitory levels of antimalarial drugs in their blood. This proportion can be 
varied according to the rate of antimalarial drug usage in the population and the half-life of the 
drug in question. Although in the current model, this level does not vary by coverage, age 
group or resistance, the model could be modified if these were felt to be important. 
Limitations 
The model is a result of compromise between comprehensiveness and parsimony. The main 
"limitations" of the model therefore lie on either end of this axis. Thus, there are assumptions 
made which simplify reality but result in a loss of detail and there are details included which 
results in the model being more "realistic" but more complex. At each point the decision of 
which details to omit and which to include was made based on how important they were thought 
to be to the outcomes of the model, practically how easy they were to incorporate and whether 
the appropriate data were available. The model is complex because of the number of factors 
that it attempts to incorporate realistically. However it is also basically a deterministic 
population-based model in which homogeneity is assumed within each age group. 
The differences between individuals or groups therefore cannot be explored and the inter- 
household risks of exposure to mosquitoes or differences in immunity between different racial 
groups are ignored. To explore the effect of this level of micro-heterogeneity within the 
population on model outcomes requires a model that tracks each individual in a population 
through time. Such an individual-based model would have added another layer of complexity 
and would have required far more computational power than was available. The current model 
as it stands is already fairly comprehensive and entails a long programme script with multiple 
arrays and loops. The programme in which it is written (Splus(&) is not particularly user- 
friendly, making it difficult to understand, check and modify. It is also time-consuming to run, 
taking up to three hours for one scenario over 12 years, depending on the computer used. 
Although this is partly due to the choice of programming language, it is also because the model 
iterates on a daily basis. It could be argued that this level of sensitivity is unnecessary and that 
iterations every five, seven or 10 days would have sufficed, as the minimum period in any state 
in the malaria transmission cycle is around 10 days. However reducing the iterations to single 
days does allow for the exploration of factors such as the delay in obtaining treatment and the 
duration of treated infections for which the differences are counted in days. 
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One of the main reasons for the complexity of the model lies in the incorporation of immunity 
and there were a number of limitations with the construction and use of the immunity functions. 
In general, the functions were based on a few age-stratified datasets at different transmission 
settings. Whilst the resulting functions described a "best fit" to the data, it is possible that the 
data were not representative for that particular EIR or that definitions of methodologies in 
collecting the data resulted in differences which were falsely assumed to be due to differences in 
age or EIR. However for the immune function used most frequently in the model - the function 
describing the relationship between parasite density, age and EIR - individual-level data were 
used and checks were made with the authors to ensure that the methods of quantifying the 
parasite densities were comparable. 
Another possible criticism of the model is that the effect of immunity is exaggerated by re- 
applying the same immune function in a number of places in the model. Thus the immune 
function based on parasite density is used to describe the relationship between age and parasite 
density and is then used to determine the relationship between age and duration of infections. 
However it is known that immunity does have important effects at several stages in the 
pathophysiology of malaria. It is not unreasonable to assume that the mechanism limiting the 
maximum parasite density reached in an individual, is the same mechanism that eliminates 
existing parasites from the bloodstream and therefore the duration of infection. To check for the 
robustness of the model to uncertainties in the immunity functions, it would be desirable to 
undertake a sensitivity analysis, varying the immune functions used. 
Like previous models of antimalarial drug resistance (Hastings 1997; Koella and Antia 2003; 
Laxminarayan 2004a), it is assumed that infections are caused by single clones so that once 
humans are infected, they cannot acquire another infection until they have cleared the original 
infection. However, in reality, often humans and sometimes mosquitoes carry two or more 
infections at any one time, especially in high transmission areas. This assumption may have 
implications for the outcome of the model in terms of transmission intensity, host immunity, 
and the spread of drug resistance. Allowing superinfection would mean that both infected and 
non-infected humans would be equally likely to be inoculated at the beginning of each iteration 
and this may result in an alteration in the course of the pre-existing infection in terms of parasite 
density, gametocytogenesis, virulence and duration of infection and therefore the transmission 
of individual clones (Paul, Lafond et al. 2004). However these intra-host dynamics have not yet 
been fully described, with sometimes contradictory results and therefore these have not been 
incorporated into the model. 
In relation to immunity, there is evidence that some aspects of immunity are clone-specific and 
therefore the acquisition of immunity depends on the clonal variation of infections as well as the 
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number of infections. In this model, there is no differentiation between different clones and it is 
assumed that all infections contribute equally to the infectious pool and have the same effect on 
host immunity. This was felt to be justifiable as there are insufficient data to describe this effect 
accurately. In addition although the model assumes a single clone, the data on which the 
immunity functions are based are derived from studies in which the number and types of clones 
in the individual infections are not known. 
How clonal multiplicity affects the development of drug resistance is more important in this 
model. This is because during recombination, when genetic material is exchanged between 
different clones during the sexual stage in the mosquito, genetic mutants that confer resistance 
can either be broken down or produced. These recombinations are much more likely to result 
in the loss of resistance rather than a gain of drug resistance (Dye and Williams 1997) and 
therefore the more clones within each infection the less likely it is that resistance will be 
retained in the population (Hastings and D'Alessandro 2000). In addition, genetic mutations 
that confer resistance may also result in a survival disadvantage to the mutant in the absence of 
drugs. This is known as a "fitness cost" of drug resistance (Peters, Chen et al. 2002). Therefore 
in untreated infections, if a resistant clone co-exists with a sensitive clone, the latter is more 
likely to survive. This is supported by observational data which suggest that discontinuation of 
chloroquine and mefloquine has resulted in a decrease in resistance to those drugs (Brockman, 
Price et al. 2000; Kublin, Cortese et al. 2003). However, we also know that even before the use 
of a drug, resistance is present at low levels in many populations, in particular for quinine and 
proquanil (Peters 1987), suggesting that for some drugs the fitness cost is low enough to allow 
the mutant to survive in the absence of drug pressure. In this model we have assumed that 
there is no fitness cost. 
In high transmission settings, resistant mutants are therefore less likely to survive because 
infections are more likely to be multi-clonal and are less likely to be exposed to drugs than in 
low transmission settings. In reality the effect of multiple clones can both favour and 
disadvantage the spread of drug resistance and the balance of these effects are likely to vary 
depending on transmission intensity (Talisuna, Erhart et al. 2005). 
Similar to most previous population genetic models of antimalarial drug resistance (Hastings 
1997), (Curtis and Otoo 1986; Dye and Williams 1997; Koella and Antia 2003), this model 
assumes that there are only two gene classes in the population: fully sensitive and fully resistant. 
The main consequence is that the relationship between the half-life of a drug and the impact of 
chemoprophylaxis cannot be fully explored in the model. The duration of the "period of 
chemoprophylaxis" is important for the spread of drug resistance (Watkins and Mosobo 1993) 
and the implications have been extensively explored in a previous study by using an 
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intermediate level of susceptibility (Hastings, Watkins et al. 2002). To avoid the complexity 
that this would involve, the model incorporates this phenomenon simplistically as a variable 
proportion of the population with inhibitory levels of an antimalarial drug in their blood. 
The other limitations of the model relate to some of the simplifying assumptions made and how 
certain relationships with age are handled. Thus treatment rates for symptomatic infections, 
coverage rates with ACT and adherence to therapy are assumed to be independent of age. In 
fact these may vary by age depending on a number of factors including the source and type of 
treatment. However it was felt that there were insufficient data on which to base the values and 
that varying them by age would make the findings more difficult to interpret. 
In considering the consequences of malaria, only the direct consequences of malaria in terms of 
acute infections and neurological sequelae of severe malaria were considered. Therefore the 
role of malaria in causing anaemia and the effects of anaemia on growth and development were 
ignored. There is an increasing amount of data elucidating the link between malaria and 
anaemia (Brabin, Prinsen-Geerligs et al. 2003; Korenromp, Armstrong-Schellenberg et al. 2004) 
and demonstrating the effect of anaemia on cognitive and motor development and growth 
(Grantham-McGregor and Ani 2001). Similarly the effect of co-morbidity with acute bacterial 
infections (Berkley, Lowe et al. 2005) and with HIV were not considered (Francesconi, Fabiani 
et al. 2001; Grimwade, French et al. 2004). However there remain substantial gaps in our 
knowledge and it was felt to be clearer to omit these outcomes and to be aware that the 
estimated outcomes therefore represent an underestimate of the morbidity and cost of malaria. 
The consequences of malaria in pregnancy were also not included. Pregnant women are 
relatively immune compromised compared to non-pregnant adults and are thus not only more 
susceptible to malaria but are also at a higher risk of going on to develop severe malaria and 
severe anaemia. The consequences to the foetus and newborn include miscarriage, stillbirth, 
intrauterine growth retardation and low birth-weight. The consequences of low birth-weight are 
multitude and include a higher risk of mortality and infection. Malaria in pregnancy is therefore 
a serious and often overlooked problem that requires a focused study. Incorporation into the 
model would have required creating a sub-population of women of child-bearing age and 
assigning to them a lower level of immunity and calculations of the likelihood of pregnancy and 
the likelihood of adverse outcomes. The effect on the overall model outcomes would be higher 
rates of morbidity, mortality, costs and DALYs. It would also be expected that the 
infectiousness of the population would be greater and therefore the transmission intensity may 
be marginally higher in low transmission settings. 
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9.2 Summary of results 
In this section the findings of the thesis are summarised and discussed starting with a summary 
of the results from the collection of secondary and primary data. This is followed by a review 
of the key factors affecting transmission of malaria and the spread of drug resistance in the 
model and a summary of its application. 
9.2.1 Primary data collection 
The aim of the data collection in Cambodia was to assess the coverage of ACT and the 
adherence to therapy in non-clinic settings and to estimate the cost and effectiveness of 
interventions aimed at increasing access to diagnosis and appropriate treatment. As described in 
the background, Cambodia is not unlike many settings in sub-Saharan Africa in terms of 
poverty and poor healthcare infrastructure. It is also heavily dependent on foreign financial and 
technical assistance. Although care has to be taken in extrapolating the results to other settings, 
they do serve as an indication of the possible problems in implementing ACTS and of the range 
of costs and effectiveness of interventions in such settings. 
9.2.1.1. Costing 
The cost of an adult dose of artesunate and mefloquine (A+M) blister-packaged in Cambodia 
was around $3.80. This compares to around $2.40 for a course of artemether-lumefantrine or 
$1.30 for non-fixed combinations of artesunate and SP or artesunate and amodiaquine. 
Although mefloquine is relatively costly compared to these other potential partner drugs, much 
of the difference in cost was due to the inefficiencies in production. The Camboidan cost could 
potentially be reduced to around $2.60 if production was more efficient. Even at this cost, the 
difference between mefloquine monotherapy at $1.11 for an adult course and blister-packaged 
A+M is substantially less than the difference between the ACTs and the current monotherapies 
in sub-Saharan Africa. This has obvious implications in terms of the cost-effectiveness of 
ACTs and also has implications in terms of the role of diagnostic tools in rationalising their use. 
The annual fixed costs per capita of increasing access to diagnosis and treatment with the 
outreach and VMV interventions were $0.44 and $0.69 respectively. However the settings were 
not comparable, with a higher prevalence of malaria and poorer access to markets in the villages 
where VMVs were piloted compared to the area serviced by outreach. Therefore many more 
patients were screened and treated in villages with VMVs and when the costs per patient seen or 
per patient treated are considered, the estimated fixed costs were less for the VMV scheme at 
$1.20 and $2.66, compared to $2.66 and $12.75 in outreach areas, respectively. 
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9.2.1.2. Community-based study of treatment seeking behaviour and drug usage 
The key findings in this arm of the study were that the coverage rate with ACTS and biological 
diagnosis was very low (8% and 17% respectively), the use of artemisinins as monotherapy was 
rife (78% of artemisinin use overall) and that both the VMV and outreach interventions 
significantly improved both of these outcomes. In addition, adherence to the blister-packaged 
artesunate and mefloquine appeared to be reasonably good. 
The poor coverage in areas without delivery interventions was partly explained by the fact that 
the vast majority (92%) of patients never sought treatment for malaria-like illness from a public 
health facility. However even when treatment was received from a public health facility, A+M 
accounted for less than half of the prescriptions for presumed P. falciparum malaria and only 
half the respondents in the study reported to have had a biological diagnosis prior to antimalarial 
treatment. 
VMVs appeared to be particularly effective in increasing the likelihood of biological diagnosis 
11-fold (95% CI 4.7 - 24.3, p<0.001) and the likelihood of A+M eight-fold (95% CI 1.84 - 
28.2, p=0.007). Outreach also increased the likelihood of biological diagnosis two-fold and 
A+M three-fold, but on adjustment for survey design and confounders, the differences just 
failed to reach significance. Use of artemisinins as monotherapy was substantially less in these 
areas with interventions. 
Adherence to the blister-packaged A+M appeared to be reasonably good, with three-quarters of 
those who received it completing the whole package in three days. Adherence was particularly 
good if the treatment had been received from outreach workers or VMVs where treatment was 
usually free and always followed a confirmed RDT diagnosis. 
The amount that people paid for treatment varied substantially, especially if the treatment was 
obtained in the private sector. The median cost of drugs alone when bought from a simple 
seller, the most popular source of treatment, was $0.77 but with a range of up to $13, and the 
median cost from private health workers was $3 and up to $41 for a single course of treatment. 
This compared to a median of $0.95 (range 0 to $9.23) from public health facilities, $0 (range 
$0-0.23) from VMVs and $0.64 ($1.28-5.1) from outreach respectively. 
Other important findings were the poor uptake of the socially marketed Malarine® in the areas 
in which it was piloted, the evidence of leakage of A+M which was supposed to be restricted to 
use in the public sector and the suggestion of the misdiagnosis of P. falciparum malaria by 
microscopy in a certain area. 
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9.2.2 Parameter estimates 
A wide range of data were reviewed and assessed for appropriateness for use in the model and 
tabulated for ease of reference. These included detailed information pertinent to the 
transmission of malaria, the spread of drug resistance, the human response to malaria infection, 
human behaviour and costs related to the treatment of malaria. Of particular note was the 
extensive amount of EIR and age-stratified data required for the construction of the immunity 
functions. There were plenty of data on certain parameters such as the age-stratified prevalence 
of malaria or estimates for the proportion of patients seeking treatment in public health 
facilities. However, there was a lack of information on other aspects of malaria, to some of 
which the outcomes of the model are particularly sensitive, such as the susceptibility of humans 
to infection. These gaps in data are discussed in more detail in the section on further research in 
the next chapter. 
9.2.3 Review of antimalarial drug usage studies 
One of the key concerns about ACTs is how effective they are likely to be in "real world 
settings". It has been argued that coverage rates are likely to be low and that the indiscriminate 
use of the artemisinin monotherapy will become widespread leading to an increased risk of 
resistance to artemisinins, a potentially disastrous consequence. However the evidence base for 
these concerns was scanty and it was therefore felt that a formal review of the literature on 
adherence to antimalarial drugs would be useful. 
The aim of the review was to collect information on three aspects of antimalarial drug usage: 
patient adherence to recommended treatment regimes; the effectiveness of interventions to 
increase adherence; and clinical effectiveness in relation to adherence or compared to 
supervised treatment. Overall, the review revealed that "adherence" was generally poorly 
defined, that methodologies varied widely and that there was a paucity of good quality data, 
although it was encouraging to see that this is rapidly changing. Adherence to chloroquine was 
generally very poor (Deming, Gayibor et al. 1989; Krause and Sauerborn 2000; Thera, 
D'Alessandro et al. 2000), however the available data did suggest better adherence to drugs 
when prescribed by trained providers and when efficacious regimes were used. Thus adherence 
rates of above 78% and 90% were reported in clinic-based studies using artesunate with SP and 
artemether-lumefantrine respectively (Depoortere, Guthmann et al. 2004; Fogg, Bajunirwe et al. 
2004). There was also evidence that interventions such as pre-packaging of drugs (Qingjun, 
Jihui et al. 1998; Yeboah-Antwi, Gyapong et al. 2001), provision of instructions (Okonkwo, 
Akpala et al. 2001) and training of providers (Marsh, Mutemi et al. 1999; Marsh, Mutemi et al. 
2004) could effectively improve adherence. However on the whole, there were large variations 
in study design and quality with a particular lack of information on ACTs, their actual usage and 
the link between adherence and actual effectiveness. 
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9.2.4 Modelling 
The two main outcomes of the biological model are the incidence of new infections, which 
reflect transmission intensity, and the rate of spread of drug resistance. Both are influenced by a 
number of interacting factors. In order to understand the results of the model it is helpful to 
review which parameters are important and how they contribute to the final outcome. This is 
therefore summarised below. 
9.2.4.1. Factors affecting transmission 
The key factors driving transmission given a stable vector population are: 
" Migrant infections 
" The susceptibility of humans to infections which is determined by: 
o The maximum susceptibility in a non-immune host 
o The shape of the immunity function based on parasite density 
o The proportion of the population with chemoprophylactic levels of antimalarial 
" The overall density of parasites in symptomatic and asymptomatic infections which is 
influenced by: 
o The maximum likelihood of symptomatic malaria 
o The shape of the immunity function based on likelihood of symptomatic malaria 
o The treatment rate 
o The coverage rate with combination therapy 
o The shape of the immune function based on parasite density 
o The parasite density in recrudescent infections compared to initial infections 
" The duration of non-treated infections, treated and recrudescent infections which is 
influenced by: 
o The maximum duration of untreated infections 
o The minimum parasite reduction ratios in treated infections 
o The shape of the immunity function based on parasite density 
" The probability of recrudescence which is influenced by: 
o The maximum failure rates in treated infections 
o The shape of the immunity function based on risk of severe malaria 
" The gametocyte switching rates in initial and recrudescent infections 
" The gametocyte half-life. 
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9.2.4.2. Factors affecting the spread of drug resistance 
The key factors driving the spread of resistance to drug A are: 
" The ratio of treated to untreated infections which is determined by: 
o The maximum likelihood of symptomatic malaria 
o The shape of the immunity function based on likelihood of symptomatic malaria 
o The treatment rate 
" The proportion of the population with chemoprophylactic levels of antimalarial 
" The relative characteristics of treated versus untreated infections i. e.: 
o The duration of infection 
o The parasite density 
o The gametocyte switching rate 
The coverage rate with combination therapy 
" The relative characteristics of treated resistant versus sensitive infections i. e.: 
o The minimum parasite reduction ratios (and therefore maximum duration) 
o The failure rates 
" The relative characteristics of recrudescent infections compared to initial infections i. e.: 
o The duration of infection 
o The parasite density 
o The gametocyte switching rate. 
9.2.5 Modelling results 
The model was run to assess how easy it was to apply and was used to explore the spread of 
drug resistance, clinical outcomes and costs with monotherapy and ACT in a low transmission 
setting. In this section the summary of the results are presented with comparisons to results 
from other models where available. The reason for some of the more surprising findings are 
discussed and where discrepancies exist between the outcomes predicted by the model and 
expected or actual findings the reasons are explored with suggestions for further investigation. 
9.2.5.1. Drug resistance 
One of the most striking model predictions is the speed at which resistance spreads going from 
1% to 100% in six years. In the model described by Laxminarayan resistance was found to 
spread even more quickly once exponential growth started, reaching 100% within one to two 
years (Figure 9-1) (Laxminarayan 2004a). However it is important to note the difference 
between the two models. Laxminarayan's model is much simpler and does not deal explicitly 
with transmission. Also, in his model, resistance to the ACT is explored with the assumption 
that all those not covered by the ACT are treated with a drug that is not part of the combination, 
unlike the model presented in this study in which the resistance to a monotherapy (drug A) is 
explored and the combination therapy in the base-case scenario does contain this drug. 
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Figure 9-1: The rate of spread of resistance to a combination therapy as predicted by 
Laxminarayan. 
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paper) 
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There is a lack of real-life data with which to validate the rate of spread of resistance predicted 
in these models. The measurement of drug resistance as described in this model is the 
proportion of the parasite population that carry the mutation(s) required to confer complete 
resistance to a drug. Measurement of this information in reality requires the use of molecular 
technology to identify the responsible mutants (or reliable genetic markers) and to monitor 
change in their frequency in the parasite population over time. As this technology has only 
recently become available, there is a paucity of longitudinal molecular data which track the 
increase in resistance from the initial emergence of a resistant infection. Limited data from 
KwaZulu-Natal suggest that the frequency of the parasites carrying dhfr alleles which are linked 
to resistance to SP, increased from around 20% to 40% in four years although slower rates were 
seen for other mutants (Anderson and Roper 2005). As more data emerge, further validation of 
the model results will be possible and the investigation of discrepancies may reveal important 
factors affecting the spread of resistance not previously considered. 
The rapid rate of spread predicted by the model may be partly explained by the choice of the 
values chosen for the parameters in the base-case scenario. As explained earlier, the spread of 
resistance is determined by the proportion of infections exposed to the drug to which the 
parasite is resistant and the selective advantage to the parasite of carrying the resistant gene. 
From the sensitivity analysis we know that in the monotherapy scenario, the parameters to 
which this outcome are particularly sensitive include: the treatment rate, the proportion of the 
population with chemoprophylaxis and the gametocyte switching rate (GSR). The data on 
which these estimates were based were scanty making it difficult to model with greater 
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accuracy. In addition we assumed that there is no fitness cost of resistance and this may have 
resulted in an overestimation of the rate at which resistance spreads. 
The main factors affecting the spread of drug resistance in the model are listed below, with the 
values used in the base-case scenario in parenthesis. 
" The maximum likelihood that a patent parasitaemia will be associated with symptoms in 
a non-immune host (0.8) 
" The proportion of symptomatic infections which are treated (0.95) 
" The duration of untreated infections (80 days) 
" The duration of treated infection, which is dependent on the parasite reduction ratio of 
infections with resistant genotype (x100) compared to the parasite reduction ratio in 
sensitive infections (x1000) when they are treated with monotherapy (SP or 
mefloquine) 
" The maximum failure rate for resistant infections (0.85) versus sensitive infections 
(0.06) for monotherapy 
" The infectiousness of recrudescent infections (mainly drug resistant) compared to initial 
infections, which is dependent on: 
o The duration of infection (same as the initial infection) 
o The parasite density (0.5x that of the initial infection) 
o The gametocyte switching rate (x20 that of the initial infection) 
Although data on the spread of drug resistance are lacking, data are available on the change of 
cure rates over time and although not directly comparable to mutation frequency, for the 
purpose of model validation, serve as a useful proxy of drug resistance. As can be seen in 
Figure 9-2, the model predicts that overall failure rates would rise from 3% to 16% in three 
years and to 24% the following year. This initial rate of rise compares reasonably well with 
data from low transmission settings in Thailand and South Africa. In the former, 28-day failure 
rates to mefloquine rose from under 10% in 1990, to 40% in 1994 in northwest Thailand (Figure 
9-3) (Nosten, van Vugt et al. 2000). In KwaZulu-Natal the failure rates to chloroquine rose 
from 0% to 21% between 1983 and 1987 (Figure 9-4) (llansford 1989; Craig, Kleinschmidt et 
at. 2004a). In both situations, the policy was switched at the end of these periods therefore it is 
not possible to compare beyond this point. 
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Figure 9-2: Age-stratified failure rates predicted by the model in the base-case scenario with 
monotherapy starting at I% resistance at year 1 
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Figure 9-3: Cumulative cure rates assessed at day 28, for mejloquine 15mg/kg (M15), 
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Figure 9-4: Drug resistance in KwaZulu-Natal (KZN) and Mpumulanga in South Africa 
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9.2.5.2. Transmission 
The model also predicts that transmission rises substantially, with a four-fold increase in the 
annual number of new cases and 25-fold increase in recrudescent cases as a result of resistance 
rising from one to 100%. Although this rise in incidence may seen extreme, there is some 
evidence to suggest that the model predictions are plausible. As shown in Figure 9-4, the 
incidence of malaria in KwaZulu-Natal increased exponentially from about 600 cases in 
1991/92 to more than 30,000 cases in 1999/2000' resulting in an incidence of 250-800 cases 
per 1000 in 1998-1999 (Barnes, Durrheim et al. 2005). Although there are several possible 
causes for this increase, including HIV, climatic determinants, agricultural developments, 
migration, insecticide resistance and changes in case reporting, there was a strong correlation 
with drug resistance (Craig, Kleinschmidt et al. 2004a). The authors identify persistent 
infections following treatment as a source of increase in the number of infections. In 1984 only 
1.2% of hospital treated cases remained positive compared to 9% in 1985, and three years later 
1 An estimated 600,000 live in malaria-risk areas (Barnes, Durrheim et al. 2005). 
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patients remained positive having been treated four times". In the model, when resistance has 
reached 100%, recrudescent infections account for around 700 out of 4,000 infections. 
Laxminarayan's model predicts that after the initial increase in the number of infections 
associated with the rise in drug resistance, there is a rapid return to lower than previous levels of 
infections due to the impact of increasing immunity. However immunity is handled 
simplistically and when modelled more realistically, as it is in the thesis model, the incidence of 
malaria infections is predicted to remain at a relatively high level. This is probably a more 
accurate prediction of what would happen in reality if drug policy is not changed in response to 
the epidemic. This is because unlike viral infections, in malaria, immunity is only gained after 
sustained exposure. In the base-case scenario, even when drug resistance has reached 100%, the 
annual incidence of patent infections is around 3,000 cases, so that each individual has less than 
a one-in-three chance of being infected each year. One would therefore not expect the average 
level of immunity in the population to increase sufficiently to cause an overall decrease in 
susceptibility to infection. 
9.2.5.3. Importance of migration 
During the development of the model, it was found that in low transmission areas, the incidence 
of malaria fell to zero, effectively reflecting the eradication of malaria. In order to ensure 
continued transmission, an input of infections from outside was required and this became an 
additional feature of the model and is interpreted as either "migrant" or reactivated "dormant" 
infections. In fact, this observation does reflect the importance of such infections in the 
maintenance of malaria transmission in areas of low and unstable transmission intensity. In 
KwaZulu-Natal from 1986 to 1992, it was estimated that between 20-40% of cases were 
imported (Craig, Kleinschmidt et al. 2004a). In Thailand the continued transmission of malaria 
is widely believed to be due to cross-border migration from Myanmar and Cambodia. From 
Mae Sot province on the Thai-Myanmar border, "foreigners" were responsible for more than 
half of the malaria cases in 2001 (Zhou, Sirichaisinthop et al. 2005). Other models have also 
noted the importance of migration in sustaining transmission (Gu, Killeen et al. 2003). 
9.2.5.4. Severe malaria and mortality 
The model suggests that the spread of resistance from one to 100% is associated with a seven- 
fold increase in the number of severe cases and deaths. There are a lack of data linking drug 
resistance to the incidence of severe malaria or mortality in low transmission settings. However 
from studies in high transmission settings in Africa, it has been estimated that the rise in drug 
"They also propose that the increase in gametocytes in the blood that has been noted following treatment 
with SP also contributed to the increased infectiousness of the population. 
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resistance has been associated with between two to 11-fold increase in mortality attributable 
malaria (Snow, Trape et al. 2001; Trape 2001; Bjorkman and Bhattarai 2005). 
9.2.5.5. The impact of ACT 
The results from the model suggest that the introduction of an ACT of drug AB at full coverage 
in a low transmission setting has a dramatic effect on both the spread of drug resistance to drug 
A, and the epidemic increase in the incidence of malaria and treatment failures, suggesting a 
decrease in annual incidence in new cases from 739 to 686 (8% reduction) when introduced at 
I% resistance to drug A. 
Therefore, even in the short term (one year) setting, the introduction of ACTs is cost-effective 
so that when the switch is made at 1% resistance, the incremental drug cost per DALY averted 
is around $130. By the end of five years the cumulative incremental drug cost per DALY is 
$4.7 and after another five years this falls by an order of magnitude. Although these results are 
obtained under the assumption that coverage is 100% which may not seem plausible, data from 
low transmission areas where high coverage rates were achieved suggest that similar results are 
possible in reality. 
In north-west Thailand, a 47% decline in malaria cases was observed within one year of the 
introduction of ACT (artesunate plus mefloquine). This increased to a six-fold reduction over 
10 years (Price, Nosten et al. 1996; Nosten, van Vugt et al. 2000). In South Africa, there was a 
94% decline in incidence of malaria in KZN in the two years following the introduction of both 
artemether-lumefantrine and the re-introduction of indoor residual spraying with DDT. It was 
estimated that around 37% of the reduction in incidence was attributable to the change in first- 
line drug (Muheki, McIntyre et al. 2004). Two years after the interventions the number of 
outpatient visits, admissions and deaths due to malaria had fallen by almost 100% (Barnes, 
Durrheim et al. 2005). Cost-effectiveness in terms of average cost-per-life-saved was estimated 
at US$18 compared with $158 with SP. Costs savings from the perspective of the provider 
were estimated at US$201,065 for that sub-district (Muheki, McIntyre et al. 2004). 
In Vietnam, the provision of free microscopic diagnosis and ACTs at the village level was 
provided from pre-existing and new health posts as part of a nationwide policy of early 
diagnosis and treatment of malaria launched in 1993 (Giao, Vries et al. 2005). This resulted in 
a reduction in presumptive self-treatment of malaria, a decrease in the delay between first 
symptoms and seeking treatment and a concomitant decline in incidence of uncomplicated and 
severe malaria. 
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In the model by Goodman et al, it was found that in low transmission areas, if it was assumed 
that ACT reduced the growth rate of SP resistance by greater than 47%, then the cost- 
effectiveness of ACT would be under $150 per DALY averted. ACT was found to be more 
cost-effective even when the impact on drug resistance was assumed to be less marked 
(Goodman, Coleman et al. 2000). 
9.2.5.6. The importance of the coverage rate with ACT 
The results from running the model with different levels of coverage with combination therapy 
suggest that even with low levels of coverage there is a noticeable impact on the incidence of 
infections. Therefore, although initially there is a direct correlation between the level of 
coverage and the annual costs of first-line drugs because of the higher costs of drugs, as the 
number of cases increases inversely proportionate to the level of coverage, by year 10 there is 
an inverse relationship between coverage rate and the annual cost of first-line drug. In terms of 
the total costs of treating malaria, ACT is cost saving compared to monotherapy within a few 
years and the higher the coverage rate, the greater the cost saving. In terms of cumulative cost- 
effectiveness, at two years, the incremental cumulative drug cost per DALY averted ranges 
from $7 at 10% coverage to $54 at 100% coverage. However over the following years the 
cumulative DALYs averted as a result of higher coverage rates compensate for the higher cost 
of drugs incurred in the earlier years and there is little difference in cost-effectiveness at year 10 
with the cost per DALY averted lying at less than $1. The results also suggest that beyond a 
coverage rate of around 50-60%, there are decreasing returns to increasing coverage. There are 
few practical or theoretical examples with which to compare these predictions of the impact of 
coverage on the effectiveness of ACTs. 
Although Laxminarayan explores the effect of treatment coverage rates on outcomes, the model 
is set up differently, so that malaria patients who are not "covered" with the combination 
therapy are treated with some other effective drug not containing either of the drugs in the 
combination. The model explores the spread of resistance to the combination under different 
levels of coverage. The findings suggest that a coverage rate of 60% is sufficient to completely 
suppress the spread of drug resistance but with coverage rates of 40% and 60%, the beginning 
of exponential growth of resistance started at around five years and seven years respectively, 
reaching 100% within one or two years (Laxminarayan 2004). 
In the recent generalised cost-effectiveness study of malaria control strategies, Morel et al. 
evaluated interventions including the introduction of different antimalarials at 50%, 80% and 
95% coverage over a 10-year time frame (Morel, Lauer et al. 2005). The analysis suggested 
that there were increasing returns to increasing coverage especially in Africa E regions 
(Southern East and Central Africa). At 50% coverage with an ACT, the average cost per DALY 
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averted was $39 compared to $14 at 80% coverage, and $12 at 95% coverage. In Africa D 
regions (West Africa) the coverage had little effect on cost-effectiveness with a cost per DALY 
averted of between $9 and $13. These values are higher than the ones predicted in this model 
and reflect substantial differences in approaches and parameter inputs. For example in their 
model both incidence of malaria and the spread of drug resistance is fixed and adherence to 
ACT is assumed to be 40%. 
9.2.5.7. Application of the model to the Cambodian data 
The analysis based on the Cambodian data suggests that although less cost-effective compared 
to the ideal situation, the replacement of monotherapy with an ACT may still be cost-effective 
and potentially cost saving in similar settings where access and utilisation of public health 
facilities is very low. This is mainly because even at the low levels of coverage with ACTs, 
there are fewer treatment failures, fewer severe outcomes and transmission is potentially 
reduced. 
Delivery of diagnosis and treatment with ACTs through outreach clinics and VMVs are both 
very cost-effective to the provider. The outreach intervention was found to increase the 
coverage rate with ACT to 32%. The cumulative incremental drug cost per DALY averted is 
estimated to be $48 at five years and $16 at 10 years. Delivery through VMVs increased 
coverage to 90% and was associated with a cumulative incremental drug cost per DALY averted 
of $68 at five years and $19 at 10 years. 
From a societal perspective, taking into account direct and indirect costs to patients and 
providers, the delivery interventions become cost saving in terms of annual costs, by year 6. Of 
note, both interventions, but especially the VMV scheme, result in a substantial shifting of costs 
from patients to providers. A switch to the ACT in the absence of any delivery interventions 
results in total annual direct costs to patients of $1,616 in the first year, rising to $14,439 at 10 
years. The implementation of VMVs results in the total annual cost to patients remaining at $65 
throughout the 10 years. With outreach, the cost savings are much less, with the total annual 
cost rising to $824 by year 10. This is due to both the higher proportion of patients seeking 
treatment from the informal sector but also because there is a higher incidence of malaria due to 
the lower level of coverage with ACT compared to the VMV villages. 
9.3 Conclusion 
The key strengths of the thesis are that it has an integrated approach, combining biology with 
economics and that the resulting model is based on an extensive amount of primary and 
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secondary data. This helps to ensure both biological realism and policy relevance. A number of 
limitations and omission have also been discussed. The most important relate to the restriction 
of the focus to the spread of drug resistance, the complexity of the model, the lack of important 
data and practical difficulties during the primary data collection in Cambodia. However despite 
the latter, the findings clearly suggest that in similar settings with poor healthcare 
infrastructures, coverage rates are likely to be low and the use of artemisinin monotherapy wide- 
spread. Improving access to appropriate management through village malaria workers and 
outreach clinics significantly improved both of these outcomes. This is important as the results 
from running the model suggest that in order to impact on the spread of drug resistance once it 
has already arisen to one of the partner drugs, high levels of coverage with the ACT are needed. 
However the other key findings from the application of the model are that ACTs are likely to 
cost-effective and to results in total cost-savings compared to monotherapy under a wide range 
of conditions, including at low coverage rates. In low transmission settings much of this benefit 
is due to the reduction in treatment failures and malaria transmission. 
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CHAPTER 10 
DISCUSSION II: 
POLICY IMPLICATIONS AND RESEARCH PRIORITIES 
In this chapter the findings from the process of developing the model, collecting and reviewing 
the primary and secondary data and the application of the model are all brought together in 
'order to discuss the implications for policy and to make recommendations for further research. 
The final conclusions of the thesis are then presented. 
10.1 Policy implications 
10.1.1 Drug resistance and ACTs 
It is clear that antimalarial drug resistance is one of the most important health issues in tropical 
countries and that the impact of antimalarial drug resistance is enormous. In this study it is 
estimated that in a low transmission setting, drug resistance can rise from 1% to almost 100% in 
five years. In a population of 10,000 in a low transmission setting it is estimated that the annual 
total (indirect and direct) cost of treating malaria would increase at least three-fold (from 
$10,600 to $32,800) as a result, with almost half the cost being due to the indirect costs 
resulting from treatment failures. We know that this represents a significant underestimate of 
the actual negative impact of antimalarial drug resistance and that if a macroeconomic approach 
had been taken the impact would be much more (Sachs and Malaney 2002; Smith, Yago et al. 
2005). 
In reality these high levels of resistance have already been reached in many countries where 
ineffective monotherapy drugs continue to be the first-line treatment in practice, if not in policy. 
It is now generally accepted that the ideal choice of treatment is an ACT. There is therefore an 
urgent need for affordable (or free) effective treatment to be made widely available to the 
vulnerable rural poor who are most at risk of dying of malaria and are least able to access 
appropriate treatment. 
However, there continue to be concerns about how ACTs should be implemented, which 
combination to switch to and what coverage levels need to be attained if benefits of a reduction 
in the growth of drug resistance are to be achieved. The existing examples of successful 
implementation of ACTs have come from South Africa and Thailand where treatment rates in 
the public sector have been high and therefore high rates of coverage have been achievable. 
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Thus in Kwazulu-Natal, 93% of those reporting a recent case of malaria had been treated at no 
charge in a public sector facility (Muheki, McIntyre et al. 2004). There have been concerns that 
these levels of coverage are exceptional and are unlikely to be replicated elsewhere. The results 
from the data collection in Cambodia certainly lend credence to these concerns - less than 10% 
of antimalarial treatment was with the recommended ACT. 
10.1.2 Coverage 
However, the implications from the modelling scenarios with different coverage rates suggest 
that the prospects of a low level of coverage should not in itself be a deterrent to switching to an 
ACT. Although in low transmission settings, very high levels of ACT coverage (above 80%) 
are required in order to delay significantly the spread of drug resistance to an already failing 
drug, other benefits are seen at much lower levels of coverage. This is because the greater 
efficacy of the ACT compared to failing monotherapy results in an immediate benefit to patients 
in terms of fewer recrudescent infections, and immediate and future externalities in terms of 
decreased transmission. The higher the coverage level attained the greater the proportion of 
patients who benefit directly and the greater the effect on decreasing transmission. Although 
there are decreasing returns to coverage above a certain level (50-60% coverage), this does not 
mean necessarily that maximum coverage should not be sought. The level of coverage aimed 
for depends on the decision-makers willingness to pay for coverage and alternative ways of 
spending money. 
The other policy implication implicit in this discussion is that there is a need to monitor the 
implementation of ACTs to ensure that they reach the targeted population. 
10.1.3 Artemisinin monotherapy 
Although high coverage rates are desirable, policy makers need to be aware that unrestricted 
access to artemisinins is not the answer. In Cambodia, artesunate was found to be widely 
available and was four times more likely to be taken without mefloquine than with it. Although 
resistance to artemisinins is theoretically very unlikely to emerge, the consequences would be 
truly disastrous should this occur. Therefore it is of paramount importance that efforts to 
increase the use of artemisinins in effective combinations are matched by efforts to limit their 
use on their own. There are a number of policy actions to ensure that only co-formulated ACTs 
are available and used. Very recently the WHO has issued an unprecedented directive banning 
the use of artemisinin monotherapy with the possibility of blacklisting manufacturers who 
continue to produce artemisinins derivatives on their own (WHO 2006c). This is a major step 
and will hopefully contribute to a limitation of the availability of the monotherapy by deterring 
at least the large pharmaceutical companies from their production. 
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However in settings such as Cambodia, there is low utilisation of the public health sector, the 
drug market is relatively unregulated, borders are porous and law enforcement weak. In such 
circumstances restrictions on the production, importation or selling of artemisinin monotherapy 
are unlikely to succeed. Raising awareness through information campaigns and training are also 
likely to have limited effect, as long as the artemisinin derivatives are available on their own 
and are cheaper to buy. This is because from the patients' perspective, there may appear to be 
no additional benefit of using combinations. Artemisinins on their own work as fast as the 
combination in relieving symptoms, have few side effects and, where they have been used 
before, are familiar to the community. The infections are much more likely to recrudesce 
because a longer duration of therapy is required but rarely adhered to. However the 
recrudescent infection may occur several weeks after the initial infection and from the patient's 
perspective, is unlikely to be interpreted as a treatment failure. 
Thus ensuring that patient with malaria have access to free, or heavily-subsidised co-formulated 
ACTs is the major challenge facing those involved in the control of malaria (Arrow, Panosian et 
al. 2004). 
10.1.4 An integrated approach 
The results from the study in Cambodia emphasize the need to take an integrated approach to 
the treatment of malaria, one that considers both the formal and the informal sector as well as 
community-based treatment, depending on the pre-existing healthcare providers and 
infrastructures. Disappointingly, the findings from the study suggested that providing free ACT 
in the public health facilities was not a sufficient incentive to effect a significant shift in 
treatment seeking behaviour from the informal to the formal sector, and that even in the public 
health facilities, use os was ow though the reasons for this are not entirely clear, large 
stocks of quinine and tetracycline remained stocked in health centres and continued to be used 
as first-line treatment. This is in contrast to the experience in Kwazulu-Natal, where the old 
stocks of antimalarial drugs were physically removed from clinics concomitantly with the 
introduction of artemether-lumefantrine. The implication is that this must become standard 
practice if change is to be affected successfully. 
There was also evidence of the leakage of blister-packaged A+M from the public sector into 
shops in Cambodia. A+M is specially packaged and is intended for use only in public health 
facilities where it is provided free. However there is very little control on the use of drugs once 
they have been distributed from the Central Medical Stores and leakage can occur easily from 
the provincial level down to the level of individual health centres. Health workers are poorly 
paid in the public sector and many therefore work in clinics and pharmacies. There is therefore 
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an incentive for them to treat patients with A+M in the private sector where they can sell it for 
profit rather than to provide it for free in public health facilities. 
The active involvement of the informal sector is therefore essential. In Cambodia, this has been 
attempted by social marketing of both the pre-packaged artesunate-mefloquine (Malarine®) and 
Paracheck® RDTs. Experience from the initial phases of implementation suggested that there 
was poor penetration of the products both in terms of availability and awareness. Malaria 
treatments bought in the informal sector were sometimes very costly, especially if they included 
parenteral treatments, and therefore the potential loss of seller earnings associated with 
providing cheap, effective treatment may be a significant deterrent to changing prescribing 
behaviour. However, during discussions with informal sector providers, it was clear that many 
were keen to learn about the appropriate diagnosis and treatment of malaria and appeared 
willing to try using both RDTs and Malarine®. Experience from other settings have shown that 
shopkeepers and market vendors can be successfully trained to improve the case management of 
fever of children (Marsh, Mutemi et al. 1999; Luby, Zaidi et at. 2002; Tavrow, Shabahang et al. 
2003; Marsh, Mutemi et al. 2004). For the successful implementation of ACTs, the utilisation 
of such strategies will need to be explored, where the informal sector is an important source of 
treatment. 
10.1.5 Community based interventions 
In some areas there is limited access even to informal sector providers. In such settings, the 
provision of effective treatment with or without biological diagnosis must be considered at the 
level of the community. The study in Cambodia found that villagers themselves could be 
trained to diagnose malaria using RDTs and to prescribe blister-packaged artesunate and 
mefloquine. The rate of coverage, in terms of proportion of respondents with malarial 
symptoms appropriately treated was over 90%. Villagers also proved to be a reliable source of 
surveillance data, especially because the RDTs were kept as "evidence" of cases treated. This 
was despite initial misgivings that the VMVs, who were largely illiterate, would find the 
diagnostic tests and treatment regimes too complicated. There is a significant cost involved in 
ensuring adequate training, monitoring and supervision resulting in the fixed costs of the 
programme being higher than the variable costs of RDTs and drugs. However the results from 
running the model using the Cambodian data suggest that VMVs can be highly cost-effective 
and that high enough coverage rates can be achieved to impact on the spread of drug resistance 
as well as transmission. The results from the household survey also suggest that the scheme 
decreased costs for the targeted population who were particularly poor, and therefore an 
additional attraction of such schemes is that they are inherently "pro-poor". 
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However there are situations in which a VMV scheme is not a practical alternative, for example 
where the population is highly mobile and there is a lack of social cohesion. In such situations, 
outreach clinics, such as the one implemented in Anlong Veng district in Cambodia, are a viable 
policy option. The coverage rates are lower and fixed cost per patient tested and treated are 
significantly higher than the VMV intervention. When the long-term cost-effectiveness of 
outreach was evaluated using the model to incorporate the impact on drug resistance and 
transmission, it was clear that this to was cost-effective. 
Both types of interventions, particularly VMVs, can therefore be strongly recommended as a 
means of implementing ACTs. However there are a number of caveats. These predictions are 
based on the assumption that the same level of coverage will be maintained over time and this 
may not be the case. It was apparent from discussions with members of the communities, and 
the providers themselves, that there was some dissatisfaction with the services. The most 
common complaint was that only treatment for malaria and specifically P. falciparum malaria 
was provided. As this represente ess than a quarter of the cases seen, the majority of patients 
dic not ecei 
e 
any treatment. This may be why in villages with VMVs, patients appeared to 
have waited longer before seeking treatment, although comparison with pre-intervention 
behaviour is not available. In recognition of this problem, and in the hope that the number of 
patients with malaria may decrease as a result of the intervention, an expanded role for VMVs 
has been discussed in Cambodia. Other countries considering similar interventions should 
perhaps, from the outset, consider a more holistic approach in which the consequences of a 
negative RDT are recognised and the management of diseases other than malaria are considered. 
One possibility is to integrate the use of RDTs into the integrated management of childhood 
illness (IMCI) approach and train village health volunteers to also recognise and treat diarrhoeal 
disease and acute respiratory infections in children. 
Finally, it remains to be seen whether the short term success as documented here continues into 
the future and how well similar schemes work in other settings. Past experience with village 
health workers has shown that such schemes can be difficult to scale up and to sustain in the 
long run. 
10.1.6 Adherence 
The results of the systematic review of adherence to antimalarial drugs and the results of the 
drug usage study in Cambodia indicate that adherence to ACTs are good when then they are 
provided free, by trained providers and either co-formulated or blister-packaged. The 
implication for policy is therefore that poor adherence should not be a deterrent to switching to 
an ACT but that they must be provided either co-formulated or blister-packaged and either free 
or at a truly affordable price so that patients do not feel that they must ration doses in order to 
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retain tablets for the treatment of future fevers. Other simple efforts can significantly improve 
adherence. This includes ensuring that patients and their carers are given adequate information 
on how to take drugs correctly and that those prescribing the regimes have sufficient training 
and support so that this happens. 
10.1.7 Biological diagnosis 
As mentioned earlier, if the singular goal of antimalarial drug policy was to maximise coverage 
with the first line drug then the most straightforward solution might be to make ACTs available 
in every home so that treatment could be instituted without delay following the onset of 
symptoms. There have been a number of studies where mothers have been trained to make 
presumptive diagnosis and provide treatment for their children and this has been found to be a 
feasible 
and affordableprQach (Pagnoni, Convelbo et al. 1997). Most encouragingly, this 
approach has been found to significantly reduce under-five mortality in a large-scale cluster 
RCT in Tigray, Ethiopia (Kidane and Morrow 2000). However, there are substantial costs and 
risks of presumptive home-based treatment with ACTs and there is an ongoing debate about the 
trade-off between maximising coverage and minimising the wastage of drugs, the costs, and the 
risk of resistance to the combination by limiting the use of ACTs to those who have biologically 
confirmed malaria (D'Alessandro, Talisuna et al. 2005). 
In the case of Cambodia, the introduction of RDTs with ACTs through VMVs and outreach 
demonstrated that they were popular and could easily be used by members of the community, as 
well as health staff. Given a test positivity rate of around 20-25% and cost of $0.83 for a P. 
falcfparum specific test, compared to an adult course of A+M at $3.80, they are highly cost- 
effective. The socially marketed RDTs, which were made available to retailers at $0.50, were 
reportedly more popular than the blister-packaged Malarine®. Further work needs to be 
undertaken to explore the optimal level of subsidy for both so that the practice of confirming 
diagnosis prior to treatment with the combination can be promoted. Utilisation of RDTs in 
public health facilities was disappointingly low, and this appeared to be partly due to stock-outs 
and low staff motivation. The implications for policy are that in a low transmission setting, 
biological diagnosis prior to treatment with ACTs should be standard and that RDTs are a 
practical and cost-effective means of achieving this. The caveats are that it is essential to ensure 
adequate stocks and to routinely monitor the quality and use of the tests (Lon, Alcantara et al. 
2005). The problem with introducing an accurate biological diagnosis for a single disease has 
already been noted, and ideally improving the case management of malaria should be integrated 
with other diseases. 
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10.1.8 Choice of combination therapy and timing of switch 
The results from the scenario analysis showed that with a 10-year time frame, any ACT is cost- 
effective compared to a failing monotherapy and that the earn r th x»r hi *T+ade + , rg 
cost-effective. This is because switching earlier averts recrudescent and severe infections that 
occur with the monotherapy as drug resistance rises prior to the switch. Previous international 
guidelines suggest different levels of clinical failure at which countries should move towards 
switching first-line antimalarial treatment: a grace period (0-4%), alert (5-14%), action (15- 
24%) and then change at 25% (Kitua 1999). More recent guidelines suggest a change at levels 
of clinical failure of 15% (WHO 2005a). However both the results of the modelling and recent 
evidence from the field suggest that these levels of resistance are often reached within a few 
years of drug resistance emerging. As the process of switching drug policy takes at least two 
years, it is therefore recommended that the process of policy change be initiated as soon as there 
is evidence that drug resistance to te irst- ine therapy has emerged. 
The results from the modelling scenario analysis also show that although artemether- 
lumefantrine is almost twice the cost of artesunate and SP, even under ideal conditions where 
coverage is 100% and the switch is made at a low level of resistance to SP, there is little 
difference in cost-effectiveness between the two drugs. At 10 years the cumulative incremental 
drug cost per DALY averted with artemether-lumefantrine is $1 compared to $0.6 for artesunate 
and SP. With a more realistic coverage rate and with higher levels of resistance to SP, the 
difference between the two regimes will be less or possibly reversed. The results of the 
modelling show that unless coverage with artesunate-SP is over 80%, the spread of resistance to 
SP will not be significantly affected by the addition of artesunate. Artesunate will thus become 
increasingly exposed over time, although this may not become apparent clinically for years. 
The implications in terms of the possible emergence of resistance to the artemisinin derivatives 
have already been noted. 
The recommendations for policy makers are therefore that the switch should be made to an ACT 
to which there is no resistance to the partner drug. Because resistance to the older 
monotherapies is now so widespread, at the moment, this means a switch to artemether- 
lumefantrine in most cases. However the co-formulated combination of dihydroartemisinin- 
piperaquine (with or without other antimalarials), has been available for several years as 
Artekin® or CV8, in China, Vietnam and increasingly in Cambodia. Piperaquine has not been 
widely used on its own and clinical trials have shown that the combination is efficacious and 
safe. It only requires once-a-day dosing, does not need to be taken with fat in the diet and 
currently costs less than artemether-lumefantrine (Tran, Dolecek et at. 2004; Ashley, McGready 
et al. 2005). For some time the main obstacle to its wider use was that it was not manufactured 
to international good manufacturing practices standard. However this has recently been 
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achieved and the combination is now in phase three trials. A priority for policy is to ensure that 
on completion of the trials, the registration process of the drug is facilitated. 
The model was also applied to explore concerns regarding the use of presumptive therapy and 
the spread of drug resistance. It suggests that in a low transmission setting, even if 10% of the 
population were assumed to have inhibitory levels of drug in their blood, that there was little 
effect on the spread of drug resistance. This analysis is being extended to explore the impact in 
higher transmission settings where there is greater use of presumptive therapy. However this 
does not address the concerns regarding the effect of presumptive therapy on the emergence of 
drug resistance and this will require further research. 
10.2 Research priorities 
In this section the priorities for research arising from this study are discussed. In Chapter 7, 
suggestions for further research specific to Cambodia were discussed and in Chapter 5 
suggestions for future studies on the adherence to and effectiveness of antimalarial drugs were 
made. These are summarised here and are followed by a more general discussion of studies of 
treatment seeking and adherence and the implementation of ACTs. Other gaps in the data that 
arose during the process of data collection are then reviewed with suggestions for how these 
may be addressed. This is followed by a discussion of research priorities for modelling, 
concentrating on validation of the model, further development and its application to explore a 
range of policy relevant questions. Finally other approaches to modelling the economics of 
antimalarial drug resistance are discussed. 
10.2.1 Antimalarial drug usage in Cambodia 
The collection of data in Cambodia revealed poor levels of coverage with ACT, and biological 
diagnosis, both of which improved with delivery interventions, in particular VMVs. Being a 
relatively small study with an emphasis on collecting information from both intervention and 
non-intervention areas and information on both treatment seeking and adherence, there was a 
need for a larger more representative study to validate the findings and to ensure that sufficient 
information was gathered on high risk sub-populations including children and pregnant women. 
Fortunately this was subsequently undertaken the following year and some of the results were 
discussed earlier. It was also felt that in order to improve coverage, a better understanding was 
required of the "supply-side" of the antimalarial drug market, and further qualitative studies 
were required with both the community and the providers, aimed at identifying barriers and 
incentives to change behaviour. 
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10.2.2 Treatment seeking behaviour and antimalarial drug usage 
10.2.2.1. Treatment seeking for "malaria" 
Community drug usage studies are constrained by not knowing whether a patient actually had 
malaria or not and therefore whether the choice of treatment was in fact appropriate. 
Microscopy at the time of interview is not useful as patients who genuinely may have had 
malaria should become non-parasitaemic soon after starting treatment. For this reason RDTs 
were used in the collection of primary data in Cambodia. Although this revealed significant 
issues in terms of undertaking blood tests during such studies and also in interpretation of 
results, it is an approach that possibly warrants further exploration. In relatively low 
transmission settings, antibody tests could be also be explored as they remain positive for much 
longer. However they too may be difficult to interpret (Edelman, Hoffman et at. 1993; Biswas, 
Tomar et al. 2005). 
10.2.2.2. Adherence 
The review of the literature revealed that there were wide discrepancies in the definition and 
measurement of "adherence". In the future, clearer definitions of adherence should be provided 
to assist in interpretation and comparison across studies, and ideally this should be based on 
dose, frequency and duration. However, as the study in Cambodia revealed, patients are 
unlikely to be able to recall this amount of detail accurately, therefore as a compromise a 
pragmatic operational definition is needed. 
Furthermore, although there is some evidence to support that self- or carer-reported drug 
histories may be reliable (Kofoed, Lopez et al. 2003; Marsh, Mutemi et al. 2004), other studies 
have shown that they can be subject to bias and error (Nwanyanwu et al. 1996). It would 
therefore be helpful to have more studies that validate drug histories with biological markers of 
adherence using modern population pharmacokinetic approaches (Simpson et al. 2001). 
However, these can only be undertaken with drugs that have a half-life of at least a few days 
and therefore can not be carried out on the artemisinin derivatives. 
It is particularly difficult to study adherence to the first-line drug in a community setting when 
the actual usage of the drug of interest is low. As the experience in Cambodia revealed, it 
would be much more efficient to identify patients supplied with the first-line drug at shops or 
clinics and to follow them up at home. Although there may be problems with this approach as 
discussed earlier, it may be the only way to obtain sufficient data. 
10.2.2.3. Effectiveness 
It may be, however, that too much emphasis has been put on adherence, rather than focusing on 
the actual consequence of poor adherence, the main one being treatment failure. The emphasis 
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should therefore shift more towards measuring the real-life effectiveness of treatments, where 
patients obtain and take drugs outside of clinical trial settings and are followed up clinically and 
parasitologically to find out whether or not they are cured. The results can then be compared to 
the efficacy of the drugs when taken supervised (Krause and Sauerborn 2000; Nsungwa-Sabiiti, 
Tomson et al. 2005). This entails a shift from the traditional clinical "efficacy" trials to 
"effectiveness" trials, a shift that is already underway (Smithuis, van der Broek et al. 2004; 
Depoortere, Guthmann et al. 2005; Piola, Fogg et al. 2005). These recent studies also address 
one of the gaps identified in the review of antimalarial drug usage studies, which was that there 
was need for studies of the effectiveness of ACTs in sub-Saharan Africa. 
10.2.2.4. Interventions to improve community drug usage 
There was a lack of good quality studies documenting the effectiveness and cost-effectiveness 
of interventions aimed at improving the treatment of malaria in the community. Ideally these 
should be community-based RCTs in which communities or clusters of communities are 
randomised into different intervention or non-intervention arms. The disadvantage with such 
studies is that they can be difficult and costly to undertake. However with sufficient planning 
--------------- and support, it should be possible to conduct useful operational research in the context of the 
planned implementation of ACTs. Many countries that have received money from the Global 
Fund for the introduction of ACTs do not plan to implement universal and nationwide coverage 
immediately. There is usually some plan for a phased introduction or a targeted approach. One 
of the important lessons from Cambodia is to encourage the exploitation of these opportunities 
as natural experiments. If the implementation strategy is well planned and the collection of 
appropriate data is organised from the outset, then the resulting information could be extremely 
useful. Differences in outcomes could be compared in communities before and after the 
introduction of the policy change and any accompanying interventions to improve access could 
be evaluated. Such studies should include information on costs and how they are calculated in 
order for policy makers to make informed decisions around policy change and implementation. 
10.2.3 Malaria and antimalarial drug resistance 
A modelling approach was taken in this thesis because of the uncertainty about the development 
of drug resistance and the effect of ACTs in different settings. Empirical data based on 
longitudinal epidemiological studies of antimalarial drug resistance would help address much of 
the uncertainty. Such studies should ideally be carried out in different epidemiological 
conditions and should monitor the use of antimalarial drugs in the community. Where the first- 
line antimalarial drug is artemether-lumefantrine, the monitoring of drug resistance will be 
dependent mainly on the in-vivo studies, until reliable molecular markers of the component 
drugs are found. The identification of such markers is therefore another important priority for 
research. In undertaking in-vivo studies, it is essential that follow-up is adequate - at least 42 
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days for drugs with a long half-life such as lumenfantrine. Otherwise, drug resistance will not 
be detected until it is already well established, because most treatment failures occur after 28 
days (Stepniewska, Taylor et al. 2004). Now that re-infections can be distinguished from 
recrudescent infections using molecular techniques, this should become standard even in high 
transmission settings. For the drugs for which molecular markers of drug resistance have been 
identified, more studies describing the relationship between carriage of resistant mutants and the 
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clinical outcomes would be useful. 
The exercise of gathering data was instructive in revealing important gaps in our current 
knowledge on certain aspects of malaria infection. For the purpose of the modelling, there was 
uncertainty to a number of parameters to which the model outcomes were particularly sensitive, 
particularly pertaining to aspects of malaria infection in the human host. For some of these 
gaps, it may not be technically possible to gather the necessary information, however in other 
areas it should not be too difficult. 
ýC-C_, lf 
Better estimates of the duration of malaria infections would be extremely useful. These could 
be based on longitudinal genotypic studies examining the duration of infection in different age 
groups and at different transmission intensities and could be related to the parasite density of 
infections and the onset of symptoms. This would help to elucidate the interaction between the 
intra-host dynamics of malaria infection, the role of general and specific immunity in 
controlling infection, and the importance of sub-patent infection in transmission. 
Much uncertainty still exists around the factors affecting the transmission of malaria and in 
particular the factors affecting gametocytogenesis and the relationship between gametocyte 
carriage, infectiousness and immunity. Some of the most eloquent work on gametocytes comes 
from work done almost 50 years ago (Eyles and Young 1951) and fortunately there has been a 
renewed interest in this area. As a first step in the further gametocyte research it would be 
desirable to agree upon a common means of measuring the rate at which asexual parasites 
switch to gametocytes. It would also be useful to have a uniform means of measuring the 
infectiousness in terms of gametocyte density and duration (Sowunmi and Fateye 2003). As 
most clinical trials of antimalarial drugs currently follow-up patients parasitologically on a 
weekly basis, it requires little additional effort to report the gametocyte density as well as 
asexual parasite density before and up to 42 days after treatment, and from this establishing a 
"gametocytes switching rate" following treatment with different drugs (Barnes, Durrheim et al. 
2005). There is also a lack of data on recrudescent infections themselves, as their onset usually 
represents the end-point of clinical trials. However they are an important source of malaria 
transmission and the spread of drug resistance and it would therefore be useful to have more 
information about them, particularly in relation to the density and duration of gametocytaemia. 
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For the purpose of a model such as the one presented here, in which immunity plays a central 
part, it would be useful to have more complete data on several age-stratified clinical outcomes at 
a range of EIRs. In particular, there is a lack of published data on age-stratified rates of 
treatment failure. Again, when clinical trials are carried out this information is inevitably 
collected and therefore only requires analysis and reporting. Other data are much more difficult 
or impossible to collect. Specifically, data on human susceptibility to infection are lacking and 
there is still a great deal of uncertainty about the existence and role of transmission-blocking 
immunity. 
Finally, for the accurate estimation of the burden of disease caused by antimalarial drug 
resistance and therefore the benefit of interventions aimed at its control, more precise estimates 
of the incidence of malaria, severe malaria and deaths are needed. In addition studies that 
elucidate the relationships between malaria and anaemia, neurodisability and other infections 
will be important in quantifying the full burden of disease. 
10.2.4 Further development of the thesis model 
The development of the model to this stage was the aim of the thesis and was all that was 
possible within the constraints of time and the computing facilities. However, there is clearly 
room for further refinement and validation and to fully exploit the application of the model. 
This section firstly describes how the model could be checked for validity and then describes 
further developments of the model that would either make it easier to use or more realistic. 
Finally some of the potential applications of the model are discussed in the context of current 
policy issues. 
10.2.4.1. Checking the model for validity 
The process of developing the model was a continuous iterative process involving the 
construction of the model, running it and making modifications in light of the findings. Ideally 
the robustness and validity of the model should be further explored by extending the sensitivity 
analysis and by comparing the results of the model to more datasets, especially in high 
transmission settings. Sensitivity analysis should ideally be extended to include testing of the 
immunity functions. Immunity forms a core part of the model and the shapes of the functions 
are key determinants of the model outcomes. Although the data on which some of the functions 
were based were comprehensive and the resulting functions described a good fit, for other 
functions there were fewer data, and the resulting functions are less precise. In addition there is 
an inherent uncertainty in using the immunity functions as proxy measures of the facets of 
immunity described in the model. It would therefore be useful to vary the shape of the 
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functions, essentially to describe more or less steep relationships between facets of immunity, 
age and EIR, in order to explore how this affects the outcome of the model. 
The best way of validating the model is to see how accurately it predicts outcomes and this was 
done for a low transmission setting, using data from KwaZulu-Natal in South Africa and 
Northern Thailand. There are several large-scale implementation programmes currently 
underway in both low and high transmission areas, which will provide opportunities for further 
validation. Such a programme is now being instituted in a large mining community in Papua 
where a switch is being made from chloroquine to artemether-lumefantrine. A rich set of 
clinical, parasitological and entomological data is currently being collected and there are plans 
to use this data to validate the model (Ric Price, personal communication). 
10.2.4.2. Developing and modifying the model 
The model, as it stands, is more comprehensive than preceding work and can already be applied 
to address policy relevant questions. However there is plenty of scope to develop it further. 
These developments mainly fall into the category of either increasing the realism of the model 
or improving its user friendliness or speed of running. 
Integration with a model of the emergence of drug resistance 
As mentioned at the beginning of the chapter, perhaps the greatest need is to incorporate the 
emergence of drug resistance. It is clear that once resistance has emerged and survived, its 
subsequent spread is rapid and therefore measures including the use of ACTs that impact on the 
likelihood of emergence will have a far greater effect on health outcomes and costs than those 
that only impact on the spread of drug resistance. It will also help to address concerns about the 
emergence of resistance to artemisinin derivatives in light of potential widespread use of the 
monotherapy. An emergence model in currently being developed. The next step will therefore 
involve dovetailing the two models so that the "spread" model starts at the point at which the 
"emergence" model ends, which is when there are enough resistant parasites to be reasonably 
certain of transmission and spread. 
Individual-based simulations 
As discussed earlier, the main limitations to the realism of the model are that it is deterministic 
and population-based and it therefore does not allow for the exploration of micro-heterogeneity 
in the population and for the stochastic nature of events. The latter is particularly important in 
realistically simulating rare events and would therefore be most useful in modelling 
transmission in low transmission settings and in the modelling of the emergence and survival of 
drug resistance. Therefore one of the next aims of this work is to adapt and transcribe the model 
to another programme such a Simul8® hich is designed to keep track of individuals. In this 
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way individual or ethnic variation, for example differences in the risk of exposure and 
immunity, can be introduced and the effect on model outcomes explored. This could also be 
useful in investigating outcomes in pregnant women and their contribution to transmission and 
the spread of drug resistance. 
Pharmacokinetics and other refinements 
Currently the model handles the phenomenon of chemoprophylaxis simplistically by presuming 
that a fixed proportion of potentially patent sensitive infections are eliminated at the beginning 
of each iteration. Recently it has become clear that the half-life of the drugs in combination 
therapies is important in determining the rate of re-infection in high transmission settings 
(Staedke, Mpimbaza et al. 2004; Mutabingwa, Anthony et al. 2005)78. Ideally the model should 
therefore be adapted so that the pharmacokinetics of drugs is handled more realistically. This 
will most likely entail the introduction of an intermediate level of drug resistance (Resl) 
between the complete resistance and complete sensitivity assumed in the current model 
(Hastings, Watkins et al. 2002). 
Other refinements 
Other possible refinements to the biological model include allowing for superinfection, var gene 
switching, a group of symptomatic but untreated patients with the immune characteristics of the 
latter, and a third arm of treatment where patients are treated with a drug other than the 
monotherapy and combination therapy. 
In addition, there are changes that could be made to the sub-models to enable more detailed 
modelling of the outcomes and costs. For example a proportion of patients with severe malaria 
should be assumed to be treated in the informal sector where the likelihood of mortality and 
costs are different from the formal sector. 
At the moment the model is not particularly easy to share with others and requires transferring 
of datasets from S-plus® to Excel®. In order to make it more accessible and useful it needs to 
be integrated and transcribed to a more user-friendly programme such as Modelmaker® or 
Simul8®, 
78 The study in Tanzania showed that although the PCR adjusted day 28 cure rates with amodiaquine. 
artesunate was 88% compared to 97.3% for artemether-lumefantrine, there were more re-infections in the 
latter so that the unadjusted "clinical cure" rates were the same (Mutabingwa, Anthony et al. 2005). In 
the Ugandan study, a similar observation was made between a group treated with amodiaquine-SP and a 
group treated with artesunate-SP (Staedke, Mpimbaza et at. 2004). 
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10.2.4.3. Applying the model 
There are many avenues for applying the model to investigate the spread of antimalarial drug 
resistance and the effectiveness and cost-effectiveness of measures aimed at its control. Some 
of these have been visited in this thesis but others remain unexplored. 
Macroeconomic analysis 
As discussed at the beginning of the thesis, the economic analysis takes a "micro" approach. In 
order to capture the full impact of drug resistance and the benefits of controlling its 
development, the results of this model could be fed into a macroeconomic analysis (Smith, 
Yago et al. 2005). The latter require data generated from micro studies including estimates of 
the impact of drug resistance on health outcomes. 
High transmission settings 
The focus of this thesis has been the spread of drug resistance in a low transmission setting, 
However, there has been much debate about the impact of combination therapy in high 
transmission settings and the model was constructed so that could it could address this question. 
Preliminary results from applying the model to a high transmission setting show that the model 
predicts that resistance spreads more slowly than in low transmission settings and that whilst the 
introduction of ACT slows this spread further, the effect is much less marked than in low 
transmission settings. As expected, the model predicts that ACTs do not appear to have any 
impact on malaria incidence (Annex 10). Because of the higher incidence of infections, the 
incremental costs of first-line drugs are much greater and the cost-effectiveness less, especially 
if only a short term perspective is taken. Clearly, there is much more scope for using the model 
to explore the implications of implementing ACTs in a high transmission setting. 
Targeting 
Perhaps the most exciting application is the use of the model to compare the effectiveness and 
cost-effectiveness of specific policy options, especially after it has been coupled with the 
emergence model. The most pertinent questions relate to addressing the trade-off between 
maximising access to ACTs versus limiting or targeting their use to those who are most 
biologically and/or economically vulnerable. The aims of targeting are to reduce the cost of 
drugs; decrease the wastage of a scar resource; reduce the risk of the inappropriate treatment of 
non-malarial fevers and the associated delays; and finally reduce drug pressure and therefore the 
risk of resistance arising. The most obvious target group is children and the model in its current 
form can be applied to compare the long term impact and cost-effectiveness of targeting 
children versus universal coverage. 
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Biological diagnosis and social marketing 
The model can also be used to address the question of whether or not the use of ACTs should be 
restricted to those who have biologically confirmed P. falciparum malaria. The question of the 
cost-effectiveness of biological diagnosis irrespective of the impact of resulting drug use on 
drug resistance is an important one and is actively being pursued by collaborators and it is 
hoped that their analysis will be able to inform this model (Catherine Goodman, personal 
communication). Inclusion of the costs and effects of introducing diagnostics immediately 
introduces the need to consider the segment of the population who are uninfected with malaria, 
but who have similar symptoms for which they seek treatment. Those that receive antimalarial 
drugs presumptively may contribute to the spread of resistance and as mentioned earlier, this 
would ideally involve adapting the model to include an intermediate level of drug resistance. 
The impact and cost implications of socially marketing ACT can also be explored using the 
model. In particular, the distribution of costs between patients, the private sector and the 
government can be estimated in different scenarios. 
Choice of drug 
Making two switches, first to artesunate-SP (or artesunate-amodiaquine) and then later to a co- 
formulated ACT such as artemether-lumefantrine, has been the policy option chosen by a 
number of countries. The main incentive is the lower cost of artesunate-SP. As discussed 
earlier, the danger of such a policy is that the spread of resistance to SP or amodiaquine is likely 
to go unchecked by the addition of artesunate. The results of the model suggest that under 
perfect conditions where coverage is 100% and the switch is made when resistance is still low 
(<20%), artesunate-SP is marginally more cost-effective than artemether-lumefantrine over a 
10-year time frame and it may be reasonable to implement such an "intermediate switch". 
However, in less than ideal circumstances, artesunate and SP may soon become less cost- 
effective than artemether-lumefantrine, necessitating an early switch. This problem warrants 
further exploration with the model. In doing so it will be important to incorporate the cost of 
making an additional change in policy, such as the costs of meetings, training, printing and 
raising public awareness. 
Time frame 
In this thesis, a time frame of 10 years was used. However, the time frame of the economic 
analysis is clearly important and some of the benefits of ACT may not be fully realised until 
after this. Extending the duration of the analysis will therefore be essential, especially when the 
"emergence model" is incorporated. Currently, one of the disincentives to using longer time 
frames is the length of time it actually takes to run the model. One of the major advantages of 
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Migration, dormant infections and seasonality 
In terms of transmission and the spread of antimalarial drug resistance, the model has a number 
of features that have not been exploited so far and warrant further investigation. This includes 
exploring the inclusion of external source of infections (migrant or dormant infections) and the 
effect of seasonality. The role of migration infections and the their importance in maintaining 
transmission in a low transmission setting has already been noted. So far in this thesis, this 
group have been assumed to have the same characteristics in terms of immune profile and level 
of drug resistance compared to the main population. However, the model allows both of these 
to vary, as well as the size and the timing of their introduction into the population. By varying 
these characteristics and the size of migrant group the effect of migration on malaria 
transmission and the spread of drug resistance can be explored. 
The effect of seasonality on the transmission of malaria can also be explored by specifying the 
timing of the external infections in order to simulate the phenomenon of sub-patent infections 
that survive through the dry months to re-emerge the following year. Seasonality can also be 
explored by varying the vectorial capacity from month to month 
Immunity 
Because the model handles immunity in a more sophisticated way than previous models, it can 
be exploited to investigate the effect of interventions on the immunity profile of the population. 
For example there are concerns that the introduction of vaccines, vector control or effective 
drug treatment in infants and young children will result in a shifting of the age and severity of 
clinical disease upwards towards the older age groups. Although not constructed for this 
purpose, there is no reason that the model can not be used to explore these issues. 
10.2.5 Alternative modelling approaches 
In this thesis, a microeconomic approach was used, in which the underlying epidemiological 
model was population-based and when the total cost of malaria was considered, a human capital 
approach was used. There are a number of alternative analytic strategies that could be explored. 
10.2.5.1. "Micro" approaches 
Other "micro" approaches that have been used to study the economics of antimalarial drug 
resistance and ACT, and warrant further exploration, include the decision-tree based models 
(Goodman, Coleman et at. 2001; Coleman, Morel et al. 2004) and adaptation of existing 
compartment models of malaria transmission and drug resistance (Laxminarayan 2004a). The 
former have also been used to explore the value of obtaining additional information for 
variables to which the cost-effectiveness of ACT is sensitive but for which there is significant 
uncertainty (Sam Shillcutt, personal communication). For the more realistic modelling of the 
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former have also been used to explore the value of obtaining additional information for 
variables to which the cost-effectiveness of ACT is sensitive but for which there is significant 
uncertainty (Sam Shillcutt,, personal communication). For the more realistic modelling of the 
epidemiology of malaria transmission and antimalarial drug resistance, models based on 
individuals rather than on the population will be necessary. Such models allow the exploration 
of the impact of individual variation in risks and behaviours on overall outcome including the 
total cost of malaria inclusive of the indirect costs of lost productivity. They also allow the 
amount of variation in the impact of drug resistance on individuals to be explored. As 
mentioned earlier such a model could be developed from a pre-existing population-based model 
such as the one presented in this thesis. 
Most economic analysis of malaria and antimalarial control strategies have utilised a human 
capital approach to measure the cost of health in monetary terms. Studies employing a 
"willingness-to-pay" approach could provide valuable information on the amount of money 
decision-makers are willing to pay in order to decrease the risk of the emergence or spread of 
drug resistance. Although, the complexity of the issues involved make it challenging to explore 
such questions in malaria-affected communities, it would be useful to estimate how much 
individuals are willing to pay for such externalities. 
10.2.5.2. "Macro" approaches 
Although macroeconomic approaches have been employed to study the economic impact of 
malaria (McCarthy, Wolf et al. 2000; Gallup and Sachs 2001) and of antimicrobial drug 
resistance (Smith, Yago et al. 2005), so far they have not been used in the economic analysis of 
antimalarial drug resistance. Such studies are needed in order to estimate the impact of 
antimalarial drug resistance on the economy more comprehensively than is possible with 
traditional microeconomic approaches. Possible means of doing this could include either using 
logistic regression analysis similar to those conducted previously on malaria or one using a 
computable equilibrium analysis. One of the disadvantages of the former is that although it may 
be useful in describing the link between antimalarial drug resistance and economic indicators, it 
cannot be easily manipulated to study the cost and impact of interventions to control drug 
resistance. This may however be possible by using a computable general equilibrium analysis 
as described by Smith et al. This could be undertaken by mathematically describing the 
economy of a country or region in a state of equilibrium, with a given level of malaria 
transmission and no drug resistance. Drug resistance could then be introduced as a "shock" to 
the system and the effects on the different sectors of the economy, observed. The effect of 
different strategies for controlling drug resistance could possibly be explored by varying the size 
of this initial shock or by the introduction of a second shock to the system. 
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10.3 Final conclusions 
This thesis started by stating the nature of problem of antimalarial drug resistance and the policy 
dilemmas facing decision-makers responsible for changing and implementing antimalarial drug 
policy. The core of the problem is that artemisinin-based combination therapies are more costly 
than the older failing monotherapies and there is a need to ensure that they are used to save the 
lives of those threatened with malaria now, whilst at the same time prolonging their useful life 
for the future. There are, in particular, concerns about how effective ACTs will be in practice 
when implemented in settings with poor health care infrastructure where low coverage rates can 
be anticipated. 
In order to address this problem with this study, a comprehensive bio-economic model of the 
spread of antimalarial drug resistance has been developed and an extensive amount of data 
collected, including empirical data from Cambodia where ACTs were first implemented. The 
model has been applied to a low transmission setting and run with the Cambodian data, in order 
to explore the spread of resistance and the costs and consequences of switching from a 
monotherapy to an ACT. 
The results from this study suggest that in a low transmission setting, ACTS are cost-effective 
and result in overall cost-savings in a wide range of scenarios. Much of the benefit in this 
setting is due to an impact on the transmission of malaria as the recrudescent infections that are 
responsible for much of the transmission are averted. The longer the time frame of the analysis, 
the more cost-effective the switch, as more cases and treatment failures in the future are averted. 
Although benefits are seen even at low coverage rates, higher coverage rates are important in 
maximising benefit to both current and future populations. The model predicts that high 
coverage rates of 80% or above are required to cause a noticeable delay in the spread of drug 
resistance to a partner drug to which resistance has already emerged. Choice of drug is 
important. Although the addition of an artemisinin to an already failing drug will result in 
short-term benefit and may be less costly in the short term, unless coverage rates are very high 
and the switch is made early, the artemisinin component will be left exposed as a monotherapy. 
Clinically, this may not be detected for years, as the majority of patients will continue to be 
cured. Therefore switching to the co-formulated ACTs is strongly recommended. 
The findings from the empirical data collection in Cambodia highlight the challenges facing 
those implementing the switch to ACTs in similar settings. Without specific strategies to 
improve access to ACTs and biological diagnosis, uptake of the new policy was extremely low 
and most worryingly the inappropriate use of artemisinins on their own was widespread. 
However delivery intervention, such as outreach clinics and in particular vi 
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volunteers appear to be an effective way of increasing coverage of ACTs. The benefits are 
multiple. The most vulnerable populations are targeted; biological confirmation to use of ACTs 
is ensured; the correct use of the drugs increased; artemisinin monotherapy use reduced; and the 
societal costs of malaria substantially ameliorated. 
The human and economic cost of antimalarial drug resistance is high. This has finally been 
recognised and a major change in global antimalarial drug policy is currently underway. Global 
subsidies have been advocated to ensure that co-formulated ACTs are available for free, or at 
very low cost to the populations at-risk of malaria (Arrow, Panosian et at. 2004). It is important 
to ensure that sufficient resources are also made available for their effective implementation and 
to evaluate the cost and effectiveness of different strategies including the social marketing of the 
drugs with or without RDTs. The bio-economic model developed in this study is intended to 
contribute to such evaluations. 
There is a trade-off between the complexity needed to ensure biological realism and the 
simplicity and clarity required to facilitate application to policy. However, by combining 
biology and economics within a single framework, this model has the advantage of ensuring that 
the economic analysis is based on realistic biological predictions. It therefore enables a wide 
range of scenarios to be explored by altering the values of the epidemiological, behavioural and 
cost inputs. By applying the model to both low and high transmission settings, it is hoped that 
it will serve as a useful tool in the further elucidation of policy decisions. 
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ANNEX 1 Background information 
A. M. Artemisinins 
History 
Artemisinin or Qinghaosu was first isolated by Chinese army scientists in1972, searching for 
new antimalarials amongst the traditional Chinese remedies'. However details of the process 
were not released and it was not until 1984 that researchers outside of China successfully 
isolated artemisinin derivatives from plants found near the Potomac river in Washington D. C.. 
The plant in fact is common in temperate areas although commercial production until now has 
been concentrated in China and Vietnam. Artemisinin can be found in all parts of the plant 
except the roots and is most highly concentrated in the flowers. Artemisinin yield is associated 
with plant age and varies from 5kg/hectare to 30kg/hectare. 
Formulations 
The most widely used derivatives are artesunate, ärtemether and dihydroartemisinin (DHA). 
Artesunate is the most widely available in tablet form on its own, in gel suppositories and in 
powder form in a vial for injection following reconstitution with 5% sodium bicarbonate. 
Artemether is available in tablet form on its own but and is more widely available co-formulated 
with lumefantrine. It is also formulated in peanut oil for intramuscular injection. 
Dihydroartemisinin is available mainly in Southeast Asia where it is usually co-formulated with 
piperaquine. 
Mechanism of action 
Artemisinins have a unique chemical structure, containing a endoperoxide bridge that is central 
to its mechanism of action. Artemisinins cause a peroxidation of lipid membranes due to the 
formation of free radicals when they comes into contact with intracellular heure or iron: The' 
may have a more specific action on malaria parasites by acting on a calcium transporter. 
Uncomplicated malaria 
The first RCTs on ACTs conducted in Asia, with the combination of three days of artesunate 
and single dose mefloquine showed that the combination was rapidly efficacious, improved cure 
rates, decreased gametocyte carriage and was well tolerated (Price, Nosten et al. 1997; Nosten, 
van Vugt et al. 2000). Subsequent trials elsewhere including the largest RCTS ever conducted 
in Africa, have confirmed these findings with different ACTs. The first of these. was a multi-, 
centre RCT of three-day amodiaquine plus artesunate against amodiaquine plus placebo, 
involving 941 children. The artesunate plus amodiaquine combination was found to be 
significantly more efficacious in Gabon (85% versus 71%, p=0.02) and Kenya (68 versus 41%, 
p<0.0001) and equivalent in efficacy in Senegal (Adjuik, Agnamey et al. 2002). In Gambia, the 
combination of three days of artesunate and a single dose of sulfadoxine-pyrimethamine (SP) 
was found to result in a significantly higher cure rate than SP alone, at a time that SP was still 
effective. Gametocyte carriage was also noted to be significantly lower with the artesunate-SP 
combination (21% versus 68%, p=0.001) (von Seidlein, Milligan et al. 2000). In contrast when 
the same combination was evaluated in Uganda where drug resistance to SP was already 
established, a significant proportion of infections treated with the artesunate-SP combination 
recrudesced. 
The fixed dose combination, artemether-lumefantrine (Coartem®), is currently the only co- 
formulated ACT on the market, and contains a partner drug that has not been widely used 
previously. It has the disadvantages of requiring twice daily dosing and the need for dietary 
intake for optimal absorption. Clinical efficacy studies have shown it to be extremely 
efficacious and well tolerated in Asia (van Vugt, Looareesuwan et al. 2000; Lefevre, Carpenter 
et al. 2002) and Africa (Falade, Makanga et al. 2005). A recent randomised study in Uganda 
compared efficacy (supervised) with the effectiveness (unsupervised) and using pharmaco- 
1 Interestingly, this programme was in response to an appeal for help from Ho Chi Minh to thou En Lai 
during the Vietnam war. 
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pharmacokinetics in 644 patients. PCR-corrected cure rates were 98% in both groups although 
the plasma concentrations of lumefantrine were lower in the unsupervised group (Piola, Fogg et 
al. 2005). However in another study in Zambia with 169 patients, effectiveness was 
significantly lower at 63.4% compared to efficacy at 83.5% (Depoortere, Guthmann et al. 2005). 
Severe malaria 
Recently the largest clinical trial of the treatment of severe malaria found that patients treated 
with intravenous artesunate had a mortality rate of 15% (107 of 730) compared with 22% (164 
of 731) in quinine recipients; an absolute reduction of 34.7% (95% CI 18.5-47.6%; p=0.0002). 
Treatment with artesunate was well tolerated, whereas quinine was associated with 
hypoglycaemia (relative risk 3.2,1.3-7.8; p=0.009)(Dondorp, Nosten et al. 2005). Artesunate 
can also be administered as a rectal suppository, making it easy to administer quickly to 
children and adults with severe malaria. Its widespread availability in peripheral health facilities 
and in communities therefore has the potential of significantly reducing the delay in treatment of 
severe infections, thereby reducing malaria deaths. It has been shown to be highly effective and 
safe in a number of randomised and open-label studies in both Asia and Africa (Cao, Bethell et 
al. 1997; Awad, Alkadru et al. 2003; Barnes, Mwenechanya et al. 2004; Aceng, Byarugaba et al. 
2005). 
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ANNEX 2 Cambodian development and economic indicators 
Table A2-1: Cambodian economic indicators 
Indicator Value 
Gross Domestic Product (GDP) (US$) 3.4 UNDP 2002) 
GDP per capita (US$) 263 (NIS 1999), 278 UNDP 2002) 
Purchasing Power Parity (PPP) (US$) 22.8 billion (UNDP 2002) 
PPP per capita (US$) 1,860 (UNDP 2002) 
Overseas Developmental Assistance (ODA) received 
(net disbursement) - Total S$ 
408.7 million (UNDP 2002) 
ODA received (net disbursement) 
Per capita (US$) 
30.3 (UNDP 2002) 
ODA received (net disbursement) 
As%ofGDP 
12 (UNDP 2002) 
Total debt service 
As % of GDP 
0.6 (UNDP 2002) 
Health expenditure 
Public as % of GDP 
1.0-2.0 (UNDP 2002) 
Health expenditure 
Private as % of GDP 
6.1 (UNDP 2002) 
Health expenditure per capita 
PPP US$ 
97 (UNDP 2002) 
Table A 2-2: Household expenditure and consumption data from Cambodian socio-economic 
survey 1999 (NIS 1999) 
Urban Rural 
Average monthly Per household 94.8 74.6 
expenditure 
(US$1999) 
Per capita 18.6 14.7 
Average monthly Total 361,736 284,444 
household 
consumption 
(Riel) 
For medical care 21,189 (5.9%) 
1" decile 3352 =2.4%, 
10' decile 92,620 = 
8.8% 
18,696 (6.6%) 
For food and tobacco 222,757 (61.6%) 198,831 (70.0%) 
For housing 61,915 (17.1%) 309,619 (10.8%) 
Average monthly Total 71,077 55,956 
per capita For medical care 4,095 5.8% 3,564 (6.4%) 
consumption For food and tobacco 43,443 61.1% 38,853 (69.4%) 
(riels) For housing 12,568 (17.7%) 6,368 (11.4%) 
Monthly income Per HH 105.7 82.4 
( US$1999) Per capita 20.8 16.4 
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Table A2-3: Poverty indicators 
Indicator Value 
Gini index 40.4 (UNDP 2002) 
% pop below national poverty line 36% IS 1999) 
Share of income or consumption 
Poorest 10% 
2.9% (UNDP 2002) 
Share of income or consumption 
Richest 10% 
33.8% (UNDP 2002) 
% of households with access to safe drinking water 29% (23.7% in rural) (NIS 1999) 
% of households with electricity as main source of 
light 
15.1% (8.6% in rural) (NIS 1999) 
% of households having toilet facility within 
remises 
14.5% (8.6% in rural) (NIS 1999) 
Table A2-4: Health related indicators from the Cambodia: general population census (NIS 
1999) and the demographic and health survey (NIS 2001) 
Indicator Value 
Under-five mortality rate (per 1000 live births) 124 (NIS 2001) 
Infant mortality rate (per 1000 live births) 95 (NIS 2001) 
Maternal mortality rate (per 100,000 live births) 437 (NIS 2001) 
Life expectancy at birth (Male) 54.5 (NIS 1999) 
Life expectancy at birth (Female) 58.3 (NIS 1999) 
Maternal mortality rate (per 100,000 live births) 1985-2001 440 (ILTIS 1999) 
% female literates 57% (NIS 1999) 
One-year olds fully immunised against TB 64% (UNDP 2002) 
One-year olds fully immunised against measles 59% (UNDP 2002) 
Physicians (per 100,000) 30 (UNDP 2002) 
Table A2-5: Other indicators from Cambodian socio-economic survey (included for 
comparison of results with this thesis) 
Indicator All Rural 
Wall construction Bamboo, thatch 48.4% 54.7% 
Wood 2.5% 2.8% 
Plywood 37.3% 34.8% 
Roof construction Thatch 39.8% 44.4% 
Tiles 29.1% 31.7% 
Iron/aluminium 22.5% 18.8% 
Clean source of water (piped, protected well or bought) 64% 24% 
Household durables Bicycle 64.5% 67.1% 
Motorcycle 24.9% 16.6% 
Radio 45.3% 41.3% 
TV 26.4% 20% 
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ANNEX 3 Classification for in-vivo antimalarial drug resistance studies 
A. M. WHO 1996 Classification 
ETF - Early Treatment Failure 
" Danger signs or severe malaria on day 1,2, or 3 in the presence of parasitaemia 
" Fever* on day 2 and parasite density greater than on day 0 
" Fever and parasitaemia on day 3 
" Parasite density on day 3 is ? 25% than on day 0 
LTF - Late Treatment Failure 
" Danger signs or severe malaria in the presence of parasitaemia on any day from day 4 to 
day 14, without previously meeting any of the criteria for ETF 
" Fever and parasitaemia on any day from day 4 to day 14, without previously meeting 
any of the criteria for ETF 
ACR - Adequate Clinical Response 
" Absence of parasitaemia on day 14, irrespective of fever status, without previously 
meeting any of the criteria for ETF or LTF. 
" Absence of fever irrespective of the parasitaemia status, without previously meeting any 
of the criteria for ETF or LTF 
A. 3.2. Revised WHO Guidelines - 2002 Classification 
ETF - Early Treatment Failure: Days 0,1,2 and 3 
" Development of danger signs or severe malaria on days 0 to 3 in the presence of 
parasitaemia 
" Parasitaemia on day 2 higher than on day 0, irrespective of temperature 
" Parasitaemia on day 3 with fever 
" Parasite density on day 3 ? 25% of count on day 0 
LCF - Late Clinical Failure: Days 4 to 14 (for intense transmission area) or 28 (for low-to 
moderate transmission area). 
" Development of danger signs or severe malaria after day 3 in the presence of 
parasitaemia, without previously meeting any of the criteria for ETF. 
" Fever (or history of fever in past 24 hours in low-to-moderate transmission area), in the 
presence of parasitaemia without previously meeting any of the criteria for ETF. 
LPF - Late Parasitological Failure: Days 7 to 14 or 28 
" Fever and presence of parasitaemia on day 14 in intense transmission area, or on any 
day from day 7 to 28 in low-to-moderate transmission area, without previously meeting 
any of the criteria for early or late treatment failure 
ACPR - Adequate Clinical and Parasitological Response 
" Absence of parasitaemia on day 14 in intense transmission area, or on day 28 in low-to- 
moderate transmission area, irrespective of fever, without meeting any of the previous 
criteria for failure 
*Fever is defined as axillary temperature >_37.5°C 
Source: Susceptibility of Plasmodium Falciparum to antimalarial drugs: Report of global 
monitoring 1996-2004. WHO 2005 
312 
ANNEX 4 Antimalarial drug policy and incidence of malaria in Cambodia 
Cambodian national antimalarial guidelines from year 2000 (CNM 2002) 
First-line treatment for uncomplicated P. falciparum malaria 
For 6 months to 6 years old children, the l line treatment is artesunate 50mg suppositories (P) 
during 5 days and mefloquine (M) dispensed by pharmacist/other health worker on D2. 
Table A4-1: Dosing of artesunate suppositories for children under 6 years old 
Weight (w) Age (a) Day Dj D2 
From D3 to 
DS 
6kg < w< 10kg 6 months 5 a< 2 years IP 1 P+'/2M 1 P/ day 
lOkgSw<14kg 2years5a<4years 1P 1P+1M 1P /day 
14kg <w< 16kg 4 years 5a<6 years 
Morning 
1P 
l Evening 
ip lp+l 
%zM 1P / day 
For others, the 1St line treatment is artesunate (or artemether) (A) + mefloquine (M), for 3 days. 
(A) is given as 50 mg tablets and (M) as 250 mg tablets. 
Table A4-2: Dosing of blister-packaged artesunate and mefloquine 
Da D D D Weight (w) Age (a) Morning Evening 2 3 
16kg <w< 25kg (A+M2) 6 years 5a<I1 years 1M+IA 1M+lA 2A 2A 
25kg :9w< 35kg (A+M3) 11 years 5a< 15 years 1M+lA 2M+2A 3A 3A 
- 
wz 35 kg (A+M4) a -- 15 years 2M+2A 2M+2A 4A 4A 
7 
During the 1s` trimester of pregnancy, the 1" line treatment is not recommended, and quinine 
given for 7 days. During the 2d and 3`4 trimester of pregnancy, the treatment of uncomplicated 
malaria is A+M. 
First line treatment of non P. falciparum malaria 
The total dose of chioroquine is 25 mg/kg over 3 days. 
DI = 10 mg/kg single dose 
D2 = 10 mg/kg single dose 
D3 =5 mg/kg single dose 
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Figure A4-1: Incidence of malaria in Cambodia 
Source: Soley L. 2003, personal communication 
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ANNEX 5 Conceptual frameworks for economic analysis 
Table A5-1: Types of costs and consequences relevant to the economic evaluation of health 
programmes 
Costs 
I Organising and operating costs, within the health sector 
(e. g. health care professionals' time, supplies, equipment, capital costs) 
II a. Costs borne by patients and their families 
  Out of pocket expenses 
  Patient and family inputs into treatment 
b. Time lost from work 
  Psychic costs 
III Costs borne external to the health care sector, patients and their families. 
Consequences 
I Change in physical, social or emotional functioning (effects) 
II Change in resource use (benefits) 
For organising and operation services within the health care sector 
  For the original condition 
" For unrelated condition 
Relating to activities of patients and their families 
  Savings in expenditure or leisure time 
  Savings in lost work time 
III Changes in the quality of life of patients and their families utilities 
Source: Adapted from Drummond & Stoddart, 1987 
Table A5-2: Conceptual framework of economic analyses of malaria control from 
"Guidelines for cost-effectiveness analysis of vector control" (Phillips, Mills et at 1993) 
I. The objective of improving health (choice of malaria control versus other means of 
health improvement); 
IT. The objective of malaria control (choice of vector control versus case detection and 
treatment and various mixes of both); 
Ill. The objective of (a) vector control and (b) case detection and treatment (choice of 
strategies for each); and 
IV. The objective of delivering a pre-determined strategy (choice of means of blood slide 
examination, choices of different mixes of staff for various activities, choices of 
organisational pattern, etc, ) 
315 
ANNEX 6 Parameter estimates 
A. 6.1. Order of presentation 
The parameters are presented in the following order: 
1. Malaria infection in the human host 
2. Immunity functions 
3. Asymptomatic infections 
4. Symptomatic infections 
5. Recrudescent infections 
6. Vector dynamics 
7. Clinical outcomes-Severe malaria and mortality 
8. Behaviour - diagnosis and treatment seeking 
9. Implementation 
10. Costs 
a. Direct costs of uncomplicated malaria 
b. Direct costs of severe malaria 
c. Indirect costs 
In reality there is obviously much overlap between the groupings and the relationships between 
the parameters forms a complex web rather than distinct linear constructions. In order to make 
this clearer, for each parameter, its relationship to other parameters is indicated in the 
"dependent on" and "affects" columns. Clearly, not all permutations could be included in the 
model and therefore those relationships that were not actually incorporated into this model are 
placed in italics. Mean or median parameter estimates, and their estimated or observed 
distributions, are listed for use in sensitivity analysis. Where distributions could not be deduced 
from the literature, the most likely characteristics were ascribed. 
A. 6.2. Rows and Columns 
Each row in the tables represents a different parameter with information presented in 9 columns. 
These are explained in Figure A6-1. 
Figure A6-1: Example of column headings 
1. 2. 3. 4. 5. 6. 7. 8. 9. 
No. Parameter Dependent Influences Value Distribution Quality Notes Source 
on and level 
range (QL) 
M4 Incubation Size of Calculation 12 Point A Assumed ])Kitchen 
period inoculation of time lag days to be in Boyd's 
between 13.1 same as (p. 995) 
(Time Immunity inoculations (1) time to 2)Dietz 
between and 15 maximum 1974 
inoculation symptomatic (2) parasite (p. 354) 
and first infections density 
febrile 
response) 
1. No. - Parameter number (to aid cross-referencing) 
2. Parameter - Usually self-explanatory and if not then a brief definition is included 
3. Dependent on - This indicates the factors that influence this parameter. If this 
relationship is incorporated into the model it is written in italics. 
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4. Influences - This indicates the parameters "downstream" to this parameter. As above, 
if the relationship is incorporated it is written in italics 
5. Value and range - The first value in italics is the one used in the model. The other 
values are those obtained from the literature. The number in brackets is a reference to 
the source which is detailed in the last column. 
6. Distribution - This is the distribution of the range of values for use in the sensitivity 
analysis e. g. uniform, normal or log-normal. For parameters for which there is little 
uncertainty a "fixed" input is used either as single value or as a vector e. g. age- 
stratified blood volume. 
As the product of the each immunity function is a matrix of age and EIR dependent 
values, the actual input into a single iteration of the model is the vector of age- 
dependent values for the EIR in that iteration. This is illustrated in the example below 
where the values in the matrix could represent likelihood of symptomatic infection and 
the EIR for the given iteration is 10. 
Age 
123456...... 
EIR 1 0.8 0.8 0.8 0.8 0.8 
0 
.3 
10 into model 
5 4I: 
6o: 5o3 
0.7 
7. Quality level (QL) - This indicates the degree of confidence in the quality of the 
data 
and was defined as follows: 
A Much data available, little uncertainty 
B Some data available, some uncertainty 
C Little or no data available, much uncertainty. 
8. Notes - Useful information about the data and assumptions made in using the parameter 
in the model are included in this column. 
9. Source - The full references are given at the end of the thesis. 
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ANNEX 7 Immune functions and formula for calculating infectivity of humans to 
mosquitoes 
A. 7.1. Immunity Function 1 (based on likelihood of symptomatic malaria) 
Data for this function were obtained from three cross-sectional prevalence studies where signs 
and symptoms of malaria in subjects were also recorded and from one longitudinal cohort 
study. One set of cross-sectional data was obtained from the Shoko refugee camp along the 
Thai-Burmese border in the north-western part of Thailand, with an estimated EIR of one in 
1997 (Nosten F, personal communication). Two sets of data were obtained from Kenya, from 
Ngerenya, with an estimated EIR of 20 and from Chonyi, Kenya, with an estimated EIR of 50 
(Mwangi T, personal communication). The longitudinal final data were taken from a 
published paper from Siaya, Tanzania with an estimated EIR of 270 (Bloland, Boriga et al. 
1999). The equation describing the best fit to the data and a graphical representation of the 
results are shown below: 
Equation A7-1 
y=0.26 * exp(-0.3AGE) + 0.02 * exp(-0.06AGE) + 1.09* exp(-0. IEIR) - 
0.28 * exp(-0.21AGE * EIR) 
Figure A7-1: Simulated curves of the proportion of symptomatic infections btiy ages in 
different transmission intensities by the non-linear immunityfunction described by 
Equation A7-1 
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A. 7.2. Immunity Function 2 (based on parasite density) 
Eight sets of data with age-stratified parasite densities were used including the four datasets 
used in Immunity Function 1. In addition, three published sources of data were used: data 
from Madang in Papua New Guinea with an EIR of 40 (Cox, Kum et al. 1994); data from 
Ghana with and EIR of 300 (Owusu-Agyei, Smith et al. 2002)and data from Diclmo, Senegal 
with and EIR of 200 (Trape, Rogier et al. 1994). One additional data set from a low 
transmission setting (EIR of 1) was obtained from Lao PDR (Mayxay M, personal 
communication). For model consistency the standard parasite detectable limit was assumed 
to be 20 parasites/ul of blood in a thin film and equivalent to 108 parasites in an adult. The 
parasite biomass for each age was calculated as described in Chapter 4. The optimal immune 
function derived from this data and the resulting curves are shown below. 
Equation A7-2 
y=9.8 exp(-(0.001AGE - 0.0001EIR + 0.000002AGE * EIR)) + 097 exp(0.01 1 AGE + 
0.003EIR - 0.0045AGE * EIR) 
Figure A7-2: Simulated curves of log1o(parasite biomass) in different age groups and 
different transmission intensities as described by Equation A7-2 
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A. 7.3. Immunity Function 3 (based on likelihood of severe malaria) 
Data for this immunity function was derived from data on adults and children in Shoklo, 
Thailand with an EIR for one (Nosten 2001) and from a large published study of severe 
malaria morbidity in children in sub-Saharan Africa (Snow, Omumbo et al. 1997). The four 
areas included in this study were: Bakau, The Gambia with an EIR of 0.5; Sukuta, The 
Gambia with an EIR of two; Kilifi, northern Kenya with an EIR of 120 and Siaya, western 
Kenya with an EIR of 100. The two-term exponential function that best described this data is 
shown below. Within the biological model, this function was used to describe the relationship 
between age, EIR and treatment failure and this is shown in Figure A7-3. 
Equation A7-3 
y =1.28 exp(-(0.59AGE + 0.003EIR)) + 0.63 exp(-(0.04AGE + 0.11 EIR)) 
Figure A7-3: Simulated curves of the normalised data of treatment failure rate in different 
age groups and different transmission intensities based on Equation A7-3 
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Equation A7-4: Formula used to calculate mosquito infectivity based on the gametocyte 
number 
Y-- 1.02 
(l+exp(-1.03 *(1oglox-8.55))) 
Where y (or i) is human infectiousness or probability of infecting mosquitoes, x is total 
gametocyte number. In the model any effect of transmission blocking immunity is ignored 
due to conflicting data. 
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ANNEX 8 Original documentation from community-based survey in Cambodia 
(also translated into Khmer) 
A. M. Letter to Head of village 
Village 
Commune 
Province 
Dear 
My name is Shunmay Yeung, I work for a University in the UK and am doing a study on 
malaria ("Kroon chang" ). I want to learn about how much of a problem Kroon Chang is 
and what people do if someone gets the symptoms. To do this, I would like to visit the 
households in your village and ask them some questions if they have had fever or malaria in 
the last 3 weeks. I would also like to do a finger prick test for malaria and to look for the 
anti-malarial medicine in their blood. I will come with four Khmer research assistants. We 
would like to stay for about 2 days. Each interview will take about 45 minutes. We hope to 
arrive on the (Date and time). We will be happy to discuss what we are doing at a community 
meeting when we arrive. People are free not to participate if they do not want to and can 
leave at any time. We hope that the results of the survey will be helpful for learning how to 
improve the provision of care to this and other villages and we will be happy to share the 
results with you at the end of the study if you are interested. 
If you have any questions or doubts please tell us either now or at any time. My contact 
details are below. 
Thank you very much for your help 
Shunmay Yeung 
Tel:. 012 723 108 (Cambodian mobile no. ) 
E-mail Shunmay. Yeung@lshtm. ac. uk 
Address: Wellcome Unit 
Faculty of Tropical Medicine 
420/6 Rajivithi Road 
Bangkok 10400 
342 
A. 8.2. Consent form 
Household 11) 
code 
Interviewer 
initials 
Date 
If the person is less than 18 years old then ask the parent for consent 
If the person is not available and you are interviewing the relative then ask the relative for 
consent 
If the person can not read, then read aloud the information sheet and statement and if they 
agree, put YOUR signature 
If they do not agree, thank them for their time and move on to nextTeerson or next household 
Line number Name of head of household Name of person with fever 
(from form A) 
----------------------------------------------------------------------------------------------------------------- 
I understand the information in the information sheet and agree to participate. 
I understand that I can choose freely and can withdraw at any time 
If patient is present and an adult: 
If patient is not present or is a child 
If patient or relative cannot write: 
Signature of patient: 
Name of relative: 
Relationship of relative to patient: 
Interviewer signature: 
343 
llouschold ID numbcr (~ v23 l' 
A. 8.3. Questionnaires 
General household 
questions (Form D) 
nia7gtSiýf1H (6: n D) 
A. Identification HEfMMan 
Interviewer (initials and date) 
ttlffliNiSitIm u (tN2Tid Bt! 5ýýa 
Checked (initials and date) 
U11n81IJ (tc8ri 3 Zu qle) 
Data entry (initials and date) 
L111u urn, m2 (tN6tt6 8k] i012) 
// 
/_, / 
// 
Commune Village Line number Name of Head of Household Personal ID numbers 
uj : IU (from form A) (Form C) 
21cl, 10811jiU t] A 
Name of person answering questions Age Sex Position in household in relation to the head 
ttlifl: HfSiütUt tiSS; jt1TSt N1r. tii9 of household tf818B9'1Yi StIMHCUIULM lriI 
MFi, Head of household tUT JU 
N 7J., 
2. Spouse LUt18 U 
3. Brother/sister UWSUt t1 
4. Mother/father 4Qr1 iW 
5* Child tt2 
98. Other ttiJt77 
(Specify) UCf1111 
B. Background CiU12=818 
1 How long have you lived in this house? 
iFfFiRlCii SS98iS: iJS1SýitÜ1CU? 
2 How many people in this household? 
PSýý ttflf ty1SýSStJS1SS1Pi ? 
[_years 
months t8 
3 How many adult men and women In this It Not including adults household? Males Females who moved away. 
te"sýnsýrsnrýctncn'#mý. rntLnrüsýsslrtrsö>:: is:? Ltjcu Lcü ýsntivrnroBýcýJtncnýur 
tumiglMOM 
4 How many people can work? 
5 How many children are there In this Including students supported by, family 
household? tiiHlßPtf3ºiLSS1SS1PfPiýýýt2:? t1t1UCflNlLtlljjSG'N99Nri1JaUtiBflLnHjt1NT11 
r 
21.6(5)household-khnlerandenglish. Page 1 6/24/2002 
J 
344 
Household ID number X2 
.' 
34 1 
6 Have you given birth to any live babies 
since the last Khmer New Year? 
YilüCl ltET9iiC11 NPiýi1Sft111N? 2 tt7 3 2i 
USS ? 
C. Mortality 910=1 
1. No t9 
2. Ycs, I Iivc birth C, 1N, T 1T 
3. Yes, 2 live births MCJ. tNnrü21I 
7 Have any children died since the last 1. No 2. Yes If No go to 2, SÜNBtG 1Nö19iUU2 9 Khmer New Year . 
eWi L-116 m2fstnrfl1 u1 U1 ? 
S9 'ný if "Yes", -, ask If you can ask about them? Ar' 
tum turmc's tünrsntrýsaýtiý; itm: 
8 Age Sex When ¢id Cause of death What symptoms did they have? How long were 
JJICSJ tng they die? (if known) tCiPliflJTSl: TilsJrlmJ: NJýt; THti2ýp they sick ? 
tFStPSdt5tg ilÜ 
ý HNTtf1E5tSPS, unü 
ri 
StSCIiJTi1SJtIJ: Tt1N 
týýW' c tüllJ2 t) t; 318Iý#G'J? 
2 
9 Did any adults die since the last I. No 2. Yes If, "No': go to 11.. SÜN6SS tNbt811S2 11 Khmer New Year? 
S8 tilN If "Yes", ask. If they mind talking about It týýnsýsN, }csnrn'#arnntite ý-,., .. 1 tÜý1N NSi11t5 SÜNBN1G19HC1fý17t2l: 
151ütfSC Igi IM: ? 
10 Age at Sex Which year did Cause of What symptoms did they have? How long wcrc 
death 
1119 they die? death rý'sýnmr: nüýýi ýtiýarz ii 
they sick ? 
Mai StStilYitLTltJt 1 l5W 1? 
+ 
HC1fttf1titnt 
rr 
tRmtilllfrrQJ: tnN 
mwrinü . eýai-lez 
f 
w 
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0 
Household ID number }{ 2 3. I 
D. Socio-economic status Cf12M; l to t 
lI flow much rice land do you own? 
IEUMH1SwSLl1S9iJ1U31SSüJ? Ha intiM 
12 How much rice did you produce since last 
Khmer New Year? t99 K 
iF5ýp3LlUßPi'1[Upýllgi ýi1St 2)2 r7 ? 
g j 
13 Did you have to borrow money to buy rice ? 1. No t9 2. Yes y1N if "No" go to IS 
sýsýszL rsttstWt3, jscnZnsixýt9 ? 11319 ylgW 9 is 
14 How many months did you have to borrow money W -buy rice? 
iEnu St1GUSJSlsiawi sü[UxPiýilszLLIPiIYislTlxý 
15 Did you sell surplus last year ? 1. No t9 2. Yes t, 1N If "No" go to 17 
SfiSiPiÜlStlfPiLýT3TüNtlTAfi1TJlüiwiUT9? $519 NJI9jt1JßJ917 
16 How much did you sell? 
sf5HPS17fY3LiufLlsüT2 jLM ? 
w 
Kg ft 
r 
17 What other source of income does this household have? Eg hired labor 
sýiýsLursncllncusr;, }ase, ýýis? t3. n"rcurcuics 
a 
18 What is the roof of the house made of 
19 What are the walls of the house made of 
1'iCRIý: LilüN 
1. No roof 1ii2 tN 
2. Lcavcs or bamboo Nti U UNj 
3. Wood tci 
4. Concrete or brick tt Lý 51 ý] 
98. Other Sdjbt99Ci 
1. No walls tilßt', [fitl 
2. Lcaves or bamboo Nf1 U Ut1ý{ 
3. Wood Ut 
4. Concrete or brick ttU IrMU 
98. Other WjbI9jt1 
20 How many cows/buffaloes or horses do you 
own? trim sen-L5ü-tcu: t3 1? 
r 
4 
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22 What kind of transport do you own? 
tESNfiHISHSGJIAICUSGWSMti2i? 
1. None M2 
2. Ox cart 119: tm 
3. Bicycle fl6 
4. Motorcycle iti 
98. Other , Jä7 
23 Do you own a radio or TV? 1. None tf12 
si±sxrtýs? sý ýrsnrýsiütts? 
2. RadioI94, 
0 
3. TV 9i9NJ$ 
26 Source of drinking Water in dry season? 
Lull Clu m pLLcunifüsnutsi18l w 
1. Drill well with pump NM, bt1id 
2. Other well HStSfsbS6gt 
3. River/lake/pond Nt]-Üfi]-LtIrM 
98. Other Wjb7NUUn111n 
27 How many years of schooling did you 
receive? wHfI5WCL 1MTTJSUMS 1Süt? 
24 Have you seen or heard any information 
about dipstick diagnosis? 
SIiUfl 1iJSLU[Tl Uýi1Sýpfi4flSJiClPflfSLinliýJSG[U 
cýcusLü 2ucürruss 
25 Have you seen or Beard any information 
about malarine? 
StSHfiM9StÜCT1 SJTi19C1CIfi4flSfiClfM fn1ir tü1t9 ? 
years 0 
1. No t9 
2. Yes, radio l l: UGld, Q: nUl9T 
3. Yes, TV UICU 1tJtltfIU8JNU8 
98. Yes, other MCJ MM%UjUtt', j 9 
0 
1. No t6" 
2. Yes, radio t+1Ntr. 'It CIMU194 
3. Yes, TV UICUtn JnmUgTq2' 
98. Yes, othcr SICO t'i MSUJUttJ#]7 
E. What is an affordable price for diagnosis and treatment? 
4 
Show them the dipstick and explain to them that the dipstick is a test for the dangerous type of malaria.. Explain that is a very 
quick and easy test to perform and that it has the benefit that the patient can also see the result and can tell if they need anti- 
malaria medicine. 
26 If the nearest private provider could do dipsticks. How much are you happy to pay for dipstick? 
TÜi11ST, 1Tt1Tß1C1f1L1RfýPfýSTSýýUfSliI, ýTYSfJt5tdi1fN1GTG$UNRL1S 1 
TeýeýicuirsýSCUýluJi WcumssTnenýý'sýýnmcu 
r 
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27 How much are they happy to pay for tablets that will always cure malaria? 
ire"sicuüsýsrýýmrn, JiýnsýýLcýsvýtýiýcu: inr, ýru sýncucnc'sincnýcýý 
28 If they could pay a little more for special quality tablets that would make sure that the cure was 
longer and that malaria did not come back. How much more do they need to pay? 
tcstýesýnmcuL ýsesvni; tsisx ninü iLýts'snstucutýc4 wiest nývh mrn, ýtlcum»it 
'sýýsi trntu , ýLýssvýcntýstsisJýicn 1 treýlýLivnmmL rstrsýs ? 
If you toolta dipstick, record the result at the end of form C.,. 
' Ex lain the result and give treatment if necessary 
D 
The End 
"That is the end of the interview. Thank you very much for your time and participation. Do you have any comments or 
Interviewer's comments or questions CTU IMnTJWUII%EiW CaS 
_questions? 
Participants comments or questions tif18IWBWTIR7MMIVI tff1UP U NJE3f YYVY 
Supervisor I comments or questions : Jqt iT it nUi11URRAMIUMI 70 
C) 
Data entry comments of questions Ai TEMUtl1 UTIU MIlIVIS 
r 
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rýj 9/ tAýtý 
Personal ID No. 2s3 sý 
Interviewer (initials and date) 
CW. -UnrvmntA ttatotj3 At 1ß1s) 
Checked (initials and date) 
spnnst1J (Cwoýa la ? gig) 
Data entry (initials and date) 
unurDwEnfns (tcvag3 la gig) 
I/ 
II 
// 
Malaria - Individual questionnaire (Form C) 
A. Identification urn um u(je1c1! 
Commune 
Lt? 
Village 
Pi i3 
Line No. (Form A) 
TM8T1jbUM6 (7A 
Name of Head of Household Household ID No. 
tcun: cvj. Mrtr trued: Form Di 
'Name of person who had feier Age Sex 
cwr1; ýcufýcuLýs: rsi Mtu CA9 
1. M LUGJ IF tN 
B. Description of illness mtºiýMSttdc`11; ý 
I '. When did your last episode of fever} start? 
1 days ago Try to get this as accurately 
cýsgnctv`ctvýcnronrnxn t1 xsýt3i as possible 
An "episode" of fever is where there is fever every day, ýtGtmdNnaJL19týNtütnc 
followed by at least 3 days without fever tLt9iL19 
2 For how many days did you have fever? 
cý: ý dýý-Eýxrsttntu cLutrnýsLvýtncv> 
a 
days sg 
3 Do you think you have fever today? I. No 2. Yes 99 Don't know 
týsxxýsx xtstcsststsiiýts: ? co 79 TIN 
Wa v: snotnýe 
4 What other symptoms did you suffer? 
iý ýd R{r1ENtti'ýS: iS1ZS ýGSýQýt? 
Do not read aloud answers. Tick the ones they say 
? H12fitT3(II 9 GIýStJTýCUNTüýUtt5L199tIf1U1 Y 
1. Fever LRecpi 
2. Chills UA 
3. Headache cuiy'cu 
4. No energy aJ 'Ji8 
S. Body pain r0m.. -TIP 
6. Nausea or vomiting nc§v y pn 
7. Dizzinesslcuvo 
8. Convulsions UM. t 
98. Other ; j53 
speci ty)I AJYt, FTf1: 
1 
349 
A: X20.6(potrait5)lndividualquestionaire-khmer. doc 
Personal ID No. 263 ! '! I. II 
5 Before this episode, have you had fever In the last I. No iv 2. Yes t, o tnnt 99. Don't know If No then go 
2 months ? yses to C 
ýs3nmrtmrotet tisHrtansLpte n=u: tnro1c'%8p? tilts tain41 C 
6 How many feier free days between these two 
episodes? 
týssýrtbýýcnný: ý: rýý4: s rtLvtsýsü; imfmro'snress 
1. <7 days r iI 
2. 7- 14 days 1-1t919Cil 
3. 15 - 30 days (mlt9 ro%J If >60 da) s. 
ý. 1-60 days mmiaoij continous or don't 
3 > 60 days >aoij 
kno\\ ;o to C 
. t . >ao uýrnisý 6. Continuous intermittent fever 
! fý tlT1lL1LTfLýt1 L"-" 
ffialtl týTIt41R192 C 
98. Other tt jö7 
99. Don't know URBI 
7 For how many days did you have fever the pre%sous 
episode ttllTll"1R5J iFw%4S9iUJ: tCýUU919: ý ? 't days 
C. Diagnosis tneMtAi 
8 Did you have a blood test for malaria? 1. No test isTsMfiJ ". No" go to D 
ti<ý! tSfISý S. ýJiLIf1ý36 Clft4ttllesjEauvilt9 tJAý8Sl8par"IMnJ 2.1 Yes, Dipstick tLvýlvtlrt 
3. Yes, Slide tLnrsmrsnsnv t tts1A. Etb 
D 
99. Don't Jtnow sie:. 6 
9 What %%as the result? 11. Negative Vswn: ýptnoj 
i? s6. f7CJr_ ttriötvni8tr 2. Positive 
3.1+ 
4.2- 
5.3"4- 
99. Don't snow ßata 
10 How many days ago? tJ S%t%V'M? days ago 11 
11 Tested i% here? _ 
2. Went to private phet tvinCkö6nldtjýis. týoýtuýtt7 
týýfJauýasrýýýJtsiStun t 3. Public health center, 'hospital U19612Jt1 
4. At home by private phet ttrtltc 9Jtttjcvvnd: 
5. Village malaria worker tirlrnjnNtn8p_esvtýIty 
6. MSF Outreach team LrlvtnojHýmtaWojryq: vnC! v 
99. Other ttij57 
99. Don't know vs? Z 
If they had more than one test in the last 2 months then write the details here 
350 
A: \20.6(potrait5)lndividuaIquestionaire-khmer. doc 2 
Personal ID No. 263 ! "f'Jj 
D. Inpatient stau rsuninnnfMtvgt; AjllflgiA; amn 
12 Did you stay over night in a clinic/hospital (public/privlte)! 1. No 2. Yes if No go to E 
tiijN1neninrsc1t1 tumbq: tnsJtu nr plimsjq rdrgt?? t7 t9 N tüte qttsinist E 
13 Which place did you stay? F 2. Private clinic talniký6titdýns_tnýJtt tv 
tFRnwlunnafm ntrtfkwtmt 3. Public health centre/hospital tvtrwaji§ 
93. Other td363 
14 How many nights did you stay? 
wwnninnc: Jtý1tvtsi`stsi: ftsmvi"3t? 7 nights mti 
E. Drugs kept from this epidsode tFsEn9tdctly'itjttrtö$nmrtrt1gstsgut9 ? 
15 Do you have any medicines kept from this episode 1. No 2. Yes If No go to F 
ti rnRi3' afujI{ p-. '=Arnwal2 i9 ? t8 MW s9w quuWji F 
16 Write don here the name or description of any drugs they show you and how many there are. 
ýtnrrcrýttcltn0 1 Sü1GC1J1t u SE IH[V7t3tUCIRifltiülSUillýltti7ý B, ý G98Lt51L1 ISdtUFf18I 
Name and form 
T1bSii 3ýt0. ü"1: G'i 
Number of 
tablets/amps 
Z; S3LfiiJýl / 
Kncu 
Where did you get It? 
IEU11=111t =, 
ý 
%N hy do you keep this Other comment 
medicine? S4TtUStJtt'iýý7 
SU1tiNGiSü1Nfl411ý1t9i 
i, 
eg Quinine 600mg labs 6 Drug seller Urt: tltir Take to forest WH161 T 
F. Prodders and drug usage ftrtßýTtTllrtfýL1H 9ö tT1ltjt7(, ý1Nj 
5. i For the last (most recent episode'of fever). How many Go to next page if they only had 
days did you have fever before you tried western days one episode of fever in the last 2 
medicine' months 
55 For the previous (second to last episode of fever). How 
many days did you have fever before you tried western 
medicine 
r_ Please tell me about all the treatment you took, starting from treatment that you received from the last provide 
and then going back in time to any previous proNiders". Please include any traditional medicine you took 
tt3ýnLtä trz nmmji nt'sýmrcýüt'uýýttuv týcu rs sagntmnLüt ni"ntrutýßýiýStcürttLmar tcntuvstvtfrtrtömroýtýcct týsýsýRývta1 JI 
d19t99A19 ? tJHS8NýTILTU lR11iI1SLÜtL1t11jý'1Sýt1Mt'iý 1 
A: \20.6(potrait5)Individualquestionaire"khmer. doc 3 351 
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Personal ID number 263 
G. Mefloouine history Lut ýrýýüLcýnnýiniss 
Show them the tablets, Meiloquine A+(11 & Malarine, it cnLrSiüýiWMMCi ITIMM. A+M. li1NiI9 
23 Did you ever take Mefloquine, A+M1 or Mtalarine 
IFUITMMIUMMIS.. 1+11 or Malarine 19 ? 
1. or 99. ;o to 31 Neer VS-5.1u 
If 
2. Yes. already described tÜ 1U 99tS1 mg 
iN. G1t tR UtÜit It 2. go to 24 
.. Yes. not > ci 
described tit _19124 
24 Did you omit %%ithin I hour of taking 
Mlefloquine/A+1V\ialarine? 
TFýfi31: 4StSTt; fi1Ü'1Sß U3'1T}CýtCUUtý1Jü 7 
Ulm. d2: mat9 If 3. ;o to 26 
3 19126 
98. Don't know Fß212 
L No 2. Yes 99. Don't know 
S9 the 69ýö 
25 Was this the first time You took 1. No 2. Yes 99. Don't know if Yes go to 31 
Mefloquine, A+N1 or Malarine? tg -Ulm 92U tu Tn. q 1tg1N9131 
tri4i, pu wnrxrt Cut ätn: a. A- \1 U 
31iUii3 
Y 
Pre-, ious time Firna II f 
26 Which one did sou take the pre%lous time? I. Mefloquine 
rnrotL. rtomis IFS rttýi; inmauý T 2. Ai-M4 
3. A-M3 
4. Malanne 4 
5. Malarine 3 
99. Don't know 
27 Rom- many days or weeks ago did you take If more than 2 months ago go to 31 
it? tctiýssn ýJi°Etn`rsri. nýgrtFEVroý`it=: ? _ ººeeks 
months EnEtvtucM 3 IO qttvi t3B 31 
28 Did you finish the packet ? 1. No .. Yes 99. Don't know 
6nwfS: JUý'7NE1J Si1$SdA7týT t9 GIN ä9ýGýJ 
29 How many tablets of Mefloquine did you If they took A=M or Malarine then calculate the 
take? Er5jI5EEUUt I4 its tl, stsLmu? number tüt(jiDIA+M g atnm9 . ýMM9'h399 
30 Did you vomit up the medicine? 11. No 2. Yes 99. Don't knoºº 
EF ýFY1EfSt5E46t"111E9 V61UC1ECUUjý1yU? 
I 
t9 Si1N 22 ti 
A: X20.6(potrait5)Individualquestionaire-khmer. doc 10 358 
$1 , 29q 
Personal ID number 2 ý` ? 
H. Lost productivity miuötc i, u 
31 What work were you doing before the last episode of 
fever? 
cr; InLurtumrsiü ýsýnLelsccüRCj, ýýucss? 
I 
i 
1. Working in field cg'TLN 
2. Wor#ing in forest je q t 
3. Looking after children and home 4; u; -mtstsi t 
4. Child staying at home neninrttsids 
'5. Child following parent to chamkar tnötvitirttttnv SgmTtst 
6. Child going to school alum js 
9S. ' Othertdj63 tkjvvctfrit 
32 How many days work/study did you miss because pf the last episode 
of fever " cý; ýrteýsicmrýir ucýswt? sscýctn`eurýBmnJqýtLmGýc. s ? 
days 2 
33 Who else had to stop work to help take care of sick 1. Put the relationship of the person 
person during the last episode of fever? If nö one go to 35 
6nfr18: f5M1iSýfiFültt9l5818iýmrýittýxjde idrrtýýt5? 2. AJtýAJtdl i1sLtL1Hä$sýrtCý, CiLraC9 
^laýair3sia 35 
34 How man, dais iN ork did each person miss? I" days 11 Not including Not including patient patient 
cýtýýrsýeieeLýr; s tvýrsiý ? Cýeubs'sýsCýndsý 2 days iii cýesrvsBF: irýrtd$eo ' 
If 
11 359 A: 120.6(potrait5)[ndividualquestionaire-khmer. doc 
Personal ID number 263 --j I 
1. Transport and costs giLJtLltIIt t1T 9a tttN 
} 
Start with last provider and ask all questions about that proyider before asking about the 2" last provider 
uýift gniutýýr2mrrGatLmm its rýrnisrýasniýinýut>zs: ýs'sanýnsi aisnfjhRIyatpnmtsJn 
Last provider to last pro%-Ider 3' to last provider 
try: tu2mnrlatýmm trýt+tYemoentýatýnm tNhniemreny+ýtLmca 
35 Provider Copy from page 4.5.7 
4.5.7 
, 
16 Ho%% did %ou tra%el there? .. r hnmr f-1ß%31 i 1.4t hone 
t rlnm; i: s I. At home t3r!: 31ýt 
\\ alk ißt 2. Walk t31 2. Walk 121 
3. Bicycle rid 3. Bicycle n$ 3. Bic>clc nö 
4. N40t0 ER 4. Moto Fin 4. Moto 
im 
S. Car US S. Car Us S. Car q PS 
9S. Other ttJiir9 9S. Other Mpg 98. Other tt; 3ro 
If they stayed at home then ago to 40 IUSM6t3i s t\t1t7IF3918 40 
37 How many people travelled? 
6e5ýSflSL°SE', ý3USlsý'i°_6UFk"IL'li3FI7? 
38 I How much time to so and 
return?: FYrtty_"^ý..? iiiný. _ösrt'"_ 
39 Total cost of Transport 
LFtt: Liý+F; ýccui: ctrst, ýti, ssa i 
40 Treatment and diagnosis cost 
41 Food, 'fruit/ drink? 
cF; Rt; cýmtusFr, ýt. Rs nTntrýjýýý: ýn7 
42 Other costs ? i 
6c3fi'ItfiGLfTlt'JGSf, 17ýF; vR i '. tf87 
I 
43 \Vhat %ere "other costs"? 
; Fos inrriituilog! J: 6JR 
ýot±ItsLntscs 
44 TOTAL mru 
Flow much? 
fts? 
45 How did you pay? 
Iftmýýc esmtsýII:? I1 
Wait for their reply jdrjidtCÜWIUAlm6 
A: X20.6(potrait5)Individualquestionairc-khmer. doc 
4 
I. Ready cash 
NtSJý6bý'%9'ý. fH1 
2. Borrowed from neighbour 
ýcgnicýsýn? r. aýö 
3. Credit from provider 
arn8wqj 
4. Sold land, animals or gold 
csrs3 curiten. Ln$ roriviný. roNtrotfijtn 
98. Other 11jö3 c purBr4) 
12 360 
Personal ID number 2631' 
J. Weight and blood test vnVs äta Inmmu 
Is the patient present? If No go to ti I 
ce"sveýcvcs: sýstrýaiscsid: cst 
1. No SS 2. Yes MCC 
ý 9ta 91 IK )I 
46 Weight sysRs Kg <- 
47 Axillary Temperature 
flit tfi i5lululf R' 
48 Spleen size cm tN , 191Lä 
49 If female is she pregnant? 1. \0 2. Yes 99. Don't know IF No or don't 
know go to 51 
Lvhrscý`i cýtýsi cm: týcsý 19 W: ij HSýij 
ÜýlSuii icvbigici f 51 
50 How many months 
pregnant InS11SC11: 631SS2 ? Months 
t2 
51 Dipstick result 11. Negative 2. Positive 3. No result rnscV jdn. t 
1 ýý; ýýtäu n1x? ýýýs ?ä Whynot^ ynntnr; q 
1 52 Treatment gi- en 
rtcýýrtcttý8cv; nt8csntumcs 
53 
I 
Filter paper taken? 1. No iß 2. Yes TV i 
ý54 
Slide taken? 1. No 19 2. Yes TV 
k 
A: \20.6(potrait5)Indi vidualquestionaire-khmer. doc 
13 361 
Personal ID number L263 
__ý__ 
1 11 
K. Other people? HShJjldjblGjti 
53 Did any one else in this 1. No i6 
household have fever/ 
malaria in last 3 seeks. 2.1 person t3SlVIJFf1R 
FrSýý'16NfiF1171iTä+J$F9ýtsaýr2os 
3.2 person 13GhJýC1131Ti 
Lrý6ýcrieý: w: fc+nr 
LsnýzsJä6F6;, st 98. Other 
d119t9Jti` 
99. Don't know kW3b 
Check form A rsrij97 A 
If No, then continue with form D 
tü129 u91I1U15usrt1Jr9rb D 
If Yes, try to fill in another form C. 
-- OESMw vrtitocnsi4r C 
If you cannot then write down as much as ou can 
iücüsxnýsrnýýtnrnýi c 
Age acsn; uýav years Sex the I. \1 2. F 
When did they have fever? Mrn: IUIULc Sns IMMUM 
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Sex mg 
When did they have fever? ttit51rq2nSt1wwnum ? 
Other Information (What treatment they took, NN here they got it, how many days they took the medicine. any delay" 
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Table A9-2: Size of land owned by households by district 
District N Mean size 
(ha) 
Median size 
ha 
Range 
(ha) 
_Anlong 
Veng 58 1.4 1 1-5 
Chik Phat 62 1.0 1 1-6 
Malai 36 2.2 0.5 0-17 
Sampalouen 46 1.7 1 1-8 
Sotnikum 26 1.1 1 0-4 
Thmar Bang 35 1.5 1 0-3 
Total 263 1.5 1 0-17 
Table A9-3: Months of food shortage in the last year 
No. 
0-3 months 16 19.5 
4-6 months 35 45.6 
7-9 months 17 22.1 
10-12 months 10( 13.0 
Unknown 8(9.3) 
Total 86 
Table A 9-4: Years of schooling (Mean 2.5, median 1, min 0, max 12) 
No. 
0 114(42.1%) 
1 22 8.1% 
2 14(5.2%) 
3 35(12.9%) 
4 26 9.6% 
5 18(6.6%) 
6 14 5.2% 
7 10(3.7%) 
8 72.6% 
9 6(2.2%) 
10 3Q. 1% 
11 1(0.4%) 
12 1(0.4%) 
Table A9-5: Building material for walls 
No. 
Wood 156(53.8%) 
Leaves or bamboo 116(40.0%) 
No walls 11(3.8%) 
Concrete or brick 2(0.7%) 
Other 5(l 
. 7% 
Total 290 
364 
Table A9-6: Building material for roof 
No. 
Leaves or bamboo 203 (70.0%) 
Metal 47( 16.2%) 
Tile, Brick, Concrete 20( 6.9%) 
Wood 9(3.1%) 
Other 10( 3.5%) 
Total 290 
Table A9-7: Number of draft animals 
No. 
0 237(85.3%) 
1 7(2.5%) 
2 20(7.2%) 
3 3(l. 1%) 
4 1(0.4%) 
5+ 10(3.6%) 
Total 278 
Table A9-8: Ownership of means of transport 
No. 
None 190(65.5%) 
Oxcart 14(4.8%) 
Bic cle 57(19.7%) 
Motorcycle 28(9.7%) 
Tractor 7(2.4%) 
Total 290 
Table A9-9: Ownership of means of telecommunications 
No. 
None 183 (64.0%) 
Radio only 74( 25.9%) 
TV only 18( 6.3%) 
Both 10( 3.5%) 
Other (video) 1 0.35% 
Total 286 
Table A9-10: Source of water 
No. 
Dug well 209(72.1%) 
Natural water 61 21.3% 
Drill well 20(6.9%) 
Total 290 
365 
Table A9-1 1: Age distribution of sample 
Age (years) No. (%) 
0-5 20( 5.5%) 
6-10 43 11.9% 
11-14 45( 12.5%0 
15+ ZL3 (70.1%) 
Total -- 
f 
361 
Table A9-12: Logistic regression analysis of likelihood of being seen by formal provider for 
recent episode of malaria like illness (adjusted for study design) 
Independent 
variable 
AOR p 95% CI 
Outreach area 4.0 0.023 1.12-13.2 
VMV area 147.5 0.002 8.46-2570.7 
Female 1.0 0.981 0.50-2.04 
Child 6-14 3.2 0.004 1.50-6.67 
Child <6 3.8 0.016 1.32-10.84 
Far* 1.0 0.977 0.30-3.41 
Poorest 40% 1.0 0.942 0.42-2.22 
Richest 20% 0.3 0.140 0.05-1.58 
N=361 
Dummy variables: Intervention=none, Sex=male, age=adult>14 years, distance fr om health 
centre <2 hours by motorcycle, poverty rank=middle 40%. 
Variables in bold are those which significantly affect the adjusted odds ratio. 
Table A 9-13: Likelihood of biological diagnosis by district 
District n % (n) 
Anlon veng 88 35%(31) 
Chik Phat 91 2%(2) 
Malai 42 47%(21) 
Sam alouen 65 23%(15) 
Sotnikum 28 14%(4) 
Thmar Bang 44 34%(15) 
361 
x° P<o. 000 i 
366 
Table A 9-14: Logistic regression analysis of likelihood of receiving biological diagnosis 
for recent episode of malaria like illness (adjusted for study design) 
AOR 95% CI 
Outreach area 2.38 0.10 0.83-6.88 
VMV area 10.67 0.00 4.70-24.25 
Sex (female) 0.80 0.356 0.50-1.30 
Age<5 1.09 0.769 0.60-1.97 
Ae 6-15 2.91 0.035 1.08-7.96 
Far 0.65 0.408 0.23-1.87 
Poverty lowest 
20% 
0.99 0.974 0.54-1.83 
Povety highest 
40% 
0.73 0.486 0.28-1.86 
N=360 
Dummy variables: Intervention=none, Sex=male, age=adult>14 years, distance from health 
centre <2 hours by motorcycle, poverty rank=middle 40%. 
Variables in bold are those which significantly affect the adjusted odds ratio. 
Table A9-15: Logistic regression analysis of receiving A+A1 for recent episode of malaria 
like illness (adjusted for study design) 
AOR 95% CI 
Outreach area 2.73 0.053 0.99-7.59 
VMV area 7.72 0.007 1.84-28.2 
Female 0.94 0.852 0.5-2.0 
Child 6-14 1.18 0.602 0.61-2.27 
Child <6 0.77 0.757 0.14-4.29 
Far from HC 1.19 0.721 0.44-1.17 
Poorest 40% 0.86 0.644 0.46-1.62 
Richest 20% 0.33 0.164 0.09-1.62 
N=297 
Dummy variables: Intervention=none, Sex=male, age=adult>14 years, distance from health 
centre <2 hours by motorcycle, poverty rank=middle 40%. 
Variables in bold are those which significantly affect the adjusted odds ratio. 
367 
Table A9-16: Average duration of treatment by antimalarial regime 
Antimalarial regime No. (%) No. with 
info on 
duration 
available 
Mean 
duration 
s. d Median 
(range) 
A+M (+/- other antimalarial) 72(13.8%) 55 2.89 0.90 3(1-6) 
Artemisinin alone 56(10.7%) 29 3.09 1.91 3 (1-7) 
Artemisinins +/- other drugs) 52(9.9%)- 36 2.57 1.70 2(1-7) 
Chloro nine and/or tetracycline 94 (18.0%) 64 2.17 1.54 2(1-7) 
Other 8(l. 5%) 5 1.8 1.30 1(14) 
Q (+/-others) 33(6.3A%) 24 2.31 1.64 2(1-7) 
Q+T +/- others) 22(4.2%) 13 3.85 3.02 3(1-10) 
Traditional or none 119(22.8%) 53 2.49 1.45 2 1-6 
Unknown 6702.8%) 38 3.87 3.38 3 1-14 
Total 523(100%) 317 2.76 1.96 3 1-14 
368 
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ANNEX 10 Modelling results for a high transmission settings 
A. 10.1. Outcomes 
The model was run using a vectorial capacity of 15 in order to simulate a high transmission 
intensity setting, with an annual entomological inoculation rate (EIR) of around 100-I50. In 
Figure A10-1, it can be seen that, as expected, when drug A is used alone as monotherapy, 
resistance to it spreads much slower in a high transmission setting than in a low transmission 
setting, taking six years to reach 20% resistance. This is because a much smaller proportion of 
patent infections are symptomatic and treated, and therefore less drug pressure is exerted with 
less opportunity for resistant infections to exhibit their survival advantage. Combination 
therapy appears to have much less impact on the spread of resistance in high transmission 
settings compared to low transmission settings because the proportion of parasites in which drug 
treatment is allowed to affect outcomes represents only a small proportion of all infections. 
Perhaps surprisingly, the rate of spread of drug resistance appears to be faster with combination 
therapy in a high transmission setting compared to a low transmission setting. This is partly 
because in all these simulations, 10% of the potentially patent infections are assumed to be 
exposed to inhibitory levels of drug A. This means that a substantial proportion of parasites are 
exposed to the drug pressure that results in selection of resistant mutants. In addition, it is also 
assumed that there is no fitness cost to drug resistance and therefore an equal chance of survival 
of resistant mutants in the absence of drug pressure. 
Figure A10-1: The spread of drug resistance in high and low transmission settings 
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Figure AlO-2 shows the incidence of new patent and treated infections. It can he seen that in a 
high transmission setting, only a small proportion of patent infections are treated, due to the 
high levels of immunity in the population76. The comparison with a low transmission setting 
seems to suggest that the incidence of symptomatic infections in the epidemic situation in low 
transmission settings is higher than that in the stable high transmission settings". Figure Al0-3 
presents the annual incidence of patent and treated infections by age group. Because the 
immunity function for symptomatic malaria describes a steep decrease in likelihood of 
symptoms with increasing age, although adults account for the majority of patent infections in 
absolute terms because they form the largest age-group, they carry the least burden of disease in 
terms of symptomatic (and therefore treated) malaria. 
76 Note the scale of the vertical axis. 
" Whilst this may be the case initially, we would expect that as immunity developed in the population, 
the incidence would fall in the low transmission setting. 
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Annual outcomes in terms of recrudescent infections and disability adjusted life years (DALYs) 
are presented in Figure A10-4. As expected, as resistance to drug A rises with continued use of 
monotherapy, the number of recrudescent infections also rises as does the number of severe 
infections and therefore DALYs. However with combination therapy, the incidence of 
recrudescent infections and DALYs remains low. This is because the majority of resistant 
infections that are treated with combination therapy are cured. 
A. 10.2. Costs 
Because CT has little impact on transmission in a high transmission setting, the annual drug 
costs of combination therapy can be expected to remain greater than if monotherapy was used. 
This is illustrated in Figure A10-5. In terms of the total costs of treating malaria, because there 
are fewer recrudescent and severe infections than with monotherapy, we might expect 
combination therapy to be cost saving overall. However, within the time frame of this analysis, 
the annual direct cost of malaria with ACT remains greater than monotherapy until after year 
10. 
A. 10.3. Cumulative cost-effectiveness 
The resulting cost-effectiveness of combination therapy in a high transmission setting is 
therefore less than in a low transmission setting. In the first few years, whilst resistance is low 
and there are few recrudescent infections with monotherapy, combination therapy makes no 
difference to the number of recrudescent or severe infections and has no impact on transmission 
intensity. Therefore, if a short time frame is used, combination therapy will not appear to be 
cost-effective and may even appear to be more costly and less effective if, due to chance, there 
happen to be fewer cases under the monotherapy scenario, as happens in this example. 
However cost-effectiveness increases over time as resistance rises and more severe cases and 
deaths are averted. At 10 years, the cumulative cost per DALY averted is $41 and therefore the 
switch can be considered cost-effective although substantially less so than in low transmission 
settings. At five years, the cost per DALY averted is $335 and would not be considered cost- 
effective using a threshold of $150. The results are show in Table A10-1 and Figure A10-6. 
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Figure A10-2: Annual incidence of new patent and treated infections in low and high 
transmission settings with monotherapy and combination therapy at 100% coverage 
a) Annual Incidence of new patent infections 
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Figure A10-3: Annual incidence of new patent and treated infections with monotherapy in a 
high transmission setting, by age group 
a) Annual Incidence of patent infections by age - 
high transmission setting, with monotherapy 
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Figure A10-4: Annual incidence of recrudescent infections and number of DAL Ys 
a) Annual Incidence of recrudescent Infections 
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Figure A10-5: Annual direct cost of drugs and of treating malaria (including recrudescent 
and severe infections, in low and high transmission settings with monotherapy and 100% 
combination therapy 
Annual Cost of first line drug per capita 
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Figure A10-6: Cost-effectiveness of combination therapy (100% coverage) over time in a 
high transmission setting compared to low transmission setting 
Cumulative incremental net cost per D4LY 
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ANNEX 11 Sensitivity analysis of biological model 
Table All-1: Parameters tested in the sensitivity analysis with code 
No. Parameter Code 
1 Vectorial capacity I1 
2 Host susceptibility 12 
3 Probability of beirr symptomatic 13 
4 Treatment coverage 14 
5 ACT coverage 15 
6 Relative parasite in non-treated 16 
7 Relative parasite in recrudescence 17 
8 Gametocyte switch rate for monotherapy 18 
9 Relative gametocyte switch rate for ACT 19 
10 Relative gametocyte switch rate in recrudescence I10 
II Relative gametocyte switch rate in non-treated III 
12 Plateau stage at the peak parasitaemia 112 
13 Plateau stage during recrudescence 113 
14 Duration of a non-treat infection 114 
15 PRR of drug-sensitive infection treated with monotherapy 115 
16 PRR of drug-resistant infection treated with monotherapy 116 
17 Relative PRR when treated with ACT 117 
18 Failure rate in drug-sensitive infection treated with monotherapy 118 
19 Failure rate in drug-resistant infection treated with monotherapy 119 
20 Relative failure rate in drug-sensitive infection treated with ACT 120 
21 Relative failure rate in drug-resistant infection treated with ACT 121 
22 Resistance level at which ACT is first considered 122 
23 Proportion of uninfected population with residual drug I23 
Scenario A: Low transmission setting and monotherapy 
Scenario B: Low transmission setting and ACT 
Scenario C: High transmission setting and monotherapy 
Scenario D: High transmission setting and ACT 
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Table All-6: The results of the sensitivity analysis shown as the statistical summaries of the 
outcomes in the 4 scenarios 
Scenario 
Output A B C D 
Mean 0.08 0.08 107.95 108.69 
Median 0.05 0.05 89.48 90,91 
EIRY2 Var 0.01 0.01 4527.54 4469.25 
SD 0.09 0.09 67.29 66.85 
SE 0.00 0.00 0.95 0.95 
CV 108.26 110.80 62.33 61.51 
Mean 0.50 0.05 119.10 115.90 
Median 0.10 0.03 100.45 97.44 
EIRy5 Var 0.57 0.01 4932.30 4844.75 
SD 0.75 0.08 70.23 69.60 
SE 0.01 0.00 0.99 0.98 
CV 149.25 153.62 58.97 60.05 
Mean 0.70 0.08 126.90 121.30 
Median 0.38 0.04 108.30 103.52 
EIRys Var 0.61 0.02 5230.75 5113.17 
SD 0.78 0.14 72.32 71.51 
SE 0.01 0.00 1.02 1.01 
CV 111.16 159.45 56.99 58.95 
Mean 0.71 0.09 128.63 122.37 
Median 0.40 0.04 110.26 104.72 EIRYlo Var 0.61 0.02 5273.86 5159.80 
SD 0.78 0.14 72.62 71.83 
SE 0.01 0.00 1.03 1.02 
CV 101.51 151.10 56.46 58.70 
Treated infectionY2 Mean 86.20 86.11 6.43 6.41 
(%) Median 85.95 85.86 6.01 5.97 
Var 22.15 22.20 3.87 3,71 
SD 4.71 4.71 1.97 1.93 3 SE 0.07 0.07 0.03 0.0 04 30 CV 5.46 5.47 30.62 . 
Treated infectiony5 Mean 86.87 84.48 5.87 6.09 
(%) Median 86.70 84.08 5.61 5.69 
Var 28.52 16.41 1.84 2.80 
SD 5.34 4.05 1.36 1.67 
SE 0.08 0.06 0.02 0.02 47 27 CV 6.15 4.79 23.11 . 
Treated infectionY8 Mean 88.36 85.36 5.61 5.88 
(%) Median 88.93 84.74 5.40 5.54 
Var 29.44 23.65 1.35 2.33 
SD 5.43 4.86 1,16 1.53 0 02 SE 0.08 0.07 0.02 . 99 25 
CV 6.14 5.70 20.75 . 
Mean 88.57 85.72 5.55 5.83 
T Median 
89.10 85,18 5,35 5.49 
reated infectionylo nf Var 28.46 24,54 1.23 2.25 ( 
SD 5.33 4.95 1.11 1.50 
SE 0.08 0.07 0.02 0.02 2 9 CV 6.02 5.78 19.96 5.6 
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(Table A11-6 continued: The results of the sensitivity analysis shown as the statistical 
summaries of the outcomes in the 4 scenarios) 
Scenario 
Output 
A B C D 
Mean 2.97 2.93 4.02 4.03 
Median 2.99 2.94 4.01 4.01 Recrudescent 
i f i Var 
0.63 0.60 1.13 1.12 
ect n 
% SD 
0.80 0.78 1.06 1.06 
) ( ) 
SE 0.01 0.01 0.02 0.01 
cv 26.83 26.48 26.44 26.34 
Mean 16.00 3.88 15.01 7.23 
Median 16.52 3.14 11.97 5.77 
Recrudescent Var 62.18 5.60 102.82 15.90 
infectiony5 SD 7.89 2.37 10.14 3.99 
NO SE 0.11 0.03 0.14 0.06 
CV 49.30 60.93 67.58 55.13 
Mean 23.33 6.93 22.40 9.95 
Median 23.89 6.37 28.25 9.72 Recrudescent 
i f i Var - 
10.76 12.47 119.32 24.44 
n ect onYe 
% SD 
3.28 3.53 10.92 4.94 
( ) 
SE 0.05 0.05 0.15 0.07 49 69 
cv 14.06 50.95 48.77 . 
Mean 24.30 8.28 24.71 10.85 
Median 24.30 8.25 29.68 10.94 
Recrudescent Var 3.84 12.11 102.73 24.02 
infectionylo SD 1.96 3.48 10.14 4.90 07 (%) SE 0.03 0.05 0.14 0. 17 45 
cv 8.06 42.05 41.01 . 
Mean 0.74 0.72 36.33 36.65 
Median 0.63 0.62 34.55 35.21 
PrevatenceY2 Var 0.13 0.12 116.42 118.70 90 (%) SD 0.36 0.35 10.79 10. 15 0 
SE 0.01 0.00 0.15 70 9 
. 73 29 
cv 48.79 48.10 2 . . 
Mean 3.81 0.70 41.27 40.53 
Median 1.61 0.56 40.04 39.37 
Prevalencey5 Var 15.95 0.25 111.24 117.35 0 83 (%) SD 3.99 0.50 10.55 1 . 0 15 
SE 0.06 0.01 0.15 6 . 26 73 cv 104.83 71.67 25.5 . 
Mean 4.60 0.88 43.20 42.11 
Median 3.47 0.65 42.20 41.04 37 9 Preva1enceY6 Var 14.93 0.47 112.45 11 . 10 93 (%) SD 3.86 0.68 10.60 . 15 0 
SE 0.05 0.01 0.15 4 54 
. 25 95 
cv 83.96 77.86 . 2 . - 
Mean 4.63 0.91 43.62 42.44 
7 
Median 3.52 0.68 42.65 41.48 
Prevalenceylo Var 14.74 0.48 112.11 119.83 10 95 (%) SD 3,84 0.69 10.59 . 0 15 SE 0.05 0.01 0.15 27 24 . 25 79 cv 82.87 75,89 . , 
381 
(Table All-6 continued: The results of the sensitivity analysis shown as the statistical 
summaries of the outcomes in the 4 scenarios) 
Scenario 
Output 
A 13 C D 
Mean 3.21 3.04 2.46 2.40 
Median 2.20 2.12 1.83 1.77 
Resistancey2 Var 8.21 5.96 3.15 3.01 
(%) SD 2.87 2.44 1.77 1.74 
SE 0.04 0.03 0.03 0.02 
CV 89.29 80.26 72.14 72.21 
Mean 71.55 33.99 46.23 43.87 
Median 86.85 24.64 39.70 33.80 
Resistancey5 Var 952.18 587.88 1454.48 1404.80 
NO SD 30.86 24.25 38.14 37.48 
SE 0.44 0.34 0.54 0.53 
CV 43.13 71.34 82.50 85.44 
Mean 96.49 65.25 69.43 67.12 
Median 99.93 67.95 94.93 91.73 
ResistanceY8 Var 74.91 795.96 1456.21 1492.60 
(%) SD 8.65 28.21 38.16 38.63 
SE 0.12 0.40 0.54 0.55 56 5 CV 8.97 43.24 54.96 7. 
Mean 99.30 78.25 77.01 74.80 
Median 99.98 88.97 99.41 98.79 Resistanceylo 
% Var 
7.56 578.19 1231.03 1302.96 
( ) SD 2.75 24.05 35.09 36.10 
SE 0.04 0.34 0,50 0.51 26 48 CV 2.77 30.73 43.56 . 
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